nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,days_since_update
NCT04382053,NA,2020-05-08,2021-11-15,NA,2021-11-25,2020-05-08,2020-05-11,Actual,2021-11-25,2021-11-30,Estimate,NA,NA,NA,2021-11-25,2021-11-30,Estimate,"May 27, 2020",Actual,2020-05-27,November 2021,2021-11-30,"December 24, 2020",Actual,2020-12-24,"December 10, 2020",Actual,2020-12-10,NA,Interventional,NA,NA,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,"Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function",Completed,NA,Phase 2,143,Actual,Novartis,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-12-04T17:06:49Z,2021-12-04T17:06:49Z,67
NCT04331899,NA,2020-03-27,2021-04-08,NA,2021-11-24,2020-04-01,2020-04-02,Actual,2021-04-19,2021-04-22,Actual,NA,NA,NA,2021-11-24,2021-11-30,Estimate,"April 25, 2020",Actual,2020-04-25,November 2021,2021-11-30,"May 6, 2021",Actual,2021-05-06,"August 14, 2020",Actual,2020-08-14,NA,Interventional,COVID-Lambda,NA,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,"A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19",Completed,NA,Phase 2,120,Actual,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,The datasets generated and analyzed during the current study are permanently available in the Stanford Digital Repository,Full access,https://purl.stanford.edu/hc972ys6733,Yes,Sharing of generated and analyzed datasets.,2021-12-04T17:06:27Z,2021-12-04T17:06:27Z,68
NCT04347954,NA,2020-04-13,2021-10-15,NA,2021-10-19,2020-04-13,2020-04-15,Actual,2021-10-19,2021-10-21,Actual,NA,NA,NA,2021-10-19,2021-10-21,Actual,"August 15, 2020",Actual,2020-08-15,October 2021,2021-10-31,"December 13, 2020",Actual,2020-12-13,"December 13, 2020",Actual,2020-12-13,NA,Interventional,NA,Participants who received the allocated intervention and completed the study; participants with negative PCR nasal swab results at baseline or incomplete data were excluded.,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers,Completed,NA,Phase 1/Phase 2,47,Actual,Stanford University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:32Z,2021-12-04T17:06:32Z,104
NCT04349098,NA,2020-04-14,2021-10-05,NA,2021-10-27,2020-04-14,2020-04-16,Actual,2021-10-27,2021-11-01,Actual,NA,NA,NA,2021-10-27,2021-11-01,Actual,"April 17, 2020",Actual,2020-04-17,October 2021,2021-10-31,"October 5, 2020",Actual,2020-10-05,"October 5, 2020",Actual,2020-10-05,NA,Interventional,Coronavirus,PV 1-6 population included participants randomized into the study under protocol versions 1-6.,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection,Completed,NA,Phase 2,190,Actual,Karyopharm Therapeutics Inc,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-04T17:06:33Z,2021-12-04T17:06:33Z,96
NCT04355767,NA,2020-04-17,2021-10-13,NA,2021-10-15,2020-04-17,2020-04-21,Actual,2021-10-15,2021-10-19,Actual,NA,NA,NA,2021-10-15,2021-10-19,Actual,"August 11, 2020",Actual,2020-08-11,October 2021,2021-10-31,"March 29, 2021",Actual,2021-03-29,"March 29, 2021",Actual,2021-03-29,NA,Interventional,C3PO,NA,Convalescent Plasma in Outpatients With COVID-19,Clinical-trial of COVID-19 Convalescent Plasma in Outpatients,Completed,NA,Phase 3,511,Actual,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data will be available indefinitely.,"Data requests will be managed by National Heart, Lung, and Blood Institute (NHLBI).",https://biodatacatalyst.nhlbi.nih.gov/,Yes,The complete de-identified patient data set will be shared.,2021-12-04T17:06:38Z,2021-12-04T17:06:38Z,108
NCT04317040,NA,2020-03-19,2021-09-28,NA,2021-10-13,2020-03-19,2020-03-20,Actual,2021-10-13,2021-10-15,Actual,NA,NA,NA,2021-10-13,2021-10-15,Actual,"April 24, 2020",Actual,2020-04-24,October 2021,2021-10-31,"October 20, 2020",Actual,2020-10-20,"October 20, 2020",Actual,2020-10-20,NA,Interventional,SAC-COVID,All randomized participants.,CD24Fc (MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007),"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment",Completed,NA,Phase 3,234,Actual,"OncoImmune, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-12-04T17:06:18Z,2021-12-04T17:06:18Z,110
NCT04435184,NA,2020-06-16,2021-11-03,NA,2021-11-03,2020-06-16,2020-06-17,Actual,2021-11-03,2021-11-09,Actual,NA,NA,NA,2021-11-03,2021-11-09,Actual,"July 9, 2020",Actual,2020-07-09,November 2021,2021-11-30,"January 4, 2021",Actual,2021-01-04,"November 28, 2020",Actual,2020-11-28,NA,Interventional,CRITICAL,Baseline characteristics data was collected for the 42 participants who completed the study.,Crizanlizumab for Treating COVID-19 Vasculopathy,Crizanlizumab for Treating COVID-19 Vasculopathy,Completed,NA,Phase 2,54,Actual,Johns Hopkins University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:07:07Z,2021-12-04T17:07:07Z,89
NCT04388826,NA,2020-05-13,2021-10-20,NA,2021-11-22,2020-05-13,2020-05-14,Actual,2021-11-22,2021-11-24,Estimate,NA,NA,NA,2021-11-22,2021-11-24,Estimate,"June 18, 2020",Actual,2020-06-18,November 2021,2021-11-30,"August 13, 2021",Actual,2021-08-13,"December 18, 2020",Actual,2020-12-18,NA,Interventional,NA,NA,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,"Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)",Completed,NA,Phase 2,39,Actual,Veru Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:50Z,2021-12-04T17:06:50Z,70
NCT04484207,NA,2020-07-21,2021-10-12,NA,2021-10-26,2020-07-21,2020-07-23,Actual,2021-10-26,2021-10-28,Actual,NA,NA,NA,2021-10-26,2021-10-28,Actual,"July 6, 2020",Actual,2020-07-06,October 2021,2021-10-31,"October 26, 2020",Actual,2020-10-26,"October 20, 2020",Actual,2020-10-20,NA,Interventional,NA,NA,Addressing COVID-19 Mental Health Problems Among US Veterans,Addressing COVID-19 Mental Health Problems Among US Veterans,Completed,NA,Not Applicable,172,Actual,"Research Foundation for Mental Hygiene, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,two months,Co-Is,NA,Yes,"Data will be shared as needed with investigators, IRB etc. A plan will be determined in the short future",2021-12-04T17:07:13Z,2021-12-04T17:07:13Z,97
NCT04401293,NA,2020-05-20,2021-10-29,NA,2021-11-17,2020-05-21,2020-05-26,Actual,2021-11-17,2021-11-22,Estimate,NA,NA,NA,2021-11-17,2021-11-22,Estimate,"April 26, 2020",Actual,2020-04-26,November 2021,2021-11-30,"May 14, 2021",Actual,2021-05-14,"May 14, 2021",Actual,2021-05-14,NA,Interventional,NA,NA,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial),Completed,NA,Phase 3,257,Actual,Northwell Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:56Z,2021-12-04T17:06:56Z,75
NCT04492475,NA,2020-07-28,2021-10-28,NA,2021-11-18,2020-07-28,2020-07-30,Actual,2021-11-18,2021-11-22,Estimate,NA,NA,NA,2021-11-18,2021-11-22,Estimate,"August 5, 2020",Actual,2020-08-05,November 2020,2020-11-30,"December 21, 2020",Actual,2020-12-21,"December 21, 2020",Actual,2020-12-21,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)",Completed,NA,Phase 3,969,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T17:07:17Z,2021-12-04T17:07:17Z,74
NCT04507867,NA,2020-08-06,2021-09-22,NA,2021-10-13,2020-08-09,2020-08-11,Actual,2021-10-13,2021-10-15,Actual,NA,NA,NA,2021-10-13,2021-10-15,Actual,"September 7, 2020",Actual,2020-09-07,October 2021,2021-10-31,"April 10, 2021",Actual,2021-04-10,"April 10, 2021",Actual,2021-04-10,NA,Interventional,NA,"all participants enrolled in the study, a total of 80 patients were compared.",Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Effect of a Nutritional Support System to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Completed,NA,Not Applicable,80,Actual,Anahuac University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:07:28Z,2021-12-04T17:07:28Z,110
NCT04411628,NA,2020-05-29,2021-11-01,NA,2021-11-10,2020-05-29,2020-06-02,Actual,2021-11-01,2021-11-09,Actual,NA,NA,NA,2021-11-10,2021-11-12,Estimate,"May 28, 2020",Actual,2020-05-28,November 2021,2021-11-30,"August 26, 2020",Actual,2020-08-26,"August 26, 2020",Actual,2020-08-26,NA,Interventional,NA,All randomized participants who received at least one dose of study drug.,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,"A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19",Completed,NA,Phase 1,26,Actual,Eli Lilly and Company,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:58Z,2021-12-04T17:06:58Z,82
NCT04418947,NA,2020-05-29,2021-10-25,NA,2021-10-26,2020-06-02,2020-06-05,Actual,2021-10-26,2021-10-28,Actual,NA,NA,NA,2021-10-26,2021-10-28,Actual,"June 15, 2020",Actual,2020-06-15,October 2021,2021-10-31,"July 17, 2020",Actual,2020-07-17,"July 17, 2020",Actual,2020-07-17,NA,Interventional,NA,NA,Project Resurgence Communication Trial,Comparison of the Effectiveness of Communication Strategies on the Return to In-Person Visits to a Medical Center After the Emergence of COVID-19: A Randomized Trial,Completed,NA,Not Applicable,11120,Actual,University of Pennsylvania,NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:59Z,2021-12-04T17:06:59Z,97
NCT04420273,NA,2020-06-03,2021-10-25,NA,2021-11-19,2020-06-05,2020-06-09,Actual,2021-11-19,2021-11-23,Estimate,NA,NA,NA,2021-11-19,2021-11-23,Estimate,"July 2, 2020",Actual,2020-07-02,November 2021,2021-11-30,"March 1, 2021",Actual,2021-03-01,"March 1, 2021",Actual,2021-03-01,NA,Interventional,TMD,NA,Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access,Targeted Melanoma Detection With Skin Self-examination: Leveraging the Mammogram Encounter,Completed,NA,Not Applicable,1000,Actual,Northwestern University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:07:01Z,2021-12-04T17:07:01Z,73
NCT04523831,NA,2020-08-19,2020-09-30,NA,2020-10-07,2020-08-20,2020-08-24,Actual,2020-10-07,2020-10-09,Actual,NA,NA,NA,2020-10-07,2020-10-09,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"September 10, 2020",Actual,2020-09-10,"August 22, 2020",Actual,2020-08-22,NA,Interventional,NA,We followed intention to treat analysis; SPSS (Statistical Package for Social Sciences) version 20 was used to analyze data. To compare mean of the two group chi square test was done.,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care,Completed,NA,Phase 3,400,Actual,Dhaka Medical College,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,September 2020 to December 2020,Person who are investigating covid-19 in various aspects,NA,Yes,"Patients age, sex, Date of covid positive report, Symtoms,Date of covid negative report, post covid symptoms, time to recover.",2021-12-04T22:27:19Z,2021-12-04T22:27:19Z,481
NCT04701658,NA,2021-01-07,2021-11-11,NA,2021-11-11,2021-01-07,2021-01-08,Actual,2021-11-11,2021-11-16,Estimate,NA,NA,NA,2021-11-11,2021-11-16,Estimate,"February 1, 2021",Actual,2021-02-01,November 2021,2021-11-30,"June 22, 2021",Actual,2021-06-22,"June 22, 2021",Actual,2021-06-22,NA,Interventional,BLAZE-5,All participants who received single dose of Bamlanivimab.,A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),"A Prospective Cohort Study to Evaluate the Real-world Effectiveness of Bamlanivimab in Participants With Mild-to-moderate COVID-19 at High Risk for Progressing to Severe Illness, With Matched Controls",Completed,NA,Phase 2,109,Actual,Eli Lilly and Company,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2021-12-04T17:07:54Z,2021-12-04T17:07:54Z,81
NCT04706416,NA,2020-12-31,2021-10-27,NA,2021-11-02,2021-01-11,2021-01-12,Actual,2021-11-02,2021-11-04,Actual,NA,NA,NA,2021-11-02,2021-11-04,Actual,"November 14, 2020",Actual,2020-11-14,November 2021,2021-11-30,"January 15, 2021",Actual,2021-01-15,"January 15, 2021",Actual,2021-01-15,NA,Interventional,NA,NA,N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),Completed,NA,Phase 1,150,Actual,Quantinosis.ai LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"We will publish based on summary data, but make individual participant data available upon request. There are no plans to publish individual participant data.",2021-12-04T17:07:56Z,2021-12-04T17:07:56Z,90
NCT04502056,NA,2020-08-02,2021-05-28,NA,2021-07-24,2020-08-04,2020-08-06,Actual,2021-07-24,2021-07-27,Actual,NA,NA,NA,2021-07-24,2021-07-27,Actual,"August 7, 2020",Actual,2020-08-07,July 2021,2021-07-31,"September 6, 2020",Actual,2020-09-06,"September 6, 2020",Actual,2020-09-06,NA,Interventional,NA,Any intervention was indeed an arm that included each sub arm of different types of message that we tested against a control and pre-specified in our study protocol and analysis plan to combine arms for analysis.,Covid-19 Messaging to Underserved Communities - 2nd Experiment,Covid-19 Messaging to Underserved Communities - 2nd Experiment,Completed,NA,Not Applicable,20460,Actual,"National Bureau of Economic Research, Inc.",NA,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:27:27Z,2021-12-04T22:27:27Z,191
NCT04491994,NA,2020-07-28,2020-07-31,NA,2020-08-18,2020-07-28,2020-07-30,Actual,2020-08-18,2020-08-21,Actual,NA,NA,NA,2020-08-18,2020-08-21,Actual,"April 10, 2020",Actual,2020-04-10,August 2020,2020-08-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,COVID-19,sample size calculation was done and 540 patients enrolled,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial,Completed,NA,Phase 3,540,Actual,UNICEF,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,any time when asked,by email,NA,Yes,data can be shared on demand in SPSS sheet,2021-12-04T22:27:34Z,2021-12-04T22:27:34Z,531
NCT04491240,NA,2020-07-27,2020-10-21,NA,2020-10-28,2020-07-27,2020-07-29,Actual,2020-10-28,2020-11-04,Actual,NA,NA,NA,2020-10-28,2020-11-04,Actual,"July 20, 2020",Actual,2020-07-20,October 2020,2020-10-31,"October 20, 2020",Actual,2020-10-20,"October 1, 2020",Actual,2020-10-01,NA,Interventional,COVID-19EXO,NA,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,The Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Two-Sided Pneumonia,Completed,NA,Phase 1/Phase 2,30,Actual,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:27:35Z,2021-12-04T22:27:35Z,460
NCT04463004,NA,2020-07-07,2021-08-04,NA,2021-08-04,2020-07-07,2020-07-09,Actual,2021-08-04,2021-08-11,Actual,NA,NA,NA,2021-08-04,2021-08-11,Actual,"September 2, 2020",Actual,2020-09-02,August 2021,2021-08-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,NA,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,NA,Phase 2,2,Actual,Virginia Commonwealth University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:27:48Z,2021-12-04T22:27:48Z,180
NCT04475588,NA,2020-07-16,2020-08-02,NA,2021-06-10,2020-07-16,2020-07-17,Actual,2021-05-17,2021-05-20,Actual,NA,NA,NA,2021-06-10,2021-06-14,Actual,"May 1, 2020",Actual,2020-05-01,June 2021,2021-06-30,"July 7, 2020",Actual,2020-07-07,"July 7, 2020",Actual,2020-07-07,NA,Interventional,NA,NA,Efficacy and Safety of Itolizumab in COVID-19 Complications,"A Multi-Centre, Open Label, Two Arm Randomized, Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications",Completed,NA,Phase 2,32,Actual,Biocon Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:27:41Z,2021-12-04T22:27:41Z,235
NCT04452435,NA,2020-06-29,2021-03-24,NA,2021-06-21,2020-06-29,2020-06-30,Actual,2021-04-28,2021-04-30,Actual,NA,NA,NA,2021-06-21,2021-06-23,Actual,"July 21, 2020",Actual,2020-07-21,June 2021,2021-06-30,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Interventional,NA,NA,Safety and Efficacy of C21 in Subjects With COVID-19,"A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial Investigating the Safety and Efficacy of C21 in Hospitalised Subjects With COVID-19 Infection Not Requiring Mechanical Ventilation",Completed,NA,Phase 2,206,Actual,Vicore Pharma AB,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:27:54Z,2021-12-04T22:27:54Z,224
NCT04402970,NA,2020-05-20,2021-03-12,NA,2021-04-12,2020-05-22,2020-05-27,Actual,2021-04-12,2021-04-14,Actual,NA,NA,NA,2021-04-12,2021-04-14,Actual,"June 19, 2020",Actual,2020-06-19,April 2021,2021-04-30,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,DORNASESARS2,NA,Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2,Completed,NA,Phase 3,30,Actual,University of Missouri-Columbia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:16Z,2021-12-04T22:28:16Z,294
NCT04410159,NA,2020-05-27,2020-07-08,NA,2020-07-17,2020-05-28,2020-06-01,Actual,2020-07-17,2020-07-21,Actual,NA,NA,NA,2020-07-17,2020-07-21,Actual,"June 22, 2020",Actual,2020-06-22,July 2020,2020-07-31,"July 6, 2020",Actual,2020-07-06,"June 29, 2020",Actual,2020-06-29,NA,Interventional,GARGLES,NA,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,"A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients",Completed,NA,Phase 2,20,Actual,Universiti Sains Islam Malaysia,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,September to December 2020,email to drnurul@usim.edu.my,NA,Yes,The participant data from the final research dataset used in the published manuscript will be shared upon reasonable request. The protocol and data analysis will be shared in clinicaltrial,2021-12-04T22:28:08Z,2021-12-04T22:28:08Z,563
NCT04392141,NA,2020-05-15,2020-11-25,NA,2021-04-16,2020-05-15,2020-05-18,Actual,2021-04-16,2021-04-20,Actual,NA,NA,NA,2021-04-16,2021-04-20,Actual,"April 1, 2020",Actual,2020-04-01,April 2021,2021-04-30,"November 1, 2020",Actual,2020-11-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,NA,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Application of Colchicine Plus Herbal Phenolic Monoterpene Fractions to Treat COVID-19,Completed,NA,Phase 1/Phase 2,120,Actual,Kermanshah University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:25Z,2021-12-04T22:28:25Z,290
NCT04422561,NA,2020-06-06,2020-08-23,NA,2020-08-23,2020-06-06,2020-06-09,Actual,2020-08-23,2020-08-27,Actual,NA,NA,NA,2020-08-23,2020-08-27,Actual,"May 31, 2020",Actual,2020-05-31,August 2020,2020-08-31,"July 27, 2020",Actual,2020-07-27,"July 14, 2020",Actual,2020-07-14,NA,Interventional,NA,NA,Prophylactic Ivermectin in COVID-19 Contacts,Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19,Completed,NA,Phase 2/Phase 3,340,Actual,Zagazig University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:10Z,2021-12-04T22:28:10Z,526
NCT04421404,NA,2020-06-03,2021-05-18,NA,2021-08-23,2020-06-05,2020-06-09,Actual,2021-08-23,2021-08-25,Actual,NA,NA,NA,2021-08-23,2021-08-25,Actual,"June 9, 2020",Actual,2020-06-09,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,CAPRI,NA,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,A Randomized Controlled Adaptive Study Comparing COVID-19 Convalescent Plasma (CCP) to Non-immune Plasma to Limit Coronavirus-associated Complications in Hospitalized Patients,Completed,NA,Phase 2,34,Actual,"University of California, San Francisco",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:11Z,2021-12-04T22:28:11Z,161
NCT04411667,NA,2020-05-29,2021-06-10,NA,2021-06-23,2020-06-01,2020-06-02,Actual,2021-06-23,2021-06-25,Actual,NA,NA,NA,2021-06-23,2021-06-25,Actual,"April 28, 2020",Actual,2020-04-28,June 2021,2021-06-30,"June 23, 2020",Actual,2020-06-23,"June 23, 2020",Actual,2020-06-23,NA,Interventional,NA,NA,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection,Completed,NA,Phase 4,34,Actual,Sharp HealthCare,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:13Z,2021-12-04T22:28:13Z,222
NCT04407507,NA,2020-05-27,2021-05-10,NA,2021-05-19,2020-05-27,2020-05-29,Actual,2021-05-19,2021-05-21,Actual,NA,NA,NA,2021-05-19,2021-05-21,Actual,"July 1, 2020",Actual,2020-07-01,May 2021,2021-05-31,"January 29, 2021",Actual,2021-01-29,"January 29, 2021",Actual,2021-01-29,NA,Interventional,SILVERBULLET,NA,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms","Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms",Completed,NA,Phase 2,66,Actual,Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:14Z,2021-12-04T22:28:14Z,257
NCT04392219,NA,2020-04-29,2021-06-15,NA,2021-07-15,2020-05-15,2020-05-18,Actual,2021-07-15,2021-07-19,Actual,NA,NA,NA,2021-07-15,2021-07-19,Actual,"April 10, 2020",Actual,2020-04-10,July 2021,2021-07-31,"August 11, 2020",Actual,2020-08-11,"August 11, 2020",Actual,2020-08-11,NA,Interventional,NA,Safety population,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers","A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers",Completed,NA,Phase 1,130,Actual,"Ridgeback Biotherapeutics, LP",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:25Z,2021-12-04T22:28:25Z,200
NCT04390022,NA,2020-05-07,2020-12-09,NA,2020-12-10,2020-05-14,2020-05-15,Actual,2020-12-10,2020-12-17,Actual,NA,NA,NA,2020-12-10,2020-12-17,Actual,"July 31, 2020",Actual,2020-07-31,December 2020,2020-12-31,"October 9, 2020",Actual,2020-10-09,"September 17, 2020",Actual,2020-09-17,NA,Interventional,SAINT,NA,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission,Completed,NA,Phase 2,24,Actual,"Clinica Universidad de Navarra, Universidad de Navarra",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:26Z,2021-12-04T22:28:26Z,417
NCT04401202,NA,2020-05-21,2021-05-23,NA,2021-05-25,2020-05-22,2020-05-26,Actual,2021-05-25,2021-05-26,Actual,NA,NA,NA,2021-05-25,2021-05-26,Actual,"May 21, 2020",Actual,2020-05-21,May 2021,2021-05-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,NA,Nigella Sativa in COVID-19,"Effects of Nigella Sativa as a Treatment of Patients With Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study",Completed,NA,Phase 2,183,Actual,King Abdulaziz University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-04T22:28:17Z,2021-12-04T22:28:17Z,251
NCT04382066,NA,2020-05-07,2021-08-02,NA,2021-09-22,2020-05-08,2020-05-11,Actual,2021-09-22,2021-09-24,Actual,NA,NA,NA,2021-09-22,2021-09-24,Actual,"May 12, 2020",Actual,2020-05-12,September 2021,2021-09-30,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,NA,Interventional,APLICOV-PC,NA,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,"Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization",Completed,NA,Phase 1,46,Actual,PharmaMar,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Data of the final publication of the study will be shared upon request.,2021-12-04T22:28:30Z,2021-12-04T22:28:30Z,131
NCT04380688,NA,2020-05-07,2021-08-19,NA,2021-09-08,2020-05-07,2020-05-08,Actual,2021-09-08,2021-09-13,Actual,NA,NA,NA,2021-09-08,2021-09-13,Actual,"June 13, 2020",Actual,2020-06-13,September 2021,2021-09-30,"November 16, 2020",Actual,2020-11-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,CALAVI US,NA,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,62,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",2021-12-04T22:28:31Z,2021-12-04T22:28:31Z,145
NCT04401579,NA,2020-05-22,2021-02-25,NA,2021-04-22,2020-05-22,2020-05-26,Actual,2021-04-22,2021-04-26,Actual,NA,NA,NA,2021-04-22,2021-04-26,Actual,"May 8, 2020",Actual,2020-05-08,April 2020,2020-04-30,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)",Completed,NA,Phase 3,1033,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:18Z,2021-12-04T22:28:18Z,284
NCT04399980,NA,2020-05-21,2021-05-06,NA,2021-05-11,2020-05-21,2020-05-22,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"May 20, 2020",Actual,2020-05-20,May 2021,2021-05-31,"April 23, 2021",Actual,2021-04-23,"April 23, 2021",Actual,2021-04-23,NA,Interventional,NA,NA,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,NA,Phase 2,40,Actual,The Cleveland Clinic,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:20Z,2021-12-04T22:28:20Z,265
NCT04371419,NA,2020-04-28,2021-05-28,NA,2021-07-24,2020-04-28,2020-05-01,Actual,2021-07-24,2021-07-27,Actual,NA,NA,NA,2021-07-24,2021-07-27,Actual,"May 13, 2020",Actual,2020-05-13,July 2021,2021-07-31,"May 26, 2020",Actual,2020-05-26,"May 24, 2020",Actual,2020-05-24,NA,Interventional,NA,Any intervention was indeed an arm that included each sub arm of different types of message that we tested against a control and pre-specified in our study protocol and analysis plan to combine arms for analysis.,COVID-19 Health Messaging to Underserved Communities,COVID-19 Health Messaging to Underserved Communities,Completed,NA,Not Applicable,14267,Actual,"National Bureau of Economic Research, Inc.",NA,17,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Generally, social scientists post code and de-identified data when the findings are published","To be determined, if published alongside the paper data and code may be gated.",NA,Yes,"Generally, economists will post code and de-identified data when the findings are published",2021-12-04T22:28:34Z,2021-12-04T22:28:34Z,191
NCT04363736,NA,2020-04-21,2021-07-30,NA,2021-08-26,2020-04-24,2020-04-27,Actual,2021-08-26,2021-08-30,Actual,NA,NA,NA,2021-08-26,2021-08-30,Actual,"May 5, 2020",Actual,2020-05-05,August 2021,2021-08-31,"August 12, 2020",Actual,2020-08-12,"August 12, 2020",Actual,2020-08-12,NA,Interventional,MARIPOSA,NA,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,"A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia",Completed,NA,Phase 2,97,Actual,Hoffmann-La Roche,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-12-04T22:28:37Z,2021-12-04T22:28:37Z,158
NCT04358081,NA,2020-04-08,2021-03-08,NA,2021-10-07,2020-04-20,2020-04-22,Actual,2021-03-08,2021-03-17,Actual,NA,NA,NA,2021-10-07,2021-10-11,Actual,"May 1, 2020",Actual,2020-05-01,October 2021,2021-10-31,"July 27, 2020",Actual,2020-07-27,"July 27, 2020",Actual,2020-07-27,NA,Interventional,NA,Full Analysis Set (FAS) was comprised of all participants to whom study treatment had been assigned by randomization excluding one mis-randomized participant.,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,"A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease",Completed,NA,Phase 3,20,Actual,Novartis,NA,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-12-04T22:28:42Z,2021-12-04T22:28:42Z,116
NCT04356937,NA,2020-04-19,2021-06-23,NA,2021-07-23,2020-04-19,2020-04-22,Actual,2021-07-23,2021-07-27,Actual,NA,NA,NA,2021-07-23,2021-07-27,Actual,"April 20, 2020",Actual,2020-04-20,July 2021,2021-07-31,"August 27, 2020",Actual,2020-08-27,"July 13, 2020",Actual,2020-07-13,NA,Interventional,NA,All randomized patients,Efficacy of Tocilizumab on Patients With COVID-19,Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19,Completed,NA,Phase 3,243,Actual,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Request for IPD can be submitted to PI for review,2021-12-04T22:28:43Z,2021-12-04T22:28:43Z,192
NCT04365699,NA,2020-04-25,2021-09-01,NA,2021-09-10,2020-04-25,2020-04-28,Actual,2021-09-10,2021-09-16,Actual,NA,NA,NA,2021-09-10,2021-09-16,Actual,"April 8, 2020",Actual,2020-04-08,September 2021,2021-09-30,"January 31, 2021",Actual,2021-01-31,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NA,NA,Cardiovascular Effects of COVID-19,A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection,Completed,NA,Phase 2,81,Actual,NYU Langone Health,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Beginning 9 months and ending 36 months following article publication,Requests may be directed to Stuart.Katz@nyulangone.org.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to Stuart.Katz@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2021-12-04T22:28:38Z,2021-12-04T22:28:38Z,143
NCT04340557,NA,2020-04-06,2021-05-20,NA,2021-05-24,2020-04-08,2020-04-09,Actual,2021-05-24,2021-05-26,Actual,NA,NA,NA,2021-05-24,2021-05-26,Actual,"March 27, 2020",Actual,2020-03-27,May 2021,2021-05-31,"June 13, 2020",Actual,2020-06-13,"June 13, 2020",Actual,2020-06-13,NA,Interventional,NA,NA,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection,Completed,NA,Phase 4,31,Actual,Sharp HealthCare,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:52Z,2021-12-04T22:28:52Z,252
NCT04365153,NA,2020-04-24,2021-04-05,NA,2021-04-13,2020-04-24,2020-04-28,Actual,2021-04-13,2021-04-15,Actual,NA,NA,NA,2021-04-13,2021-04-15,Actual,"April 24, 2020",Actual,2020-04-24,April 2021,2021-04-30,"April 1, 2021",Actual,2021-04-01,"February 2, 2021",Actual,2021-02-02,NA,Interventional,NA,NA,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened Inflammation,Completed,NA,Phase 2,45,Actual,The Cleveland Clinic,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:38Z,2021-12-04T22:28:38Z,293
NCT04362137,NA,2020-04-22,2021-04-15,NA,2021-10-07,2020-04-22,2020-04-24,Actual,2021-05-28,2021-06-02,Actual,NA,NA,NA,2021-10-07,2021-10-11,Actual,"May 2, 2020",Actual,2020-05-02,October 2021,2021-10-31,"October 17, 2020",Actual,2020-10-17,"October 17, 2020",Actual,2020-10-17,NA,Interventional,RUXCOVID,NA,Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Completed,NA,Phase 3,432,Actual,Novartis,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-12-04T22:28:40Z,2021-12-04T22:28:40Z,116
NCT04346199,NA,2020-04-09,2021-09-08,NA,2021-09-15,2020-04-14,2020-04-15,Actual,2021-09-08,2021-09-13,Actual,NA,NA,NA,2021-09-15,2021-09-17,Actual,"June 12, 2020",Actual,2020-06-12,September 2021,2021-09-30,"November 17, 2020",Actual,2020-11-17,"November 17, 2020",Actual,2020-11-17,NA,Interventional,CALAVI,NA,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,177,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.,2021-12-04T22:28:49Z,2021-12-04T22:28:49Z,138
NCT04354870,NA,2020-04-16,2021-09-29,NA,2021-10-04,2020-04-16,2020-04-21,Actual,2021-10-04,2021-10-06,Actual,NA,NA,NA,2021-10-04,2021-10-06,Actual,"April 3, 2020",Actual,2020-04-03,October 2021,2021-10-31,"October 1, 2020",Actual,2020-10-01,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,NA,COVID-19 PrEP HCW HCQ Study,Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2,Completed,NA,Phase 2,130,Actual,NYU Langone Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Study internal to NYU at this time,2021-12-04T22:28:44Z,2021-12-04T22:28:44Z,119
NCT04338009,NA,2020-04-01,2021-01-28,NA,2021-04-07,2020-04-07,2020-04-08,Actual,2021-04-07,2021-04-09,Actual,NA,NA,NA,2021-04-07,2021-04-09,Actual,"March 31, 2020",Actual,2020-03-31,April 2021,2021-04-30,"August 20, 2020",Actual,2020-08-20,"August 20, 2020",Actual,2020-08-20,NA,Interventional,REPLACECOVID,NA,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019,Completed,NA,Not Applicable,152,Actual,University of Pennsylvania,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Not making it available,2021-12-04T22:28:54Z,2021-12-04T22:28:54Z,299
NCT04334876,NA,2020-04-02,2021-07-19,NA,2021-09-10,2020-04-02,2020-04-06,Actual,2021-09-10,2021-09-16,Actual,NA,NA,NA,2021-09-10,2021-09-16,Actual,"April 1, 2020",Actual,2020-04-01,September 2021,2021-09-30,"January 1, 2021",Actual,2021-01-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,COVID-Antibody,NA,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers and Candidacy for Convalescent Plasma Therapy/Prophylaxis,Completed,NA,Not Applicable,571,Actual,Indiana University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:57Z,2021-12-04T22:28:57Z,143
NCT04333225,NA,2020-04-01,2021-08-02,NA,2021-08-18,2020-04-02,2020-04-03,Actual,2021-08-18,2021-08-20,Actual,NA,NA,NA,2021-08-18,2021-08-20,Actual,"April 3, 2020",Actual,2020-04-03,May 2020,2020-05-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,NA,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures,Completed,NA,Phase 2,221,Actual,Baylor Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:58Z,2021-12-04T22:28:58Z,166
NCT04332991,NA,2020-03-31,2021-02-09,NA,2021-03-12,2020-03-31,2020-04-03,Actual,2021-03-12,2021-03-17,Actual,NA,NA,NA,2021-03-12,2021-03-17,Actual,"April 2, 2020",Actual,2020-04-02,March 2021,2021-03-31,"July 23, 2020",Actual,2020-07-23,"June 19, 2020",Actual,2020-06-19,NA,Interventional,ORCHID,NA,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,NA,Phase 3,479,Actual,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:58Z,2021-12-04T22:28:58Z,325
NCT04345653,NA,2020-04-08,2021-04-01,NA,2021-05-10,2020-04-13,2020-04-14,Actual,2021-05-05,2021-05-10,Actual,NA,NA,NA,2021-05-10,2021-05-12,Actual,"April 14, 2020",Actual,2020-04-14,May 2021,2021-05-31,"May 10, 2021",Actual,2021-05-10,"June 5, 2020",Actual,2020-06-05,NA,Interventional,NA,High risk healthcare providers,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers",Completed,NA,Phase 2,48,Actual,Hackensack Meridian Health,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:49Z,2021-12-04T22:28:49Z,266
NCT04343261,NA,2020-04-08,2020-09-01,NA,2020-09-22,2020-04-08,2020-04-13,Actual,2020-09-15,2020-09-17,Actual,NA,NA,NA,2020-09-22,2020-09-24,Actual,"April 10, 2020",Actual,2020-04-10,September 2020,2020-09-30,"August 13, 2020",Actual,2020-08-13,"July 23, 2020",Actual,2020-07-23,NA,Interventional,NA,NA,Convalescent Plasma in the Treatment of COVID 19,Convalescent Plasma in the Treatment of COVID 19,Completed,NA,Phase 2,48,Actual,Saint Francis Care,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:50Z,2021-12-04T22:28:50Z,496
NCT04343092,NA,2020-04-05,2020-06-11,NA,2020-11-02,2020-04-08,2020-04-13,Actual,2020-11-02,2020-11-04,Actual,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 18, 2020",Actual,2020-04-18,November 2020,2020-11-30,"June 1, 2020",Actual,2020-06-01,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,NA,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial),Completed,NA,Phase 1,16,Actual,University of Baghdad,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:51Z,2021-12-04T22:28:51Z,455
NCT04342663,NA,2020-04-08,2021-07-01,NA,2021-07-07,2020-04-08,2020-04-13,Actual,2021-07-07,2021-07-09,Actual,NA,NA,NA,2021-07-07,2021-07-09,Actual,"April 10, 2020",Actual,2020-04-10,July 2021,2021-07-31,"December 12, 2020",Actual,2020-12-12,"August 20, 2020",Actual,2020-08-20,NA,Interventional,STOP COVID,NA,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,NA,Phase 2,152,Actual,Washington University School of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:51Z,2021-12-04T22:28:51Z,208
NCT04328467,NA,2020-03-27,2021-06-25,NA,2021-06-30,2020-03-30,2020-03-31,Actual,2021-06-25,2021-06-30,Actual,NA,NA,NA,2021-06-30,2021-07-02,Actual,"April 6, 2020",Actual,2020-04-06,June 2021,2021-06-30,"July 13, 2020",Actual,2020-07-13,"July 13, 2020",Actual,2020-07-13,NA,Interventional,NA,NA,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1483,Actual,University of Minnesota,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-04T22:29:05Z,2021-12-04T22:29:05Z,215
NCT04327388,NA,2020-03-26,2021-04-28,NA,2021-05-11,2020-03-26,2020-03-31,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 28, 2020",Actual,2020-03-28,May 2021,2021-05-31,"September 2, 2020",Actual,2020-09-02,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,Analysis was performed on randomized population.,Sarilumab COVID-19,"An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",Completed,NA,Phase 3,420,Actual,Sanofi,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-12-04T22:29:05Z,2021-12-04T22:29:05Z,265
NCT04335136,NA,2020-04-01,2021-06-07,NA,2021-07-29,2020-04-03,2020-04-06,Actual,2021-07-29,2021-08-02,Actual,NA,NA,NA,2021-07-29,2021-08-02,Actual,"April 30, 2020",Actual,2020-04-30,July 2021,2021-07-31,"December 26, 2020",Actual,2020-12-26,"December 26, 2020",Actual,2020-12-26,NA,Interventional,APN01-COVID-19,All randomized patients who received at least 1 dose of investigational medicinal product (IMP).,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Completed,NA,Phase 2,185,Actual,Apeiron Biologics,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:56Z,2021-12-04T22:28:56Z,186
NCT04320615,NA,2020-03-23,2021-06-23,NA,2021-06-28,2020-03-23,2020-03-25,Actual,2021-06-28,2021-06-30,Actual,NA,NA,NA,2021-06-28,2021-06-30,Actual,"April 3, 2020",Actual,2020-04-03,June 2021,2021-06-30,"July 28, 2020",Actual,2020-07-28,"June 24, 2020",Actual,2020-06-24,NA,Interventional,COVACTA,NA,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 3,452,Actual,Hoffmann-La Roche,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform https://vivli.org.

Further details on Roche's criteria for eligible studies are available here: https://vivli.org.

For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm",2021-12-04T22:29:09Z,2021-12-04T22:29:09Z,217
NCT04315298,NA,2020-03-15,2021-07-23,NA,2021-09-16,2020-03-17,2020-03-19,Actual,2021-09-16,2021-09-23,Actual,NA,NA,NA,2021-09-16,2021-09-23,Actual,"March 18, 2020",Actual,2020-03-18,September 2021,2021-09-30,"September 2, 2020",Actual,2020-09-02,"July 24, 2020",Actual,2020-07-24,NA,Interventional,NA,NA,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19",Completed,NA,Phase 2/Phase 3,1912,Actual,Regeneron Pharmaceuticals,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All IPD that underlie publicly available results will be considered for sharing,2021-12-04T22:29:12Z,2021-12-04T22:29:12Z,137
NCT04308668,NA,2020-03-11,2021-04-26,NA,2021-05-11,2020-03-11,2020-03-16,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 17, 2020",Actual,2020-03-17,May 2021,2021-05-31,"May 20, 2020",Actual,2020-05-20,"May 20, 2020",Actual,2020-05-20,NA,Interventional,COVID-19 PEP,NA,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1312,Actual,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,at time of publication,To be publicly provided. Please register at the website to receive the dataset.,https://covidpep.umn.edu/data,Yes,De-identified dataset will be available within 1 month of publication.,2021-12-04T22:29:18Z,2021-12-04T22:29:18Z,265
NCT04280705,NA,2020-02-20,2020-09-16,NA,2020-12-05,2020-02-20,2020-02-21,Actual,2020-09-22,2020-09-25,Actual,NA,NA,NA,2020-12-05,2020-12-09,Actual,"February 21, 2020",Actual,2020-02-21,April 2020,2020-04-30,"May 21, 2020",Actual,2020-05-21,"May 21, 2020",Actual,2020-05-21,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,1062,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:29:29Z,2021-12-04T22:29:29Z,422
NCT04292899,NA,2020-02-28,2020-12-15,NA,2020-12-15,2020-02-28,2020-03-03,Actual,2020-12-15,2020-12-31,Actual,NA,NA,NA,2020-12-15,2020-12-31,Actual,"March 6, 2020",Actual,2020-03-06,December 2020,2020-12-31,"June 30, 2020",Actual,2020-06-30,"April 9, 2020",Actual,2020-04-09,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment.

Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into part B of the study and received at least 1 dose of study treatment.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe COVID-19,Completed,NA,Phase 3,4891,Actual,Gilead Sciences,NA,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-12-04T22:29:24Z,2021-12-04T22:29:24Z,412
NCT04292730,NA,2020-02-28,2020-12-15,NA,2021-01-21,2020-02-28,2020-03-03,Actual,2021-01-21,2021-01-26,Actual,NA,NA,NA,2021-01-21,2021-01-26,Actual,"March 15, 2020",Actual,2020-03-15,January 2021,2021-01-31,"June 26, 2020",Actual,2020-06-26,"April 29, 2020",Actual,2020-04-29,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment or completed the Day 1 visit (SOC only group).

Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into Part B of the study and received at least 1 dose of study drug.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment,Completed,NA,Phase 3,1113,Actual,Gilead Sciences,NA,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-12-04T22:29:25Z,2021-12-04T22:29:25Z,375
NCT04944368,NA,2021-06-19,NA,NA,2022-01-02,2021-06-28,2021-06-29,Actual,NA,NA,NA,NA,NA,NA,2022-01-02,2022-01-04,Estimate,"May 30, 2021",Actual,2021-05-30,January 2022,2022-01-31,"December 30, 2021",Actual,2021-12-30,"July 19, 2021",Actual,2021-07-19,NA,Interventional,NA,NA,Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen),"A Phase II, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)",Completed,NA,Phase 2,400,Actual,Cinnagen,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T19:49:17Z,2022-01-04T19:49:17Z,29
NCT04858542,NA,2021-03-22,NA,NA,2021-12-31,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-12-31,2022-01-04,Estimate,"February 26, 2021",Actual,2021-02-26,December 2021,2021-12-31,"September 1, 2021",Actual,2021-09-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,NA,NA,Evaluating the Impact of Vocal Health Education on Mask-wearing Workers During COVID-19,Developing Educational Modules to Improve Communication and Vocal Health Among Mask-wearing Healthcare Workers: Phase 2 of the COVID-19 Critical Community Challenge Grant,Completed,NA,Not Applicable,5,Actual,University of Cincinnati,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T19:50:48Z,2022-01-04T19:50:48Z,31
NCT04279197,NA,2020-02-15,NA,NA,2021-12-12,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-12-12,2022-01-03,Actual,"April 23, 2020",Actual,2020-04-23,December 2021,2021-12-31,"March 24, 2021",Actual,2021-03-24,"March 24, 2021",Actual,2021-03-24,NA,Interventional,NA,NA,Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu,Efficacy and Safety of Fuzheng Huayu Tablets in Post-COVID-19 Patients With Pulmonary Inflammation and Fibrosis : A Multicenter Double-blind Randomized Controlled Trial,Completed,NA,Phase 2,142,Actual,ShuGuang Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T19:56:53Z,2022-01-04T19:56:53Z,50
NCT05178160,NA,2021-12-31,NA,NA,2022-01-04,2022-01-04,2022-01-05,Estimate,NA,NA,NA,NA,NA,NA,2022-01-04,2022-01-05,Estimate,"January 1, 2021",Actual,2021-01-01,January 2022,2022-01-31,"December 31, 2021",Actual,2021-12-31,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,Positive End Espiratory Pressure Trial in Coronavirus Disease 19 Treated With Continuous Positive Airway Pressure,Lung Ultrasound-Guided PEEP Titration Versus Standard Protocol in Patients With COVID-19 ARDS Treated With CPAP: a Single Center Prospective Trial,Completed,NA,Not Applicable,60,Actual,Santa Maria delle Grazie Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-06T19:11:55Z,2022-01-06T19:11:55Z,27
NCT04706403,NA,2021-01-05,2021-12-20,NA,2022-01-03,2021-01-11,2021-01-12,Actual,2022-01-03,2022-01-05,Estimate,NA,NA,NA,2022-01-03,2022-01-05,Estimate,"January 12, 2021",Actual,2021-01-12,January 2022,2022-01-31,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,Views on COVID-19 and Vaccination,"If We Build It, Will They Come? A Pilot Study to Develop and Test Messages to Maximize Uptake of Coronavirus Vaccine When Available",Completed,NA,Not Applicable,756,Actual,"University of Massachusetts, Worcester",NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-06T19:19:02Z,2022-01-06T19:19:02Z,28
NCT04661839,NA,2020-12-09,NA,NA,2021-12-15,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2021-12-15,2022-01-06,Estimate,"December 24, 2020",Actual,2020-12-24,December 2021,2021-12-31,"July 27, 2021",Actual,2021-07-27,"July 27, 2021",Actual,2021-07-27,NA,Interventional,NA,NA,A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults,"A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Evaluate Safety and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) Administered as a Single Dose Regimen to Healthy Adults",Completed,NA,Phase 1,28,Actual,Emergent BioSolutions,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Study Protocol, Statistical Analysis Plan, and Informed Consent Form (redacted) to be shared.",2022-01-07T11:44:21Z,2022-01-07T11:44:21Z,47
NCT04523181,NA,2020-08-19,NA,NA,2022-01-04,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2022-01-04,2022-01-06,Estimate,"October 8, 2020",Actual,2020-10-08,August 2021,2021-08-31,"December 23, 2021",Actual,2021-12-23,"December 23, 2021",Actual,2021-12-23,NA,Interventional,NA,NA,Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients,"A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19",Completed,NA,Phase 2,124,Actual,Golden Biotechnology Corporation,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-07T11:45:42Z,2022-01-07T11:45:42Z,27
NCT05185804,NA,2021-12-29,NA,NA,2022-01-10,2022-01-10,2022-01-11,Estimate,NA,NA,NA,NA,NA,NA,2022-01-10,2022-01-11,Estimate,"February 8, 2021",Actual,2021-02-08,December 2021,2021-12-31,"October 29, 2021",Actual,2021-10-29,"August 6, 2021",Actual,2021-08-06,NA,Interventional,NA,NA,Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19,Multicenter Randomized Prospective Open-label Clinical Trial of the Safety and Efficacy of Amidine Hydrochloride (DD217) in Prevention of Thrombotic Complications in Hospitalized Patients Diagnosed With COVID-19,Completed,NA,Phase 3,399,Actual,PharmaDiall Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-11T22:59:25Z,2022-01-11T22:59:25Z,21
NCT05185687,NA,2022-01-07,NA,NA,2022-01-07,2022-01-07,2022-01-11,Estimate,NA,NA,NA,NA,NA,NA,2022-01-07,2022-01-11,Estimate,"January 4, 2022",Actual,2022-01-04,January 2022,2022-01-31,"January 6, 2022",Actual,2022-01-06,"January 6, 2022",Actual,2022-01-06,NA,Interventional,NA,NA,Public Support for COVID-19 Test Allocation,"Race, Status, Vaccines, Tests, and Place: Public Attitudes and Support for Equitable COVID-19 Vaccine and Test Allocation",Completed,NA,Not Applicable,2019,Actual,University of Pennsylvania,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Only de-identified individual participant data will be shared by Harris Insights & Analytics to the research team. Each participant will have a unique identifier to protect their confidentiality. Only authorized research personnel will have access to the data which will be maintained on encrypted hard-drives. Individual participant data may be made available to other researchers in an open-access repository.,2022-01-11T22:59:33Z,2022-01-11T22:59:33Z,24
NCT05185284,NA,2022-01-07,NA,NA,2022-01-07,2022-01-07,2022-01-11,Estimate,NA,NA,NA,NA,NA,NA,2022-01-07,2022-01-11,Estimate,"August 11, 2021",Actual,2021-08-11,January 2022,2022-01-31,"December 30, 2021",Actual,2021-12-30,"December 30, 2021",Actual,2021-12-30,NA,Interventional,NA,NA,Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19,"Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of AREPLIVIRÂ® (Favipiravir) for Parenteral Administration (PROMOMED RUS LLC, Russia) in Hospitalized Patients With COVID-19",Completed,NA,Phase 3,217,Actual,"Promomed, LLC",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,January 2022,NA,NA,Yes,NA,2022-01-11T22:59:53Z,2022-01-11T22:59:53Z,24
NCT05157230,NA,2021-12-11,NA,NA,2022-01-08,2021-12-11,2021-12-14,Actual,NA,NA,NA,NA,NA,NA,2022-01-08,2022-01-11,Estimate,"September 1, 2021",Actual,2021-09-01,January 2022,2022-01-31,"December 25, 2021",Actual,2021-12-25,"December 15, 2021",Actual,2021-12-15,NA,Interventional,NA,NA,Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 Vaccination,"Evaluation of Deltoid Muscle Exercises on Injection Site and Arm Pain After Pfizer - BioNTech (BNT162b2) COVID - 19 Vaccination, A Randomized Controlled Study",Completed,NA,Not Applicable,401,Actual,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-11T23:04:04Z,2022-01-11T23:04:04Z,23
NCT04412785,NA,2020-06-01,NA,NA,2022-01-07,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2022-01-07,2022-01-11,Estimate,"June 30, 2020",Actual,2020-06-30,January 2022,2022-01-31,"October 25, 2021",Actual,2021-10-25,"October 25, 2021",Actual,2021-10-25,NA,Interventional,NA,NA,Cyclosporine in Patients With Moderate COVID-19,Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19,Completed,NA,Phase 1,11,Actual,University of Pennsylvania,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2022-01-11T23:22:44Z,2022-01-11T23:22:44Z,24
NCT04377711,NA,2020-05-05,2021-12-08,NA,2022-01-06,2020-05-05,2020-05-06,Actual,2022-01-04,2022-01-06,Actual,NA,NA,NA,2022-01-06,2022-01-11,Estimate,"June 8, 2020",Actual,2020-06-08,January 2022,2022-01-31,"January 5, 2021",Actual,2021-01-05,"January 5, 2021",Actual,2021-01-05,NA,Interventional,NA,NA,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection",Completed,NA,Phase 3,400,Actual,Covis Pharma S.Ã .r.l.,NA,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-11T23:23:23Z,2022-01-11T23:23:23Z,25
NCT04560881,NA,2020-09-16,NA,NA,2022-01-11,2020-09-21,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2022-01-11,2022-01-12,Estimate,"September 16, 2020",Actual,2020-09-16,January 2022,2022-01-31,"December 13, 2021",Actual,2021-12-13,"December 13, 2021",Actual,2021-12-13,NA,Interventional,NA,NA,"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years",Completed,NA,Phase 3,3000,Actual,Laboratorio Elea Phoenix S.A.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-13T12:55:27Z,2022-01-13T12:55:27Z,20
NCT04668950,NA,2020-12-11,NA,NA,2022-01-12,2020-12-11,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2022-01-12,2022-01-13,Estimate,"December 22, 2020",Actual,2020-12-22,January 2022,2022-01-31,"September 28, 2021",Actual,2021-09-28,"September 28, 2021",Actual,2021-09-28,NA,Interventional,NA,NA,Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2),"Fluvoxamine for Early Treatment of Covid-19: a Fully-remote, Randomized Placebo Controlled Trial",Completed,NA,Phase 3,683,Actual,Washington University School of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-14T12:10:59Z,2022-01-14T12:10:59Z,19
NCT04494646,NA,2020-07-29,2022-01-07,NA,2022-01-11,2020-07-29,2020-07-31,Actual,2022-01-07,2022-01-12,Actual,NA,NA,NA,2022-01-11,2022-01-13,Estimate,"September 8, 2020",Actual,2020-09-08,January 2022,2022-01-31,"January 8, 2021",Actual,2021-01-08,"January 8, 2021",Actual,2021-01-08,NA,Interventional,NA,NA,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),"BARCONA: A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)",Completed,NA,Phase 2,40,Actual,NYU Langone Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data will become available beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Sripal.Bangalore@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices) will be shared upon reasonable request.",2022-01-14T12:13:38Z,2022-01-14T12:13:38Z,20
NCT04535674,NA,2020-08-31,NA,NA,2022-01-13,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2022-01-13,2022-01-14,Estimate,"October 9, 2020",Actual,2020-10-09,July 2021,2021-07-31,"December 21, 2021",Actual,2021-12-21,"October 29, 2021",Actual,2021-10-29,NA,Interventional,ASUNCTIS,NA,Asunercept in Patients With Severe COVID-19,"A Multicenter, Randomised, Controlled, Open Label Trial on the Efficacy and Safety of Asunercept for Patients With Severe COVID-19 Disease",Completed,NA,Phase 2,438,Actual,Apogenix AG,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-16T02:38:08Z,2022-01-16T02:38:08Z,18
NCT04497415,NA,2020-08-02,2021-12-24,NA,2022-01-12,2020-08-02,2020-08-04,Actual,2021-12-24,2022-01-11,Actual,NA,NA,NA,2022-01-12,2022-01-14,Estimate,"October 21, 2020",Actual,2020-10-21,January 2022,2022-01-31,"January 30, 2021",Actual,2021-01-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,NA,The COVID-19 and Healthcare Workers: An Active Intervention,The COVID-19 and Healthcare Workers: An Active Intervention,Completed,NA,Not Applicable,350,Actual,"Research Foundation for Mental Hygiene, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-16T02:38:30Z,2022-01-16T02:38:30Z,19
NCT04493242,NA,2020-07-29,NA,NA,2022-01-13,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2022-01-13,2022-01-14,Estimate,"September 24, 2020",Actual,2020-09-24,January 2022,2022-01-31,"May 22, 2021",Actual,2021-05-22,"May 1, 2021",Actual,2021-05-01,NA,Interventional,EXIT-COVID19,NA,Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Phase II Clinical Trial,Completed,NA,Phase 2,120,Actual,"Direct Biologics, LLC",NA,3,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-16T02:38:36Z,2022-01-16T02:38:36Z,18
NCT04647604,NA,2020-06-12,NA,NA,2022-01-04,2020-11-27,2020-12-01,Actual,NA,NA,NA,NA,NA,NA,2022-01-04,2022-01-05,Estimate,"June 23, 2020",Actual,2020-06-23,January 2022,2022-01-31,"July 7, 2021",Actual,2021-07-07,"January 5, 2021",Actual,2021-01-05,NA,Interventional,NA,NA,Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -,"Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids - A Single-blind, Randomized, Placebo-controlled Feasibility Study",Completed,NA,Phase 2,23,Actual,Karolinska University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 9 months following article publication and finishing 36 months following article publication.,Study protocol will be published. Investigators interested in data should contact the principal investigator.,NA,Yes,"Individual participant data that underlie the results reported will be shared, after deidentification, with researchers who provide a methodologically sound proposal.",2022-01-06T19:19:32Z,2022-01-06T19:19:32Z,27
NCT04389333,NA,2020-05-09,2021-12-20,NA,2022-01-03,2020-05-14,2020-05-15,Actual,2021-12-31,2022-01-04,Actual,NA,NA,NA,2022-01-03,2022-01-05,Estimate,"March 26, 2020",Actual,2020-03-26,December 2021,2021-12-31,"May 20, 2020",Actual,2020-05-20,"April 26, 2020",Actual,2020-04-26,NA,Interventional,NA,"From March 26, 2020 to April 26, 2020, 40 patients (19 men and 21 women) were enrolled and included in the analysis. Of them, 20 accepted MCE and 20 underwent ncMCE according to the random number table.",Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,"Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic: a Prospective, Open-label, Pilot, Randomized Trial",Completed,NA,Not Applicable,40,Actual,Changhai Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-06T19:22:09Z,2022-01-06T19:22:09Z,28
NCT05184127,NA,2022-01-07,NA,NA,2022-01-07,2022-01-07,2022-01-11,Estimate,NA,NA,NA,NA,NA,NA,2022-01-07,2022-01-11,Estimate,"April 27, 2021",Actual,2021-04-27,January 2022,2022-01-31,"September 7, 2021",Actual,2021-09-07,"September 7, 2021",Actual,2021-09-07,NA,Interventional,NA,NA,Evaluation of Safety & Efficacy of MIR 19 Â® Inhalation Solution in Patients With Moderate COVID-19,Open Multicenter Controlled Clinical Trial to Evaluate Safety and Efficacy of Aerosolized MIR 19 Â® Inhalation in Patients With Moderate COVID-19 Who Did Not Require Treatment in the Intensive Care Unit.,Completed,NA,Phase 2,156,Actual,National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-11T23:00:54Z,2022-01-11T23:00:54Z,24
NCT05065879,NA,2021-09-28,NA,NA,2022-01-05,2021-10-01,2021-10-04,Actual,NA,NA,NA,NA,NA,NA,2022-01-05,2022-01-10,Actual,"October 5, 2021",Actual,2021-10-05,January 2022,2022-01-31,"January 5, 2022",Actual,2022-01-05,"January 5, 2022",Actual,2022-01-05,NA,Interventional,NA,NA,Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes,A Post-marketing Clinical Study of the Inactivated SARS-CoV-2 Vaccine (Vero Cells) (Produced in Beijing): Immunogenicity and Safety Assessments in Patients With Hypertension and/or Diabetes,Completed,NA,Phase 4,1440,Actual,China National Biotec Group Company Limited,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-11T23:08:00Z,2022-01-11T23:08:00Z,26
NCT04602312,NA,2020-10-19,NA,NA,2022-01-10,2020-10-22,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2022-01-10,2022-01-11,Estimate,"October 28, 2020",Actual,2020-10-28,January 2022,2022-01-31,"September 26, 2021",Actual,2021-09-26,"September 26, 2021",Actual,2021-09-26,NA,Interventional,NA,NA,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Healthy Sample),"Online RCT Comparing the Effects of Mindfulness, Sham Mindfulness and Book Listening Control on Coronavirus-related Catastrophizing in Adults",Completed,NA,Not Applicable,744,Actual,The University of Queensland,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately following publication up and for a further 10 years .,"Investigators whose proposed use of the data has been approved by an independent review committee. Initial contact should be directed to the contact person for scientific enquiries (Mr Jonathan Davies, jonathan.davies@uq.edu.au).

Note: Requestors will need to sign a data access agreement.",https://sites.google.com/view/uqcovidmeditation,Yes,"All of the individual trial-related participant data collected during the trial, after de-identification.",2022-01-11T23:19:02Z,2022-01-11T23:19:02Z,21
NCT04602286,NA,2020-10-19,NA,NA,2022-01-10,2020-10-22,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2022-01-10,2022-01-11,Estimate,"October 28, 2020",Actual,2020-10-28,October 2020,2020-10-31,"September 28, 2021",Actual,2021-09-28,"September 28, 2021",Actual,2021-09-28,NA,Interventional,NA,NA,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample),"An Online Randomized Controlled Trial Comparing the Effects of Mindfulness, Sham Mindfulness and Book Listening Control on Pain Experience in Adults With Recurrent and Chronic Pain",Completed,NA,Not Applicable,373,Actual,The University of Queensland,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately following publication up and for a further 10 years .,"Investigators whose proposed use of the data has been approved by an independent review committee. Initial contact should be directed to the contact person for scientific enquiries (Mr Jonathan Davies, jonathan.davies@uq.edu.au).

Note: Requestors will need to sign a data access agreement.",https://sites.google.com/view/uqcovidmeditation,Yes,"All of the individual trial-related participant data collected during the trial, after de-identification.",2022-01-11T23:19:03Z,2022-01-11T23:19:03Z,21
NCT04449276,NA,2020-06-18,NA,NA,2021-12-22,2020-06-23,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2021-12-22,2022-01-11,Estimate,"June 18, 2020",Actual,2020-06-18,July 2021,2021-07-31,"December 21, 2021",Actual,2021-12-21,"December 21, 2021",Actual,2021-12-21,NA,Interventional,NA,NA,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","COVID-19: A Phase 1, Partially Blind, Placebo-controlled, Dose Escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults",Completed,NA,Phase 1,280,Actual,CureVac AG,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-11T23:22:05Z,2022-01-11T23:22:05Z,40
NCT04386616,NA,2020-05-11,2021-12-16,NA,2022-01-05,2020-05-12,2020-05-13,Actual,2022-01-05,2022-01-10,Actual,NA,NA,NA,2022-01-05,2022-01-10,Actual,"June 2, 2020",Actual,2020-06-02,January 2022,2022-01-31,"February 12, 2021",Actual,2021-02-12,"January 8, 2021",Actual,2021-01-08,NA,Interventional,COVASTIL,"Modified Intent-to-Treat (mITT) Population: all participants randomized in the study who received at least one dose of study drug, with participants grouped according to the treatment assigned at randomization.",A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 2,396,Actual,"Genentech, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).

For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2022-01-11T23:23:13Z,2022-01-11T23:23:13Z,26
NCT04460183,NA,2020-07-03,NA,NA,2022-01-11,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2022-01-11,2022-01-12,Estimate,"July 29, 2020",Actual,2020-07-29,January 2022,2022-01-31,"May 21, 2021",Actual,2021-05-21,"April 24, 2021",Actual,2021-04-24,NA,Interventional,NA,NA,A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19,"An Open-label, Adaptive Randomized, Controlled Multicenter Study to Evaluate the Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19 WHO Grade 3&4 (NOCoV2)",Completed,NA,Phase 2/Phase 3,19,Actual,Thirty Respiratory Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-13T12:56:16Z,2022-01-13T12:56:16Z,20
NCT04410562,NA,2020-05-26,NA,NA,2022-01-11,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2022-01-11,2022-01-12,Estimate,"May 13, 2020",Actual,2020-05-13,April 2021,2021-04-30,"October 31, 2021",Actual,2021-10-31,"June 30, 2021",Actual,2021-06-30,NA,Interventional,COVID-Preg,NA,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum,Completed,NA,Phase 3,129,Actual,Barcelona Institute for Global Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,By the end of study,NA,NA,Yes,It would be shared at time of publication.,2022-01-13T12:56:51Z,2022-01-13T12:56:51Z,20
NCT04700137,NA,2021-01-05,NA,NA,2022-01-12,2021-01-05,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2022-01-12,2022-01-13,Estimate,"January 18, 2021",Actual,2021-01-18,January 2022,2022-01-31,"January 6, 2022",Actual,2022-01-06,"January 6, 2022",Actual,2022-01-06,NA,Interventional,MHAPPS,NA,"Mental Health Among Patients, Providers, and Staff During the COVID-19 Era","Investigating the Mental Health Impact of COVID-19 and Comparing the Effectiveness of Two Caring Contact Interventions on Patients, Providers, and Staff of St. Luke's Health System",Completed,NA,Not Applicable,666,Actual,"St. Luke's Health System, Boise, Idaho",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,5 years following the completion of the primary endpoint,"Data from this trial may be requested by other researchers 5 years after the completion of the primary endpoint by contacting the PI. The PI will ensure all mechanisms used to share data will include proper plans and safeguards for the protection of privacy, confidentiality, and security for data dissemination and reuse (e.g., all data will be thoroughly de-identified and will not be traceable to a specific study participant).",NA,Yes,Data from this trial may be requested from other researchers 5 years after the completion of the primary endpoint by contacting the PIs.,2022-01-14T12:10:23Z,2022-01-14T12:10:23Z,19
NCT04517123,NA,2020-08-14,NA,NA,2022-01-12,2020-08-14,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2022-01-12,2022-01-13,Estimate,"September 1, 2020",Actual,2020-09-01,October 2021,2021-10-31,"December 31, 2021",Actual,2021-12-31,"December 31, 2021",Actual,2021-12-31,NA,Interventional,PRONE,NA,"Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study","Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study",Completed,NA,Not Applicable,35,Actual,Johns Hopkins University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-14T12:13:26Z,2022-01-14T12:13:26Z,19
NCT04508075,NA,2020-08-07,NA,NA,2021-12-27,2020-08-08,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-12-27,2022-01-13,Estimate,"August 10, 2020",Actual,2020-08-10,December 2021,2021-12-31,"August 31, 2021",Actual,2021-08-31,"January 9, 2021",Actual,2021-01-09,NA,Interventional,COVID-19,NA,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine","A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia",Completed,NA,Phase 3,1620,Actual,PT Bio Farma,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-14T12:13:28Z,2022-01-14T12:13:28Z,35
NCT05197582,NA,2022-01-11,NA,NA,2022-01-14,2022-01-14,2022-01-19,Estimate,NA,NA,NA,NA,NA,NA,2022-01-14,2022-01-19,Estimate,"January 1, 2021",Actual,2021-01-01,January 2022,2022-01-31,"September 1, 2021",Actual,2021-09-01,"June 1, 2021",Actual,2021-06-01,NA,Interventional,NA,NA,The Effect of Telemonitoring on Anxiety and Quality of Life in Patients in COVID 19 Quarantine,The Effect of Tele-Health Application on Anxiety Level and Quality of Life of Patients in COVID-19 Quarantine: A Quasi-experimental Study,Completed,NA,Not Applicable,56,Actual,Yuksek Ihtisas University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-20T10:51:55Z,2022-01-20T10:51:55Z,17
NCT05035186,NA,2021-09-02,NA,NA,2022-01-14,2021-09-02,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2022-01-14,2022-01-18,Actual,"March 21, 2021",Actual,2021-03-21,January 2022,2022-01-31,"November 30, 2021",Actual,2021-11-30,"September 30, 2021",Actual,2021-09-30,NA,Interventional,NA,NA,Efficacy of Clarithromycin and Flouroquinolones Based Regimens in H.Pylori Eradication in Covid-19 Era,Efficacy of Clarithromycin and Flouroquinolones Based Regimens in H.Pylori Eradication in Covid-19 Era: a Randomized Controlled Trial,Completed,NA,Not Applicable,233,Actual,Alexandria University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2022-01-20T11:01:02Z,2022-01-20T11:01:02Z,17
NCT05032950,NA,2021-08-27,NA,NA,2022-01-18,2021-08-27,2021-09-02,Actual,NA,NA,NA,NA,NA,NA,2022-01-18,2022-01-19,Estimate,"September 17, 2021",Actual,2021-09-17,January 2022,2022-01-31,"December 9, 2021",Actual,2021-12-09,"December 9, 2021",Actual,2021-12-09,NA,Interventional,NA,NA,Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants,"COVID-19: A PHASE 1, OPEN-LABEL, 3-TREATMENT, 6-SEQUENCE, 3-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF PF-07321332/RITONAVIR AND RITONAVIR ON THE PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY PARTICIPANTS.",Completed,NA,Phase 1,12,Actual,Pfizer,NA,3,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2022-01-20T11:01:05Z,2022-01-20T11:01:05Z,13
NCT04878055,NA,2021-04-30,NA,NA,2022-01-14,2021-05-06,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2022-01-14,2022-01-18,Actual,"February 14, 2021",Actual,2021-02-14,January 2022,2022-01-31,"October 31, 2021",Actual,2021-10-31,"September 30, 2021",Actual,2021-09-30,NA,Interventional,NA,NA,Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.,"A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 3,312,Actual,DompÃ© Farmaceutici S.p.A,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-20T11:04:53Z,2022-01-20T11:04:53Z,17
NCT04546841,NA,2020-08-26,NA,NA,2022-01-14,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2022-01-14,2022-01-18,Actual,"November 27, 2020",Actual,2020-11-27,August 2021,2021-08-31,"December 2, 2021",Actual,2021-12-02,"September 30, 2021",Actual,2021-09-30,NA,Interventional,pVAC,NA,Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,P-pVAC-SARS-CoV-2: Phase I Single-center Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,Completed,NA,Phase 1,36,Actual,University Hospital Tuebingen,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-20T11:11:13Z,2022-01-20T11:11:13Z,17
NCT04572399,NA,2020-09-28,2021-09-22,NA,2022-01-13,2020-09-29,2020-10-01,Actual,2022-01-13,2022-01-18,Actual,NA,NA,NA,2022-01-13,2022-01-18,Actual,"October 30, 2020",Actual,2020-10-30,January 2022,2022-01-31,"December 28, 2020",Actual,2020-12-28,"December 28, 2020",Actual,2020-12-28,NA,Interventional,NA,NA,UVA Light Device to Treat COVID-19,Respiratory Application of a Novel Ultraviolet Light Delivery Device for Patients Infected With COVID-19: A Pilot Study,Completed,NA,Not Applicable,5,Actual,Cedars-Sinai Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2022-01-20T11:10:53Z,2022-01-20T11:10:53Z,18
NCT04530409,NA,2020-08-24,NA,NA,2022-01-03,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2022-01-03,2022-01-18,Actual,"March 20, 2021",Actual,2021-03-20,January 2022,2022-01-31,"December 15, 2021",Actual,2021-12-15,"November 1, 2021",Actual,2021-11-01,NA,Interventional,NA,NA,Timing of Corticosteroids in COVID-19,Timing of Corticosteroids in COVID-19,Completed,NA,Phase 4,752,Actual,ClinAmygate,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-20T11:11:28Z,2022-01-20T11:11:28Z,28
NCT04583592,NA,2020-10-07,2021-12-14,NA,2022-01-13,2020-10-08,2020-10-12,Actual,2022-01-13,2022-01-18,Actual,NA,NA,NA,2022-01-13,2022-01-18,Actual,"November 9, 2020",Actual,2020-11-09,January 2022,2022-01-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,The Intent-to-Treat population includes all subjects who were randomized. [Note: Subjects may have more than one risk factor upon entry into study.],Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for Treatment of COVID-19 in Outpatients",Completed,NA,Phase 2,295,Actual,Sagent Pharmaceuticals Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-20T11:10:36Z,2022-01-20T11:10:36Z,18
NCT04495816,NA,2020-07-30,NA,NA,2022-01-14,2020-07-30,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2022-01-14,2022-01-19,Estimate,"July 15, 2020",Actual,2020-07-15,January 2022,2022-01-31,"December 31, 2021",Actual,2021-12-31,"December 31, 2021",Actual,2021-12-31,NA,Interventional,NA,NA,COVID-19 Anosmia Study,COVID-19 Anosmia Study,Completed,NA,Phase 2,117,Actual,Icahn School of Medicine at Mount Sinai,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-20T11:12:00Z,2022-01-20T11:12:00Z,17
NCT04424212,NA,2020-06-04,NA,NA,2022-01-15,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2022-01-15,2022-01-19,Estimate,"June 10, 2020",Actual,2020-06-10,January 2022,2022-01-31,"October 1, 2021",Actual,2021-10-01,"September 10, 2021",Actual,2021-09-10,NA,Interventional,NA,NA,ICBT for Mental Health Problems Related to the Coronavirus Pandemic,CoronaCope - Internet-based Cognitive Behavioural Therapy for Adults Suffering From Mental Health Problems Related to the Coronavirus Pandemic,Completed,NA,Not Applicable,76,Actual,Linkoeping University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-20T11:12:47Z,2022-01-20T11:12:47Z,16
NCT04361396,NA,2020-04-22,NA,NA,2022-01-14,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2022-01-14,2022-01-18,Actual,"June 16, 2020",Actual,2020-06-16,January 2022,2022-01-31,"December 16, 2021",Actual,2021-12-16,"December 16, 2021",Actual,2021-12-16,NA,Interventional,LAPTRANSCOV,NA,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum During an Emergency Laparoscopy Conducted on Confirmed or Suspected COVID-19 Patients,Completed,NA,Not Applicable,17,Actual,Centre Hospitalier RenÃ© Dubos,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-20T11:13:51Z,2022-01-20T11:13:51Z,17
NCT05178225,NA,2022-01-03,NA,NA,2022-01-04,2022-01-03,2022-01-05,Actual,NA,NA,NA,NA,NA,NA,2022-01-04,2022-01-20,Estimate,"May 1, 2021",Actual,2021-05-01,January 2022,2022-01-31,"January 1, 2022",Actual,2022-01-01,"June 30, 2021",Actual,2021-06-30,NA,Interventional,SpaCOVID,NA,"Spa Rehabilitation, Antioxidant and Bioenergetic Supportive Treatment of Patients With Post-Covid-19 Syndrome","Spa Rehabilitation, Antioxidant and Bioenergetic Supportive Treatment of Patients With Post-Covid-19 Syndrome",Completed,NA,Not Applicable,51,Actual,Comenius University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-21T12:06:03Z,2022-01-21T12:06:03Z,27
NCT04872686,NA,2021-04-26,NA,NA,2022-01-19,2021-05-02,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2022-01-19,2022-01-20,Estimate,"April 10, 2021",Actual,2021-04-10,January 2022,2022-01-31,"May 30, 2021",Actual,2021-05-30,"May 25, 2021",Actual,2021-05-25,NA,Interventional,COVID-19,NA,Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx,"A Multicenter, Single Blind, Randomized Controlled Trial of Virucidal Effect of Polyvinyl Pyrrol-Iodine on SARS-CoV-2 as Well as Safety of Its Application on Nasopharynx & Oropharynx of COVID-19 Positive Patients",Completed,NA,Phase 3,798,Actual,Bangladesh Reference Institute of Chemical Measurements (BRICM),NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,3 months,"Available on public domain like figure share, research gate, Linkdin and others",NA,Yes,"After completion of the project, a manuscript will be prepared and will be shared to the journal authority for publication. Data will be shared with the journal authority and make public as part of the publication.",2022-01-21T12:10:25Z,2022-01-21T12:10:25Z,12
NCT04579549,NA,2020-10-06,2021-12-27,NA,2022-01-18,2020-10-06,2020-10-08,Actual,2022-01-14,2022-01-19,Actual,NA,NA,NA,2022-01-18,2022-01-20,Estimate,"September 29, 2020",Actual,2020-09-29,January 2022,2022-01-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,NA,Repeat Testing for SARS-CoV-2,Repeat Saliva Testing for SARS-CoV-2 Using RT-LAMP Assay,Completed,NA,Not Applicable,464,Actual,"University of Wisconsin, Madison",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,Data from this study may be requested from other researchers 7 years after the completion of the primary endpoint by contacting David O'Connor at the University of Wisconsin -Madison.,NA,NA,Yes,"Participants will consent to having their data (not their name) and viral sequences shared with the public via manuscripts, presentations and online databases; the study team will share that with other researchers when needed. Samples can be shared with UW researchers internally and non UW researchers through the Material Transfer Agreement process.",2022-01-21T12:12:56Z,2022-01-21T12:12:56Z,13
NCT04460690,NA,2020-07-06,2021-12-23,NA,2022-01-18,2020-07-06,2020-07-07,Actual,2022-01-14,2022-01-19,Actual,NA,NA,NA,2022-01-18,2022-01-20,Estimate,"July 13, 2020",Actual,2020-07-13,January 2022,2022-01-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,NA,"Rapid, Onsite COVID-19 Detection","Rapid, Onsite COVID-19 Detection",Completed,NA,Not Applicable,93,Actual,"University of Wisconsin, Madison",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,NA,NA,NA,Data from this study may be requested from other researchers 7 years after the completion of the primary endpoint by contacting David O'Connor at the University of Wisconsin - Madison.,NA,NA,Yes,"Participants will consent to having their data (not their name) and viral sequences shared with the public via manuscripts, presentations and online databases; the study team will share that with other researchers when needed. Samples can be shared with UW researchers internally and non UW researchers through the Material Transfer Agreement process.",2022-01-21T12:14:05Z,2022-01-21T12:14:05Z,13
NCT04357730,NA,2020-04-18,2021-11-07,NA,2022-01-18,2020-04-21,2020-04-22,Actual,2022-01-18,2022-01-20,Estimate,NA,NA,NA,2022-01-18,2022-01-20,Estimate,"May 14, 2020",Actual,2020-05-14,January 2022,2022-01-31,"September 30, 2021",Actual,2021-09-30,"March 21, 2021",Actual,2021-03-21,NA,Interventional,NA,NA,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection: A Phase 2a Clinical Trial,Completed,NA,Phase 2,50,Actual,Denver Health and Hospital Authority,NA,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,A de-identified dataset will be made available to other investigators who may submit proposals to the PI for additional analyses or validation.,2022-01-21T12:14:58Z,2022-01-21T12:14:58Z,13
NCT04685213,NA,2020-12-23,2021-10-12,NA,2022-01-18,2020-12-23,2020-12-28,Actual,2022-01-12,2022-01-18,Actual,NA,NA,NA,2022-01-18,2022-01-21,Estimate,"December 22, 2020",Actual,2020-12-22,January 2022,2022-01-31,"March 18, 2021",Actual,2021-03-18,"March 18, 2021",Actual,2021-03-18,NA,Interventional,Phase I,NA,Electrical Stimulation for Critically Ill Covid-19 Patients,Electrical Stimulation Therapy for Preventing Hospital-acquired Weakness in Critically Ill COVID-19 Patients - A Proof of Concept Randomized Controlled Trial,Completed,NA,Phase 1,19,Actual,Baylor College of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-23T06:53:00Z,2022-01-23T06:53:00Z,13
NCT05205655,NA,2022-01-23,NA,NA,2022-01-23,2022-01-23,2022-01-25,Estimate,NA,NA,NA,NA,NA,NA,2022-01-23,2022-01-25,Estimate,"March 1, 2021",Actual,2021-03-01,January 2022,2022-01-31,"August 31, 2021",Actual,2021-08-31,"August 31, 2021",Actual,2021-08-31,NA,Interventional,COVDOG,NA,Detection Dogs as a Help in the Detection of COVID-19,Dogs Olfactory Detection and Its Relevance to COVID-19 Detection,Completed,NA,Not Applicable,100,Actual,HÃ´pital Universitaire Sahloul,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-26T00:33:04Z,2022-01-26T00:33:04Z,8
NCT05175833,NA,2021-12-26,NA,NA,2022-01-06,2021-12-28,2022-01-04,Actual,NA,NA,NA,NA,NA,NA,2022-01-06,2022-01-24,Actual,"September 11, 2020",Actual,2020-09-11,January 2022,2022-01-31,"February 7, 2021",Actual,2021-02-07,"January 25, 2021",Actual,2021-01-25,NA,Interventional,NA,NA,Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19,Effect of Oral Probiotics Streptococcus Salivarius K12 and Lactobacillus Brevis CD2 on the Prevention of Secondary Bacterial Pneumonia in Patients With Severe COVID-19: a Phase II Randomized Clinical Trial,Completed,NA,Phase 2,70,Actual,Universidade de Passo Fundo,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-26T00:36:30Z,2022-01-26T00:36:30Z,25
NCT05172050,NA,2021-12-23,NA,NA,2022-01-10,2021-12-23,2021-12-29,Actual,NA,NA,NA,NA,NA,NA,2022-01-10,2022-01-25,Estimate,"January 22, 2021",Actual,2021-01-22,January 2022,2022-01-31,"June 12, 2021",Actual,2021-06-12,"June 12, 2021",Actual,2021-06-12,NA,Interventional,NA,NA,"Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.","Multicenter, Adaptive, Randomized, Placebo-controlled, Double Blind, Parallel-group Phase 2/3 Trial, to Study Efficacy and Safety of Two Doses of Raloxifene in Adult Paucisymptomatic COVID-19 Patients.",Completed,NA,Phase 2/Phase 3,68,Actual,DompÃ© Farmaceutici S.p.A,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-26T00:36:43Z,2022-01-26T00:36:43Z,21
NCT04980573,NA,2021-07-26,NA,NA,2022-01-20,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2022-01-20,2022-01-24,Actual,"August 5, 2021",Actual,2021-08-05,January 2022,2022-01-31,"November 30, 2021",Actual,2021-11-30,"November 30, 2021",Actual,2021-11-30,NA,Interventional,NA,NA,Essential Oils and Post COVID-19 Fatigue,"The Effects of Aromatherapy on Post COVID-19 Fatigue: A Randomized, Double Blind, Controlled Trial",Completed,NA,Not Applicable,47,Actual,Franklin School of Integrative Health Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-26T00:41:56Z,2022-01-26T00:41:56Z,11
NCT04787211,NA,2021-03-04,NA,NA,2022-01-24,2021-03-04,2021-03-08,Actual,NA,NA,NA,NA,NA,NA,2022-01-24,2022-01-25,Estimate,"June 20, 2021",Actual,2021-06-20,January 2022,2022-01-31,"December 2, 2021",Actual,2021-12-02,"December 2, 2021",Actual,2021-12-02,NA,Interventional,NA,NA,"A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198","A Phase 2 Study to Evaluate the Safety and Efficacy of Human Monoclonal Antibodies, BRII-196 and BRII-198, Administered by Intravenous Infusion for the Treatment of COVID-19 Patients",Completed,NA,Phase 2,48,Actual,Brii Biosciences Limited,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-26T00:45:08Z,2022-01-26T00:45:08Z,7
NCT04754113,NA,2021-02-06,NA,NA,2022-01-21,2021-02-12,2021-02-15,Actual,NA,NA,NA,NA,NA,NA,2022-01-21,2022-01-25,Estimate,"February 8, 2021",Actual,2021-02-08,January 2022,2022-01-31,"January 15, 2022",Actual,2022-01-15,"January 1, 2022",Actual,2022-01-01,NA,Interventional,NA,NA,Effect of Prone Position onV/Q Matching in Non-intubated Patients With COVID-19,Effect of Prone Position on Lung Ventilation and Perfusion Matching in Non-intubated Patients With COVID-19 Pneumonia,Completed,NA,Not Applicable,14,Actual,"Southeast University, China",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-26T00:45:42Z,2022-01-26T00:45:42Z,10
NCT04771598,NA,2021-02-21,NA,NA,2022-01-21,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2022-01-21,2022-01-24,Actual,"February 25, 2021",Actual,2021-02-25,January 2022,2022-01-31,"July 30, 2021",Actual,2021-07-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,NA,Breathing Exercise After COVID-19 Pneumonia,THE EFFECT OF BREATHING EXERCISE AFTER COVID-19 PNEUMONIA: A Randomised Controlled Study,Completed,NA,Not Applicable,52,Actual,Tokat Gaziosmanpasa University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-26T00:45:28Z,2022-01-26T00:45:28Z,10
NCT04425720,NA,2020-06-02,2021-11-04,NA,2022-01-20,2020-06-08,2020-06-11,Actual,2021-11-18,2021-11-19,Actual,NA,NA,NA,2022-01-20,2022-01-24,Actual,"September 1, 2020",Actual,2020-09-01,January 2022,2022-01-31,"December 10, 2021",Actual,2021-12-10,"February 10, 2021",Actual,2021-02-10,NA,Interventional,RPM,NA,Use of Remote Monitoring for COVID-19 Patient,Use of Remote Patient Monitoring (RPM) Platform for COVID-19 Patient,Completed,NA,Not Applicable,300,Actual,Montefiore Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-26T00:50:22Z,2022-01-26T00:50:22Z,11
NCT04570384,NA,2020-09-17,NA,NA,2022-01-24,2020-09-29,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2022-01-24,2022-01-25,Estimate,"October 15, 2020",Actual,2020-10-15,January 2022,2022-01-31,"September 30, 2021",Actual,2021-09-30,"August 30, 2021",Actual,2021-08-30,NA,Interventional,NA,NA,Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness,"Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline (Turnobi) to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness",Completed,NA,Phase 2,65,Actual,"Asklepion Pharmaceuticals, LLC",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-26T00:48:52Z,2022-01-26T00:48:52Z,7
NCT04409509,NA,2020-05-28,2021-12-23,NA,2022-01-20,2020-05-28,2020-06-01,Actual,2022-01-20,2022-01-24,Actual,NA,NA,NA,2022-01-20,2022-01-24,Actual,"July 1, 2020",Actual,2020-07-01,January 2022,2022-01-31,"January 12, 2021",Actual,2021-01-12,"January 12, 2021",Actual,2021-01-12,NA,Interventional,NA,NA,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),"A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)",Completed,NA,Phase 2,124,Actual,CSL Behring,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.,"Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.

An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.

The requesting party must execute an appropriate data sharing agreement before IPD will be made available.",NA,Yes,"CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.

If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.",2022-01-26T00:50:33Z,2022-01-26T00:50:33Z,11
NCT04549376,NA,2020-09-11,NA,NA,2022-01-10,2020-09-12,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2022-01-10,2022-01-25,Estimate,"July 1, 2020",Actual,2020-07-01,January 2022,2022-01-31,"October 30, 2020",Actual,2020-10-30,"October 20, 2020",Actual,2020-10-20,NA,Interventional,VEP-COV,NA,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo: an Open Label Randomized Clinical Trial,Completed,NA,Phase 2,200,Actual,Bangladesh Reference Institute of Chemical Measurements (BRICM),NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,6 months,"Available on public domain like figshare, researchgate and others",NA,Yes,"After completion of the project, a manuscript will be prepared and will be shared to the journal authority for publication. Data will be shared with the journal authority and make public as part of the publication.",2022-01-26T00:49:07Z,2022-01-26T00:49:07Z,21
NCT04380519,NA,2020-05-06,2022-01-10,NA,2022-01-21,2020-05-06,2020-05-08,Actual,2022-01-21,2022-01-24,Actual,NA,NA,NA,2022-01-21,2022-01-24,Actual,"April 23, 2020",Actual,2020-04-23,January 2022,2022-01-31,"July 24, 2020",Actual,2020-07-24,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,NA,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),"An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)",Completed,NA,Phase 2/Phase 3,372,Actual,R-Pharm,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-26T00:51:03Z,2022-01-26T00:51:03Z,10
NCT04362813,NA,2020-04-24,2021-07-30,2021-02-08,2022-01-21,2020-04-24,2020-04-27,Actual,2021-08-12,2021-08-16,Actual,2021-08-12,2021-08-16,Actual,2022-01-21,2022-01-24,Actual,"April 30, 2020",Actual,2020-04-30,January 2022,2022-01-31,"December 22, 2020",Actual,2020-12-22,"September 16, 2020",Actual,2020-09-16,NA,Interventional,CAN-COVID,"While patient flow and baseline measure tables show 454 participants enrolled, only 451 randomized. 3 were ""mis-randomized"" i.e. assigned a randomization number in error and not treated.",Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,"Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)",Completed,NA,Phase 3,454,Actual,Novartis,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2022-01-26T00:51:16Z,2022-01-26T00:51:16Z,10
NCT04379336,NA,2020-05-04,NA,NA,2022-01-24,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2022-01-24,2022-01-25,Estimate,"May 4, 2020",Actual,2020-05-04,October 2021,2021-10-31,"January 2, 2022",Actual,2022-01-02,"January 2, 2022",Actual,2022-01-02,NA,Interventional,NA,NA,BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,"Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial",Completed,NA,Phase 3,1000,Actual,TASK Applied Science,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD will only be shared among researchers included in the protocol team at this stage.,2022-01-26T00:51:05Z,2022-01-26T00:51:05Z,7
NCT04519437,NA,2020-07-24,NA,NA,2022-01-10,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2022-01-10,2022-01-26,Estimate,"July 26, 2020",Actual,2020-07-26,January 2022,2022-01-31,"November 22, 2021",Actual,2021-11-22,"November 22, 2021",Actual,2021-11-22,NA,Interventional,NA,NA,"Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers",Completed,NA,Phase 1,974,Actual,Regeneron Pharmaceuticals,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2022-01-27T10:28:49Z,2022-01-27T10:28:49Z,21
NCT05214196,NA,2022-01-25,NA,NA,2022-01-25,2022-01-25,2022-01-28,Estimate,NA,NA,NA,NA,NA,NA,2022-01-25,2022-01-28,Estimate,"September 1, 2021",Actual,2021-09-01,January 2022,2022-01-31,"December 7, 2021",Actual,2021-12-07,"December 1, 2021",Actual,2021-12-01,NA,Interventional,NA,NA,The Efficacy of Oral Antiseptics Against SARS-CoV-2,The Effectiveness of Oral Antiseptics on the Intraoral Viral Load of SARS-CoV-2,Completed,NA,Phase 4,75,Actual,Ataturk University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-28T22:05:33Z,2022-01-28T22:05:33Z,6
NCT05212675,NA,2022-01-24,NA,NA,2022-01-26,2022-01-26,2022-01-28,Estimate,NA,NA,NA,NA,NA,NA,2022-01-26,2022-01-28,Estimate,"March 1, 2021",Actual,2021-03-01,January 2022,2022-01-31,"August 30, 2021",Actual,2021-08-30,"June 1, 2021",Actual,2021-06-01,NA,Interventional,NA,NA,Short Daily Versus Conventional Hemodialysis for COVID-19 Patients,Short Daily Versus Conventional Hemodialysis for COVID-19 Patients: A Randomized Study,Completed,NA,Not Applicable,47,Actual,Shahid Beheshti University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-28T22:06:48Z,2022-01-28T22:06:48Z,5
NCT05130671,NA,2021-11-21,NA,NA,2022-01-13,2021-11-21,2021-11-23,Actual,NA,NA,NA,NA,NA,NA,2022-01-13,2022-01-28,Estimate,"October 25, 2021",Actual,2021-10-25,January 2022,2022-01-31,"December 31, 2021",Actual,2021-12-31,"December 31, 2021",Actual,2021-12-31,NA,Interventional,NA,NA,Nutritional Supplementation of Flavonoids Quercetin and Curcumin for Early Mild Symptoms of COVID-19,Treatment Benefits of Flavonoids Quercetin and Curcumin Supplements for Mild Symptoms of COVID-19,Completed,NA,Not Applicable,50,Actual,King Edward Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-28T22:12:52Z,2022-01-28T22:12:52Z,18
NCT05033223,NA,2021-09-01,NA,NA,2022-01-26,2021-09-01,2021-09-02,Actual,NA,NA,NA,NA,NA,NA,2022-01-26,2022-01-27,Actual,"October 12, 2021",Actual,2021-10-12,January 2022,2022-01-31,"January 16, 2022",Actual,2022-01-16,"January 16, 2022",Actual,2022-01-16,NA,Interventional,COVER PRO LT,NA,Psycho-traumatic Consequences of the COVID-19 Health Crisis Among Professionals in Emergency Services,Psycho-traumatic Consequences of the COVID-19 Health Crisis Among Professionals in Emergency Services and SAMU: Multicenter Cohort Study (COVid in EmeRgency PROfessionnals Long Term),Completed,NA,Not Applicable,71,Actual,Hospices Civils de Lyon,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-28T22:15:58Z,2022-01-28T22:15:58Z,5
NCT04854941,NA,2021-04-07,NA,NA,2022-01-13,2021-04-21,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2022-01-13,2022-01-28,Estimate,"December 10, 2020",Actual,2020-12-10,April 2021,2021-04-30,"April 10, 2021",Actual,2021-04-10,"March 10, 2021",Actual,2021-03-10,NA,Interventional,NA,NA,Efficacy of Probiotics in the Treatment of Hospitalised Patients With Novel Coronavirus Infection,"Efficacy of Probiotics (Lactobacillus Rhamnosus, Bifidobacterium Bifidum, Bifidobacterium Longum Subsp. Infantis and Bifidobacterium Longum) in the Treatment of Hospitalised Patients With Novel Coronavirus Infection",Completed,NA,Not Applicable,200,Actual,I.M. Sechenov First Moscow State Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The provision of data is prohibited by Local Ethical Committee and is possible upon receipt of an official request addressed to the principal investigator,2022-01-28T22:19:47Z,2022-01-28T22:19:47Z,18
NCT04630054,NA,2020-11-13,NA,NA,2022-01-12,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2022-01-12,2022-01-28,Estimate,"November 15, 2020",Actual,2020-11-15,January 2022,2022-01-31,"June 29, 2021",Actual,2021-06-29,"June 29, 2021",Actual,2021-06-29,NA,Interventional,NA,NA,Face Masks to Reduce COVID-19 in Bangladesh,Can Face Masks Reduce Transmission of SARS-CoV-2 in Bangladesh? A Cluster Randomized Controlled Trial,Completed,NA,Not Applicable,350000,Actual,Yale University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,We do not plan to share individual participant data with other researchers,2022-01-28T22:24:02Z,2022-01-28T22:24:02Z,19
NCT04659746,NA,2020-12-07,NA,NA,2022-01-12,2020-12-07,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2022-01-12,2022-01-27,Actual,"December 9, 2020",Actual,2020-12-09,January 2022,2022-01-31,"December 9, 2021",Actual,2021-12-09,"February 28, 2021",Actual,2021-02-28,NA,Interventional,MejoraCare_P,NA,MejoraCare-Paraguay: mHealth Solution for Chronic Patients During the COVID-19 Outbreak in Paraguay,mHealth Technology to Optimize Mental Health in Chronic Patients During the COVID-19 Outbreak in Paraguay,Completed,NA,Not Applicable,138,Actual,Universidad AutÃ³noma de EncarnaciÃ³n,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-28T22:23:19Z,2022-01-28T22:23:19Z,19
NCT04647656,NA,2020-11-29,NA,NA,2022-01-12,2020-11-29,2020-12-01,Actual,NA,NA,NA,NA,NA,NA,2022-01-12,2022-01-27,Actual,"December 14, 2020",Actual,2020-12-14,January 2022,2022-01-31,"January 10, 2022",Actual,2022-01-10,"December 27, 2021",Actual,2021-12-27,NA,Interventional,HBOTpCOVID,NA,Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome,"Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome: a Prospective, Randomized, Double Blind Study.",Completed,NA,Not Applicable,91,Actual,Assaf-Harofeh Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-28T22:23:37Z,2022-01-28T22:23:37Z,19
NCT04565379,NA,2020-09-23,NA,NA,2022-01-27,2020-09-23,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2022-01-27,2022-01-28,Estimate,"September 24, 2020",Actual,2020-09-24,January 2022,2022-01-31,"April 13, 2021",Actual,2021-04-13,"April 13, 2021",Actual,2021-04-13,NA,Interventional,NA,NA,Clinical Trial to Investigate the Efficacy and Safety of NuSepinÂ® in COVID-19 Pneumonia Patients,"A Randomized, Double Blind, Placebo-controlled, Phase 2 Clinical Trial to Investigate the Efficacy and Safety of 2 Doses of NuSepinÂ® Intravenous Infusion in COVID-19 Pneumonia Patients",Completed,NA,Phase 2,64,Actual,Shaperon,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-28T22:25:18Z,2022-01-28T22:25:18Z,4
NCT04397614,NA,2020-05-20,NA,NA,2022-01-26,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2022-01-26,2022-01-27,Actual,"July 22, 2020",Actual,2020-07-22,January 2022,2022-01-31,"November 12, 2021",Actual,2021-11-12,"November 12, 2021",Actual,2021-11-12,NA,Interventional,NA,NA,Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients,Mobile Health Study and Enhanced Symptom Monitoring to Prevent Severe Illness From COVID-19 in Cancer Patients,Completed,NA,Not Applicable,128,Actual,University of Oklahoma,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-28T22:28:03Z,2022-01-28T22:28:03Z,5
NCT04532294,NA,2020-08-27,2022-01-19,NA,2022-01-19,2020-08-27,2020-08-31,Actual,2022-01-19,2022-01-27,Actual,NA,NA,NA,2022-01-19,2022-01-27,Actual,"September 8, 2020",Actual,2020-09-08,January 2022,2022-01-31,"February 13, 2021",Actual,2021-02-13,"February 13, 2021",Actual,2021-02-13,NA,Interventional,NA,Safety Analysis Set (SAS) : Includes all participants who received the study drug or placebo,"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants","A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy Subjects",Completed,NA,Phase 1,18,Actual,BeiGene,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2022-01-28T22:26:07Z,2022-01-28T22:26:07Z,12
NCT04479332,NA,2020-07-16,NA,NA,2022-01-18,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2022-01-18,2022-01-28,Estimate,"August 19, 2020",Actual,2020-08-19,July 2020,2020-07-31,"February 23, 2021",Actual,2021-02-23,"February 23, 2021",Actual,2021-02-23,NA,Interventional,NA,NA,The Change of Critical Patient Managements and Subsequent Influences Under Epidemic of Coronavirus Disease 19 (COVID-19),The Change of Critical Patient Managements and Subsequent Influences Under Epidemic of Coronavirus Disease 19 (COVID-19),Completed,NA,Not Applicable,198,Actual,National Taiwan University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-28T22:26:51Z,2022-01-28T22:26:51Z,13
NCT04382755,NA,2020-05-07,NA,NA,2022-01-26,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2022-01-26,2022-01-27,Actual,"May 22, 2020",Actual,2020-05-22,January 2022,2022-01-31,"April 9, 2021",Actual,2021-04-09,"December 29, 2020",Actual,2020-12-29,NA,Interventional,ZILU-COV,NA,ZilucoplanÂ® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With ZilucoplanÂ® in Improving Oxygenation and short-and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure",Completed,NA,Phase 2,81,Actual,"University Hospital, Ghent",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2022-01-28T22:28:20Z,2022-01-28T22:28:20Z,5
NCT04379154,NA,2020-04-28,NA,NA,2022-01-12,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2022-01-12,2022-01-27,Actual,"April 14, 2020",Actual,2020-04-14,January 2022,2022-01-31,"June 1, 2021",Actual,2021-06-01,"June 1, 2021",Actual,2021-06-01,NA,Interventional,VOC-COVID,NA,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19),Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by (SARS-CoV-2): Predictive Interest in Short-term Evolution,Completed,NA,Not Applicable,65,Actual,Hopital Foch,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-28T22:28:25Z,2022-01-28T22:28:25Z,19
NCT04360980,NA,2020-04-22,NA,NA,2022-01-27,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2022-01-27,2022-01-28,Estimate,"March 20, 2020",Actual,2020-03-20,January 2022,2022-01-31,"January 30, 2021",Actual,2021-01-30,"January 1, 2021",Actual,2021-01-01,NA,Interventional,NA,NA,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection: A Randomized Double Blind Clinical Trial,Completed,NA,Phase 2,80,Actual,Shahid Beheshti University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-28T22:28:39Z,2022-01-28T22:28:39Z,4
NCT05075304,NA,2021-08-22,NA,NA,2021-10-08,2021-10-08,2021-10-12,Estimate,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-12,Estimate,"February 21, 2020",Actual,2020-02-21,August 2021,2021-08-31,"April 14, 2020",Actual,2020-04-14,"April 14, 2020",Actual,2020-04-14,NA,Interventional,NA,NA,"A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients","A Phase Ib, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BDB-001 Injection in Patients With Novel Coronavirus (2019-nCoV) Infection",Completed,NA,Phase 1,18,Actual,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T17:59:42Z,2021-10-12T17:59:42Z,115
NCT04333732,NA,2020-03-31,NA,NA,2022-01-25,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2022-01-25,2022-01-27,Actual,"September 4, 2020",Actual,2020-09-04,October 2021,2021-10-31,"December 3, 2021",Actual,2021-12-03,"August 10, 2021",Actual,2021-08-10,NA,Interventional,CROWN CORONA,NA,CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION,"An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Adults",Completed,NA,Phase 3,3545,Actual,Washington University School of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,From 3 months after the last patient last visit onward.,Investigators whose proposed use of the data has been approved by a review committee identified for this purpose.,NA,Yes,"Individual participant data that underlie the results reported in the main publication may be shared, after de-identification.",2022-01-28T22:29:06Z,2022-01-28T22:29:06Z,6
NCT04962022,NA,2021-07-10,NA,NA,2021-10-11,2021-07-10,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"July 20, 2021",Actual,2021-07-20,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 30, 2021",Actual,2021-09-30,NA,Interventional,NA,NA,Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants,"COVID-19: A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF PF-07321332/RITONAVIR IN HEALTHY PARTICIPANTS",Completed,NA,Phase 1,12,Actual,Pfizer,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-12T18:00:17Z,2021-10-12T18:00:17Z,112
NCT04649736,NA,2020-11-30,NA,NA,2021-12-01,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-12-01,2021-12-03,Estimate,"October 26, 2020",Actual,2020-10-26,May 2021,2021-05-31,"June 19, 2021",Actual,2021-06-19,"June 19, 2021",Actual,2021-06-19,NA,Interventional,WAYRA,NA,Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients,Prevalence of Altered Pulmonary Function Post-infection by COVID-19 and Impact of Participation in a Pilot Program of Comprehensive Rehabilitation in the Short and Medium-term,Completed,NA,Not Applicable,108,Actual,Universidad Peruana Cayetano Heredia,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Results will be published in an indexed peer-review journals.,2021-12-06T10:38:54Z,2021-12-06T10:38:54Z,61
NCT04830033,NA,2021-03-31,NA,NA,2021-11-22,2021-03-31,2021-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-12-03,Estimate,"April 28, 2021",Actual,2021-04-28,November 2021,2021-11-30,"September 23, 2021",Actual,2021-09-23,"September 23, 2021",Actual,2021-09-23,NA,Interventional,SHIELD ENO,NA,ENO Breathe vs Usual Care in COVID-19 Recovery,A Randomised Controlled Trial of the English National Opera Breathe Programme Compared With Usual Care in People Recovering From COVID-19,Completed,NA,Not Applicable,153,Actual,Imperial College London,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"The data will be available from the date of publication of the main study, and will remain available for at least 2 years.",Data will be shared on reasonable request.,NA,Yes,Data will be shared on reasonable request.,2021-12-06T10:34:53Z,2021-12-06T10:34:53Z,70
NCT04600895,NA,2020-09-15,NA,NA,2021-11-29,2020-10-22,2020-10-23,Actual,NA,NA,NA,NA,NA,NA,2021-11-29,2021-12-03,Estimate,"November 30, 2020",Actual,2020-11-30,November 2021,2021-11-30,"October 20, 2021",Actual,2021-10-20,"October 20, 2021",Actual,2021-10-20,NA,Interventional,PRESECO,NA,The Prevent Severe COVID-19 (PRESECO) Study,Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19),Completed,NA,Phase 3,1231,Actual,Appili Therapeutics Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-06T10:39:42Z,2021-12-06T10:39:42Z,63
NCT04551898,NA,2020-09-10,NA,NA,2021-12-02,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-12-02,2021-12-03,Estimate,"December 2, 2020",Actual,2020-12-02,December 2021,2021-12-31,"May 25, 2021",Actual,2021-05-25,"May 25, 2021",Actual,2021-05-25,NA,Interventional,NA,NA,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients WithMild-to-Moderate COVID-19",Completed,NA,Phase 2,181,Actual,BeiGene,NA,4,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-06T10:40:27Z,2021-12-06T10:40:27Z,60
NCT04524507,NA,2020-08-21,2021-11-15,NA,2021-12-01,2020-08-21,2020-08-24,Actual,2021-11-15,2021-11-23,Actual,NA,NA,NA,2021-12-01,2021-12-03,Estimate,"August 27, 2020",Actual,2020-08-27,June 2021,2021-06-30,"June 4, 2021",Actual,2021-06-04,"January 4, 2021",Actual,2021-01-04,NA,Interventional,UNC CCP RCT,NA,Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients,"IGHID 12021 - A Randomized, Phase II Study Comparing the Efficacy and Safety of Standard Versus High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody Plasma in Hospitalized Patients With COVID-19",Completed,NA,Phase 2,56,Actual,"University of North Carolina, Chapel Hill",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,12-24 months after publication,"Investigators/researchers who propose to use study data will need to have IRB, IEC, or REB approval and an executed data use/sharing agreement with UNC.",NA,Yes,"De-identified individual data that supports the results will be shared beginning 12 to 24 months following publication provided the investigator/researcher who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2021-12-06T10:40:55Z,2021-12-06T10:40:55Z,61
NCT04384497,NA,2020-05-07,NA,NA,2021-12-02,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-12-02,2021-12-03,Estimate,"May 7, 2020",Actual,2020-05-07,December 2021,2021-12-31,"December 1, 2020",Actual,2020-12-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,NA,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Completed,NA,Phase 1/Phase 2,10,Actual,Karolinska University Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"The investigators will be sharing the data, but the management plan is being designed.",2021-12-06T10:42:36Z,2021-12-06T10:42:36Z,60
NCT04382924,NA,2020-05-08,2021-11-22,NA,2021-12-01,2020-05-08,2020-05-11,Actual,2021-12-01,2021-12-03,Estimate,NA,NA,NA,2021-12-01,2021-12-03,Estimate,"August 5, 2020",Actual,2020-08-05,December 2021,2021-12-31,"January 26, 2021",Actual,2021-01-26,"December 24, 2020",Actual,2020-12-24,NA,Interventional,NA,NA,Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,Completed,NA,Phase 2/Phase 3,168,Actual,Algernon Pharmaceuticals,NA,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-06T10:42:42Z,2021-12-06T10:42:42Z,61
NCT04425538,NA,2020-06-08,2021-08-23,NA,2021-12-01,2020-06-08,2020-06-11,Actual,2021-12-01,2021-12-03,Estimate,NA,NA,NA,2021-12-01,2021-12-03,Estimate,"June 1, 2020",Actual,2020-06-01,December 2021,2021-12-31,"January 22, 2021",Actual,2021-01-22,"January 22, 2021",Actual,2021-01-22,NA,Interventional,NA,NA,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,Completed,NA,Phase 2,17,Actual,Tufts Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T10:42:16Z,2021-12-06T10:42:16Z,61
NCT04635943,NA,2020-11-09,NA,NA,2021-12-03,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-12-03,2021-12-06,Estimate,"August 29, 2020",Actual,2020-08-29,March 2021,2021-03-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,SAINT-PERU,NA,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Completed,NA,Phase 2,186,Actual,Universidad Peruana Cayetano Heredia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-06T20:11:40Z,2021-12-06T20:11:40Z,59
NCT04355728,NA,2020-04-13,2021-10-15,NA,2021-12-01,2020-04-17,2020-04-21,Actual,2021-12-01,2021-12-06,Estimate,NA,NA,NA,2021-12-01,2021-12-06,Estimate,"April 25, 2020",Actual,2020-04-25,December 2021,2021-12-31,"October 31, 2020",Actual,2020-10-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,NA,Use of UC-MSCs for COVID-19 Patients,Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS),Completed,NA,Phase 1/Phase 2,24,Actual,University of Miami,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T20:13:48Z,2021-12-06T20:13:48Z,61
NCT04894721,NA,2021-05-06,NA,NA,2021-12-01,2021-05-12,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-12-01,2021-12-07,Estimate,"June 1, 2021",Actual,2021-06-01,December 2021,2021-12-31,"October 1, 2021",Actual,2021-10-01,"September 30, 2021",Actual,2021-09-30,NA,Interventional,IVERNEX-TUC,NA,Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC),Study of Efficacy and Safety of Ivermectin for COVID-19 Prophylaxis in Post-exposure Contact or Epidemiological Link,Completed,NA,Phase 2/Phase 3,172,Actual,"Ministry of Public Health, Argentina",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-08T10:24:40Z,2021-12-08T10:24:40Z,61
NCT04343989,NA,2020-04-09,NA,NA,2021-12-03,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-12-03,2021-12-07,Estimate,"March 31, 2020",Actual,2020-03-31,December 2021,2021-12-31,"March 12, 2021",Actual,2021-03-12,"February 3, 2021",Actual,2021-02-03,NA,Interventional,NA,NA,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Completed,NA,Phase 2,180,Actual,NYU Langone Health,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,Upon reasonable request by an investigator who proposes to use the data.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2021-12-08T10:29:54Z,2021-12-08T10:29:54Z,59
NCT04392232,NA,2020-05-15,NA,NA,2021-12-03,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-12-03,2021-12-07,Estimate,"May 5, 2020",Actual,2020-05-05,December 2021,2021-12-31,"September 21, 2021",Actual,2021-09-21,"September 21, 2021",Actual,2021-09-21,NA,Interventional,NA,NA,A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,A Phase 2 Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,Completed,NA,Phase 2,159,Actual,TriHealth Inc.,NA,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-08T10:29:40Z,2021-12-08T10:29:40Z,59
NCT04920942,NA,2021-05-31,NA,NA,2021-11-24,2021-06-08,2021-06-10,Actual,NA,NA,NA,NA,NA,NA,2021-11-24,2021-12-08,Estimate,"May 31, 2021",Actual,2021-05-31,November 2021,2021-11-30,"October 31, 2021",Actual,2021-10-31,"October 31, 2021",Actual,2021-10-31,NA,Interventional,I-TECH,NA,Ivermectin Treatment Efficacy in Covid-19 High Risk Patients,Ivermectin Treatment Efficacy in Covid-19 High Risk Patients (I-TECH Study): A Multicenter Open-label Randomized Controlled Trial,Completed,NA,Phase 3,500,Actual,"Clinical Research Centre, Malaysia",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-09T09:15:58Z,2021-12-09T09:15:58Z,68
NCT05151614,NA,2021-11-27,NA,NA,2021-11-27,2021-11-27,2021-12-09,Estimate,NA,NA,NA,NA,NA,NA,2021-11-27,2021-12-09,Estimate,"April 1, 2021",Actual,2021-04-01,November 2021,2021-11-30,"October 30, 2021",Actual,2021-10-30,"October 30, 2021",Actual,2021-10-30,NA,Interventional,NA,NA,Adjuvant Use Of Colchicine With The Standard Therapy In Moderate And Severe Corona Virus Disease-19 Infection,Adjuvant Use Of Colchicine With The Standard Therapy In Moderate And Severe Corona Virus Disease-19 Infection: Randomized Controlled Clinical Trial,Completed,NA,Phase 1,160,Actual,University of Baghdad,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-10T11:29:40Z,2021-12-10T11:29:40Z,65
NCT04516512,NA,2020-08-17,NA,NA,2021-11-26,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-26,2021-12-09,Estimate,"January 14, 2021",Actual,2021-01-14,November 2021,2021-11-30,"July 8, 2021",Actual,2021-07-08,"July 8, 2021",Actual,2021-07-08,NA,Interventional,COVIDET,NA,Assessment of SARS-CoV-2 Seroprevalence in Detention,SARS-CoV-2 Seroprevalence Among Adults People Living in Jail,Completed,NA,Not Applicable,1044,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-10T11:40:38Z,2021-12-10T11:40:38Z,66
NCT04527198,NA,2020-06-02,NA,NA,2021-11-26,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-26,2021-12-09,Estimate,"September 14, 2020",Actual,2020-09-14,November 2021,2021-11-30,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,BRAINSTEM-COV,NA,Brainstem Dysfunction in COVID-19 Critically Ill Patients: a Prospective Observational Study,Brainstem Dysfunction in Ventilated and Deeply Sedated COVID-19 Critically Ill Patients: a Prospective Observational Study,Completed,NA,Not Applicable,52,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-10T11:40:30Z,2021-12-10T11:40:30Z,66
NCT04446429,NA,2020-06-22,2021-01-22,NA,2021-12-08,2020-06-23,2020-06-24,Actual,2021-01-29,2021-02-03,Actual,NA,NA,NA,2021-12-08,2021-12-10,Estimate,"October 21, 2020",Actual,2020-10-21,December 2021,2021-12-31,"January 21, 2021",Actual,2021-01-21,"December 24, 2020",Actual,2020-12-24,NA,Interventional,NA,NA,Anti-Androgen Treatment for COVID-19,Anti-Androgen Treatment for COVID-19,Completed,NA,Not Applicable,268,Actual,"Applied Biology, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-13T10:24:19Z,2021-12-13T10:24:19Z,54
NCT04331366,NA,2020-03-31,2021-02-05,NA,2021-02-16,2020-03-31,2020-04-02,Actual,2021-02-05,2021-02-10,Actual,NA,NA,NA,2021-02-16,2021-02-18,Actual,"April 8, 2020",Actual,2020-04-08,February 2021,2021-02-28,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,GO2 PEEP,NA,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,NA,Not Applicable,2,Actual,Emory University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-13T22:54:58Z,2021-12-13T22:54:58Z,349
NCT04876274,NA,2021-05-05,2021-10-05,NA,2021-11-03,2021-05-05,2021-05-06,Actual,2021-11-03,2021-12-13,Estimate,NA,NA,NA,2021-11-03,2021-12-13,Estimate,"July 14, 2020",Actual,2020-07-14,November 2021,2021-11-30,"December 29, 2020",Actual,2020-12-29,"December 29, 2020",Actual,2020-12-29,NA,Interventional,NA,NA,Social Media-Delivered Patient Education in Enhancing Type 2 Diabetics Self-Management and Attitudes During the COVID-19 Pandemic,Social Media-Delivered Patient Education in Enhancing Type 2 Diabetics Self-Management and Attitudes During the COVID-19 Pandemic: a Randomized Controlled Trial in Taiwan,Completed,NA,Not Applicable,181,Actual,Taipei Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:37:25Z,2021-12-14T09:37:25Z,89
NCT04721457,NA,2021-01-19,NA,NA,2021-12-10,2021-01-19,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-12-10,2021-12-13,Estimate,"January 3, 2021",Actual,2021-01-03,December 2021,2021-12-31,"December 10, 2021",Actual,2021-12-10,"March 28, 2021",Actual,2021-03-28,NA,Interventional,NA,NA,The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load,The Efficacy of Pre-procedural Mouth Rinses on SARS-CoV-2 Saliva Viral Load: A Randomized Control Clinical Trial,Completed,NA,Phase 4,120,Actual,King Abdulaziz University,NA,5,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:38:32Z,2021-12-14T09:38:32Z,52
NCT04749173,NA,2021-01-20,NA,NA,2021-11-29,2021-02-09,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-11-29,2021-12-13,Estimate,"November 21, 2020",Actual,2020-11-21,February 2021,2021-02-28,"June 18, 2021",Actual,2021-06-18,"June 18, 2021",Actual,2021-06-18,NA,Interventional,NA,NA,"To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers.","A Double-blind, Randomized, Placebo-controlled, Single-ascending Dose Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Following Intramuscular Administration in Healthy Volunteers",Completed,NA,Phase 1,24,Actual,Daewoong Pharmaceutical Co. LTD.,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:38:19Z,2021-12-14T09:38:19Z,63
NCT04366856,NA,2020-04-26,NA,NA,2021-12-10,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-12-10,2021-12-13,Estimate,"June 26, 2020",Actual,2020-06-26,December 2021,2021-12-31,"September 23, 2021",Actual,2021-09-23,"September 23, 2021",Actual,2021-09-23,NA,Interventional,PROVID,NA,PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),Completed,NA,Not Applicable,446,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-14T09:41:05Z,2021-12-14T09:41:05Z,52
NCT04441996,NA,2020-06-19,NA,2021-12-08,2021-12-08,2020-06-19,2020-06-22,Actual,NA,NA,NA,2021-12-08,2021-12-13,Estimate,2021-12-08,2021-12-13,Estimate,"July 17, 2020",Actual,2020-07-17,December 2021,2021-12-31,"March 18, 2021",Actual,2021-03-18,"March 18, 2021",Actual,2021-03-18,NA,Interventional,NA,NA,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Completed,NA,Phase 4,20,Actual,Emory University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:40:39Z,2021-12-14T09:40:39Z,54
NCT04904744,NA,2021-05-25,NA,NA,2021-12-13,2021-05-25,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-12-13,2021-12-14,Estimate,"May 28, 2021",Actual,2021-05-28,December 2021,2021-12-31,"December 10, 2021",Actual,2021-12-10,"October 31, 2021",Actual,2021-10-31,NA,Interventional,NA,NA,"Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination","Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination",Completed,NA,Not Applicable,1235,Actual,"Children's Hospital Medical Center, Cincinnati",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-15T09:13:24Z,2021-12-15T09:13:24Z,49
NCT04394169,NA,2020-05-13,NA,NA,2021-12-13,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-12-13,2021-12-14,Estimate,"May 25, 2020",Actual,2020-05-25,December 2021,2021-12-31,"October 22, 2021",Actual,2021-10-22,"October 15, 2021",Actual,2021-10-15,NA,Interventional,PAIN-COVID,NA,Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.,"Early Care, Therapeutic Education, and Psychological Intervention for the Management of Post-intensive Care Syndrome and Chronic Pain After Coronavirus Disease 2019 Infection. Simple-blind, Controlled, Randomized Trial.",Completed,NA,Not Applicable,102,Actual,Hospital Clinic of Barcelona,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-15T09:18:51Z,2021-12-15T09:18:51Z,49
NCT04456153,NA,2020-06-30,2021-11-10,NA,2021-12-12,2020-06-30,2020-07-02,Actual,2021-12-12,2021-12-14,Estimate,NA,NA,NA,2021-12-12,2021-12-14,Estimate,"July 22, 2020",Actual,2020-07-22,December 2021,2021-12-31,"January 31, 2021",Actual,2021-01-31,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NA,NA,Atovaquone for Treatment of COVID-19,Atovaquone for Treatment of COVID-19,Completed,NA,Phase 2,60,Actual,University of Texas Southwestern Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,There is no specified plan made.,2021-12-15T09:18:20Z,2021-12-15T09:18:20Z,50
NCT04351243,NA,2020-04-15,2021-11-26,NA,2021-12-10,2020-04-15,2020-04-17,Actual,2021-12-06,2021-12-10,Actual,NA,NA,NA,2021-12-10,2021-12-14,Estimate,"April 15, 2020",Actual,2020-04-15,December 2021,2021-12-31,"April 1, 2021",Actual,2021-04-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,NA,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),"A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)",Completed,NA,Phase 2,227,Actual,Kinevant Sciences GmbH,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-15T09:19:10Z,2021-12-15T09:19:10Z,52
NCT05076253,NA,2021-10-08,NA,NA,2021-12-14,2021-10-12,2021-10-13,Actual,NA,NA,NA,NA,NA,NA,2021-12-14,2021-12-15,Estimate,"September 1, 2021",Actual,2021-09-01,December 2021,2021-12-31,"December 1, 2021",Actual,2021-12-01,"December 1, 2021",Actual,2021-12-01,NA,Interventional,NA,NA,Efficacy of Ivermectin in COVID-19,"Efficacy and Safety of Ivermectin in Treatment of Mild to Moderate COVID-19 Infection: a Randomized ,Double Blind,Placebo,Controlled Trial",Completed,NA,Phase 1/Phase 2,72,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After publication,NA,NA,Yes,Data will be made available upon request after publication,2021-12-16T09:12:36Z,2021-12-16T09:12:36Z,48
NCT05115071,NA,2021-11-06,NA,NA,2021-12-14,2021-11-09,2021-11-10,Actual,NA,NA,NA,NA,NA,NA,2021-12-14,2021-12-15,Estimate,"November 8, 2021",Actual,2021-11-08,December 2021,2021-12-31,"December 10, 2021",Actual,2021-12-10,"November 25, 2021",Actual,2021-11-25,NA,Interventional,NA,NA,Online Childbirth Preparation Education in Covid-19 Pandemic,"The Effect of Online Childbirth Preparation Education in Pregnancy on Worries and Fear of Birth, Preparation for Birth, and Well-being of Self and Baby in the Covid 19 Pandemic",Completed,NA,Not Applicable,44,Actual,Pamukkale University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-16T09:11:58Z,2021-12-16T09:11:58Z,48
NCT04377672,NA,2020-05-04,NA,NA,2021-12-14,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-12-14,2021-12-15,Estimate,"May 28, 2020",Actual,2020-05-28,December 2021,2021-12-31,"December 13, 2021",Actual,2021-12-13,"September 1, 2021",Actual,2021-09-01,NA,Interventional,NA,NA,Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2,Completed,NA,Phase 1,14,Actual,Johns Hopkins University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-16T09:19:45Z,2021-12-16T09:19:45Z,48
NCT04519216,NA,2020-08-12,NA,NA,2021-12-13,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-12-13,2021-12-15,Estimate,"July 31, 2020",Actual,2020-07-31,December 2021,2021-12-31,"December 10, 2021",Actual,2021-12-10,"October 30, 2021",Actual,2021-10-30,NA,Interventional,NA,NA,Breastfeeding Education in the Time of COVID-19,"Breastfeeding Education in the Time of COVID-19. Hybrid Telesimulation With Standardized Patients for Pediatric and Family Medicine Trainees, a Randomized Trial",Completed,NA,Not Applicable,46,Actual,"University of California, Davis",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-16T09:18:48Z,2021-12-16T09:18:48Z,49
NCT04967742,NA,2021-07-12,NA,NA,2021-12-15,2021-07-15,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-12-15,2021-12-16,Estimate,"August 5, 2021",Actual,2021-08-05,September 2021,2021-09-30,"October 31, 2021",Actual,2021-10-31,"August 22, 2021",Actual,2021-08-22,NA,Interventional,NA,NA,"A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-Label Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Completed,NA,Phase 1,50,Actual,"United Biomedical Inc., Asia",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-17T09:17:19Z,2021-12-17T09:17:19Z,47
NCT04690387,NA,2020-12-28,NA,NA,2021-12-14,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-12-14,2021-12-16,Estimate,"December 7, 2020",Actual,2020-12-07,December 2021,2021-12-31,"January 15, 2021",Actual,2021-01-15,"January 13, 2021",Actual,2021-01-13,NA,Interventional,NA,NA,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection","Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies",Completed,NA,Phase 1,27,Actual,"Aivita Biomedical, Inc.",NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-17T09:21:07Z,2021-12-17T09:21:07Z,48
NCT04499677,NA,2020-06-16,NA,NA,2021-12-14,2020-08-03,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-12-14,2021-12-16,Estimate,"September 24, 2020",Actual,2020-09-24,December 2021,2021-12-31,"December 1, 2021",Actual,2021-12-01,"December 1, 2021",Actual,2021-12-01,NA,Interventional,FLARE,NA,FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals,"Favipiravir, Lopinavir/Ritonavir or Combination Therapy: a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19",Completed,NA,Phase 2,240,Actual,"University College, London",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,No plan to share IPD has been made at this time.,2021-12-17T09:23:27Z,2021-12-17T09:23:27Z,48
NCT04378920,NA,2020-05-05,NA,NA,2021-12-15,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-12-15,2021-12-16,Estimate,"April 14, 2020",Actual,2020-04-14,December 2021,2021-12-31,"August 24, 2021",Actual,2021-08-24,"August 24, 2021",Actual,2021-08-24,NA,Interventional,NA,NA,"A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes","A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes",Completed,NA,Phase 1/Phase 2,37,Actual,Institut de cancÃ©rologie Strasbourg Europe,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-17T09:24:54Z,2021-12-17T09:24:54Z,47
NCT04390178,NA,2020-04-10,NA,NA,2021-12-01,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-12-01,2021-12-16,Estimate,"April 10, 2020",Actual,2020-04-10,December 2021,2021-12-31,"December 31, 2020",Actual,2020-12-31,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,NA,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),Plasma From Individuals Who Have Recovered From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection as Treatment for Acute COVID-19 Disease,Completed,NA,Phase 1/Phase 2,10,Actual,Karolinska University Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,We will be sharing data but data the management plan is being designed.,2021-12-17T09:24:35Z,2021-12-17T09:24:35Z,61
NCT04328961,NA,2020-03-23,2021-10-08,NA,2021-12-14,2020-03-29,2020-04-01,Actual,2021-12-14,2021-12-16,Estimate,NA,NA,NA,2021-12-14,2021-12-16,Estimate,"March 31, 2020",Actual,2020-03-31,December 2021,2021-12-31,"October 8, 2020",Actual,2020-10-08,"September 24, 2020",Actual,2020-09-24,NA,Interventional,NA,The above participants contributed to the Modified Intention-to-Treat Cohort.,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study",Completed,NA,Phase 2/Phase 3,943,Actual,University of Washington,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2021-12-17T09:25:19Z,2021-12-17T09:25:19Z,48
NCT04244591,NA,2020-01-23,NA,NA,2020-06-13,2020-01-25,2020-01-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-13,2020-06-16,Actual,"January 26, 2020",Actual,2020-01-26,February 2020,2020-02-29,"April 13, 2020",Actual,2020-04-13,"April 13, 2020",Actual,2020-04-13,NA,Interventional,NA,NA,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,"Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial",Completed,NA,Phase 2/Phase 3,80,Actual,Peking Union Medical College Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T11:48:01Z,2022-01-04T11:48:01Z,597
NCT05140005,NA,2021-11-29,NA,NA,2021-12-17,2021-11-29,2021-12-01,Actual,NA,NA,NA,NA,NA,NA,2021-12-17,2021-12-20,Estimate,"December 6, 2021",Actual,2021-12-06,December 2021,2021-12-31,"December 17, 2021",Actual,2021-12-17,"December 14, 2021",Actual,2021-12-14,NA,Interventional,NA,NA,GlowTest COVID-19 Antigen Home Test Kit QRI Use Study,GlowTest COVID-19 Antigen Home Test Kit Usability Study,Completed,NA,Not Applicable,33,Actual,Arion Bio,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:13:33Z,2021-12-21T09:13:33Z,45
NCT04816669,NA,2021-03-24,NA,NA,2021-12-17,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-12-17,2021-12-20,Estimate,"April 1, 2021",Actual,2021-04-01,December 2021,2021-12-31,"December 1, 2021",Actual,2021-12-01,"December 1, 2021",Actual,2021-12-01,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE",Completed,NA,Phase 3,629,Actual,BioNTech SE,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-21T09:18:14Z,2021-12-21T09:18:14Z,45
NCT04588480,NA,2020-10-14,NA,NA,2021-12-17,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-12-17,2021-12-20,Estimate,"October 21, 2020",Actual,2020-10-21,December 2021,2021-12-31,"November 25, 2021",Actual,2021-11-25,"November 25, 2021",Actual,2021-11-25,NA,Interventional,NA,NA,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, AND OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY JAPANESE ADULTS",Completed,NA,Phase 1/Phase 2,160,Actual,BioNTech SE,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-21T09:20:13Z,2021-12-21T09:20:13Z,45
NCT04373707,NA,2020-05-01,NA,NA,2021-12-17,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-12-17,2021-12-20,Estimate,"May 13, 2020",Actual,2020-05-13,December 2021,2021-12-31,"September 14, 2021",Actual,2021-09-14,"April 29, 2021",Actual,2021-04-29,NA,Interventional,COVI-DOSE,NA,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE,Completed,NA,Phase 4,1000,Actual,"Central Hospital, Nancy, France",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:21:42Z,2021-12-21T09:21:42Z,45
NCT04952857,NA,2021-06-08,NA,NA,2021-12-19,2021-07-03,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-12-19,2021-12-21,Estimate,"August 1, 2021",Actual,2021-08-01,December 2021,2021-12-31,"December 10, 2021",Actual,2021-12-10,"November 30, 2021",Actual,2021-11-30,NA,Interventional,SHADE-S,NA,"Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease","Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease",Completed,NA,Phase 4,90,Actual,Postgraduate Institute of Medical Education and Research,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:15:07Z,2021-12-22T09:15:07Z,43
NCT04821934,NA,2021-03-26,NA,NA,2021-12-20,2021-03-29,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-12-20,2021-12-21,Estimate,"March 26, 2021",Actual,2021-03-26,December 2021,2021-12-31,"December 20, 2021",Actual,2021-12-20,"December 20, 2021",Actual,2021-12-20,NA,Interventional,NA,NA,Tele-rehabilitation Program After Hospitalization for COVID-19,Efficacy of a Tele-rehabilitation Program After Hospitalization for COVID-19 Pneumonia: a Randomized Controlled Trial,Completed,NA,Not Applicable,74,Actual,Istituti Clinici Scientifici Maugeri SpA,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-22T09:16:47Z,2021-12-22T09:16:47Z,42
NCT04644328,NA,2020-11-13,2021-10-26,NA,2021-12-15,2020-11-20,2020-11-25,Actual,2021-12-15,2021-12-21,Estimate,NA,NA,NA,2021-12-15,2021-12-21,Estimate,"November 12, 2020",Actual,2020-11-12,December 2021,2021-12-31,"February 11, 2021",Actual,2021-02-11,"February 11, 2021",Actual,2021-02-11,NA,Interventional,NA,"The experiment was run during two periods: Thanksgiving (Period 1) and Christmas (Period 2). During Thanksgiving, 820 counties were analyzed (410 high-intensity, 410 low-intensity). Of these counties, 767 were analyzed during Christmas (386 high-intensity, 381 low-intensity). Fewer counties were analyzed at Christmas because we removed counties in rural, conservative areas from the study due to potential negative impacts resulting from polarization in the wake of the 2020 presidential election.",The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign,The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign,Completed,NA,Not Applicable,820,Actual,"National Bureau of Economic Research, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,The pre-analysis plan will be posted publicly. The ability to share IPD will be based on discussions with our partner organization.,2021-12-22T09:18:25Z,2021-12-22T09:18:25Z,47
NCT05148832,NA,2021-12-05,NA,NA,2021-12-07,2021-12-05,2021-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-12-07,2021-12-22,Actual,"May 1, 2021",Actual,2021-05-01,December 2021,2021-12-31,"November 15, 2021",Actual,2021-11-15,"August 20, 2021",Actual,2021-08-20,NA,Interventional,NA,NA,Administration of Systemic Corticosteroids and the Recovery of Gustatory Functions in Patients With COVID-19,Association Between Administration of Systemic Corticosteroids and the Recovery of Olfactory and/or Gustatory Functions in Patients With COVID-19: A Prospective Cohort Study,Completed,NA,Not Applicable,80,Actual,Fayoum University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:21:55Z,2021-12-29T08:21:55Z,55
NCT05063825,NA,2021-09-30,NA,NA,2021-12-22,2021-09-30,2021-10-01,Actual,NA,NA,NA,NA,NA,NA,2021-12-22,2021-12-23,Actual,"October 6, 2021",Actual,2021-10-06,December 2021,2021-12-31,"December 13, 2021",Actual,2021-12-13,"December 13, 2021",Actual,2021-12-13,NA,Interventional,NA,NA,Understanding Reactions to Emotional Material in the Media During COVID-19 - Study 2,Understanding Reactions to Emotional Material in the Media During COVID-19 and the Connections to Cognitive Activities - Study 2,Completed,NA,Not Applicable,98,Actual,Uppsala University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:25:52Z,2021-12-29T08:25:52Z,40
NCT05057923,NA,2021-09-21,2021-12-18,NA,2021-12-22,2021-09-23,2021-09-27,Actual,2021-12-22,2021-12-23,Actual,NA,NA,NA,2021-12-22,2021-12-23,Actual,"July 10, 2021",Actual,2021-07-10,December 2021,2021-12-31,"November 1, 2021",Actual,2021-11-01,"October 20, 2021",Actual,2021-10-20,NA,Interventional,NA,The baseline population does not differ from the participant flow.,The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores,The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores Expressing and Displaying the Receptor Binding Domain of Spike Protein of SARS-COV2,Completed,NA,Not Applicable,9,Actual,DreamTec Research Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:25:59Z,2021-12-29T08:25:59Z,40
NCT04951310,NA,2021-06-16,NA,NA,2021-12-21,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-12-21,2021-12-22,Actual,"June 7, 2021",Actual,2021-06-07,December 2021,2021-12-31,"August 14, 2021",Actual,2021-08-14,"August 14, 2021",Actual,2021-08-14,NA,Interventional,NA,NA,COVID-19 Vaccinations With a Sweepstakes,COVID-19 Vaccinations With a Sweepstakes,Completed,NA,Not Applicable,1241810,Actual,University of Pennsylvania,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:28:39Z,2021-12-29T08:28:39Z,41
NCT04920890,NA,2021-05-26,NA,NA,2021-12-21,2021-06-09,2021-06-10,Actual,NA,NA,NA,NA,NA,NA,2021-12-21,2021-12-23,Actual,"May 16, 2021",Actual,2021-05-16,December 2021,2021-12-31,"November 29, 2021",Actual,2021-11-29,"July 20, 2021",Actual,2021-07-20,NA,Interventional,NA,NA,Radiofrequency Intervention in Post COVID-19 Patients,"Radiofrequency Intervention in Neurological, Pneumological and Musculoskeletal Pathologies Post COVID-19",Completed,NA,Not Applicable,24,Actual,Clinica Gema Leon,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The request for the data will be studied and considered upon prior and justified request.,2021-12-29T08:29:21Z,2021-12-29T08:29:21Z,41
NCT04894305,NA,2021-05-18,NA,NA,2021-12-21,2021-05-18,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-12-21,2021-12-22,Actual,"May 25, 2021",Actual,2021-05-25,December 2021,2021-12-31,"December 8, 2021",Actual,2021-12-08,"December 8, 2021",Actual,2021-12-08,NA,Interventional,NA,NA,A Study of Ad26.COV2.S in Healthy Adults (COVID-19),"A Phase 1, Randomized, Observer-blind Study to Compare the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S at a Single Dose of 5*10^10 vp in 2 Different Volumes in Healthy Adults",Completed,NA,Phase 1,380,Actual,Janssen Vaccines & Prevention B.V.,NA,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-29T08:29:56Z,2021-12-29T08:29:56Z,41
NCT04841759,NA,2021-04-07,NA,NA,2021-12-23,2021-04-09,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-12-23,2021-12-27,Actual,"April 1, 2021",Actual,2021-04-01,December 2021,2021-12-31,"December 22, 2021",Actual,2021-12-22,"December 3, 2021",Actual,2021-12-03,NA,Interventional,NA,NA,The Effects of a Multi-factorial Rehabilitation Program for Healthcare Workers Suffering From Post-COVID-19 Fatigue Syndrome,The Effects of a Multi-factorial Rehabilitation Program for Healthcare Workers Suffering From Post-COVID-19 Fatigue Syndrome,Completed,NA,Not Applicable,46,Actual,Medical University of Vienna,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:30:56Z,2021-12-29T08:30:56Z,39
NCT04795557,NA,2021-03-08,NA,NA,2021-12-27,2021-03-11,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-12-27,2021-12-28,Estimate,"April 19, 2021",Actual,2021-04-19,December 2021,2021-12-31,"December 26, 2021",Actual,2021-12-26,"November 11, 2021",Actual,2021-11-11,NA,Interventional,NA,NA,Efficacy of Adaptogens in Patients With Long COVID-19,"Effect of ADAPT232 Supplementation on Recovery of Patients in Rehabilitation Period in Long COVID-19: a Randomized, Double-blind, Placebo-controlled Trial",Completed,NA,Phase 2/Phase 3,100,Actual,Swedish Herbal Institute AB,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:31:44Z,2021-12-29T08:31:44Z,35
NCT04537208,NA,2020-09-02,NA,NA,2021-12-23,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-12-23,2021-12-27,Actual,"September 3, 2020",Actual,2020-09-03,December 2021,2021-12-31,"November 19, 2021",Actual,2021-11-19,"November 19, 2021",Actual,2021-11-19,NA,Interventional,NA,NA,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older,Completed,NA,Phase 1/Phase 2,442,Actual,Sanofi,NA,21,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-12-29T08:36:50Z,2021-12-29T08:36:50Z,39
NCT04632706,NA,2020-10-26,2021-12-14,NA,2021-12-22,2020-11-16,2020-11-17,Actual,2021-12-22,2021-12-27,Actual,NA,NA,NA,2021-12-22,2021-12-27,Actual,"September 22, 2020",Actual,2020-09-22,December 2021,2021-12-31,"March 9, 2021",Actual,2021-03-09,"March 9, 2021",Actual,2021-03-09,NA,Interventional,NA,NA,Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19,"A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Active IMP in Healthy Volunteers",Completed,NA,Phase 1,24,Actual,MedinCell S.A,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:34:54Z,2021-12-29T08:34:54Z,40
NCT04631367,NA,2020-11-13,NA,NA,2021-12-23,2020-11-13,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-12-23,2021-12-28,Estimate,"February 1, 2021",Actual,2021-02-01,December 2021,2021-12-31,"October 31, 2021",Actual,2021-10-31,"August 20, 2021",Actual,2021-08-20,NA,Interventional,NA,NA,mHealth Intervention for Increasing COVID-19 Prevention Practices With Urban Refugee and Displaced Youth in Uganda,"Kukaa Salama (Staying Safe): A Pre-Post Trial of a mHealth Social Group for Increasing COVID-19 Prevention Practices With Urban Refugee and Displaced Youth in Kampala, Uganda",Completed,NA,Not Applicable,330,Actual,University of Toronto,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The data collected during this study will not be made publicly available due to the possibility of identifying participants using a combination of common demographic and response characteristics. The data may be made available from the corresponding author on reasonable request and upon completing suitable data sharing agreements.,2021-12-29T08:34:58Z,2021-12-29T08:34:58Z,39
NCT04646044,NA,2020-11-14,NA,NA,2021-12-23,2020-11-24,2020-11-27,Actual,NA,NA,NA,NA,NA,NA,2021-12-23,2021-12-27,Actual,"November 13, 2020",Actual,2020-11-13,December 2021,2021-12-31,"May 18, 2021",Actual,2021-05-18,"May 11, 2021",Actual,2021-05-11,NA,Interventional,NA,NA,A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19,"A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Mild COVID-19",Completed,NA,Phase 1,30,Actual,Nektar Therapeutics,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:34:37Z,2021-12-29T08:34:37Z,39
NCT04559035,NA,2020-09-21,NA,NA,2021-12-15,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-12-15,2021-12-28,Estimate,"September 24, 2020",Actual,2020-09-24,December 2021,2021-12-31,"November 4, 2021",Actual,2021-11-04,"January 18, 2021",Actual,2021-01-18,NA,Interventional,NA,NA,Nasal Irrigation to Reduce COVID-19 Morbidity,Nasal Irrigation to Reduce COVID-19 Morbidity,Completed,NA,Not Applicable,239,Actual,Augusta University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:36:28Z,2021-12-29T08:36:28Z,47
NCT04535791,NA,2020-07-30,NA,NA,2021-12-07,2020-08-31,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-12-07,2021-12-22,Actual,"July 15, 2020",Actual,2020-07-15,December 2021,2021-12-31,"July 15, 2021",Actual,2021-07-15,"December 30, 2020",Actual,2020-12-30,NA,Interventional,COVID-19,NA,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring or Evolving Into the Severe Form of COVID-19 in Healthcare Workers Caring for Patients With the Disease. Blinded Randomized Clinical Trial,Completed,NA,Phase 3,321,Actual,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:36:51Z,2021-12-29T08:36:51Z,55
NCT04412018,NA,2020-05-29,NA,NA,2021-12-21,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-12-21,2021-12-22,Actual,"June 4, 2020",Actual,2020-06-04,December 2021,2021-12-31,"December 12, 2020",Actual,2020-12-12,"November 6, 2020",Actual,2020-11-06,NA,Interventional,NA,NA,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19),Completed,NA,Phase 2,100,Actual,Canadian Medical and Surgical Knowledge Translation Research Group,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:38:35Z,2021-12-29T08:38:35Z,41
NCT04359797,NA,2020-04-20,2021-12-13,NA,2021-12-22,2020-04-20,2020-04-24,Actual,2021-12-22,2021-12-27,Actual,NA,NA,NA,2021-12-22,2021-12-27,Actual,"April 27, 2020",Actual,2020-04-27,December 2021,2021-12-31,"January 17, 2021",Actual,2021-01-17,"December 17, 2020",Actual,2020-12-17,NA,Interventional,NA,NA,COVID-19 Patient Positioning Pragmatic Trial,Pragmatic Trial Exploring Impact of Patient Positioning in the Management of Patients Infected With COVID-19: Supine vs. Prone,Completed,NA,Not Applicable,501,Actual,Vanderbilt University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.,Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee.,NA,Yes,Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.,2021-12-29T08:39:21Z,2021-12-29T08:39:21Z,40
NCT04682873,NA,2020-12-22,NA,NA,2021-12-08,2020-12-23,2020-12-24,Actual,NA,NA,NA,NA,NA,NA,2021-12-08,2021-12-29,Actual,"May 15, 2020",Actual,2020-05-15,November 2021,2021-11-30,"March 26, 2021",Actual,2021-03-26,"March 26, 2021",Actual,2021-03-26,NA,Interventional,NA,NA,"A Clinical Study to Assess the Efficacy and Safety of AmizonÂ® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus","A Multi-centre, Double-blind, Randomised, Placebo-controlled, Trial to Assess the Efficacy and Safety of AmizonÂ® Max, Manufactured by Farmak JSC, in Combination With Basic Treatment, in Subjects With Moderate Covid-19, Which is Caused by the SARS-CoV-2 Virus",Completed,NA,Phase 3,592,Actual,"Joint Stock Company ""Farmak""",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-30T20:42:53Z,2021-12-30T20:42:53Z,54
NCT04420741,NA,2020-06-04,NA,NA,2021-12-08,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-12-08,2021-12-29,Actual,"June 15, 2020",Actual,2020-06-15,December 2021,2021-12-31,"April 23, 2021",Actual,2021-04-23,"February 23, 2021",Actual,2021-02-23,NA,Interventional,COMBAT-COVID,NA,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng)/ Kilo(kg)/Minute(Min)) in Patients With COVID-19 Induced Pulmonary Endotheliopathy,Completed,NA,Phase 2,80,Actual,"Rigshospitalet, Denmark",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-30T20:45:23Z,2021-12-30T20:45:23Z,54
NCT04407286,NA,2020-05-19,NA,NA,2021-12-29,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-12-29,2021-12-30,Estimate,"May 19, 2020",Actual,2020-05-19,December 2021,2021-12-31,"November 30, 2020",Actual,2020-11-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,NA,Vitamin D Testing and Treatment for COVID 19,Vitamin D Testing and Treatment for Adults With COVID 19,Completed,NA,Phase 1,41,Actual,Arizona State University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Contact us if you wish to discuss sharing of de-identified data,2021-12-30T20:45:30Z,2021-12-30T20:45:30Z,33
NCT04527081,NA,2020-08-24,NA,NA,2021-10-01,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"August 31, 2020",Actual,2020-08-31,October 2021,2021-10-31,"September 24, 2021",Actual,2021-09-24,"November 9, 2020",Actual,2020-11-09,NA,Interventional,NA,NA,Study of COVID-19 DNA Vaccine (AG0302-COVID19),"A Randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults",Completed,NA,Phase 1/Phase 2,30,Actual,"AnGes, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:14:32Z,2022-01-04T08:14:32Z,122
NCT04525742,NA,2020-06-28,NA,NA,2020-10-31,2020-08-23,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2020-10-31,2020-11-03,Actual,"July 5, 2020",Actual,2020-07-05,October 2020,2020-10-31,"September 15, 2020",Actual,2020-09-15,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,NA,COVID-19 Pandemic and Parents of Disabled Children,COVID-19 Pandemic From the Perspective of Parents of Disabled Children,Completed,NA,Not Applicable,309,Actual,Gaziosmanpasa Research and Education Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Research is planned to bu conducted between June 15 th and July 15 th 2020. After 15 th of July in 1 week coming statistical analysis will be finished and than in 3 weeks article will be written,In necessary cases colleced data from the research will be shared with the local ethical committe,NA,Yes,Study protocol was established by Berrin Huner and Ebru Yilmaz YalcÄ±nkaya Statistical analysis (Power analysis) was established by Ozden Ozyemisci Taskiran Informed consent was written by Berrin Huner,2022-01-04T08:15:38Z,2022-01-04T08:15:38Z,457
NCT04525417,NA,2020-08-21,NA,NA,2021-02-02,2020-08-22,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"April 25, 2020",Actual,2020-04-25,August 2020,2020-08-31,"October 25, 2020",Actual,2020-10-25,"September 25, 2020",Actual,2020-09-25,NA,Interventional,NA,NA,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,Use of Rapid Covid-19 Antibody Test Marketed by AAZ Laboratories in Healthcare Workers Presumably Being Infected by SARS-CoV-2,Completed,NA,Not Applicable,75,Actual,Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:15:52Z,2022-01-04T08:15:52Z,363
NCT04522986,NA,2020-08-20,NA,NA,2021-03-16,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-18,Actual,"August 21, 2020",Actual,2020-08-21,March 2021,2021-03-31,"February 2, 2021",Actual,2021-02-02,"February 2, 2021",Actual,2021-02-02,NA,Interventional,COVID-19,NA,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,Completed,NA,Phase 1,6,Actual,"Rohto Pharmaceutical Co., Ltd.",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T08:17:45Z,2022-01-04T08:17:45Z,321
NCT04524663,NA,2020-04-10,NA,NA,2021-06-08,2020-08-20,2020-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-11,Actual,"December 19, 2020",Actual,2020-12-19,June 2021,2021-06-30,"May 15, 2021",Actual,2021-05-15,"May 15, 2021",Actual,2021-05-15,NA,Interventional,COPS-2003,NA,Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients,"A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild-Moderate COVID-19",Completed,NA,Phase 2,48,Actual,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:16:24Z,2022-01-04T08:16:24Z,237
NCT04522830,NA,2020-08-18,NA,NA,2021-04-09,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-13,Actual,"July 30, 2020",Actual,2020-07-30,April 2021,2021-04-30,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,BTL-TML-COVID,NA,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,"A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 Infection",Completed,NA,Phase 2,28,Actual,"Beech Tree Labs, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:17:41Z,2022-01-04T08:17:41Z,297
NCT04522128,NA,2020-05-12,NA,NA,2021-09-29,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-09-30,Actual,"May 22, 2020",Actual,2020-05-22,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"September 1, 2021",Actual,2021-09-01,NA,Interventional,NA,NA,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Completed,NA,Not Applicable,274,Actual,University of Manchester,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,WHOQOL COMBI data cannot be shared with researchers outside of the research team.,2022-01-04T08:18:18Z,2022-01-04T08:18:18Z,124
NCT04521309,NA,2020-05-07,NA,NA,2021-03-21,2020-08-19,2020-08-20,Actual,NA,NA,NA,NA,NA,NA,2021-03-21,2021-03-24,Actual,"June 19, 2020",Actual,2020-06-19,March 2021,2021-03-31,"February 8, 2021",Actual,2021-02-08,"January 26, 2021",Actual,2021-01-26,NA,Interventional,NA,NA,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 Patients,Completed,NA,Phase 1/Phase 2,50,Actual,Dow University of Health Sciences,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:19:01Z,2022-01-04T08:19:01Z,316
NCT04519385,NA,2020-08-17,NA,NA,2020-08-21,2020-08-17,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-21,2020-08-25,Actual,"March 1, 2020",Actual,2020-03-01,August 2020,2020-08-31,"August 5, 2020",Actual,2020-08-05,"July 1, 2020",Actual,2020-07-01,NA,Interventional,NA,NA,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Completed,NA,Not Applicable,69,Actual,South Valley University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T08:20:31Z,2022-01-04T08:20:31Z,528
NCT04517422,NA,2020-08-16,NA,NA,2021-05-02,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-06,Actual,"August 19, 2020",Actual,2020-08-19,May 2021,2021-05-31,"February 2, 2021",Actual,2021-02-02,"February 2, 2021",Actual,2021-02-02,NA,Interventional,NA,NA,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Efficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota: A Randomized Clinical Trial,Completed,NA,Not Applicable,300,Actual,"AB Biotics, SA",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"From the moment of manuscript publication, without time limit.",Formal request with a defined analysis plan. Please contact espadaler@ab-biotics.com or medical@ab-biotics.com,NA,Yes,"Deidentified individual patient data (IPD), together with data dictionary defining each field in the set, will be made public upon any formal requests with a defined analysis plan.",2022-01-04T08:21:49Z,2022-01-04T08:21:49Z,274
NCT04517006,NA,2020-08-14,NA,NA,2021-05-25,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-26,Actual,"January 31, 2021",Actual,2021-01-31,May 2021,2021-05-31,"April 4, 2021",Actual,2021-04-04,"April 4, 2021",Actual,2021-04-04,NA,Interventional,NA,NA,Prosocial Behavior Can Safeguard Mental Health and Foster Emotional Well-being During the COVID-19 Pandemic,Prosocial Behavior Can Safeguard Mental Health and Foster Emotional Well-being During the COVID-19 Pandemic: A Randomized Clinical Trial,Completed,NA,Not Applicable,1328,Actual,University of Toronto,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"After the publication of the paper and perpetually. The investigators plan to publish the study as a registered report, so study information will also be available as part of the report protocol.",NA,https://osf.io/63yg9/,Yes,"Using an OSF repository, other researchers and readers of the published study will have access to the IPD.",2022-01-04T08:21:57Z,2022-01-04T08:21:57Z,251
NCT04516759,NA,2020-08-14,NA,NA,2021-09-09,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-16,Actual,"August 12, 2020",Actual,2020-08-12,September 2021,2021-09-30,"May 12, 2021",Actual,2021-05-12,"April 25, 2021",Actual,2021-04-25,NA,Interventional,ARCADIA,NA,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,"A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19",Completed,NA,Phase 2,156,Actual,St George Street Capital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Requests for access to the data will be accepted beginning 6 months after article publication and will continue to be accepted for up to 5 years after publication.,Researchers must submit a methodologically sound research proposal to St George Street using the contact details provided on our website. See link below.,http://www.sgscapital.org,Yes,Qualified researchers can request access to deidentified individual participant data (IDP) that underlie the published clinical trial results.,2022-01-04T08:22:11Z,2022-01-04T08:22:11Z,144
NCT04514900,NA,2020-07-20,NA,NA,2021-04-27,2020-08-12,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-30,Actual,"September 23, 2020",Actual,2020-09-23,April 2021,2021-04-30,"March 8, 2021",Actual,2021-03-08,"March 8, 2021",Actual,2021-03-08,NA,Interventional,iREACH,NA,Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program,Exploring the Optimal Treatment Components for a Contactless Online Group-based Behavioral Weight Loss Program for the COVID 19 Pandemic,Completed,NA,Not Applicable,73,Actual,University of South Carolina,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:23:27Z,2022-01-04T08:23:27Z,279
NCT04512027,NA,2020-08-11,NA,NA,2020-10-16,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"September 15, 2020",Actual,2020-09-15,October 2020,2020-10-31,"October 16, 2020",Actual,2020-10-16,"September 19, 2020",Actual,2020-09-19,NA,Interventional,Prolectin-M,NA,Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,"Effect of Prolectin-M; a (1-6)-Alpha-D-Mannopyranose on SarsCoV2 Viral Copy Numbers: A Proof of Concept, Open Label Randomized Controlled Trial",Completed,NA,Not Applicable,10,Actual,Composite Interceptive Med Science,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:25:28Z,2022-01-04T08:25:28Z,472
NCT04511949,NA,2020-08-12,NA,NA,2021-02-02,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"July 12, 2020",Actual,2020-07-12,February 2021,2021-02-28,"November 30, 2020",Actual,2020-11-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,FAMICOV,NA,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Completed,NA,Not Applicable,500,Actual,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T08:25:51Z,2022-01-04T08:25:51Z,363
NCT04510493,NA,2020-08-11,NA,NA,2021-09-07,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"October 23, 2020",Actual,2020-10-23,September 2021,2021-09-30,"August 17, 2021",Actual,2021-08-17,"August 17, 2021",Actual,2021-08-17,NA,Interventional,CanCovDia,NA,Canakinumab in Patients With COVID-19 and Type 2 Diabetes,Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial,Completed,NA,Phase 3,116,Actual,"University Hospital, Basel, Switzerland",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T08:26:47Z,2022-01-04T08:26:47Z,146
NCT04506268,NA,2020-08-07,NA,NA,2021-03-10,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-03-10,2021-03-11,Actual,"September 9, 2020",Actual,2020-09-09,March 2021,2021-03-31,"October 30, 2020",Actual,2020-10-30,"October 30, 2020",Actual,2020-10-30,NA,Interventional,COVID SAFE,NA,COVID-19 SAFE Enrollment,Opt-In Versus Opt-Out for COVID Screening Assessment for Exposure,Completed,NA,Not Applicable,412,Actual,University of Pennsylvania,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:30:03Z,2022-01-04T08:30:03Z,327
NCT04505761,NA,2020-07-03,NA,NA,2021-04-05,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-06,Actual,"August 1, 2020",Actual,2020-08-01,June 2020,2020-06-30,"March 31, 2021",Actual,2021-03-31,"February 1, 2021",Actual,2021-02-01,NA,Interventional,COVRehab,NA,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19","The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19: An Explorative Study",Completed,NA,Not Applicable,48,Actual,Radboud University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Only upon asking.,2022-01-04T08:30:35Z,2022-01-04T08:30:35Z,301
NCT04504877,NA,2020-08-04,NA,NA,2021-09-27,2020-08-06,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"June 16, 2020",Actual,2020-06-16,September 2021,2021-09-30,"December 16, 2020",Actual,2020-12-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,BONSAI,NA,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling (Bonsai Study) wIth COVID-19: a Randomised Controlled Trial,Completed,NA,Phase 2/Phase 3,120,Actual,University of Sao Paulo,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately the following publication. No end date,"Researchers who provide a methodologically sound proposal. Depending on the level of the proposed use of data, approval by an independent review committee will be required for the identified purpose.",NA,Yes,"All of the individual participant data collected during the trial, after deidentification",2022-01-04T08:31:08Z,2022-01-04T08:31:08Z,126
NCT04501445,NA,2020-08-04,NA,NA,2021-09-15,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"September 14, 2020",Actual,2020-09-14,September 2021,2021-09-30,"July 31, 2021",Actual,2021-07-31,"April 8, 2021",Actual,2021-04-08,NA,Interventional,NA,NA,Psychological Symptoms and Families of COVID-19 Patients,Relieving the Burden of Psychological Symptoms Among Families of Critically Ill Patients With COVID-19,Completed,NA,Not Applicable,90,Actual,Rush University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T08:33:41Z,2022-01-04T08:33:41Z,138
NCT04500067,NA,2020-07-15,NA,NA,2020-10-12,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"May 7, 2020",Actual,2020-05-07,October 2020,2020-10-31,"September 15, 2020",Actual,2020-09-15,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,NA,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment","An Open-label Multicenter Randomized Trial to Evaluate the Efficacy of Bioven, Manufactured by Biopharma Plasma, LLC, in Complex Therapy of Patients With Pneumonia Induced by COVID-19 / SARS-CoV-2",Completed,NA,Phase 3,76,Actual,Biopharma Plasma LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After trial result publication 3 months later,"For specialists in medicine, pharmacy, scientists",NA,Yes,"After completion of the trial, results will be published. Access to parts CSR planned after the release of scientific publications",2022-01-04T08:34:34Z,2022-01-04T08:34:34Z,476
NCT04498442,NA,2020-08-03,NA,NA,2021-09-23,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"May 22, 2020",Actual,2020-05-22,September 2021,2021-09-30,"October 22, 2020",Actual,2020-10-22,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,NA,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls","A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",Completed,NA,Not Applicable,8519,Actual,Beth Israel Deaconess Medical Center,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:35:41Z,2022-01-04T08:35:41Z,130
NCT04498936,NA,2020-04-14,NA,NA,2020-11-10,2020-08-03,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"July 15, 2020",Actual,2020-07-15,November 2020,2020-11-30,"October 30, 2020",Actual,2020-10-30,"October 30, 2020",Actual,2020-10-30,NA,Interventional,NA,NA,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,"Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial",Completed,NA,Phase 4,240,Actual,Assiut University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:35:35Z,2022-01-04T08:35:35Z,447
NCT04497987,NA,2020-07-31,NA,NA,2021-07-02,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-06,Actual,"August 2, 2020",Actual,2020-08-02,July 2021,2021-07-31,"May 20, 2021",Actual,2021-05-20,"January 16, 2021",Actual,2021-01-16,NA,Interventional,BLAZE-2,NA,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 Alone and in Combination With LY3832479 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff; a NIAID and Lilly Collaborative Study",Completed,NA,Phase 3,1374,Actual,Eli Lilly and Company,NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2022-01-04T08:36:26Z,2022-01-04T08:36:26Z,213
NCT04497623,NA,2020-07-27,NA,NA,2020-09-22,2020-08-01,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-24,Actual,"July 28, 2020",Actual,2020-07-28,September 2020,2020-09-30,"September 20, 2020",Actual,2020-09-20,"August 13, 2020",Actual,2020-08-13,NA,Interventional,SabanaHerons,NA,"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.","Clinical Evaluation of Ventilator Innovation Product in Colombia in the SARS Pandemic Covid 19, Unisabana Herons - A Cohort Study - Phase 1",Completed,NA,Not Applicable,5,Actual,FundaciÃ³n Neumologica Colombiana,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The clinical and ventilatory data of the patients will be entered into an anonymized database hosted on the RedCap platform with which the University of La Sabana has an agreement.,2022-01-04T08:36:31Z,2022-01-04T08:36:31Z,496
NCT04497298,NA,2020-07-31,NA,NA,2021-07-06,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-09,Actual,"August 10, 2020",Actual,2020-08-10,July 2021,2021-07-31,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,COVID-19-101,NA,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,"A Randomized, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, a Measles Vector-based Vaccine Candidate Against COVID-19 in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase",Completed,NA,Phase 1,90,Actual,Institut Pasteur,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:36:47Z,2022-01-04T08:36:47Z,209
NCT04495101,NA,2020-07-28,NA,NA,2021-07-07,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"July 29, 2020",Actual,2020-07-29,July 2021,2021-07-31,"June 10, 2021",Actual,2021-06-10,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19,"A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19",Completed,NA,Phase 2,100,Actual,Grifols Therapeutics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:38:23Z,2022-01-04T08:38:23Z,208
NCT04494984,NA,2020-07-29,NA,NA,2021-02-09,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-11,Actual,"July 27, 2020",Actual,2020-07-27,February 2021,2021-02-28,"December 30, 2020",Actual,2020-12-30,"November 23, 2020",Actual,2020-11-23,NA,Interventional,NA,NA,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.","A Stage 2/3, Adaptive, Randomized, Controlled, Double-blind Study to Investigate the Pharmacokinetics, Efficacy and Safety of the Hyperimmune Equine Serum (INM005) in Adult Patients With Moderate to Severe Confirmed SARS-CoV2 Disease.",Completed,NA,Phase 2/Phase 3,242,Actual,Inmunova S.A.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:38:35Z,2022-01-04T08:38:35Z,356
NCT04494204,NA,2020-07-28,NA,NA,2020-12-19,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-19,2020-12-22,Actual,"August 7, 2020",Actual,2020-08-07,December 2020,2020-12-31,"December 20, 2020",Actual,2020-12-20,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,NA,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,"An Open Label, Multicenter, Randomized, Controlled, Clinical Study to Evaluate the Efficacy and Safety of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets Compared With Standard Treatment Protocol in the Treatment of Mild to Moderate COVID-19 Patients.",Completed,NA,Phase 2/Phase 3,100,Actual,Nutrin GmbH,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"The trial is meant for pandemic, and any data is fruitful to the society will be shared with researchers only, without compromising personal data of the participant.",2022-01-04T08:39:15Z,2022-01-04T08:39:15Z,408
NCT04492501,NA,2020-07-28,NA,NA,2020-07-28,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-30,Actual,"April 1, 2020",Actual,2020-04-01,July 2020,2020-07-31,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,NA,Interventional,NA,NA,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,"Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19",Completed,NA,Not Applicable,600,Actual,UNICEF,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months from completion of study,email,NA,Yes,data can be shared on demand in SPSS sheet,2022-01-04T08:40:37Z,2022-01-04T08:40:37Z,552
NCT04492527,NA,2020-07-28,NA,NA,2021-08-26,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-30,Actual,"July 28, 2020",Actual,2020-07-28,August 2021,2021-08-31,"June 30, 2021",Actual,2021-06-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,Student-delivered Telehealth Program for COVID-19 Education and Health Promotion,A Student-delivered Community Outreach teleheAlth Program for Covid Education and Health Promotion (COACH),Completed,NA,Not Applicable,75,Actual,University of British Columbia,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:40:38Z,2022-01-04T08:40:38Z,158
NCT04490278,NA,2020-07-23,NA,NA,2021-10-04,2020-07-23,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-06,Actual,"September 29, 2020",Actual,2020-09-29,October 2021,2021-10-31,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,NA,CoV-PICS: A Virtual Post-ICU Clinic,"COVID-19 Virtual Post Intensive Care Syndrome (CoV-PICS) Clinic: Modern, Convenient and Practical Recovery Care",Completed,NA,Not Applicable,23,Actual,Washington University School of Medicine,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T08:42:07Z,2022-01-04T08:42:07Z,119
NCT04489446,NA,2020-07-25,NA,NA,2021-09-27,2020-07-25,2020-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"August 19, 2020",Actual,2020-08-19,September 2021,2021-09-30,"June 30, 2021",Actual,2021-06-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,Sildenafil in COVID-19,Sildenafil for Treating Patients With COVID-19 and Perfusion Mismatch: A Pilot Randomised Trial,Completed,NA,Phase 1/Phase 2,40,Actual,Universidad Nacional Andres Bello,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T08:42:41Z,2022-01-04T08:42:41Z,126
NCT04488796,NA,2020-07-22,NA,NA,2021-04-06,2020-07-26,2020-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"September 7, 2020",Actual,2020-09-07,April 2021,2021-04-30,"December 16, 2020",Actual,2020-12-16,"December 16, 2020",Actual,2020-12-16,NA,Interventional,NA,NA,STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,"STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers, a Pilot Randomized Controlled Trial",Completed,NA,Not Applicable,148,Actual,"Western University, Canada",NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:43:02Z,2022-01-04T08:43:02Z,300
NCT04487574,NA,2020-07-22,NA,NA,2020-11-11,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"July 25, 2020",Actual,2020-07-25,November 2020,2020-11-30,"October 29, 2020",Actual,2020-10-29,"October 29, 2020",Actual,2020-10-29,NA,Interventional,NA,NA,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,"A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With COVID-19",Completed,NA,Phase 3,118,Actual,RSV Therapeutics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:44:14Z,2022-01-04T08:44:14Z,446
NCT04486508,NA,2020-07-22,NA,NA,2021-08-14,2020-07-22,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-14,2021-08-17,Actual,"July 30, 2020",Actual,2020-07-30,August 2021,2021-08-31,"July 5, 2021",Actual,2021-07-05,"April 4, 2021",Actual,2021-04-04,NA,Interventional,INSPIRATION,NA,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19,Completed,NA,Phase 3,600,Actual,Rajaie Cardiovascular Medical and Research Center,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:44:40Z,2022-01-04T08:44:40Z,170
NCT04486313,NA,2020-07-23,NA,NA,2021-03-31,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-01,Actual,"August 13, 2020",Actual,2020-08-13,March 2021,2021-03-31,"February 8, 2021",Actual,2021-02-08,"February 8, 2021",Actual,2021-02-08,NA,Interventional,NA,NA,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,"Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19",Completed,NA,Phase 3,1092,Actual,Romark Laboratories L.C.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T08:44:54Z,2022-01-04T08:44:54Z,306
NCT04486482,NA,2020-07-23,NA,NA,2021-08-12,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"January 12, 2021",Actual,2021-01-12,August 2021,2021-08-31,"March 30, 2021",Actual,2021-03-30,"March 30, 2021",Actual,2021-03-30,NA,Interventional,NA,NA,A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function,"An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients With Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting",Completed,NA,Not Applicable,49,Actual,Kaleido Biosciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:44:52Z,2022-01-04T08:44:52Z,172
NCT04485169,NA,2020-07-21,NA,NA,2020-09-24,2020-07-22,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,Plex,NA,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm; a Retrospective Propensity Matched Control Study,Completed,NA,Not Applicable,280,Actual,UNICEF,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Data is available right now and will remain available (6 months),By email,NA,Yes,data can be shared on demand in SPSS sheet,2022-01-04T08:45:34Z,2022-01-04T08:45:34Z,494
NCT04484493,NA,2020-07-22,NA,NA,2020-11-11,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"August 8, 2020",Actual,2020-08-08,November 2020,2020-11-30,"November 3, 2020",Actual,2020-11-03,"October 25, 2020",Actual,2020-10-25,NA,Interventional,NA,NA,Corticosteroid Nasal Spray in COVID-19 Anosmia,Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients,Completed,NA,Phase 3,100,Actual,Benha University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:46:11Z,2022-01-04T08:46:11Z,446
NCT04483830,NA,2020-07-22,NA,NA,2020-09-07,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-09,Actual,"June 5, 2020",Actual,2020-06-05,September 2020,2020-09-30,"September 7, 2020",Actual,2020-09-07,"August 6, 2020",Actual,2020-08-06,NA,Interventional,SulES-COVID,NA,Suloexide in the Treatment of Early Stages of COVID-19,Sulodexide in the Treatment of Early Stages of COVID-19,Completed,NA,Phase 2/Phase 3,243,Actual,Clinedem,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,individual participant data will be confidential,2022-01-04T08:46:41Z,2022-01-04T08:46:41Z,511
NCT04483375,NA,2020-07-17,NA,NA,2021-03-21,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-21,2021-03-23,Actual,"July 24, 2020",Actual,2020-07-24,July 2020,2020-07-31,"November 17, 2020",Actual,2020-11-17,"November 17, 2020",Actual,2020-11-17,NA,Interventional,NA,NA,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects","A Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of SCTA01 in Healthy Subjects",Completed,NA,Phase 1,33,Actual,Sinocelltech Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2022-01-04T08:46:56Z,2022-01-04T08:46:56Z,316
NCT04481685,NA,2020-07-15,NA,NA,2021-06-22,2020-07-20,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-23,Actual,"July 20, 2020",Actual,2020-07-20,May 2020,2020-05-31,"June 1, 2021",Actual,2021-06-01,"February 25, 2021",Actual,2021-02-25,NA,Interventional,NA,NA,"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)","A Double-blind, Randomized, Controlled Trial of ATI-450 in Patients With Moderate-severe COVID-19",Completed,NA,Phase 2,20,Actual,University of Kansas Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T08:48:12Z,2022-01-04T08:48:12Z,223
NCT04480957,NA,2020-07-17,NA,NA,2021-08-12,2020-07-17,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-18,Actual,"August 4, 2020",Actual,2020-08-04,August 2021,2021-08-31,"January 29, 2021",Actual,2021-01-29,"January 29, 2021",Actual,2021-01-29,NA,Interventional,NA,NA,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,"A Phase 1/2 Randomised, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Immunogenicity of ARCT-021 in Healthy Adult Subjects",Completed,NA,Phase 1/Phase 2,106,Actual,"Arcturus Therapeutics, Inc.",NA,8,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T08:49:01Z,2022-01-04T08:49:01Z,172
NCT04480593,NA,2020-07-12,NA,NA,2020-09-28,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"June 2, 2020",Actual,2020-06-02,September 2020,2020-09-30,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,Bee-Covid,NA,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,"The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.",Completed,NA,Phase 2/Phase 3,120,Actual,D'Or Institute for Research and Education,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T08:49:14Z,2022-01-04T08:49:14Z,490
NCT04480112,NA,2020-07-19,NA,NA,2021-08-27,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"June 2, 2020",Actual,2020-06-02,August 2021,2021-08-31,"June 11, 2021",Actual,2021-06-11,"June 11, 2021",Actual,2021-06-11,NA,Interventional,NA,NA,Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults,Impact of Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults With and Without Cognitive Impairment,Completed,NA,Not Applicable,196,Actual,Boston University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:49:31Z,2022-01-04T08:49:31Z,157
NCT04479163,NA,2020-06-29,NA,NA,2020-12-19,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-19,2020-12-22,Actual,"June 4, 2020",Actual,2020-06-04,December 2020,2020-12-31,"October 25, 2020",Actual,2020-10-25,"October 25, 2020",Actual,2020-10-25,NA,Interventional,NA,NA,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2.,Completed,NA,Not Applicable,165,Actual,Fundacion Infant,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:50:10Z,2022-01-04T08:50:10Z,408
NCT04479202,NA,2020-05-13,NA,NA,2020-07-19,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-19,2020-07-21,Actual,"February 8, 2020",Actual,2020-02-08,May 2020,2020-05-31,"April 23, 2020",Actual,2020-04-23,"April 18, 2020",Actual,2020-04-18,NA,Interventional,BOIFIM,NA,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,NA,Phase 4,76,Actual,Chinese Medical Association,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,We have other articles about covid-19 yet to be published,2022-01-04T08:50:11Z,2022-01-04T08:50:11Z,561
NCT04476888,NA,2020-07-16,NA,NA,2021-01-18,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-18,2021-01-20,Actual,"April 26, 2020",Actual,2020-04-26,January 2021,2021-01-31,"October 10, 2020",Actual,2020-10-10,"September 15, 2020",Actual,2020-09-15,NA,Interventional,COLLATE,NA,Convalescent Plasma Treatment in COVID-19,Convalescent Plasma Treatment in COVID-19 Patients at a Tertiary Care Center in Pakistan,Completed,NA,Not Applicable,110,Actual,Aga Khan University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:51:44Z,2022-01-04T08:51:44Z,378
NCT04477655,NA,2020-07-15,NA,NA,2021-04-12,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-13,Actual,"May 3, 2020",Actual,2020-05-03,April 2021,2021-04-30,"January 26, 2021",Actual,2021-01-26,"January 26, 2021",Actual,2021-01-26,NA,Interventional,PRO-CARF,NA,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Prone Positioning in Non-intubated Patients With Severe COVID-19: a Randomized Controlled Trial,Completed,NA,Not Applicable,430,Actual,Hospital Civil de Guadalajara,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:51:21Z,2022-01-04T08:51:21Z,294
NCT04476667,NA,2020-07-13,NA,NA,2021-09-07,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-09,Actual,"June 15, 2020",Actual,2020-06-15,September 2021,2021-09-30,"May 1, 2021",Actual,2021-05-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,NA,NA,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19","Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Completed,NA,Not Applicable,80,Actual,Queen's University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Ethics and Data Privacy: Only care providers involved in care of participant will have access to charts. Patients will only be identifiable by ID number on OPTT platform and real identity and consent forms will be stored locally in locked file cabinet and destroyed 5 years after study completion date. Only anonymized data will be provided to analysis team members.

OPTT is HIPAA, PIPEDA and SOC-2 compliant and all servers and databases are hosted in AWS Canada cloud infrastructure which is managed by Medstack to assure all provincial and federal privacy and security regulations are met. OPTT will not collect any identifiable personal information or IP addresses for privacy purposes. OPTT will only collect anonymized metadata to improve its service quality and provide advanced analytics to the clinician team. All data is encrypted by OPTT and no employee has direct access to patient data. All encrypted backups are kept in the S3 storage that is dedicated to Queen's University.",2022-01-04T08:52:05Z,2022-01-04T08:52:05Z,146
NCT04475913,NA,2020-07-14,NA,NA,2021-02-24,2020-07-14,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-24,2021-03-01,Actual,"July 11, 2018",Actual,2018-07-11,July 2020,2020-07-31,"August 20, 2020",Actual,2020-08-20,"July 11, 2020",Actual,2020-07-11,NA,Interventional,NA,NA,Digital vs Analog Impression in Cases of All-on-4 - Prosthesis,"In a Post -Covid-19 World, What is the Clinical Influence of Digital vs Analog Impression in Cases of All-on-4 - Prosthesis ?",Completed,NA,Not Applicable,56,Actual,October University for Modern Sciences and Arts,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T08:52:35Z,2022-01-04T08:52:35Z,341
NCT04475562,NA,2020-07-15,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 6, 2020",Actual,2020-04-06,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"May 6, 2020",Actual,2020-05-06,NA,Interventional,NA,NA,Can the Electronic Nose Smell COVID-19?,Can the Electronic Nose Smell COVID-19? A Proof-of-principle Study,Completed,NA,Not Applicable,219,Actual,Maastricht University Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2022-01-04T08:52:54Z,2022-01-04T08:52:54Z,564
NCT04475575,NA,2020-07-15,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 6, 2020",Actual,2020-04-06,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,NA,Can the Electronic Nose Smell COVID-19 Antibodies?,Can the Electronic Nose Smell COVID-19 Antibodies? A Proof-of-principle Study,Completed,NA,Not Applicable,222,Actual,Maastricht University Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2022-01-04T08:52:57Z,2022-01-04T08:52:57Z,564
NCT04475107,NA,2020-07-14,NA,NA,2021-05-27,2020-07-15,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"July 9, 2020",Actual,2020-07-09,April 2021,2021-04-30,"April 15, 2021",Actual,2021-04-15,"March 25, 2021",Actual,2021-03-25,NA,Interventional,NA,NA,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,"A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase â…¡ Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients",Completed,NA,Phase 2,113,Actual,Shin Poong Pharmaceutical Co. Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T08:53:09Z,2022-01-04T08:53:09Z,249
NCT04475120,NA,2020-07-16,NA,NA,2021-05-12,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-14,Actual,"April 15, 2020",Actual,2020-04-15,May 2021,2021-05-31,"July 2, 2020",Actual,2020-07-02,"July 2, 2020",Actual,2020-07-02,NA,Interventional,NA,NA,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Interventional Pilot Study to Assess the Use of Oral and Intra-nasal Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Completed,NA,Phase 2/Phase 3,92,Actual,University of Rome Tor Vergata,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2022-01-04T08:53:13Z,2022-01-04T08:53:13Z,264
NCT04473898,NA,2020-07-14,NA,NA,2021-02-17,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"June 19, 2020",Actual,2020-06-19,July 2020,2020-07-31,"February 17, 2021",Actual,2021-02-17,"October 19, 2020",Actual,2020-10-19,NA,Interventional,NA,NA,Telerehabilitation After Coronavirus,Telerehabilitation After Covid-19: Effectiveness of Respiratory and Aerobic Training,Completed,NA,Not Applicable,35,Actual,KTO Karatay University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:54:01Z,2022-01-04T08:54:01Z,348
NCT04473274,NA,2020-06-22,NA,NA,2020-12-02,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-04,Actual,"May 21, 2020",Actual,2020-05-21,December 2020,2020-12-31,"December 1, 2020",Actual,2020-12-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,GOTCHA,NA,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study","GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Completed,NA,Phase 4,10,Actual,Samaritan Health Services,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:54:18Z,2022-01-04T08:54:18Z,425
NCT04473248,NA,2020-07-14,NA,NA,2020-11-11,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"June 28, 2020",Actual,2020-06-28,July 2020,2020-07-31,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,NA,Spartan COVID-19 System: Evaluation of Clinical Sample Collection,Evaluation of Clinical Sample Collection Project: Spartan COVID-19,Completed,NA,Not Applicable,27,Actual,Spartan Bioscience Inc.,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T08:54:28Z,2022-01-04T08:54:28Z,446
NCT04473170,NA,2020-07-14,NA,NA,2020-07-15,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"April 4, 2020",Actual,2020-04-04,July 2020,2020-07-31,"July 14, 2020",Actual,2020-07-14,"May 20, 2020",Actual,2020-05-20,NA,Interventional,SENTAD-COVID,NA,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,"Adaptive Open-label Study Evaluating the Safety and Efficacy of Autologous Non- Hematopoietic Peripheral Blood Stem Cells Therapy in COVID-19 Outbreak in Abu Dhabi, 2020 (SENTAD-COVID Study)",Completed,NA,Phase 1/Phase 2,146,Actual,Abu Dhabi Stem Cells Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:54:35Z,2022-01-04T08:54:35Z,565
NCT04470258,NA,2020-06-10,NA,NA,2021-04-18,2020-07-11,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-18,2021-04-20,Actual,"June 25, 2020",Actual,2020-06-25,April 2021,2021-04-30,"November 30, 2020",Actual,2020-11-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,NA,Elmo Respiratory Support Project - COVID-19,Elmo Respiratory Support Project for Patients With Hypoxemic Respiratory Insufficiency in Covid-19: Proof Of Concept and Usability,Completed,NA,Not Applicable,10,Actual,Escola de SaÃºde PÃºblica do CearÃ¡,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:56:21Z,2022-01-04T08:56:21Z,288
NCT04469621,NA,2020-06-28,NA,NA,2020-11-10,2020-07-12,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-13,Actual,"July 17, 2020",Actual,2020-07-17,November 2020,2020-11-30,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,NA,NA,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19",Completed,NA,Phase 1,68,Actual,Sanofi,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2022-01-04T08:57:12Z,2022-01-04T08:57:12Z,447
NCT04469114,NA,2020-07-10,NA,NA,2021-08-02,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-09,Actual,"September 16, 2020",Actual,2020-09-16,July 2020,2020-07-31,"January 9, 2021",Actual,2021-01-09,"January 9, 2021",Actual,2021-01-09,NA,Interventional,NA,NA,Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia",Completed,NA,Phase 3,289,Actual,Hospital Israelita Albert Einstein,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T08:57:26Z,2022-01-04T08:57:26Z,182
NCT04467840,NA,2020-07-09,NA,NA,2021-07-19,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"August 21, 2020",Actual,2020-08-21,July 2021,2021-07-31,"July 18, 2021",Actual,2021-07-18,"July 18, 2021",Actual,2021-07-18,NA,Interventional,NA,NA,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia","Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia",Completed,NA,Phase 2/Phase 3,475,Actual,RedHill Biopharma Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:58:17Z,2022-01-04T08:58:17Z,196
NCT04468009,NA,2020-07-09,NA,NA,2021-08-23,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-25,Actual,"June 25, 2020",Actual,2020-06-25,August 2021,2021-08-31,"June 19, 2021",Actual,2021-06-19,"January 19, 2021",Actual,2021-01-19,NA,Interventional,NA,NA,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Completed,NA,Phase 2,134,Actual,Hospital de Infecciosas Francisco Javier Muniz,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T08:58:15Z,2022-01-04T08:58:15Z,161
NCT04466605,NA,2020-07-09,NA,NA,2020-07-09,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-10,Actual,"March 30, 2020",Actual,2020-03-30,July 2020,2020-07-31,"July 6, 2020",Actual,2020-07-06,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,NA,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown: Randomized Clinical Trial,Completed,NA,Not Applicable,64,Actual,Aarogyam UK,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T08:59:18Z,2022-01-04T08:59:18Z,571
NCT04465513,NA,2020-07-08,NA,NA,2021-10-04,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"August 31, 2020",Actual,2020-08-31,June 2021,2021-06-30,"October 4, 2021",Actual,2021-10-04,"October 4, 2021",Actual,2021-10-04,NA,Interventional,NA,NA,Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19,"A Randomized, Open-label, Parallel Study to Investigate the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19 Who Are Hospitalized as Well as Patients Following the Guidance From Public Health",Completed,NA,Not Applicable,14,Actual,Hofseth Biocare ASA,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:00:05Z,2022-01-04T09:00:05Z,119
NCT04464395,NA,2020-07-07,NA,NA,2021-07-20,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"July 1, 2020",Actual,2020-07-01,July 2021,2021-07-31,"July 9, 2021",Actual,2021-07-09,"March 1, 2021",Actual,2021-03-01,NA,Interventional,NA,NA,Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,Immunotherapy of COVID-19 With B-Cell Activating CPI-006 Monoclonal Antibody,Completed,NA,Phase 1,30,Actual,"Corvus Pharmaceuticals, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:01:03Z,2022-01-04T09:01:03Z,195
NCT04463602,NA,2020-07-07,NA,NA,2021-04-22,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-23,Actual,"July 25, 2020",Actual,2020-07-25,April 2021,2021-04-30,"March 31, 2021",Actual,2021-03-31,"January 25, 2021",Actual,2021-01-25,NA,Interventional,NA,NA,Desidustat in the Management of COVID-19 Patients,"A Phase 2b, Multicenter, Open-label, Randomized, Comparator-Controlled, Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of COVID-19 Patients",Completed,NA,Phase 2,24,Actual,Cadila Healthcare Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:01:51Z,2022-01-04T09:01:51Z,284
NCT04463472,NA,2020-07-08,NA,NA,2021-08-17,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"June 29, 2020",Actual,2020-06-29,August 2021,2021-08-31,"August 12, 2021",Actual,2021-08-12,"September 28, 2020",Actual,2020-09-28,NA,Interventional,NA,NA,Study of COVID-19 DNA Vaccine (AG0301-COVID19),"A Non-randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Two Doses of Intramuscular AG0301-COVID19 (1mg/2mg) in Healthy Adults",Completed,NA,Phase 1/Phase 2,30,Actual,"AnGes, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:01:48Z,2022-01-04T09:01:48Z,167
NCT04460651,NA,2020-07-02,NA,NA,2021-09-10,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-17,Actual,"August 14, 2020",Actual,2020-08-14,August 2021,2021-08-31,"August 30, 2021",Actual,2021-08-30,"August 30, 2021",Actual,2021-08-30,NA,Interventional,PREPARE-IT,NA,PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial,PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial,Completed,NA,Phase 3,4093,Actual,Estudios ClÃ­nicos Latino AmÃ©rica,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:03:55Z,2022-01-04T09:03:55Z,143
NCT04460534,NA,2020-07-02,NA,NA,2021-08-16,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"May 7, 2020",Actual,2020-05-07,August 2021,2021-08-31,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,COVISPERM,NA,Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Detection of SARS-CoV-2 in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Completed,NA,Not Applicable,52,Actual,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:04:09Z,2022-01-04T09:04:09Z,168
NCT04460027,NA,2020-07-01,NA,NA,2021-04-26,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-28,Actual,"June 22, 2020",Actual,2020-06-22,April 2021,2021-04-30,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,NA,W-SUDs for COVID-19,Woebot for Substance Use Disorders During COVID-19,Completed,NA,Phase 1,180,Actual,"Woebot Labs, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:04:37Z,2022-01-04T09:04:37Z,280
NCT04459325,NA,2020-07-03,NA,NA,2020-10-13,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,NA,Interventional,NA,NA,TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,A Prospective Open-label Study of the TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,Completed,NA,Phase 3,100,Actual,AO GENERIUM,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:04:55Z,2022-01-04T09:04:55Z,475
NCT04459520,NA,2020-07-05,NA,NA,2020-08-19,2020-07-05,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-20,Actual,"July 23, 2020",Actual,2020-07-23,August 2020,2020-08-31,"July 29, 2020",Actual,2020-07-29,"July 28, 2020",Actual,2020-07-28,NA,Interventional,NA,NA,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Completed,NA,Not Applicable,1400,Actual,"University of California, Los Angeles",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:04:41Z,2022-01-04T09:04:41Z,530
NCT04459455,NA,2020-06-29,NA,NA,2020-10-19,2020-07-05,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"August 19, 2020",Actual,2020-08-19,October 2020,2020-10-31,"October 15, 2020",Actual,2020-10-15,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,NA,"Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic","Project HF-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",Completed,NA,Not Applicable,500,Actual,Stony Brook University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:05:00Z,2022-01-04T09:05:00Z,469
NCT04459962,NA,2020-07-03,NA,NA,2021-01-28,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"June 29, 2020",Actual,2020-06-29,July 2020,2020-07-31,"January 7, 2021",Actual,2021-01-07,"January 7, 2021",Actual,2021-01-07,NA,Interventional,NA,NA,Covid-19 Breath Test,Breath Test Feasibility Trial for Covid-19 Infection Diagnosis,Completed,NA,Not Applicable,330,Actual,Ancon Technologies Ltd,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:04:45Z,2022-01-04T09:04:45Z,368
NCT04458519,NA,2020-07-01,NA,NA,2021-05-27,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"July 16, 2020",Actual,2020-07-16,July 2020,2020-07-31,"May 27, 2021",Actual,2021-05-27,"May 27, 2021",Actual,2021-05-27,NA,Interventional,NA,NA,Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Randomised Single Blinded Clinical Study of Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Completed,NA,Not Applicable,23,Actual,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:05:30Z,2022-01-04T09:05:30Z,249
NCT04457388,NA,2020-06-30,NA,NA,2020-07-07,2020-06-30,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"March 25, 2020",Actual,2020-03-25,July 2020,2020-07-31,"June 15, 2020",Actual,2020-06-15,"June 15, 2020",Actual,2020-06-15,NA,Interventional,NA,NA,Tele-Yoga Therapy for Chronic Pain,Tele- Yoga Therapy for Patients With Chronic Pain During Covid-19 Lockdown: A Prospective Non-randomized Single Arm Clinical Trial,Completed,NA,Not Applicable,18,Actual,Aarogyam UK,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T09:06:21Z,2022-01-04T09:06:21Z,573
NCT04456452,NA,2020-06-30,NA,NA,2021-01-12,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-12,2021-01-13,Actual,"July 27, 2020",Actual,2020-07-27,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"September 8, 2020",Actual,2020-09-08,NA,Interventional,NA,NA,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,A Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampionâ„¢ in Adult COVID-19 Patients Requiring Oxygen Supplementation,Completed,NA,Phase 1,10,Actual,Ampio Pharmaceuticals. Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:07:06Z,2022-01-04T09:07:06Z,384
NCT04455308,NA,2020-06-30,NA,NA,2020-11-03,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"July 21, 2020",Actual,2020-07-21,November 2020,2020-11-30,"October 19, 2020",Actual,2020-10-19,"October 19, 2020",Actual,2020-10-19,NA,Interventional,ECCES,NA,COVID-19 and Chilblains,"Chilblains, COVID-19 and Lockdown: Epidemiologic Study",Completed,NA,Not Applicable,269,Actual,Rennes University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:08:18Z,2022-01-04T09:08:18Z,454
NCT04455360,NA,2020-06-26,NA,NA,2021-09-28,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"October 1, 2020",Actual,2020-10-01,September 2021,2021-09-30,"September 20, 2021",Actual,2021-09-20,"September 20, 2021",Actual,2021-09-20,NA,Interventional,Cov-EMERALD,NA,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,EMERALD: Can a Virtual Eye Movement Desensitisation and Reprocessing Intervention Improve Psychological Outcome Following Covid-19 Related Critical Illness: A Feasibility Trial,Completed,NA,Not Applicable,26,Actual,University Hospital Southampton NHS Foundation Trust,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:08:05Z,2022-01-04T09:08:05Z,125
NCT04454606,NA,2020-06-26,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"May 31, 2020",Actual,2020-05-31,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,NA,The New Silicone N99 Half-Piece Respirator,The New Silicone N99 Half-Piece Respirator:VJR-NMU N99:New and Effective Tool to Prevent COVID-19,Completed,NA,Not Applicable,43,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T09:08:46Z,2022-01-04T09:08:46Z,580
NCT04453852,NA,2020-06-03,NA,NA,2021-05-05,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"June 30, 2020",Actual,2020-06-30,May 2021,2021-05-31,"April 14, 2021",Actual,2021-04-14,"February 1, 2021",Actual,2021-02-01,NA,Interventional,COVAX19,NA,Monovalent Recombinant COVID19 Vaccine,"A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects",Completed,NA,Phase 1,40,Actual,Vaxine Pty Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:09:10Z,2022-01-04T09:09:10Z,271
NCT04453514,NA,2020-06-30,NA,NA,2021-07-20,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"July 21, 2020",Actual,2020-07-21,July 2021,2021-07-31,"June 19, 2021",Actual,2021-06-19,"June 19, 2021",Actual,2021-06-19,NA,Interventional,NA,NA,Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic,Cultivating Calm During COVID-19: A Feasibility Study of Video-based Trauma-informed Yoga,Completed,NA,Not Applicable,212,Actual,National University of Natural Medicine,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:09:44Z,2022-01-04T09:09:44Z,195
NCT04452669,NA,2020-06-29,NA,NA,2021-08-04,2020-06-29,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"September 15, 2020",Actual,2020-09-15,August 2021,2021-08-31,"June 29, 2021",Actual,2021-06-29,"June 29, 2021",Actual,2021-06-29,NA,Interventional,VPCOVID,NA,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,"Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation",Completed,NA,Phase 2,11,Actual,Aerogen Pharma Limited,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:10:12Z,2022-01-04T09:10:12Z,180
NCT04452318,NA,2020-06-26,NA,NA,2021-10-06,2020-06-26,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-07,Actual,"July 13, 2020",Actual,2020-07-13,October 2021,2021-10-31,"October 4, 2021",Actual,2021-10-04,"October 4, 2021",Actual,2021-10-04,NA,Interventional,NA,NA,COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2",Completed,NA,Phase 3,3303,Actual,Regeneron Pharmaceuticals,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2022-01-04T09:10:32Z,2022-01-04T09:10:32Z,117
NCT04448756,NA,2020-06-25,NA,NA,2021-09-05,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2021-09-05,2021-09-08,Actual,"July 29, 2020",Actual,2020-07-29,September 2021,2021-09-30,"August 16, 2021",Actual,2021-08-16,"August 16, 2021",Actual,2021-08-16,NA,Interventional,NA,NA,Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE),"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia (ANEMONE)",Completed,NA,Phase 2,151,Actual,EMD Serono,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html",2022-01-04T09:12:55Z,2022-01-04T09:12:55Z,148
NCT04449718,NA,2020-06-16,NA,NA,2020-11-16,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-16,2020-11-17,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"October 7, 2020",Actual,2020-10-07,"October 7, 2020",Actual,2020-10-07,NA,Interventional,NA,NA,Vitamin D Supplementation in Patients With COVID-19,"Vitamin D Supplementation in Patients With COVID-19: A Randomized, Double-blind, Placebo-controlled Trial",Completed,NA,Not Applicable,240,Actual,University of Sao Paulo,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:12:16Z,2022-01-04T09:12:16Z,441
NCT04448769,NA,2020-06-23,NA,NA,2020-08-18,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"June 26, 2020",Actual,2020-06-26,August 2020,2020-08-31,"July 24, 2020",Actual,2020-07-24,"July 24, 2020",Actual,2020-07-24,NA,Interventional,COVAL-NANCY,NA,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19) in the Population of the Grand Nancy Metropolitan Area,Completed,NA,Not Applicable,2006,Actual,"Central Hospital, Nancy, France",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2022-01-04T09:13:08Z,2022-01-04T09:13:08Z,531
NCT04446104,NA,2020-05-11,NA,NA,2020-10-13,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-19,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,NA,NA,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial),Completed,NA,Phase 3,4257,Actual,"National University Hospital, Singapore",NA,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:15:11Z,2022-01-04T09:15:11Z,475
NCT04445376,NA,2020-06-22,NA,NA,2020-10-06,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"July 3, 2020",Actual,2020-07-03,October 2020,2020-10-31,"October 3, 2020",Actual,2020-10-03,"September 10, 2020",Actual,2020-09-10,NA,Interventional,NA,NA,Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,Effect of Aerobic Exercises on Cardio-respiratory Fitness and Quality of Life in Recovered COVID 19 Recovered Patients.,Completed,NA,Not Applicable,20,Actual,Government College University Faisalabad,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:15:34Z,2022-01-04T09:15:34Z,482
NCT04445272,NA,2020-06-13,NA,NA,2021-05-31,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-31,2021-06-02,Actual,"May 22, 2020",Actual,2020-05-22,June 2020,2020-06-30,"December 23, 2020",Actual,2020-12-23,"December 23, 2020",Actual,2020-12-23,NA,Interventional,NA,NA,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,"A Multicentre, Open-label Clinical Trial to Evaluate the Effectiveness and Safety of Intravenous Tocilizumab for Treating Patients With COVID-19 Pneumonia: the BREATH-19 Study",Completed,NA,Phase 2,495,Actual,Fundacion SEIMC-GESIDA,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:15:36Z,2022-01-04T09:15:36Z,245
NCT04443881,NA,2020-06-18,NA,NA,2021-05-27,2020-06-20,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"May 8, 2020",Actual,2020-05-08,May 2021,2021-05-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,ANA-COVID-GEAS,NA,Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS),"Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2/3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS- CoV-2 Infection",Completed,NA,Phase 2/Phase 3,179,Actual,Fundacion Miguel Servet,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,"All collected IPD will be available for exploitation in future research projects. This statement also includes the availability of the study protocol, the statistical analysis plan, the informed consent form, the clinical study report and the analytic code.",2022-01-04T09:17:12Z,2022-01-04T09:17:12Z,249
NCT04442958,NA,2020-06-17,NA,NA,2020-06-30,2020-06-19,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,"June 17, 2020",Actual,2020-06-17,"June 15, 2020",Actual,2020-06-15,NA,Interventional,NA,NA,Effectiveness of Convalescent Immune Plasma Therapy,Effectiveness of Convalescent Immune Plasma Therapy in Severe COVID-19 Patients With Acute Respiratory Distress Syndrome,Completed,NA,Not Applicable,60,Actual,Bagcilar Training and Research Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:17:35Z,2022-01-04T09:17:35Z,580
NCT04441684,NA,2020-05-20,NA,NA,2021-07-26,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"April 17, 2020",Actual,2020-04-17,July 2021,2021-07-31,"July 16, 2021",Actual,2021-07-16,"May 7, 2020",Actual,2020-05-07,NA,Interventional,SeroCoV-HUS,NA,"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)","Study of the Seroprevalence of SARS-CoV-2 in Hospital Staff in Strasbourg University Hospital, Strasbourg, France",Completed,NA,Not Applicable,1466,Actual,"University Hospital, Strasbourg, France",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:18:14Z,2022-01-04T09:18:14Z,189
NCT04441632,NA,2020-06-18,NA,NA,2020-08-11,2020-06-18,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 15, 2020",Actual,2020-06-15,August 2020,2020-08-31,"July 30, 2020",Actual,2020-07-30,"July 26, 2020",Actual,2020-07-26,NA,Interventional,TEAM-ICU,NA,Effect of Positive Attitudes on Behavior and Wellness,"The Impact of Positive Reinforcement on Teamwork Climate, Resiliency, and Burnout During the COVID-19 Pandemic: the TEAM-ICU Study (Transforming Employee Attitudes Via Messaging Strengthens Interconnection, Communication, and Unity)",Completed,NA,Not Applicable,24,Actual,Cedars-Sinai Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:18:26Z,2022-01-04T09:18:26Z,538
NCT04439825,NA,2020-06-18,NA,NA,2021-03-11,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-15,Actual,"July 20, 2020",Actual,2020-07-20,March 2021,2021-03-31,"December 1, 2020",Actual,2020-12-01,"September 3, 2020",Actual,2020-09-03,NA,Interventional,NA,NA,Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction,Randomized Controlled Single Blind Cross Over Trial Evaluating the Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction in a Post Covid Period.,Completed,NA,Phase 1,45,Actual,DeNova Research,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:19:59Z,2022-01-04T09:19:59Z,326
NCT04441424,NA,2020-06-12,NA,NA,2020-06-20,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-20,2020-06-23,Actual,"April 3, 2020",Actual,2020-04-03,June 2020,2020-06-30,"June 1, 2020",Actual,2020-06-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,NA,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,"The Therapeutic Potential of Convalescent Plasma Therapy on Treating Critically-ill COVID-19 Patients Residing in Respiratory Care Units in Hospitals in Baghdad, Iraq",Completed,NA,Not Applicable,49,Actual,Alkarkh Health Directorate-Baghdad,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:18:39Z,2022-01-04T09:18:39Z,590
NCT04438980,NA,2020-06-18,NA,NA,2021-05-14,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-17,Actual,"May 15, 2020",Actual,2020-05-15,May 2021,2021-05-31,"April 9, 2021",Actual,2021-04-09,"March 12, 2021",Actual,2021-03-12,NA,Interventional,CORTIVID,NA,Glucocorticoids in COVID-19 (CORTIVID),Treatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled Trial,Completed,NA,Phase 3,72,Actual,Fundacion Miguel Servet,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"All collected IPD will be available for exploitation in future research projects. This statement also includes the availability of the study protocol, the statistical analysis plan, the informed consent form, the clinical study report and the analytic code.",2022-01-04T09:20:22Z,2022-01-04T09:20:22Z,262
NCT04437875,NA,2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,NA,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac Lyo"" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:21:20Z,2022-01-04T09:21:20Z,538
NCT04436471,NA,2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,NA,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:22:27Z,2022-01-04T09:22:27Z,538
NCT04435522,NA,2020-06-15,NA,NA,2021-02-02,2020-06-15,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-04,Actual,"October 1, 2020",Actual,2020-10-01,June 2020,2020-06-30,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,NA,Maraviroc in Patients With Moderate and Severe COVID-19,Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2,Completed,NA,Phase 1,9,Actual,Rhode Island Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:23:08Z,2022-01-04T09:23:08Z,363
NCT04433910,NA,2020-05-06,NA,NA,2021-03-16,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-17,Actual,"August 30, 2020",Actual,2020-08-30,March 2021,2021-03-31,"February 22, 2021",Actual,2021-02-22,"January 21, 2021",Actual,2021-01-21,NA,Interventional,CAPSID,NA,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,"A Randomized, Prospective, Open Label Clinical Trial on the Use of Convalescent Plasma Compared to Best Supportive Care in Patients With Severe COVID-19",Completed,NA,Phase 2,106,Actual,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:24:04Z,2022-01-04T09:24:04Z,321
NCT04431856,NA,2020-06-12,NA,NA,2020-11-30,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-01,Actual,"May 15, 2020",Actual,2020-05-15,November 2020,2020-11-30,"November 17, 2020",Actual,2020-11-17,"November 17, 2020",Actual,2020-11-17,NA,Interventional,Co-PARENT,NA,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,Completed,NA,Not Applicable,80,Actual,University of Miami,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:25:54Z,2022-01-04T09:25:54Z,427
NCT04432324,NA,2020-06-12,NA,NA,2021-03-09,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-10,Actual,"June 2, 2020",Actual,2020-06-02,March 2021,2021-03-31,"March 3, 2021",Actual,2021-03-03,"March 3, 2021",Actual,2021-03-03,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),"A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19",Completed,NA,Phase 2,100,Actual,Grifols Therapeutics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:25:28Z,2022-01-04T09:25:28Z,328
NCT04431297,NA,2020-06-12,NA,NA,2021-08-19,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"March 22, 2021",Actual,2021-03-22,August 2021,2021-08-31,"May 14, 2021",Actual,2021-05-14,"May 14, 2021",Actual,2021-05-14,NA,Interventional,NA,NA,Virtual Mindfulness Rounds in the Time of COVID-19 Pandemic,The Impact of Virtual Mindfulness Education Sessions on Staff Perceived Stress During COVID-19,Completed,NA,Not Applicable,15,Actual,Icahn School of Medicine at Mount Sinai,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:26:24Z,2022-01-04T09:26:24Z,165
NCT04429529,NA,2020-06-09,NA,NA,2021-04-06,2020-06-10,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"June 9, 2020",Actual,2020-06-09,September 2020,2020-09-30,"January 20, 2021",Actual,2021-01-20,"November 19, 2020",Actual,2020-11-19,NA,Interventional,NA,NA,"Safety of TY027, a Treatment for COVID-19, in Humans","Phase 1 First-in-Human, Time Lagged, Randomised, Placebo Controlled, Double Blind, Single Ascending Dose Study of TY027 in Healthy Adult Volunteers",Completed,NA,Phase 1,32,Actual,Tychan Pte Ltd.,NA,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:27:39Z,2022-01-04T09:27:39Z,300
NCT04429828,NA,2020-06-11,NA,NA,2021-08-26,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-27,Actual,"June 13, 2020",Actual,2020-06-13,August 2021,2021-08-31,"December 30, 2020",Actual,2020-12-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,PoWerS,NA,COVID-19 Psychological Wellbeing for Healthcare Students,PoWerS Study: Psychological Wellbeing for Healthcare Students: Evaluation of a COVID-19 Digital Learning Package,Completed,NA,Not Applicable,42,Actual,University of Nottingham,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Interview data will be available on request at study end (after publication of findings).,On request.,NA,Yes,Interview data will be made available on request (after study end).,2022-01-04T09:27:30Z,2022-01-04T09:27:30Z,158
NCT04426305,NA,2020-06-03,NA,NA,2021-06-07,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-08,Actual,"May 21, 2020",Actual,2020-05-21,May 2020,2020-05-31,"October 30, 2020",Actual,2020-10-30,"June 20, 2020",Actual,2020-06-20,NA,Interventional,NA,NA,Community Health Workers Against COVID19,Community Health Workers Against COVID19 Tackling Psychosocial Suffering Due to Physical Distancing,Completed,NA,Not Applicable,140,Actual,University Ghent,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2022-01-04T09:30:01Z,2022-01-04T09:30:01Z,238
NCT04426318,NA,2020-06-09,NA,NA,2021-01-22,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-26,Actual,"June 14, 2020",Actual,2020-06-14,November 2020,2020-11-30,"January 12, 2021",Actual,2021-01-12,"January 12, 2021",Actual,2021-01-12,NA,Interventional,CAHMP-ED,NA,COVID-19 and the Healthy Minds Program for Educators,COVID-19 and the Healthy Minds Program for Educators,Completed,NA,Not Applicable,733,Actual,"University of Wisconsin, Madison",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be de-identified and made publicly available based on the publication of preregistered study hypotheses following peer review.,Researcher consent. Any reasonable request will be granted.,NA,Yes,"Data will be de-identified and listed in public data registries (i.e., osf) based on the publication of preregistered study hypotheses on a manuscript by manuscript basis.",2022-01-04T09:30:03Z,2022-01-04T09:30:03Z,374
NCT04425252,NA,2020-06-09,NA,NA,2021-01-15,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-19,Actual,"August 1, 2020",Actual,2020-08-01,January 2021,2021-01-31,"December 29, 2020",Actual,2020-12-29,"December 29, 2020",Actual,2020-12-29,NA,Interventional,CRISIS,NA,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,The CRISIS Study: A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19),Completed,NA,Phase 1/Phase 2,23,Actual,"Clear Creek Bio, Inc.",NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:30:53Z,2022-01-04T09:30:53Z,381
NCT04425005,NA,2020-06-08,NA,NA,2021-01-18,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-18,2021-01-22,Actual,"May 10, 2020",Actual,2020-05-10,January 2021,2021-01-31,"December 7, 2020",Actual,2020-12-07,"December 7, 2020",Actual,2020-12-07,NA,Interventional,NA,NA,Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric,Effect of Home-based Exercise Training Program During the Covid-19 Pandemic in Post-bariatric Patients: A Randomized Controlled Trial,Completed,NA,Not Applicable,55,Actual,University of Sao Paulo,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:30:54Z,2022-01-04T09:30:54Z,378
NCT04424953,NA,2020-06-01,NA,NA,2021-03-16,2020-06-05,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-17,Actual,"June 1, 2020",Actual,2020-06-01,March 2021,2021-03-31,"September 25, 2020",Actual,2020-09-25,"September 25, 2020",Actual,2020-09-25,NA,Interventional,NA,NA,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,A Randomised Controlled Trial to Compare McGrath Videolaryngoscope Against Direct Laryngoscope for Endotracheal Intubation When Powered Air Purifying Respirator is Worn During the Current Coronavirus Disease 2019 Pandemic,Completed,NA,Not Applicable,28,Actual,Singapore General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:30:56Z,2022-01-04T09:30:56Z,321
NCT04423991,NA,2020-06-08,NA,NA,2020-06-08,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"March 10, 2020",Actual,2020-03-10,June 2020,2020-06-30,"June 4, 2020",Actual,2020-06-04,"June 4, 2020",Actual,2020-06-04,NA,Interventional,IDENTIFY,NA,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning: the IDENTIFY Trial,Completed,NA,Not Applicable,290,Actual,Dascena,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:31:28Z,2022-01-04T09:31:28Z,602
NCT04424082,NA,2020-06-07,NA,NA,2021-05-27,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-05-28,Actual,"June 9, 2020",Actual,2020-06-09,May 2021,2021-05-31,"May 27, 2021",Actual,2021-05-27,"June 25, 2020",Actual,2020-06-25,NA,Interventional,NA,NA,External Dead Space in Ventilated COVID-19 Patients,Influence of External Dead Space on Volumetric Capnography Derived Parameters in Mechanically Ventilated COVID-19 Patients,Completed,NA,Not Applicable,10,Actual,Karolinska Institutet,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:31:39Z,2022-01-04T09:31:39Z,249
NCT04422509,NA,2020-06-03,NA,NA,2021-07-11,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-11,2021-07-13,Actual,"October 30, 2020",Actual,2020-10-30,July 2021,2021-07-31,"April 30, 2021",Actual,2021-04-30,"February 25, 2021",Actual,2021-02-25,NA,Interventional,COVID_LAN,NA,Lanadelumab for Treatment of COVID-19 Disease,Lanadelumab for Treatment of COVID-19 Disease,Completed,NA,Phase 1/Phase 2,43,Actual,Radboud University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,this has not yet been decided,2022-01-04T09:32:51Z,2022-01-04T09:32:51Z,204
NCT04423289,NA,2020-06-06,NA,NA,2020-06-08,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"March 31, 2020",Actual,2020-03-31,June 2020,2020-06-30,"May 18, 2020",Actual,2020-05-18,"May 4, 2020",Actual,2020-05-04,NA,Interventional,NA,NA,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,COVID Follow-App: Telematic Monitoring Through a Mobile Application of Patients With COVID-19: A Randomized Clinical Trial,Completed,NA,Not Applicable,150,Actual,Hospital Universitari Vall d'Hebron Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:32:18Z,2022-01-04T09:32:18Z,602
NCT04421612,NA,2020-06-04,NA,NA,2021-05-05,2020-06-04,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"April 2, 2020",Actual,2020-04-02,August 2020,2020-08-31,"January 1, 2021",Actual,2021-01-01,"January 1, 2021",Actual,2021-01-01,NA,Interventional,Co-COVID-19,NA,COVID-19 - No Health Without Mental Health,COVID-19 - No Health Without Mental Health,Completed,NA,Not Applicable,91,Actual,Haukeland University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,There is a plan to share anonymous interaction-data. Health data are undecided,2022-01-04T09:33:19Z,2022-01-04T09:33:19Z,271
NCT04420247,NA,2020-06-02,NA,NA,2021-05-10,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,"April 16, 2020",Actual,2020-04-16,May 2021,2021-05-31,"September 3, 2020",Actual,2020-09-03,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,NA,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Completed,NA,Phase 3,142,Actual,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:34:47Z,2022-01-04T09:34:47Z,266
NCT04420260,NA,2020-05-25,NA,NA,2021-07-08,2020-06-04,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-08,2021-07-15,Actual,"March 18, 2021",Actual,2021-03-18,July 2021,2021-07-31,"July 5, 2021",Actual,2021-07-05,"June 23, 2021",Actual,2021-06-23,NA,Interventional,PI-Covid-19,NA,Primary Prevention of Infection by COVID-19 in Workers,"Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in MedellÃ­n-Antioquia",Completed,NA,Not Applicable,152,Actual,Unidad de InvestigaciÃ³n GenÃ©tica Molecular,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:34:25Z,2022-01-04T09:34:25Z,207
NCT04420806,NA,2020-06-05,NA,NA,2020-11-12,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Actual,"March 14, 2020",Actual,2020-03-14,November 2020,2020-11-30,"October 30, 2020",Actual,2020-10-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,NA,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Effects of Three Months of COVID-19 Lockdown Induced Deconditioning After 13 Months of High Intensity Exercise Training in Early Postmenopausal Women,Completed,NA,Not Applicable,21,Actual,University of Erlangen-NÃ¼rnberg Medical School,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T09:34:12Z,2022-01-04T09:34:12Z,445
NCT04421027,NA,2020-06-05,NA,NA,2021-07-15,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-15,2021-07-19,Actual,"June 12, 2020",Actual,2020-06-12,July 2021,2021-07-31,"June 10, 2021",Actual,2021-06-10,"February 12, 2021",Actual,2021-02-12,NA,Interventional,COV-BARRIER,NA,A Study of Baricitinib (LY3009104) in Participants With COVID-19,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection",Completed,NA,Phase 3,1585,Actual,Eli Lilly and Company,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement,2022-01-04T09:34:15Z,2022-01-04T09:34:15Z,200
NCT04419610,NA,2020-04-16,NA,NA,2021-05-25,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-27,Actual,"October 9, 2020",Actual,2020-10-09,May 2021,2021-05-31,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,NA,NA,RAS and Coagulopathy in COVID19,Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19,Completed,NA,Early Phase 1,30,Actual,Imperial College London,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:34:57Z,2022-01-04T09:34:57Z,251
NCT04419623,NA,2020-06-03,NA,NA,2021-05-10,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,"July 9, 2020",Actual,2020-07-09,May 2021,2021-05-31,"December 15, 2020",Actual,2020-12-15,"September 22, 2020",Actual,2020-09-22,NA,Interventional,NA,NA,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,"A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer",Completed,NA,Phase 1,7,Actual,"Telios Pharma, Inc.",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:34:58Z,2022-01-04T09:34:58Z,266
NCT04419025,NA,2020-06-03,NA,NA,2021-05-26,2020-06-03,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-28,Actual,"September 23, 2020",Actual,2020-09-23,May 2021,2021-05-31,"May 14, 2021",Actual,2021-05-14,"May 14, 2021",Actual,2021-05-14,NA,Interventional,NA,NA,Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease,Completed,NA,Phase 2,165,Actual,Cambridge Health Alliance,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Six months after publication available for a year,Written request; to be reviewed by the PI,http://www.NACinCOVID.info,Yes,Information that underlies results in published data,2022-01-04T09:35:30Z,2022-01-04T09:35:30Z,250
NCT04417270,NA,2020-06-01,NA,NA,2021-03-01,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-02,Actual,"June 12, 2020",Actual,2020-06-12,March 2021,2021-03-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,NA,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Completed,NA,Not Applicable,52,Actual,Northwell Health,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,The team has not decided whether to share the results with other researchers. The team will consider publishing results after study completion,2022-01-04T09:36:52Z,2022-01-04T09:36:52Z,336
NCT04416308,NA,2020-05-27,NA,NA,2021-04-13,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-14,Actual,"May 29, 2020",Actual,2020-05-29,April 2021,2021-04-30,"October 12, 2020",Actual,2020-10-12,"July 10, 2020",Actual,2020-07-10,NA,Interventional,AntiCoV-HB,NA,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne,Completed,NA,Not Applicable,9453,Actual,Rennes University Hospital,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T09:37:27Z,2022-01-04T09:37:27Z,293
NCT04414618,NA,2020-05-26,NA,NA,2021-03-08,2020-05-29,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-10,Actual,"July 2, 2020",Actual,2020-07-02,March 2021,2021-03-31,"December 23, 2020",Actual,2020-12-23,"November 26, 2020",Actual,2020-11-26,NA,Interventional,COVID-19,NA,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia",Completed,NA,Phase 2,42,Actual,RedHill Biopharma Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:39:02Z,2022-01-04T09:39:02Z,329
NCT04414267,NA,2020-06-01,NA,NA,2021-05-09,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"May 26, 2020",Actual,2020-05-26,May 2021,2021-05-31,"May 7, 2021",Actual,2021-05-07,"April 28, 2021",Actual,2021-04-28,NA,Interventional,ACTIVATEII,NA,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial,Completed,NA,Phase 4,301,Actual,Hellenic Institute for the Study of Sepsis,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:39:10Z,2022-01-04T09:39:10Z,267
NCT04414124,NA,2020-06-01,NA,NA,2021-08-12,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"August 2, 2020",Actual,2020-08-02,August 2021,2021-08-31,"February 2, 2021",Actual,2021-02-02,"February 2, 2021",Actual,2021-02-02,NA,Interventional,NA,NA,A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,"A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19",Completed,NA,Not Applicable,350,Actual,Kaleido Biosciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:39:13Z,2022-01-04T09:39:13Z,172
NCT04413968,NA,2020-06-02,NA,NA,2020-10-23,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"June 2, 2020",Actual,2020-06-02,May 2020,2020-05-31,"October 2, 2020",Actual,2020-10-02,"July 2, 2020",Actual,2020-07-02,NA,Interventional,COVIDOCRECHE,NA,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants","Contamination and Transmission of the SARS-CoV-2 Virus in Exposed, Confined and Community-based Infants: A Cross-sectional, Multicentre, Interventional Seroprevalence Study",Completed,NA,Not Applicable,600,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:39:21Z,2022-01-04T09:39:21Z,465
NCT04412668,NA,2020-06-01,NA,NA,2021-01-28,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"June 12, 2020",Actual,2020-06-12,January 2021,2021-01-31,"December 21, 2020",Actual,2020-12-21,"December 21, 2020",Actual,2020-12-21,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,A Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19),Completed,NA,Phase 2,32,Actual,"aTyr Pharma, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:40:16Z,2022-01-04T09:40:16Z,368
NCT04412343,NA,2020-05-29,NA,NA,2020-11-02,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"May 23, 2020",Actual,2020-05-23,November 2020,2020-11-30,"October 5, 2020",Actual,2020-10-05,"October 5, 2020",Actual,2020-10-05,NA,Interventional,SCOPE,NA,The Seniors COvid-19 Pandemic and Exercise Study,The Seniors COvid-19 Pandemic and Exercise Study: A Randomized Controlled Trial,Completed,NA,Not Applicable,241,Actual,University of British Columbia,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available from this trial 1 year after completion of the study. The data will remain available indefinitely.,"The nature of the request for sharing access will be reviewed by the PI (Beauchamp, M) and the data management team. Data will be shared via secure platforms (Redcap). Contact for data access can be done through personal communications (e.g., email) with PI Beauchamp.",https://osf.io/xw9gm,Yes,"The protocol for this study will be available on Open Science Framework (after 4 months to allow for study completion). The Statistical Analysis Plan will also be available on Open Science Framework. The Consent form is freely available if requested from the Primary Investigator (PI: Beauchamp, M.).",2022-01-04T09:40:30Z,2022-01-04T09:40:30Z,455
NCT04412356,NA,2020-05-24,NA,NA,2021-09-20,2020-05-31,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-22,Actual,"June 6, 2020",Actual,2020-06-06,September 2021,2021-09-30,"September 20, 2021",Actual,2021-09-20,"June 1, 2021",Actual,2021-06-01,NA,Interventional,TTCOV19,NA,Timing of Tracheotomy in Covid-19 Patients,"Timing of Tracheotomy in Covid-19 Positive Patients: a Randomized, Controlled Trial",Completed,NA,Not Applicable,150,Actual,"Sahlgrenska University Hospital, Sweden",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:40:31Z,2022-01-04T09:40:31Z,133
NCT04412330,NA,2020-05-12,NA,NA,2021-06-08,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-11,Actual,"May 1, 2020",Actual,2020-05-01,June 2021,2021-06-30,"May 5, 2021",Actual,2021-05-05,"May 5, 2021",Actual,2021-05-05,NA,Interventional,OPTIMAL,NA,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19 (OPTImAL) - a Single Center Prospective Study,Completed,NA,Not Applicable,32,Actual,University of Kentucky,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:40:36Z,2022-01-04T09:40:36Z,237
NCT04412057,NA,2020-05-29,NA,NA,2021-03-01,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-02,Actual,"June 9, 2020",Actual,2020-06-09,September 2020,2020-09-30,"January 19, 2021",Actual,2021-01-19,"December 2, 2020",Actual,2020-12-02,NA,Interventional,NA,NA,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CERC-002 in Adults With COVID 19 Pneumonia and Acute Lung Injury",Completed,NA,Phase 2,83,Actual,Cerecor Inc,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:40:47Z,2022-01-04T09:40:47Z,336
NCT04411680,NA,2020-05-29,NA,NA,2021-06-17,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"August 18, 2020",Actual,2020-08-18,June 2021,2021-06-30,"May 19, 2021",Actual,2021-05-19,"March 2, 2021",Actual,2021-03-02,NA,Interventional,iLeukPulm,NA,Study of Sargramostim in Patients With COVID-19,A Phase 2 Trial Evaluating Sargramostim in Patients With COVID-19 Associated Acute Hypoxemia,Completed,NA,Phase 2,122,Actual,"Partner Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T09:40:49Z,2022-01-04T09:40:49Z,228
NCT04411446,NA,2020-05-26,NA,NA,2021-07-28,2020-05-31,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-30,Actual,"August 11, 2020",Actual,2020-08-11,March 2021,2021-03-31,"July 28, 2021",Actual,2021-07-28,"July 28, 2021",Actual,2021-07-28,NA,Interventional,CARED,NA,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients,Completed,NA,Phase 4,218,Actual,Vitamin D Study Group,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:41:22Z,2022-01-04T09:41:22Z,187
NCT04410692,NA,2020-05-27,NA,NA,2020-05-30,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"May 17, 2020",Actual,2020-05-17,"May 16, 2020",Actual,2020-05-16,NA,Interventional,NA,NA,Can the Prediction Market Improve Predictions of COVID-19?,Can the Prediction Market Improve Predictions of COVID-19?,Completed,NA,Not Applicable,560,Actual,"National University, Singapore",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,After completion of all analysis. It will be made available in the supporting documentation.,It will be made available in the supporting documentation.,NA,Yes,"Investigators will not be storing or sharing any personal identifiers. All individual level data will be anonymized, and only anonymized data will be shared with other researchers, upon request.",2022-01-04T09:41:45Z,2022-01-04T09:41:45Z,611
NCT04410016,NA,2020-05-22,NA,NA,2021-08-26,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-30,Actual,"May 25, 2020",Actual,2020-05-25,August 2021,2021-08-31,"October 30, 2020",Actual,2020-10-30,"July 31, 2020",Actual,2020-07-31,NA,Interventional,COVID-WELL,NA,Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study,Evaluation of a Workplace Intervention to Implement Supported COVID-19 Wellbeing Centres in a Healthcare Workplace During and After the Coronavirus Pandemic: The COVID-WELL Study,Completed,NA,Not Applicable,819,Actual,University of Nottingham,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Interview data will be available on request at study end (after publication of findings).,On request.,NA,Yes,Interview data will be made available on request (after study end).,2022-01-04T09:42:12Z,2022-01-04T09:42:12Z,158
NCT04409496,NA,2020-05-26,NA,NA,2021-03-02,2020-05-26,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-04,Actual,"June 2, 2020",Actual,2020-06-02,March 2021,2021-03-31,"January 22, 2021",Actual,2021-01-22,"January 22, 2021",Actual,2021-01-22,NA,Interventional,NA,NA,Chat-based Support for Preventing Smoking Relapse,Chat-based Instant Messaging Support for Preventing Smoking Relapse in the Context of COVID-19 Outbreak: a Pilot Randomised Clinical Trial,Completed,NA,Not Applicable,108,Actual,The University of Hong Kong,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:42:55Z,2022-01-04T09:42:55Z,335
NCT04409262,NA,2020-05-28,NA,NA,2021-03-09,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"June 16, 2020",Actual,2020-06-16,March 2021,2021-03-31,"March 8, 2021",Actual,2021-03-08,"February 1, 2021",Actual,2021-02-01,NA,Interventional,REMDACTA,NA,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,"A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 3,649,Actual,Hoffmann-La Roche,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2022-01-04T09:42:54Z,2022-01-04T09:42:54Z,328
NCT04408456,NA,2020-05-24,NA,NA,2020-08-01,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-08-01,2020-08-04,Actual,"March 1, 2020",Actual,2020-03-01,August 2020,2020-08-31,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,PEP-CQ,NA,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Open Level Control Clinical Trial,Completed,NA,Phase 3,325,Actual,Postgraduate Institute of Medical Education and Research,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data will be shared with the concerned authority and Institutional Ethics committee as and when required.,2022-01-04T09:43:30Z,2022-01-04T09:43:30Z,548
NCT04407182,NA,2020-05-25,NA,NA,2021-01-07,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"October 1, 2020",Actual,2020-10-01,"August 1, 2020",Actual,2020-08-01,NA,Interventional,NA,NA,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19,Completed,NA,Phase 2,60,Actual,Catalysis SL,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2022-01-04T09:44:12Z,2022-01-04T09:44:12Z,389
NCT04407208,NA,2020-05-16,NA,NA,2020-06-27,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-27,2020-06-30,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"June 22, 2020",Actual,2020-06-22,"June 22, 2020",Actual,2020-06-22,NA,Interventional,NA,NA,Convalescent Plasma Therapy in Patients With COVID-19,Convalescent Plasma Therapy in Patients With COVID-19,Completed,NA,Phase 1,10,Actual,Biofarma,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:44:21Z,2022-01-04T09:44:21Z,583
NCT04407130,NA,2020-05-17,NA,NA,2021-02-01,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-04,Actual,"June 16, 2020",Actual,2020-06-16,June 2020,2020-06-30,"November 20, 2020",Actual,2020-11-20,"October 30, 2020",Actual,2020-10-30,NA,Interventional,NA,NA,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,"Ivermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19: a Randomised, Double-blind, Placebo-controlled Trial.",Completed,NA,Phase 2,72,Actual,"International Centre for Diarrhoeal Disease Research, Bangladesh",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:44:23Z,2022-01-04T09:44:23Z,364
NCT04406246,NA,2020-05-24,NA,NA,2021-03-29,2020-05-27,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-03-30,Actual,"May 21, 2020",Actual,2020-05-21,March 2021,2021-03-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,NA,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide,Completed,NA,Phase 4,150,Actual,Materno-Perinatal Hospital of the State of Mexico,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,The Data will be available upon request after a publication is reached.,2022-01-04T09:44:59Z,2022-01-04T09:44:59Z,308
NCT04405999,NA,2020-05-18,NA,NA,2020-09-02,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-03,Actual,"May 14, 2020",Actual,2020-05-14,September 2020,2020-09-30,"August 31, 2020",Actual,2020-08-31,"August 9, 2020",Actual,2020-08-09,NA,Interventional,NA,NA,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial,Completed,NA,Phase 4,50,Actual,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:45:07Z,2022-01-04T09:45:07Z,516
NCT04405570,NA,2020-05-26,NA,NA,2021-02-22,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-23,Actual,"June 16, 2020",Actual,2020-06-16,February 2021,2021-02-28,"February 21, 2021",Actual,2021-02-21,"February 21, 2021",Actual,2021-02-21,NA,Interventional,NA,NA,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19","A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19",Completed,NA,Phase 2,204,Actual,"Ridgeback Biotherapeutics, LP",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:45:23Z,2022-01-04T09:45:23Z,343
NCT04405843,NA,2020-05-23,NA,NA,2020-12-24,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-24,2020-12-28,Actual,"July 14, 2020",Actual,2020-07-14,December 2020,2020-12-31,"December 21, 2020",Actual,2020-12-21,"December 21, 2020",Actual,2020-12-21,NA,Interventional,EPIC,NA,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),"Randomized, Placebo Controlled, Double Blind Clinical Trial to Evaluate the Efficacy of Molecule D11AX22 in Adults Patients From Valle Del Cauca, Colombia With Early Stages of SARS COV2 / COVID-19",Completed,NA,Phase 2/Phase 3,476,Actual,Centro de Estudios en InfectogÃ­a Pediatrica,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2022-01-04T09:45:16Z,2022-01-04T09:45:16Z,403
NCT04405986,NA,2020-05-08,NA,NA,2021-04-07,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-08,Actual,"May 19, 2020",Actual,2020-05-19,April 2021,2021-04-30,"March 10, 2021",Actual,2021-03-10,"March 10, 2021",Actual,2021-03-10,NA,Interventional,BRAINCOV,NA,Exploring Brain Damages After COVID-19 Infection,Exploring Brain Damages After COVID-19 Infection,Completed,NA,Not Applicable,38,Actual,"University Hospital, Bordeaux",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:45:13Z,2022-01-04T09:45:13Z,299
NCT04405544,NA,2020-05-26,NA,NA,2020-10-29,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"May 22, 2020",Actual,2020-05-22,October 2020,2020-10-31,"October 29, 2020",Actual,2020-10-29,"July 22, 2020",Actual,2020-07-22,NA,Interventional,NA,NA,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Completed,NA,Not Applicable,51,Actual,"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:45:39Z,2022-01-04T09:45:39Z,459
NCT04405310,NA,2020-05-26,NA,NA,2020-12-16,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-16,2020-12-21,Actual,"May 20, 2020",Actual,2020-05-20,December 2020,2020-12-31,"December 10, 2020",Actual,2020-12-10,"November 20, 2020",Actual,2020-11-20,NA,Interventional,CPC-SARS,NA,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,"Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial",Completed,NA,Phase 2,42,Actual,Grupo Mexicano para el Estudio de la Medicina Intensiva,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,3 months after completion up to five years,"proposal should be directed to gmemiinv@gmails.com, to gain access, requestor will need to sign a data access agreement",NA,Yes,IPD will be shared by petition.,2022-01-04T09:45:57Z,2022-01-04T09:45:57Z,411
NCT04404426,NA,2020-05-22,NA,NA,2021-05-28,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-28,2021-06-02,Actual,"November 4, 2020",Actual,2020-11-04,May 2021,2021-05-31,"May 28, 2021",Actual,2021-05-28,"March 25, 2021",Actual,2021-03-25,NA,Interventional,CACOLAC,NA,CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,CACOLAC : Randomized Trial of Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,Completed,NA,Not Applicable,33,Actual,Rennes University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T09:46:22Z,2022-01-04T09:46:22Z,248
NCT04403555,NA,2020-05-23,NA,NA,2021-07-29,2020-05-23,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-02,Actual,"June 1, 2020",Actual,2020-06-01,July 2021,2021-07-31,"December 1, 2020",Actual,2020-12-01,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,NA,Ivermectin as a Novel Therapy in COVID-19 Treatment,The Efficacy of Ivermectin in COVID-19 Treatment,Completed,NA,Phase 2/Phase 3,164,Actual,Tanta University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:47:04Z,2022-01-04T09:47:04Z,186
NCT04402866,NA,2020-05-22,NA,NA,2021-05-17,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-19,Actual,"June 24, 2020",Actual,2020-06-24,May 2021,2021-05-31,"April 21, 2021",Actual,2021-04-21,"April 21, 2021",Actual,2021-04-21,NA,Interventional,NA,NA,TD-0903 for ALI Associated With COVID-19,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated With COVID-19",Completed,NA,Phase 2,235,Actual,Theravance Biopharma,NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2022-01-04T09:47:24Z,2022-01-04T09:47:24Z,259
NCT04402983,NA,2020-05-22,NA,NA,2020-12-11,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"May 27, 2020",Actual,2020-05-27,May 2020,2020-05-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,NA,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,Completed,NA,Not Applicable,34,Actual,Istanbul Medipol University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T09:47:26Z,2022-01-04T09:47:26Z,416
NCT04402060,NA,2020-05-22,NA,NA,2021-08-30,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"May 28, 2020",Actual,2020-05-28,August 2021,2021-08-31,"February 19, 2021",Actual,2021-02-19,"February 19, 2021",Actual,2021-02-19,NA,Interventional,NA,NA,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,"A Randomized, Double-Blinded, Vehicle-Controlled, Multicenter, Parallel-Group Study of APL-9 in Mild to Moderate Acute Respiratory Distress Syndrome Due to COVID-19",Completed,NA,Phase 1/Phase 2,65,Actual,"Apellis Pharmaceuticals, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:48:01Z,2022-01-04T09:48:01Z,154
NCT04402918,NA,2020-05-18,NA,NA,2021-08-02,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"May 17, 2020",Actual,2020-05-17,July 2021,2021-07-31,"August 2, 2021",Actual,2021-08-02,"May 19, 2020",Actual,2020-05-19,NA,Interventional,TRANSCOVID,NA,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 During Pregnancy,Completed,NA,Not Applicable,160,Actual,Centre Hospitalier Universitaire de Besancon,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:47:38Z,2022-01-04T09:47:38Z,182
NCT04401423,NA,2020-05-21,NA,NA,2021-07-27,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-29,Actual,"February 10, 2021",Actual,2021-02-10,July 2021,2021-07-31,"June 10, 2021",Actual,2021-06-10,"June 10, 2021",Actual,2021-06-10,NA,Interventional,NA,NA,TXA127 for the Treatment of Severe COVID-19,Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19,Completed,NA,Phase 2,22,Actual,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:48:38Z,2022-01-04T09:48:38Z,188
NCT04401046,NA,2020-05-22,NA,NA,2021-07-21,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"May 20, 2020",Actual,2020-05-20,July 2021,2021-07-31,"February 2, 2021",Actual,2021-02-02,"November 26, 2020",Actual,2020-11-26,NA,Interventional,COVID-TRAUMA,NA,COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,COVID-19 EPIDEMIC Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,Completed,NA,Not Applicable,1096,Actual,Institut Paoli-Calmettes,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:48:43Z,2022-01-04T09:48:43Z,194
NCT04400279,NA,2020-05-21,NA,NA,2021-01-08,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"June 1, 2020",Actual,2020-06-01,January 2021,2021-01-31,"November 28, 2020",Actual,2020-11-28,"November 28, 2020",Actual,2020-11-28,NA,Interventional,COPE,NA,The COVID-19 Pandemic and Exercise Study,COvid-19 Pandemic and Exercise (COPE) Trial: A Randomized Study Examining Physical Activities and Wellbeing in Individuals Mandated to Stay at Home,Completed,NA,Not Applicable,334,Actual,University of British Columbia,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"4 months following trial's end, materials will be made available. following publication, all data will be made available.",Investigators whose proposed use of the data has been approved by an independent review committee identified for the purpose for the purpose of meta-analyses and to achieve aims in the approved proposal. Investigators of the study need to approve the proposals. Proposals should be directed to eli.puterman@Ubc.ca,https://osf.io/g9xqp,Yes,"All of the individual participant data collected during the trial, after de-identification upon request and cleared for approval by principal investigator.

All of the protocols, statistical analysis plan, informed consent form, analytic code.",2022-01-04T09:49:19Z,2022-01-04T09:49:19Z,388
NCT04400032,NA,2020-04-27,NA,NA,2021-04-23,2020-05-20,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-26,Actual,"May 15, 2020",Actual,2020-05-15,April 2021,2021-04-30,"April 22, 2021",Actual,2021-04-22,"April 22, 2021",Actual,2021-04-22,NA,Interventional,CIRCA-19,NA,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome,Cellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19),Completed,NA,Phase 1/Phase 2,15,Actual,Ottawa Hospital Research Institute,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:49:23Z,2022-01-04T09:49:23Z,283
NCT04399252,NA,2020-05-19,NA,NA,2021-07-12,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-14,Actual,"June 24, 2020",Actual,2020-06-24,July 2021,2021-07-31,"July 8, 2021",Actual,2021-07-08,"July 8, 2021",Actual,2021-07-08,NA,Interventional,NA,NA,Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,A Randomized Trial of the Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,Completed,NA,Not Applicable,182,Actual,Duke University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:49:49Z,2022-01-04T09:49:49Z,203
NCT04399005,NA,2020-05-19,NA,NA,2020-06-23,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"June 10, 2020",Actual,2020-06-10,"June 5, 2020",Actual,2020-06-05,NA,Interventional,NA,NA,The Efficacy Comparing Daily and After-each-case Room Disinfection.,The Efficacy Comparing Daily and After-each-case Room Disinfection in the Endoscopy Unit During the COVID-19 Pandemic.,Completed,NA,Not Applicable,240,Actual,The First Affiliated Hospital of Zhejiang Chinese Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,individual participant data sharing will be consider after study,2022-01-04T09:50:00Z,2022-01-04T09:50:00Z,587
NCT04398004,NA,2020-05-17,NA,NA,2021-01-08,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"May 6, 2020",Actual,2020-05-06,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,ACHIEVE,NA,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early: The ACHIEVE Open-label Non-randomized Clinical Trial,Completed,NA,Phase 2,90,Actual,Hellenic Institute for the Study of Sepsis,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:50:47Z,2022-01-04T09:50:47Z,388
NCT04397757,NA,2020-05-19,NA,NA,2021-06-09,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-10,Actual,"May 13, 2020",Actual,2020-05-13,June 2021,2021-06-30,"March 8, 2021",Actual,2021-03-08,"February 6, 2021",Actual,2021-02-06,NA,Interventional,NA,NA,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,"An Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2.",Completed,NA,Phase 1,80,Actual,University of Pennsylvania,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:50:53Z,2022-01-04T09:50:53Z,236
NCT04397523,NA,2020-05-20,NA,NA,2021-05-10,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-11,Actual,"April 30, 2020",Actual,2020-04-30,February 2021,2021-02-28,"May 10, 2021",Actual,2021-05-10,"May 10, 2021",Actual,2021-05-10,NA,Interventional,NA,NA,Efficacy and Safety of COVID-19 Convalescent Plasma,Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety,Completed,NA,Not Applicable,200,Actual,Institute for Transfusion Medicine of RNM,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T09:51:06Z,2022-01-04T09:51:06Z,266
NCT04397718,NA,2020-05-14,NA,NA,2021-06-30,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-30,2021-07-02,Actual,"July 6, 2020",Actual,2020-07-06,June 2021,2021-06-30,"June 8, 2021",Actual,2021-06-08,"June 8, 2021",Actual,2021-06-08,NA,Interventional,HITCH,NA,Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization,"Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH): A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus Degarelix",Completed,NA,Phase 2,96,Actual,VA Office of Research and Development,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:51:04Z,2022-01-04T09:51:04Z,215
NCT04395911,NA,2020-05-17,NA,NA,2021-08-04,2020-05-18,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"September 10, 2020",Actual,2020-09-10,August 2021,2021-08-31,"July 21, 2021",Actual,2021-07-21,"July 5, 2021",Actual,2021-07-05,NA,Interventional,NA,NA,Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,A Multi-Center Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Patients Developing Acute Kidney Injury (AKI) or Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 Infection,Completed,NA,Not Applicable,22,Actual,SeaStar Medical,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,Data will be collected throughout the study conduct.,Participant data will be accessible to the Investigational Site and CRO through a secured electronic data capture system. CRO personnel will be responsible for data verification. De-identified Participant information will be accessible to the CRO and the Sponsor.,NA,Yes,Unidentified participant data collected for this study will be submitted to a CRO for data analysis. All data will be submitted to the Sponsor.,2022-01-04T09:52:12Z,2022-01-04T09:52:12Z,180
NCT04395144,NA,2020-05-15,NA,NA,2021-03-21,2020-05-18,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-03-21,2021-03-23,Actual,"May 15, 2020",Actual,2020-05-15,March 2021,2021-03-31,"March 15, 2021",Actual,2021-03-15,"March 15, 2021",Actual,2021-03-15,NA,Interventional,COVAYDE,NA,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Randomized-controlled Trial of HFNC Alone vs HFNC and Awake Self-proning for Treatment of Severe COVID-19,Completed,NA,Not Applicable,13,Actual,HÃ´pital de Verdun,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:52:49Z,2022-01-04T09:52:49Z,316
NCT04394377,NA,2020-05-08,NA,NA,2021-06-08,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-10,Actual,"June 21, 2020",Actual,2020-06-21,May 2020,2020-05-31,"May 30, 2021",Actual,2021-05-30,"March 26, 2021",Actual,2021-03-26,NA,Interventional,ACTION,NA,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial,Completed,NA,Phase 4,615,Actual,Brazilian Clinical Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,All data provided during study is anonymized to respect the privacy of patients who have participated in the trial in line with applicable regulations.,2022-01-04T09:53:35Z,2022-01-04T09:53:35Z,237
NCT04393818,NA,2020-05-18,NA,NA,2020-09-09,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-10,Actual,"May 5, 2020",Actual,2020-05-05,August 2020,2020-08-31,"August 24, 2020",Actual,2020-08-24,"August 24, 2020",Actual,2020-08-24,NA,Interventional,PsyCovid_App,NA,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,A Double-blinded Randomized Controlled Trial to Examine the Effectiveness of a Mobile-based Intervention to Reduce Mental Health Problems in Healthcare Workers at the Frontline Against COVID-19 in Spain: the PsyCovidApp Trial,Completed,NA,Phase 3,560,Actual,FundaciÃ³ d'investigaciÃ³ SanitÃ ria de les Illes Balears,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T09:53:50Z,2022-01-04T09:53:50Z,509
NCT04394013,NA,2020-05-18,NA,NA,2021-02-22,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-24,Actual,"August 26, 2020",Actual,2020-08-26,February 2021,2021-02-28,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,NA,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,Completed,NA,Not Applicable,70,Actual,Monash University Malaysia,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Upon request via direct contact to researcher,2022-01-04T09:53:52Z,2022-01-04T09:53:52Z,343
NCT04394039,NA,2020-05-13,NA,NA,2021-07-09,2020-05-13,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-15,Actual,"June 1, 2020",Actual,2020-06-01,July 2021,2021-07-31,"December 31, 2020",Actual,2020-12-31,"August 1, 2020",Actual,2020-08-01,NA,Interventional,NA,NA,Post-Pandemic Perception of Public Space in Singapore,Effects of COVID-19-Related Self-isolation on Psychological Response to Different Outdoor Environments in Singapore - Before & After Brain and Behavior Study,Completed,NA,Not Applicable,34,Actual,"National University, Singapore",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:53:53Z,2022-01-04T09:53:53Z,206
NCT04393077,NA,2020-05-11,NA,NA,2020-11-20,2020-05-15,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-11-20,2020-11-24,Actual,"May 10, 2020",Actual,2020-05-10,November 2020,2020-11-30,"May 20, 2020",Actual,2020-05-20,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,NA,Emotional Freedom Technique (EFT) Effect on Nurses,"Emotional Freedom Technique (EFT) Effect on Nurses' Stress, Anxiety and Burnout Levels During the COVID-19 Pandemic Process: A Randomized Controlled Study",Completed,NA,Not Applicable,80,Actual,Istanbul Saglik Bilimleri University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:54:18Z,2022-01-04T09:54:18Z,437
NCT04392973,NA,2020-05-10,NA,NA,2021-08-19,2020-05-13,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"May 21, 2020",Actual,2020-05-21,August 2021,2021-08-31,"April 26, 2021",Actual,2021-04-26,"January 26, 2021",Actual,2021-01-26,NA,Interventional,FACCT,NA,FAvipiravir and HydroxyChloroquine Combination Therapy,A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19,Completed,NA,Not Applicable,268,Actual,King Abdullah International Medical Research Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:54:26Z,2022-01-04T09:54:26Z,165
NCT04392778,NA,2020-04-25,NA,NA,2021-05-22,2020-05-17,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-22,2021-05-25,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"November 30, 2020",Actual,2020-11-30,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,NA,Clinical Use of Stem Cells for the Treatment of Covid-19,What is the Effect of Mesenchymal Stem Cell Therapy on Seriously Ill Patients With Covid 19 in Intensive Care? (Prospective Double Controlled Study),Completed,NA,Phase 1/Phase 2,30,Actual,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:54:36Z,2022-01-04T09:54:36Z,254
NCT04392414,NA,2020-05-13,NA,NA,2020-09-23,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"September 23, 2020",Actual,2020-09-23,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,NA,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,"Randomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease",Completed,NA,Phase 2,60,Actual,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no current plan to share individual participant data (IPD).,2022-01-04T09:54:44Z,2022-01-04T09:54:44Z,495
NCT04392531,NA,2020-05-03,NA,NA,2021-08-26,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-27,Actual,"April 16, 2020",Actual,2020-04-16,August 2021,2021-08-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,NA,Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,"Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection",Completed,NA,Phase 4,111,Actual,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:55:00Z,2022-01-04T09:55:00Z,158
NCT04390477,NA,2020-05-07,NA,NA,2021-07-20,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"May 4, 2020",Actual,2020-05-04,July 2021,2021-07-31,"April 30, 2021",Actual,2021-04-30,"March 21, 2021",Actual,2021-03-21,NA,Interventional,NA,NA,Study to Evaluate the Effect of a Probiotic in COVID-19,The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection,Completed,NA,Not Applicable,41,Actual,Bioithas SL,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:56:23Z,2022-01-04T09:56:23Z,195
NCT04390516,NA,2020-05-14,NA,NA,2020-06-10,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"March 24, 2020",Actual,2020-03-24,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"May 4, 2020",Actual,2020-05-04,NA,Interventional,READY,NA,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Prediction Of Respiratory Decompensation In Covid-19 Patients Using Machine Learning: The READY Trial,Completed,NA,Not Applicable,197,Actual,Dascena,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:56:26Z,2022-01-04T09:56:26Z,600
NCT04391712,NA,2020-05-04,NA,NA,2020-08-03,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-05,Actual,"April 30, 2020",Actual,2020-04-30,August 2020,2020-08-31,"July 16, 2020",Actual,2020-07-16,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,NA,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Multiwave Locked System (MLS) Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Completed,NA,Phase 2,10,Actual,Lowell General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:55:32Z,2022-01-04T09:55:32Z,546
NCT04391127,NA,2020-05-12,NA,NA,2020-11-06,2020-05-14,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"May 4, 2020",Actual,2020-05-04,November 2020,2020-11-30,"November 6, 2020",Actual,2020-11-06,"November 6, 2020",Actual,2020-11-06,NA,Interventional,NA,NA,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial,Completed,NA,Phase 3,108,Actual,Centenario Hospital Miguel Hidalgo,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:56:05Z,2022-01-04T09:56:05Z,451
NCT04391179,NA,2020-05-15,NA,NA,2021-03-16,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-18,Actual,"May 31, 2020",Actual,2020-05-31,March 2021,2021-03-31,"February 22, 2021",Actual,2021-02-22,"February 22, 2021",Actual,2021-02-22,NA,Interventional,DICER,NA,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Completed,NA,Phase 2,100,Actual,University of Michigan,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:56:06Z,2022-01-04T09:56:06Z,321
NCT04389944,NA,2020-05-12,NA,NA,2020-08-03,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-04,Actual,"March 31, 2020",Actual,2020-03-31,August 2020,2020-08-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,NA,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe Coronavirus Disease 2019 Infectious Disease (COVID-19),Completed,NA,Not Applicable,15,Actual,"University Hospital, Basel, Switzerland",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:56:43Z,2022-01-04T09:56:43Z,546
NCT04389710,NA,2020-04-27,NA,NA,2021-06-03,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-04,Actual,"April 15, 2020",Actual,2020-04-15,June 2021,2021-06-30,"December 7, 2020",Actual,2020-12-07,"November 3, 2020",Actual,2020-11-03,NA,Interventional,NA,NA,Convalescent Plasma for the Treatment of COVID-19,Convalescent Plasma for the Treatment of Patients With COVID-19,Completed,NA,Phase 2,52,Actual,Thomas Jefferson University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:57:03Z,2022-01-04T09:57:03Z,242
NCT04388527,NA,2020-05-04,NA,NA,2021-06-09,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-10,Actual,"April 30, 2020",Actual,2020-04-30,June 2021,2021-06-30,"January 30, 2021",Actual,2021-01-30,"January 25, 2021",Actual,2021-01-25,NA,Interventional,NA,NA,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,"An Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2",Completed,NA,Phase 1,32,Actual,University of Pennsylvania,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:58:02Z,2022-01-04T09:58:02Z,236
NCT04387292,NA,2020-05-12,NA,NA,2021-08-02,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"September 7, 2020",Actual,2020-09-07,August 2021,2021-08-31,"May 15, 2021",Actual,2021-05-15,"January 21, 2021",Actual,2021-01-21,NA,Interventional,SOCOVID,NA,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Completed,NA,Not Applicable,34,Actual,Fondation Ophtalmologique Adolphe de Rothschild,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:58:40Z,2022-01-04T09:58:40Z,182
NCT04386694,NA,2020-05-08,NA,NA,2020-10-28,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"May 18, 2020",Actual,2020-05-18,October 2020,2020-10-31,"September 17, 2020",Actual,2020-09-17,"September 17, 2020",Actual,2020-09-17,NA,Interventional,NA,NA,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,Is Photobiomodulation Therapy (PBMT) Combined With Static Magnetic Field (sMF) Able to Decrease the Intensive Care Unit (ICU) Length of Stay for Patients With COVID-19?,Completed,NA,Not Applicable,30,Actual,University of Nove de Julho,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:59:03Z,2022-01-04T09:59:03Z,460
NCT04385810,NA,2020-04-29,NA,NA,2020-11-13,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-13,2020-11-16,Actual,"April 27, 2020",Actual,2020-04-27,November 2020,2020-11-30,"July 29, 2020",Actual,2020-07-29,"July 29, 2020",Actual,2020-07-29,NA,Interventional,DOCOV,NA,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Completed,NA,Not Applicable,23,Actual,Fondation Ophtalmologique Adolphe de Rothschild,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T09:59:56Z,2022-01-04T09:59:56Z,444
NCT04385901,NA,2020-05-06,NA,NA,2021-02-04,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-04,2021-02-08,Actual,"May 19, 2020",Actual,2020-05-19,February 2021,2021-02-28,"September 19, 2020",Actual,2020-09-19,"September 19, 2020",Actual,2020-09-19,NA,Interventional,NA,NA,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Completed,NA,Not Applicable,26,Actual,University of Missouri-Columbia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T09:59:56Z,2022-01-04T09:59:56Z,361
NCT04385199,NA,2020-05-09,NA,NA,2021-05-26,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"May 4, 2020",Actual,2020-05-04,May 2021,2021-05-31,"August 1, 2020",Actual,2020-08-01,"August 1, 2020",Actual,2020-08-01,NA,Interventional,NA,NA,Convalescent Plasma for Patients With COVID-19,The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease,Completed,NA,Phase 2,30,Actual,Henry Ford Health System,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:00:04Z,2022-01-04T10:00:04Z,250
NCT04384380,NA,2020-04-07,NA,NA,2020-07-31,2020-05-10,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"April 1, 2020",Actual,2020-04-01,March 2020,2020-03-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,NA,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,"A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",Completed,NA,Not Applicable,33,Actual,Taoyuan General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The study outcome will be shared with the experts and persons interested in this field.,2022-01-04T10:00:55Z,2022-01-04T10:00:55Z,549
NCT04383535,NA,2020-05-06,NA,NA,2020-09-29,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"May 15, 2020",Actual,2020-05-15,September 2020,2020-09-30,"September 27, 2020",Actual,2020-09-27,"September 27, 2020",Actual,2020-09-27,NA,Interventional,PLASM-AR,NA,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,"Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria",Completed,NA,Not Applicable,333,Actual,Hospital Italiano de Buenos Aires,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:01:39Z,2022-01-04T10:01:39Z,489
NCT04382651,NA,2020-05-08,NA,2021-07-07,2021-07-07,2020-05-08,2020-05-11,Actual,NA,NA,NA,2021-07-07,2021-07-08,Actual,2021-07-07,2021-07-08,Actual,"June 11, 2020",Actual,2020-06-11,July 2021,2021-07-31,"April 21, 2021",Actual,2021-04-21,"January 6, 2021",Actual,2021-01-06,NA,Interventional,MAS-COVID,NA,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,"A Phase 2, Randomized, Placebo-controlled, Participant and Investigator Blinded, Multi-center Study to Assess Efficacy and Safety of MAS825 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function",Completed,NA,Phase 2,140,Actual,Novartis,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2022-01-04T10:02:21Z,2022-01-04T10:02:21Z,208
NCT04382560,NA,2020-05-05,NA,NA,2021-03-30,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-01,Actual,"May 2, 2020",Actual,2020-05-02,March 2021,2021-03-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,NA,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,Resting Heart Rate Variability as a Predictor of Coping Strategies and Responsiveness to a Brief Online Intervention During Forced Quarantine,Completed,NA,Not Applicable,69,Actual,University of Parma,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:02:26Z,2022-01-04T10:02:26Z,307
NCT04382547,NA,2020-05-08,NA,NA,2021-08-20,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"May 11, 2020",Actual,2020-05-11,August 2021,2021-08-31,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,NA,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Completed,NA,Phase 1/Phase 2,32,Actual,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:02:27Z,2022-01-04T10:02:27Z,164
NCT04382586,NA,2020-05-07,NA,NA,2021-06-15,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-15,2021-06-16,Actual,"July 6, 2020",Actual,2020-07-06,June 2021,2021-06-30,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,"A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress",Completed,NA,Phase 2,67,Actual,BeiGene,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2022-01-04T10:02:37Z,2022-01-04T10:02:37Z,230
NCT04382092,NA,2020-05-06,NA,NA,2020-05-08,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"March 23, 2020",Actual,2020-03-23,May 2020,2020-05-31,"April 24, 2020",Actual,2020-04-24,"April 24, 2020",Actual,2020-04-24,NA,Interventional,NA,NA,Co-infection Management in COVID-19 Critically Ill,Co-infections in COVID-19 Critically Ill and Antibiotic Management,Completed,NA,Not Applicable,32,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:02:43Z,2022-01-04T10:02:43Z,633
NCT04381884,NA,2020-05-05,NA,NA,2020-10-01,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"May 18, 2020",Actual,2020-05-18,October 2020,2020-10-31,"September 29, 2020",Actual,2020-09-29,"September 29, 2020",Actual,2020-09-29,NA,Interventional,NA,NA,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,"A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19",Completed,NA,Phase 2,45,Actual,Laboratorio Elea Phoenix S.A.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:02:55Z,2022-01-04T10:02:55Z,487
NCT04381962,NA,2020-05-07,NA,NA,2021-05-04,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-04,2021-05-06,Actual,"June 3, 2020",Actual,2020-06-03,May 2020,2020-05-31,"April 20, 2021",Actual,2021-04-20,"January 29, 2021",Actual,2021-01-29,NA,Interventional,ATOMIC2,NA,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),A Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2),Completed,NA,Phase 3,298,Actual,University of Oxford,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:02:58Z,2022-01-04T10:02:58Z,272
NCT04382040,NA,2020-05-07,NA,NA,2021-08-25,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-31,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"December 21, 2020",Actual,2020-12-21,"November 5, 2020",Actual,2020-11-05,NA,Interventional,NA,NA,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19","A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",Completed,NA,Phase 2,50,Actual,MGC Pharmaceuticals d.o.o,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:02:53Z,2022-01-04T10:02:53Z,159
NCT04381000,NA,2020-05-07,NA,NA,2020-06-30,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,"June 10, 2020",Actual,2020-06-10,"May 29, 2020",Actual,2020-05-29,NA,Interventional,NA,NA,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,The Impact of Quarantine and the Effectiveness of Telerehabilitation in Patients With Chronic Pain During COVID-19 Pandemic.,Completed,NA,Not Applicable,170,Actual,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:03:31Z,2022-01-04T10:03:31Z,580
NCT04380961,NA,2020-05-07,NA,NA,2021-07-13,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-14,Actual,"April 24, 2020",Actual,2020-04-24,July 2021,2021-07-31,"June 24, 2021",Actual,2021-06-24,"April 9, 2021",Actual,2021-04-09,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease",Completed,NA,Phase 2,212,Actual,"Janssen Pharmaceutica N.V., Belgium",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2022-01-04T10:03:32Z,2022-01-04T10:03:32Z,202
NCT04381052,NA,2020-05-06,NA,NA,2021-09-17,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-23,Actual,"May 18, 2020",Actual,2020-05-18,September 2021,2021-09-30,"March 12, 2021",Actual,2021-03-12,"February 3, 2021",Actual,2021-02-03,NA,Interventional,NA,NA,Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-Controlled Safety and Dose-Finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Completed,NA,Phase 2,1,Actual,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Coded data will be shared with New York University (NYU) Langone for the purpose of statistical analysis and scientific reporting.,2022-01-04T10:03:33Z,2022-01-04T10:03:33Z,136
NCT04380909,NA,2020-05-07,NA,NA,2021-08-23,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"May 6, 2020",Actual,2020-05-06,August 2021,2021-08-31,"July 29, 2021",Actual,2021-07-29,"July 29, 2021",Actual,2021-07-29,NA,Interventional,ROCO,NA,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,Randomized Controlled Trial (RCT) to Evaluate the Efficacy of an Internet-based Self-help Program for People With Psychological Distress Due to Covid-19,Completed,NA,Not Applicable,107,Actual,University of Bern,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:03:34Z,2022-01-04T10:03:34Z,161
NCT04381858,NA,2020-05-06,NA,NA,2020-11-26,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,NA,Interventional,NA,NA,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial,Completed,NA,Phase 3,196,Actual,Centenario Hospital Miguel Hidalgo,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:03:19Z,2022-01-04T10:03:19Z,431
NCT04379531,NA,2020-04-30,NA,NA,2020-06-10,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"May 22, 2020",Actual,2020-05-22,"May 22, 2020",Actual,2020-05-22,NA,Interventional,LDCTiP,NA,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Low-dose Computed Tomography in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,NA,Not Applicable,230,Actual,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:04:28Z,2022-01-04T10:04:28Z,600
NCT04379271,NA,2020-05-01,NA,NA,2021-04-23,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-26,Actual,"June 11, 2020",Actual,2020-06-11,April 2021,2021-04-30,"February 23, 2021",Actual,2021-02-23,"January 12, 2021",Actual,2021-01-12,NA,Interventional,NA,NA,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)","A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19",Completed,NA,Phase 2/Phase 3,223,Actual,Immunic AG,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:04:48Z,2022-01-04T10:04:48Z,283
NCT04379661,NA,2020-05-05,NA,NA,2021-01-07,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"May 7, 2020",Actual,2020-05-07,January 2021,2021-01-31,"August 31, 2020",Actual,2020-08-31,"July 7, 2020",Actual,2020-07-07,NA,Interventional,NA,NA,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,SUNLIGHT Study: Online Support Groups for Multiple Sclerosis (MS) to Address COVID-19,Completed,NA,Not Applicable,32,Actual,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:04:36Z,2022-01-04T10:04:36Z,389
NCT04379037,NA,2020-05-05,NA,NA,2021-06-01,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-04,Actual,"June 27, 2020",Actual,2020-06-27,June 2021,2021-06-30,"November 1, 2020",Actual,2020-11-01,"September 1, 2020",Actual,2020-09-01,NA,Interventional,NA,NA,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Completed,NA,Not Applicable,50,Actual,Nemechek Technologies,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:05:02Z,2022-01-04T10:05:02Z,244
NCT04378803,NA,2020-05-04,NA,NA,2020-08-14,2020-05-04,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-17,Actual,"May 13, 2020",Actual,2020-05-13,August 2020,2020-08-31,"August 4, 2020",Actual,2020-08-04,"August 4, 2020",Actual,2020-08-04,NA,Interventional,NA,NA,Mindfulness Training for Seniors,Mindfulness Training for Older Adults During the COVID-19 Pandemic,Completed,NA,Not Applicable,53,Actual,University of Miami,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:05:03Z,2022-01-04T10:05:03Z,535
NCT04378712,NA,2020-04-29,NA,NA,2020-05-13,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"January 21, 2020",Actual,2020-01-21,May 2020,2020-05-31,"March 23, 2020",Actual,2020-03-23,"March 23, 2020",Actual,2020-03-23,NA,Interventional,NA,NA,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),"Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial",Completed,NA,Not Applicable,90,Actual,Guangzhou Institute of Respiratory Disease,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T10:05:10Z,2022-01-04T10:05:10Z,628
NCT04377789,NA,2020-05-01,NA,NA,2021-02-17,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"March 20, 2020",Actual,2020-03-20,February 2021,2021-02-28,"August 31, 2020",Actual,2020-08-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,NA,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19,Completed,NA,Not Applicable,447,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:05:44Z,2022-01-04T10:05:44Z,348
NCT04376814,NA,2020-05-03,NA,NA,2020-06-12,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-12,2020-06-16,Actual,"March 29, 2020",Actual,2020-03-29,May 2020,2020-05-31,"May 25, 2020",Actual,2020-05-25,"April 5, 2020",Actual,2020-04-05,NA,Interventional,NA,NA,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,"The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study",Completed,NA,Not Applicable,40,Actual,Baqiyatallah Medical Sciences University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:06:54Z,2022-01-04T10:06:54Z,598
NCT04376684,NA,2020-05-04,NA,NA,2021-09-10,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-14,Actual,"May 28, 2020",Actual,2020-05-28,September 2021,2021-09-30,"August 16, 2021",Actual,2021-08-16,"July 15, 2021",Actual,2021-07-15,NA,Interventional,OSCAR,NA,Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease,"A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease",Completed,NA,Phase 2,1156,Actual,GlaxoSmithKline,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2022-01-04T10:06:50Z,2022-01-04T10:06:50Z,143
NCT04375397,NA,2020-05-04,NA,NA,2021-07-07,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"June 6, 2020",Actual,2020-06-06,July 2021,2021-07-31,"June 8, 2021",Actual,2021-06-08,"May 10, 2021",Actual,2021-05-10,NA,Interventional,iNSPIRE,NA,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE),Completed,NA,Phase 2,46,Actual,AbbVie,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.",Requests for access to individual participant data from ibrutinib clinical studies conducted by AbbVie can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu,http://yoda.yale.edu/,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2022-01-04T10:07:46Z,2022-01-04T10:07:46Z,208
NCT04375098,NA,2020-05-03,NA,NA,2020-09-12,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-12,2020-09-16,Actual,"May 4, 2020",Actual,2020-05-04,September 2020,2020-09-30,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,NA,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial,Completed,NA,Phase 2,58,Actual,Pontificia Universidad Catolica de Chile,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:07:59Z,2022-01-04T10:07:59Z,506
NCT04374526,NA,2020-05-02,NA,NA,2021-05-27,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-05-28,Actual,"May 27, 2020",Actual,2020-05-27,May 2020,2020-05-31,"May 26, 2021",Actual,2021-05-26,"May 26, 2021",Actual,2021-05-26,NA,Interventional,LIFESAVER,NA,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Early transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression.,Completed,NA,Phase 2/Phase 3,29,Actual,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:08:45Z,2022-01-04T10:08:45Z,249
NCT04374032,NA,2020-04-30,NA,NA,2020-12-23,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"May 1, 2020",Actual,2020-05-01,December 2020,2020-12-31,"November 3, 2020",Actual,2020-11-03,"October 7, 2020",Actual,2020-10-07,NA,Interventional,NA,NA,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,"An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTENÂ® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection",Completed,NA,Phase 2/Phase 3,120,Actual,Bosnalijek D.D,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T10:09:00Z,2022-01-04T10:09:00Z,404
NCT04373291,NA,2020-05-01,NA,NA,2021-10-07,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-08,Actual,"May 18, 2020",Actual,2020-05-18,October 2021,2021-10-31,"October 1, 2021",Actual,2021-10-01,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,NA,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial,Completed,NA,Phase 3,1293,Actual,Bandim Health Project,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,When follow-up has been completed and the dataset have been closed,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,2022-01-04T10:09:12Z,2022-01-04T10:09:12Z,116
NCT04373161,NA,2020-04-30,NA,NA,2020-05-05,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"March 20, 2020",Actual,2020-03-20,May 2020,2020-05-31,"April 22, 2020",Actual,2020-04-22,"April 22, 2020",Actual,2020-04-22,NA,Interventional,NA,NA,Home Pulse Oximeter Use in Patients With COVID-19,Utilizing Home Pulse Oximetry for Patients With COVID-19 To Monitor Disease Progression,Completed,NA,Not Applicable,209,Actual,Swedish Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:09:27Z,2022-01-04T10:09:27Z,636
NCT04372589,NA,2020-04-24,NA,NA,2021-07-26,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"May 20, 2020",Actual,2020-05-20,January 2021,2021-01-31,"May 17, 2021",Actual,2021-05-17,"May 17, 2021",Actual,2021-05-17,NA,Interventional,ATTACC,NA,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC), in Collaboration With Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4)",Completed,NA,Phase 2/Phase 3,1200,Actual,University of Manitoba,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:09:54Z,2022-01-04T10:09:54Z,189
NCT04371965,NA,2020-04-29,NA,NA,2020-10-23,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"September 1, 2020",Actual,2020-09-01,July 2020,2020-07-31,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,KILLER,NA,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19","Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2",Completed,NA,Phase 2,24,Actual,Poitiers University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:10:15Z,2022-01-04T10:10:15Z,465
NCT04370782,NA,2020-04-26,NA,NA,2020-12-08,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-09,Actual,"April 28, 2020",Actual,2020-04-28,December 2020,2020-12-31,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting,Completed,NA,Phase 4,18,Actual,"St. Francis Hospital, New York",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:11:03Z,2022-01-04T10:11:03Z,419
NCT04370886,NA,2020-04-28,NA,NA,2020-05-28,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"April 30, 2020",Actual,2020-04-30,April 2020,2020-04-30,"May 10, 2020",Actual,2020-05-10,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,NA,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19,Completed,NA,Not Applicable,456517,Actual,Guangzhou Blood Center,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:10:53Z,2022-01-04T10:10:53Z,613
NCT04371367,NA,2020-04-29,NA,NA,2021-05-26,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"April 27, 2020",Actual,2020-04-27,May 2021,2021-05-31,"March 30, 2021",Actual,2021-03-30,"March 30, 2021",Actual,2021-03-30,NA,Interventional,FORCE,NA,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )","A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia",Completed,NA,Phase 2,208,Actual,Assistance Publique Hopitaux De Marseille,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:10:42Z,2022-01-04T10:10:42Z,250
NCT04371029,NA,2020-04-28,NA,NA,2021-06-04,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"April 28, 2020",Actual,2020-04-28,June 2021,2021-06-30,"December 9, 2020",Actual,2020-12-09,"September 9, 2020",Actual,2020-09-09,NA,Interventional,COVISLEEP,NA,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Completed,NA,Not Applicable,17,Actual,"University Hospital, Bordeaux",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:11:08Z,2022-01-04T10:11:08Z,241
NCT04370262,NA,2020-04-27,NA,NA,2020-12-10,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-10,2020-12-11,Actual,"April 7, 2020",Actual,2020-04-07,December 2020,2020-12-31,"September 7, 2020",Actual,2020-09-07,"September 7, 2020",Actual,2020-09-07,NA,Interventional,NA,NA,Multi-site Adaptive Trials for COVID-19,"A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,233,Actual,Northwell Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:11:19Z,2022-01-04T10:11:19Z,417
NCT04369378,NA,2020-04-24,NA,NA,2021-08-27,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"August 19, 2020",Actual,2020-08-19,August 2021,2021-08-31,"August 26, 2021",Actual,2021-08-26,"April 28, 2021",Actual,2021-04-28,NA,Interventional,NA,NA,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Completed,NA,Not Applicable,103,Actual,Lake Erie College of Osteopathic Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Upon publication of findings,Upon written request to corresponding author on publication,NA,Yes,"De-identified participant data will be reported as individual data points, as well as means +/- SD or medians with quartiles.",2022-01-04T10:12:06Z,2022-01-04T10:12:06Z,157
NCT04368377,NA,2020-04-23,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"April 23, 2020",Actual,2020-04-23,"April 23, 2020",Actual,2020-04-23,NA,Interventional,PIC-19,NA,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol,Completed,NA,Phase 2,5,Actual,University of Milan,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:12:59Z,2022-01-04T10:12:59Z,643
NCT04367662,NA,2020-04-16,NA,NA,2020-06-05,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 9, 2020",Actual,2020-04-09,June 2020,2020-06-30,"May 14, 2020",Actual,2020-05-14,"May 14, 2020",Actual,2020-05-14,NA,Interventional,COVID'HEMOS,NA,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Completed,NA,Not Applicable,99,Actual,"University Hospital, Rouen",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:13:25Z,2022-01-04T10:13:25Z,605
NCT04367831,NA,2020-04-27,NA,NA,2021-09-27,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"May 2, 2020",Actual,2020-05-02,September 2021,2021-09-30,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,IMPROVE,NA,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID),Completed,NA,Phase 4,94,Actual,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:13:36Z,2022-01-04T10:13:36Z,126
NCT04366297,NA,2020-04-23,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"January 12, 2020",Actual,2020-01-12,April 2020,2020-04-30,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,NA,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Intraosseous Versus Intravenous Access During COVID-19 Patients Performed by Paramedics Wearing Level C Personal Protective Equipment. A Multi-center Prospective Randomized Crossover Single-blinded Simulation Trial,Completed,NA,Not Applicable,41,Actual,Lazarski University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,the investigators will add data into manuscript,2022-01-04T10:14:28Z,2022-01-04T10:14:28Z,644
NCT04366141,NA,2020-04-24,NA,NA,2021-02-23,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-24,Actual,"May 1, 2020",Actual,2020-05-01,February 2021,2021-02-28,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box,The Impact of a Barrier Enclosure on Endotracheal Intubation Duration and First Pass Attempt - A Randomized Controlled Trial,Completed,NA,Not Applicable,100,Actual,University of British Columbia,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:14:32Z,2022-01-04T10:14:32Z,342
NCT04365972,NA,2020-04-24,NA,NA,2020-05-06,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,NA,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic: An Open Pilot Trial,Completed,NA,Not Applicable,20,Actual,Tel Aviv University,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:14:52Z,2022-01-04T10:14:52Z,635
NCT04365127,NA,2020-04-24,NA,NA,2021-01-25,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"April 27, 2020",Actual,2020-04-27,January 2021,2021-01-31,"August 20, 2020",Actual,2020-08-20,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,NA,Progesterone for the Treatment of COVID-19 in Hospitalized Men,"A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men",Completed,NA,Phase 1,40,Actual,Cedars-Sinai Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:15:23Z,2022-01-04T10:15:23Z,371
NCT04364594,NA,2020-04-22,NA,NA,2020-07-22,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-23,Actual,"March 26, 2020",Actual,2020-03-26,July 2020,2020-07-31,"May 30, 2020",Actual,2020-05-30,"April 24, 2020",Actual,2020-04-24,NA,Interventional,COVID-T,NA,COVID-19 Search in Conjunctival Cells,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Diagnostic Targets for Customized Medicine.,Completed,NA,Not Applicable,50,Actual,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will be available immediately after the statistical analysis of the results and will remain available for at least 1 year,On request by e-mail,NA,Yes,"Study Protocol approved by Ethical Committee, informed consent, clinical study report, will be available",2022-01-04T10:16:02Z,2022-01-04T10:16:02Z,558
NCT04363593,NA,2020-04-24,NA,NA,2020-12-09,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-09,2020-12-10,Actual,"May 4, 2020",Actual,2020-05-04,December 2020,2020-12-31,"November 16, 2020",Actual,2020-11-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,ROCOCO,NA,Serology COVID-19 From the Cornwall Hospital Union,Serology COVID-19 From the Cornwall Hospital Union,Completed,NA,Not Applicable,2587,Actual,Centre Hospitalier de Cornouaille,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:16:41Z,2022-01-04T10:16:41Z,418
NCT04362358,NA,2020-04-21,NA,NA,2021-09-24,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-27,Actual,"July 20, 2020",Actual,2020-07-20,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"September 1, 2021",Actual,2021-09-01,NA,Interventional,REST,NA,Online Cognitive Behavioral Therapy (CBT) for Stress Disorders in Health Workers Involved in the Care of Patients During the Covid-19 Epidemic,Efficacy of an Online Cognitive Behavioral Therapy (CBT) Programme Aiming at Reducing the Stress of Health Workers Involved in the Care of Patients During the Covid-19 Epidemic: a Randomized-controlled Trial,Completed,NA,Not Applicable,156,Actual,"University Hospital, Strasbourg, France",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:17:46Z,2022-01-04T10:17:46Z,129
NCT04359875,NA,2020-04-18,NA,NA,2021-04-07,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-12,Actual,"April 30, 2020",Actual,2020-04-30,April 2021,2021-04-30,"December 31, 2020",Actual,2020-12-31,"June 30, 2020",Actual,2020-06-30,NA,Interventional,COVIQuest,NA,A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment,Does a Systematic Phone-call by a Medical Student/General Practitioner Team in Patients Suffering From a Chronic Condition During the COVID-19 Containment Period Impact One-month Hospitalization's Rate in France? A Cluster Randomized Trial,Completed,NA,Not Applicable,22000,Actual,"University Hospital, Tours",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,1 year,email,NA,Yes,"One-month-data can be shared, whereas 6-month data are not legally sharable (electronic health records).",2022-01-04T10:19:26Z,2022-01-04T10:19:26Z,299
NCT04359810,NA,2020-04-21,NA,NA,2021-05-16,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-16,2021-05-18,Actual,"April 21, 2020",Actual,2020-04-21,May 2021,2021-05-31,"December 30, 2020",Actual,2020-12-30,"December 30, 2020",Actual,2020-12-30,NA,Interventional,NA,NA,Plasma Therapy of COVID-19 in Severely Ill Patients,"A Phase 2, Multi-Center, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19",Completed,NA,Phase 2,223,Actual,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,The data-sharing plans for this study will be made available at a later date.,2022-01-04T10:19:53Z,2022-01-04T10:19:53Z,260
NCT04358939,NA,2020-04-16,NA,NA,2021-04-15,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-15,2021-04-19,Actual,"April 27, 2020",Actual,2020-04-27,January 2021,2021-01-31,"February 21, 2021",Actual,2021-02-21,"February 21, 2021",Actual,2021-02-21,NA,Interventional,NA,NA,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome,Completed,NA,Not Applicable,405,Actual,"University Hospital, Tours",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available immediately following publication and ending in 5 years.,Contact with the corresponding author.,NA,Yes,Individual participant data after de-identification can be obtained by contacting the corresponding author.,2022-01-04T10:20:20Z,2022-01-04T10:20:20Z,291
NCT04358614,NA,2020-04-19,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"April 7, 2020",Actual,2020-04-07,"April 5, 2020",Actual,2020-04-05,NA,Interventional,NA,NA,Baricitinib Therapy in COVID-19,Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact,Completed,NA,Phase 2/Phase 3,12,Actual,Hospital of Prato,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:20:22Z,2022-01-04T10:20:22Z,650
NCT04358783,NA,2020-04-21,NA,NA,2021-05-24,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-24,2021-05-26,Actual,"April 27, 2020",Actual,2020-04-27,May 2021,2021-05-31,"May 1, 2021",Actual,2021-05-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,COP-COVID-19,NA,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,"Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia",Completed,NA,Phase 2,31,Actual,Hospital Universitario Dr. Jose E. Gonzalez,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:20:29Z,2022-01-04T10:20:29Z,252
NCT04358926,NA,2020-04-21,NA,NA,2021-02-01,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-03,Actual,"April 30, 2020",Actual,2020-04-30,November 2020,2020-11-30,"November 1, 2020",Actual,2020-11-01,"October 15, 2020",Actual,2020-10-15,NA,Interventional,HBOTCOVID19,NA,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Completed,NA,Not Applicable,30,Actual,Assaf-Harofeh Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Within 1 month of request,Specific requests,NA,Yes,Sharing upon specific requests will be considered,2022-01-04T10:20:34Z,2022-01-04T10:20:34Z,364
NCT04367545,NA,2020-04-27,NA,NA,2020-11-04,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,"May 17, 2020",Actual,2020-05-17,"May 17, 2020",Actual,2020-05-17,NA,Interventional,MolCOVID,NA,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Completed,NA,Not Applicable,130,Actual,"University Hospital, Rouen",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:13:42Z,2022-01-04T10:13:42Z,453
NCT04366960,NA,2020-04-24,NA,NA,2021-06-07,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-08,Actual,"May 14, 2020",Actual,2020-05-14,June 2021,2021-06-30,"May 25, 2021",Actual,2021-05-25,"May 25, 2021",Actual,2021-05-25,NA,Interventional,X-Covid 19,NA,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients: Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial,Completed,NA,Phase 3,189,Actual,Niguarda Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T10:14:23Z,2022-01-04T10:14:23Z,238
NCT04366947,NA,2020-04-23,NA,NA,2020-12-17,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-19,Actual,"April 14, 2020",Actual,2020-04-14,December 2020,2020-12-31,"October 30, 2020",Actual,2020-10-30,"September 20, 2020",Actual,2020-09-20,NA,Interventional,NA,NA,Intravascular Access in Suspected/Confirmed COVID-19 Patient,Comparison of Intraosseous Versus Intravenous Access in Suspected/Confirmed COVID-19 Patient in Prehospital Setting,Completed,NA,Not Applicable,60,Actual,Lazarski University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,the investigators will decide after study finishing,2022-01-04T10:14:24Z,2022-01-04T10:14:24Z,410
NCT04365738,NA,2020-04-26,NA,NA,2020-04-26,2020-04-26,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"March 11, 2020",Actual,2020-03-11,April 2020,2020-04-30,"April 26, 2020",Actual,2020-04-26,"April 10, 2020",Actual,2020-04-10,NA,Interventional,NA,NA,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection: Prospective Randomized Controlled Trial,Completed,NA,Not Applicable,270,Actual,Istanbul Bilgi University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T10:15:06Z,2022-01-04T10:15:06Z,645
NCT04365608,NA,2020-04-24,NA,NA,2020-12-17,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-19,Actual,"March 20, 2020",Actual,2020-03-20,December 2020,2020-12-31,"December 10, 2020",Actual,2020-12-10,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,NA,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Safety and Efficacy of Endotracheal Intubation by Paramedics in Suspected/Confirmed COVID-19 Patients Under Cardiac Arrest Using Vie Scope Laryngoscope,Completed,NA,Not Applicable,90,Actual,Lazarski University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,after manuscript publishing,NA,NA,Yes,NA,2022-01-04T10:15:12Z,2022-01-04T10:15:12Z,410
NCT04364022,NA,2020-04-23,NA,NA,2021-04-09,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-12,Actual,"April 23, 2020",Actual,2020-04-23,April 2021,2021-04-30,"March 24, 2021",Actual,2021-03-24,"March 24, 2021",Actual,2021-03-24,NA,Interventional,COPEP,NA,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland: an Open-label Cluster Randomized Trial,Completed,NA,Phase 3,326,Actual,"University Hospital, Geneva",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:16:28Z,2022-01-04T10:16:28Z,297
NCT04363749,NA,2020-04-20,NA,NA,2021-08-27,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"April 27, 2020",Actual,2020-04-27,August 2021,2021-08-31,"January 11, 2021",Actual,2021-01-11,"January 11, 2021",Actual,2021-01-11,NA,Interventional,CRC-COVID,NA,COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities,Do Respiratory Control Center Anomalies Explain the Lack of Respiratory Sensations Perceptions Observed in Patients Affected by COVID-19 ?,Completed,NA,Not Applicable,50,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:16:33Z,2022-01-04T10:16:33Z,157
NCT04361474,NA,2020-04-22,NA,NA,2021-08-02,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"May 18, 2020",Actual,2020-05-18,August 2021,2021-08-31,"June 25, 2021",Actual,2021-06-25,"November 24, 2020",Actual,2020-11-24,NA,Interventional,COVIDORL,NA,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,Completed,NA,Phase 3,120,Actual,Fondation Ophtalmologique Adolphe de Rothschild,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:18:45Z,2022-01-04T10:18:45Z,182
NCT04359095,NA,2020-04-15,NA,NA,2021-08-04,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-12,Actual,"August 18, 2020",Actual,2020-08-18,August 2021,2021-08-31,"June 30, 2021",Actual,2021-06-30,"March 20, 2021",Actual,2021-03-20,NA,Interventional,NA,NA,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial,Completed,NA,Phase 2/Phase 3,650,Actual,Universidad Nacional de Colombia,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,As soon we have checked the quality of data of recruited participants,Approved by the monitor committee of the study,NA,Yes,Communicating trial results and data to be able to combine data from multiple studies (live SR),2022-01-04T10:20:02Z,2022-01-04T10:20:02Z,180
NCT04359290,NA,2020-04-15,NA,NA,2021-08-23,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"July 1, 2020",Actual,2020-07-01,November 2020,2020-11-30,"July 30, 2021",Actual,2021-07-30,"December 31, 2020",Actual,2020-12-31,NA,Interventional,RuXoCoil,NA,Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,"Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study",Completed,NA,Phase 2,15,Actual,Philipps University Marburg Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,3 Months after publication,Central server,NA,Yes,Study protocol will be provided after publication,2022-01-04T10:20:10Z,2022-01-04T10:20:10Z,161
NCT04359251,NA,2020-04-13,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"March 5, 2020",Actual,2020-03-05,April 2020,2020-04-30,"March 25, 2020",Actual,2020-03-25,"March 25, 2020",Actual,2020-03-25,NA,Interventional,NA,NA,Different PEEP Settings of COVID-19 Induced ARDS,Avoiding High PEEP in COVID-19 Induced ARDS: a Multi-center Study,Completed,NA,Not Applicable,20,Actual,"Southeast University, China",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:20:15Z,2022-01-04T10:20:15Z,650
NCT04358549,NA,2020-04-16,NA,2021-09-30,2021-09-30,2020-04-21,2020-04-24,Actual,NA,NA,NA,2021-09-30,2021-10-05,Actual,2021-09-30,2021-10-05,Actual,"April 17, 2020",Actual,2020-04-17,September 2021,2021-09-30,"October 30, 2020",Actual,2020-10-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,"Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir Compared to Standard of Care in Hospitalized Subjects With COVID-19",Completed,NA,Phase 2,50,Actual,"Fujifilm Pharmaceuticals U.S.A., Inc.",NA,2,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:20:47Z,2022-01-04T10:20:47Z,123
NCT04357782,NA,2020-04-17,NA,NA,2020-12-21,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-21,2020-12-23,Actual,"April 16, 2020",Actual,2020-04-16,December 2020,2020-12-31,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Interventional,AVoCaDO,NA,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,"Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial",Completed,NA,Phase 1/Phase 2,20,Actual,Hunter Holmes Mcguire Veteran Affairs Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:21:23Z,2022-01-04T10:21:23Z,406
NCT04357340,NA,2020-04-13,NA,NA,2020-05-30,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"April 2, 2020",Actual,2020-04-02,May 2020,2020-05-31,"May 30, 2020",Actual,2020-05-30,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,NA,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Efficacy of Pulmonary Physiotherapy on Hospitalized Patients With Novel Coronavirus 2019 Pneumonia,Completed,NA,Not Applicable,40,Actual,Tehran University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months and ending 12 months following article publication,Researchers who provide an approved methodologically proposal in the same purpose,NA,Yes,"Individual participant data that underline the results reported in this article, after de-identification",2022-01-04T10:21:33Z,2022-01-04T10:21:33Z,611
NCT04357444,NA,2020-04-10,NA,NA,2021-10-01,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"October 23, 2020",Actual,2020-10-23,April 2021,2021-04-30,"April 5, 2021",Actual,2021-04-05,"November 2, 2020",Actual,2020-11-02,NA,Interventional,LILIADE-COVID,NA,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,Completed,NA,Phase 2,30,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:21:35Z,2022-01-04T10:21:35Z,122
NCT04357860,NA,2020-04-20,NA,NA,2021-07-06,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-07,Actual,"April 28, 2020",Actual,2020-04-28,April 2020,2020-04-30,"April 6, 2021",Actual,2021-04-06,"March 9, 2021",Actual,2021-03-09,NA,Interventional,SARICOR,NA,Clinical Trial of Sarilumab in Adults With COVID-19,Clinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome,Completed,NA,Phase 2,120,Actual,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After the end of the trial.,Contact uicec@imibic.org,NA,Yes,All the information will be published and it will be available in open access.,2022-01-04T10:21:09Z,2022-01-04T10:21:09Z,209
NCT04357808,NA,2020-04-14,NA,NA,2021-02-10,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 13, 2020",Actual,2020-04-13,February 2021,2021-02-28,"December 4, 2020",Actual,2020-12-04,"November 30, 2020",Actual,2020-11-30,NA,Interventional,SARCOVID,NA,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection,Completed,NA,Phase 2,30,Actual,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:21:26Z,2022-01-04T10:21:26Z,355
NCT04357327,NA,2020-04-15,NA,NA,2020-11-02,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,"July 31, 2020",Actual,2020-07-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,NA,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19): a Diagnostic Accuracy Study,Completed,NA,Not Applicable,122,Actual,UniversitÃ  degli Studi dell'Insubria,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Data will be available at the end of the study, once statistical analyses is conducted",Contact Principal Investigator,NA,Yes,"We could provide anamnestic, clinical and serological data of each participant at the end of the study, or at least at the end of the first phase.",2022-01-04T10:21:48Z,2022-01-04T10:21:48Z,455
NCT04355637,NA,2020-04-15,NA,NA,2021-09-21,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"April 21, 2020",Actual,2020-04-21,September 2021,2021-09-30,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,NA,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia,Completed,NA,Phase 4,120,Actual,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:22:57Z,2022-01-04T10:22:57Z,132
NCT04355936,NA,2020-04-17,NA,NA,2020-12-23,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"May 19, 2020",Actual,2020-05-19,December 2020,2020-12-31,"November 30, 2020",Actual,2020-11-30,"November 2, 2020",Actual,2020-11-02,NA,Interventional,NA,NA,Telmisartan for Treatment of COVID-19 Patients,Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial,Completed,NA,Phase 4,400,Actual,Laboratorio Elea Phoenix S.A.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:22:51Z,2022-01-04T10:22:51Z,404
NCT04355962,NA,2020-03-26,NA,NA,2021-07-16,2020-04-19,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-16,2021-07-19,Actual,"April 23, 2020",Actual,2020-04-23,July 2021,2021-07-31,"July 16, 2021",Actual,2021-07-16,"June 25, 2021",Actual,2021-06-25,NA,Interventional,NA,NA,Sevoflurane in COVID-19 ARDS (SevCov),Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial,Completed,NA,Phase 3,68,Actual,University of Zurich,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:22:47Z,2022-01-04T10:22:47Z,199
NCT04354155,NA,2020-04-13,NA,NA,2021-07-19,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"June 2, 2020",Actual,2020-06-02,July 2021,2021-07-31,"June 4, 2021",Actual,2021-06-04,"June 4, 2021",Actual,2021-06-04,NA,Interventional,NA,NA,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,Completed,NA,Phase 2,40,Actual,Johns Hopkins All Children's Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:24:14Z,2022-01-04T10:24:14Z,196
NCT04354610,NA,2020-04-14,NA,NA,2021-09-30,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"April 27, 2020",Actual,2020-04-27,January 2021,2021-01-31,"March 26, 2021",Actual,2021-03-26,"December 19, 2020",Actual,2020-12-19,NA,Interventional,Nancy-CovH-AKI,NA,Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,Prediction of Acute Heart or Kidney Injury With Cardiovascular-renal Biomarkers in Patients Hospitalised for Severe or Critical Covid-19 Infection,Completed,NA,Not Applicable,73,Actual,"Central Hospital, Nancy, France",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:24:00Z,2022-01-04T10:24:00Z,123
NCT04353596,NA,2020-04-14,NA,NA,2021-02-25,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-02,Actual,"April 20, 2020",Actual,2020-04-20,February 2021,2021-02-28,"February 24, 2021",Actual,2021-02-24,"February 16, 2021",Actual,2021-02-16,NA,Interventional,ACEI-COVID,NA,Stopping ACE-inhibitors in COVID-19,Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial,Completed,NA,Phase 4,216,Actual,Medical University Innsbruck,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T10:24:33Z,2022-01-04T10:24:33Z,340
NCT04353336,NA,2020-04-15,NA,NA,2021-07-29,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-02,Actual,"March 23, 2020",Actual,2020-03-23,July 2021,2021-07-31,"July 1, 2020",Actual,2020-07-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,NA,Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Completed,NA,Phase 2/Phase 3,194,Actual,Tanta University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:24:37Z,2022-01-04T10:24:37Z,186
NCT04353284,NA,2020-04-16,NA,NA,2021-10-06,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-08,Actual,"June 9, 2020",Actual,2020-06-09,October 2021,2021-10-31,"April 22, 2021",Actual,2021-04-22,"March 3, 2021",Actual,2021-03-03,NA,Interventional,NA,NA,Camostat Mesylate in COVID-19 Outpatients,"The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients: An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial",Completed,NA,Phase 2,74,Actual,Yale University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:24:48Z,2022-01-04T10:24:48Z,117
NCT04352959,NA,2020-04-15,NA,NA,2021-02-10,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 27, 2020",Actual,2020-04-27,February 2021,2021-02-28,"December 11, 2020",Actual,2020-12-11,"December 11, 2020",Actual,2020-12-11,NA,Interventional,BBCovid,NA,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,"COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study",Completed,NA,Not Applicable,176,Actual,Claude Bernard University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:24:58Z,2022-01-04T10:24:58Z,355
NCT04351763,NA,2020-04-14,NA,NA,2021-08-30,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-05,Actual,"May 20, 2020",Actual,2020-05-20,August 2021,2021-08-31,"June 5, 2021",Actual,2021-06-05,"May 25, 2021",Actual,2021-05-25,NA,Interventional,ReCOVery-SIRIO,NA,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Completed,NA,Phase 2/Phase 3,804,Actual,Nicolaus Copernicus University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:25:45Z,2022-01-04T10:25:45Z,154
NCT04351542,NA,2020-04-14,NA,NA,2020-04-15,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"March 6, 2020",Actual,2020-03-06,April 2020,2020-04-30,"April 12, 2020",Actual,2020-04-12,"April 6, 2020",Actual,2020-04-06,NA,Interventional,NA,NA,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Ayurveda for Flu-like Illness During the Covid 19 Outbreak: Non Randomised Single-blind Controlled Trial,Completed,NA,Not Applicable,32,Actual,Aarogyam UK,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T10:26:13Z,2022-01-04T10:26:13Z,656
NCT04350736,NA,2020-04-14,NA,NA,2021-06-29,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-07-01,Actual,"April 23, 2020",Actual,2020-04-23,June 2021,2021-06-30,"July 1, 2020",Actual,2020-07-01,"June 24, 2020",Actual,2020-06-24,NA,Interventional,NA,NA,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19","A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Completed,NA,Phase 1,54,Actual,Theravance Biopharma,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2022-01-04T10:26:47Z,2022-01-04T10:26:47Z,216
NCT04350593,NA,2020-04-14,NA,NA,2021-09-13,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-14,Actual,"April 22, 2020",Actual,2020-04-22,September 2021,2021-09-30,"June 11, 2021",Actual,2021-06-11,"March 31, 2021",Actual,2021-03-31,NA,Interventional,DARE-19,NA,Dapagliflozin in Respiratory Failure in Patients With COVID-19,"An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19",Completed,NA,Phase 3,1250,Actual,Saint Luke's Health System,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:27:02Z,2022-01-04T10:27:02Z,140
NCT04350320,NA,2020-04-14,NA,NA,2021-01-11,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"April 30, 2020",Actual,2020-04-30,January 2021,2021-01-31,"December 30, 2020",Actual,2020-12-30,"October 20, 2020",Actual,2020-10-20,NA,Interventional,COL-COVID,NA,Trial to Study the Benefit of Colchicine in Patients With COVID-19,"Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria.",Completed,NA,Phase 3,102,Actual,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:26:51Z,2022-01-04T10:26:51Z,385
NCT04350580,NA,2020-04-08,NA,NA,2021-08-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-14,2021-08-19,Actual,"April 11, 2020",Actual,2020-04-11,August 2021,2021-08-31,"February 20, 2021",Actual,2021-02-20,"November 20, 2020",Actual,2020-11-20,NA,Interventional,ICAR,NA,Polyvalent Immunoglobulin in COVID-19 Related ARds,Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections,Completed,NA,Phase 3,146,Actual,Centre Hospitalier St Anne,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:27:00Z,2022-01-04T10:27:00Z,170
NCT04349592,NA,2020-04-12,NA,NA,2021-02-21,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-21,2021-02-23,Actual,"April 14, 2020",Actual,2020-04-14,February 2021,2021-02-28,"August 30, 2020",Actual,2020-08-30,"August 14, 2020",Actual,2020-08-14,NA,Interventional,NA,NA,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Completed,NA,Not Applicable,456,Actual,Hamad Medical Corporation,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:27:29Z,2022-01-04T10:27:29Z,344
NCT04350281,NA,2020-04-13,NA,NA,2020-07-27,2020-04-13,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"April 9, 2020",Actual,2020-04-09,July 2020,2020-07-31,"July 7, 2020",Actual,2020-07-07,"July 1, 2020",Actual,2020-07-01,NA,Interventional,NA,NA,Double Therapy With IFN-beta 1b and Hydroxychloroquine,"An Open-label Randomized Controlled Trial on Interferon Î²-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection",Completed,NA,Phase 2,60,Actual,The University of Hong Kong,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:27:16Z,2022-01-04T10:27:16Z,553
NCT04348305,NA,2020-04-11,NA,NA,2021-09-20,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"April 17, 2020",Actual,2020-04-17,September 2021,2021-09-30,"September 8, 2021",Actual,2021-09-08,"September 10, 2020",Actual,2020-09-10,NA,Interventional,COVID STEROID,NA,Hydrocortisone for COVID-19 and Severe Hypoxia,Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial,Completed,NA,Phase 3,30,Actual,Scandinavian Critical Care Trials Group,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Immediate sharing of protocol, SAP and ICF. CSR will be shared no later than 6 months after last-patient-last-visit",Contact to the trial management committee,http://www.cric.nu/covid-steroid-trial/,Yes,Fully de-identified IPD will be shared after the approval by the the trial management committee,2022-01-04T10:28:24Z,2022-01-04T10:28:24Z,133
NCT04349631,NA,2020-04-06,NA,NA,2021-07-02,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-07,Actual,"April 22, 2020",Actual,2020-04-22,March 2021,2021-03-31,"May 1, 2021",Actual,2021-05-01,"November 24, 2020",Actual,2020-11-24,NA,Interventional,NA,NA,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,"A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease",Completed,NA,Phase 2,56,Actual,Hope Biosciences,NA,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:27:45Z,2022-01-04T10:27:45Z,213
NCT04349410,NA,2020-04-11,NA,NA,2020-11-10,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"April 11, 2020",Actual,2020-04-11,October 2020,2020-10-31,"September 14, 2020",Actual,2020-09-14,"September 14, 2020",Actual,2020-09-14,NA,Interventional,FMTVDM,NA,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Completed,NA,Phase 2/Phase 3,1800,Actual,The Camelot Foundation,NA,11,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,This will depend upon the availability of staff given the multi-nation approach to this project.,Expressed request through email as listed.,NA,Yes,Data will be made available through electronic request from approved individuals and institutions.,2022-01-04T10:27:56Z,2022-01-04T10:27:56Z,447
NCT04349241,NA,2020-04-13,NA,NA,2020-06-24,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-24,2020-06-25,Actual,"April 18, 2020",Actual,2020-04-18,June 2020,2020-06-30,"June 20, 2020",Actual,2020-06-20,"June 1, 2020",Actual,2020-06-01,NA,Interventional,FAV-001,NA,Efficacy and Safety of Favipiravir in Management of COVID-19,Efficacy and Safety of Favipiravir in Management of COVID-19,Completed,NA,Phase 3,100,Actual,Ain Shams University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:27:57Z,2022-01-04T10:27:57Z,586
NCT04348435,NA,2020-04-14,NA,NA,2021-08-19,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"May 14, 2020",Actual,2020-05-14,March 2021,2021-03-31,"July 30, 2021",Actual,2021-07-30,"July 9, 2021",Actual,2021-07-09,NA,Interventional,NA,NA,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19",Completed,NA,Phase 2,55,Actual,Hope Biosciences,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:28:25Z,2022-01-04T10:28:25Z,165
NCT04347382,NA,2020-04-11,NA,NA,2020-11-09,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"April 30, 2020",Actual,2020-04-30,November 2020,2020-11-30,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,HNS-COVID-PK,NA,Honey & Nigella Sativa Trial Against COVID-19,"The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Pakistan",Completed,NA,Phase 3,313,Actual,Sheikh Zayed Federal Postgraduate Medical Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:29:11Z,2022-01-04T10:29:11Z,448
NCT04347031,NA,2020-04-07,NA,NA,2021-01-26,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"April 8, 2020",Actual,2020-04-08,January 2021,2021-01-31,"November 20, 2020",Actual,2020-11-20,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,NA,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,"An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC ""Farmzashita"" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19",Completed,NA,Phase 2/Phase 3,320,Actual,Burnasyan Federal Medical Biophysical Center,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:29:29Z,2022-01-04T10:29:29Z,370
NCT04346927,NA,2020-04-13,NA,NA,2021-03-24,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-26,Actual,"August 10, 2020",Actual,2020-08-10,March 2021,2021-03-31,"November 30, 2020",Actual,2020-11-30,"October 10, 2020",Actual,2020-10-10,NA,Interventional,COVID-19,NA,Telerehabilitation for Patients Diagnosed With Coronavirus,Investigation of the Effects of Exercise Using Telerehabilitation in Patients Diagnosed With Coronavirus (COVID-19) and Followed at Home,Completed,NA,Not Applicable,30,Actual,Istinye University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:29:22Z,2022-01-04T10:29:22Z,313
NCT04347174,NA,2020-03-31,NA,NA,2021-01-25,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"April 30, 2020",Actual,2020-04-30,January 2021,2021-01-31,"August 21, 2020",Actual,2020-08-21,"August 10, 2020",Actual,2020-08-10,NA,Interventional,NA,NA,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection,Completed,NA,Not Applicable,40,Actual,Cadila Pharnmaceuticals,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:29:37Z,2022-01-04T10:29:37Z,371
NCT04346446,NA,2020-04-14,NA,NA,2020-06-11,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-12,Actual,"April 20, 2020",Actual,2020-04-20,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"May 30, 2020",Actual,2020-05-30,NA,Interventional,NA,NA,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial,Completed,NA,Phase 2,29,Actual,"Institute of Liver and Biliary Sciences, India",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T10:29:49Z,2022-01-04T10:29:49Z,599
NCT04346420,NA,2020-04-08,NA,NA,2020-06-05,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 9, 2020",Actual,2020-04-09,June 2020,2020-06-30,"May 1, 2020",Actual,2020-05-01,"May 1, 2020",Actual,2020-05-01,NA,Interventional,NA,NA,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Impact of the Double-Trunk Mask on Oxygenation Titration in Patients With COVID-19,Completed,NA,Not Applicable,12,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:29:49Z,2022-01-04T10:29:49Z,605
NCT04346628,NA,2020-04-10,NA,NA,2021-04-19,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-04-19,2021-04-20,Actual,"July 12, 2020",Actual,2020-07-12,April 2021,2021-04-30,"April 16, 2021",Actual,2021-04-16,"April 16, 2021",Actual,2021-04-16,NA,Interventional,NA,NA,Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,"A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19",Completed,NA,Phase 2,149,Actual,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,No current plan to share individual participant data (IPD).,2022-01-04T10:29:53Z,2022-01-04T10:29:53Z,287
NCT04345549,NA,2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"February 26, 2020",Actual,2020-02-26,April 2020,2020-04-30,"March 30, 2020",Actual,2020-03-30,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,NA,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Ayurveda Self-Management for Flu Like Symptoms in People Self-Isolated for 7 Days During the Coronavirus Disease 2019 (COVID-19) Outbreak,Completed,NA,Not Applicable,18,Actual,Aarogyam UK,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:30:34Z,2022-01-04T10:30:34Z,661
NCT04346017,NA,2020-04-13,NA,NA,2021-09-28,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"March 20, 2020",Actual,2020-03-20,September 2021,2021-09-30,"November 23, 2020",Actual,2020-11-23,"November 23, 2020",Actual,2020-11-23,NA,Interventional,NA,NA,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome,Completed,NA,Not Applicable,63,Actual,Brugmann University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:30:24Z,2022-01-04T10:30:24Z,125
NCT04345523,NA,2020-04-02,NA,NA,2021-05-12,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-13,Actual,"April 3, 2020",Actual,2020-04-03,May 2021,2021-05-31,"April 5, 2021",Actual,2021-04-05,"February 5, 2021",Actual,2021-02-05,NA,Interventional,ConPlas-19,NA,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients,"Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients",Completed,NA,Phase 2,350,Actual,Puerta de Hierro University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research,The investigator who proposed to use the data will have access to the data upon reasonable request.,NA,Yes,"PD that underlie the results reported in this article, after deidenficiation (text, tables, figures, and appendices) will be shared. The data will be available after main report is published.",2022-01-04T10:30:33Z,2022-01-04T10:30:33Z,264
NCT04345419,NA,2020-04-11,NA,NA,2021-07-29,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-02,Actual,"June 16, 2020",Actual,2020-06-16,July 2021,2021-07-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,NA,Remdesivir Efficacy in Coronavirus Disease,Remdesivir in COVID-19 Treatment: A Randomised Trial,Completed,NA,Phase 2/Phase 3,200,Actual,Tanta University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:30:43Z,2022-01-04T10:30:43Z,186
NCT04345614,NA,2020-04-07,NA,NA,2021-07-30,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-03,Actual,"April 8, 2020",Actual,2020-04-08,July 2021,2021-07-31,"July 30, 2021",Actual,2021-07-30,"June 28, 2021",Actual,2021-06-28,NA,Interventional,NA,NA,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,"A Randomized Double Blind, Placebo-Controlled Study of Auxora for the Treatment of Severe COVID-19 Pneumonia (CARDEA)",Completed,NA,Phase 2,284,Actual,"CalciMedica, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:30:48Z,2022-01-04T10:30:48Z,185
NCT04345276,NA,2020-04-10,NA,NA,2020-06-01,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"March 18, 2020",Actual,2020-03-18,March 2020,2020-03-31,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,NA,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,10,Actual,Huoshenshan Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T10:31:09Z,2022-01-04T10:31:09Z,609
NCT04344379,NA,2020-03-27,NA,NA,2021-07-31,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-31,2021-08-03,Actual,"April 17, 2020",Actual,2020-04-17,July 2021,2021-07-31,"June 18, 2020",Actual,2020-06-18,"June 18, 2020",Actual,2020-06-18,NA,Interventional,PREP-COVID,NA,Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,Randomized Multicenter Study Evaluating the Efficacy of Azithromycin and Hydroxychloroquine in the Prevention of SARS-CoV-2 Infection in the Hospital Population Exposed to Virus,Completed,NA,Phase 3,122,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:31:43Z,2022-01-04T10:31:43Z,184
NCT04344080,NA,2020-04-09,NA,NA,2021-06-30,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-30,2021-07-02,Actual,"April 1, 2020",Actual,2020-04-01,June 2021,2021-06-30,"April 28, 2021",Actual,2021-04-28,"April 10, 2021",Actual,2021-04-10,NA,Interventional,CYTOCOV-19,NA,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Completed,NA,Not Applicable,24,Actual,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:32:01Z,2022-01-04T10:32:01Z,215
NCT04344041,NA,2020-04-09,NA,NA,2021-04-29,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-04-30,Actual,"April 15, 2020",Actual,2020-04-15,April 2021,2021-04-30,"January 14, 2021",Actual,2021-01-14,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,NA,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Completed,NA,Phase 3,260,Actual,"University Hospital, Angers",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:32:02Z,2022-01-04T10:32:02Z,277
NCT04344015,NA,2020-04-09,NA,NA,2021-05-07,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-07,2021-05-10,Actual,"April 13, 2020",Actual,2020-04-13,May 2021,2021-05-31,"June 2, 2020",Actual,2020-06-02,"June 2, 2020",Actual,2020-06-02,NA,Interventional,NA,NA,COVID-19 Plasma Collection,Collection of COVID-19 Convalescent Plasma,Completed,NA,Not Applicable,206,Actual,Thomas Jefferson University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:32:03Z,2022-01-04T10:32:03Z,269
NCT04344210,NA,2020-04-07,NA,NA,2020-10-11,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-11,2020-10-14,Actual,"April 17, 2020",Actual,2020-04-17,October 2020,2020-10-31,"September 20, 2020",Actual,2020-09-20,"September 20, 2020",Actual,2020-09-20,NA,Interventional,NA,NA,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial,Completed,NA,Not Applicable,149,Actual,Federal University of Rio Grande do Sul,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2022-01-04T10:31:46Z,2022-01-04T10:31:46Z,477
NCT04343729,NA,2020-04-09,NA,NA,2021-07-21,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-28,Actual,"April 18, 2020",Actual,2020-04-18,July 2021,2021-07-31,"October 20, 2020",Actual,2020-10-20,"June 16, 2020",Actual,2020-06-16,NA,Interventional,MetCOVID,NA,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,"Efficacy of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.",Completed,NA,Phase 2,416,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,after study publication.,upon formal request.,NA,Yes,all patient data will be shared after study publication,2022-01-04T10:32:21Z,2022-01-04T10:32:21Z,194
NCT04343768,NA,2020-04-08,NA,NA,2020-05-02,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-02,2020-05-05,Actual,"April 9, 2020",Actual,2020-04-09,May 2020,2020-05-31,"April 27, 2020",Actual,2020-04-27,"April 27, 2020",Actual,2020-04-27,NA,Interventional,COVIFERON,NA,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,NA,Phase 2,60,Actual,Shahid Beheshti University of Medical Sciences,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,One year after the publication of the results in a journal.,"Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question.",NA,Yes,"One year after the publication of the results in a journal, Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question can have access to data and supporting information.",2022-01-04T10:32:20Z,2022-01-04T10:32:20Z,639
NCT04343651,NA,2020-03-31,NA,NA,2021-09-28,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"April 1, 2020",Actual,2020-04-01,September 2021,2021-09-30,"September 20, 2021",Actual,2021-09-20,"July 21, 2020",Actual,2020-07-21,NA,Interventional,NA,NA,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)",Completed,NA,Phase 2,86,Actual,"CytoDyn, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T10:32:27Z,2022-01-04T10:32:27Z,125
NCT04342728,NA,2020-04-08,NA,NA,2021-02-12,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-16,Actual,"April 8, 2020",Actual,2020-04-08,February 2021,2021-02-28,"February 11, 2021",Actual,2021-02-11,"December 30, 2020",Actual,2020-12-30,NA,Interventional,COVIDAtoZ,NA,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",Completed,NA,Not Applicable,214,Actual,The Cleveland Clinic,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:32:57Z,2022-01-04T10:32:57Z,353
NCT04342650,NA,2020-04-04,NA,NA,2021-08-02,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-09,Actual,"April 8, 2020",Actual,2020-04-08,July 2020,2020-07-31,"June 8, 2020",Actual,2020-06-08,"May 14, 2020",Actual,2020-05-14,NA,Interventional,CloroCOVID19II,NA,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,"Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial",Completed,NA,Phase 2,152,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,after study publication,Upon formal request to researchers.,NA,Yes,all patient data will be shared after study publication,2022-01-04T10:33:02Z,2022-01-04T10:33:02Z,182
NCT04341584,NA,2020-04-07,NA,NA,2021-01-29,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2021-01-29,2021-02-01,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"July 25, 2020",Actual,2020-07-25,"May 10, 2020",Actual,2020-05-10,NA,Interventional,CORIMUNO-ANA,NA,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,"CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19",Completed,NA,Phase 2,161,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T10:33:36Z,2022-01-04T10:33:36Z,367
NCT04340050,NA,2020-04-07,NA,NA,2020-12-23,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-28,Actual,"April 10, 2020",Actual,2020-04-10,December 2020,2020-12-31,"December 23, 2020",Actual,2020-12-23,"December 23, 2020",Actual,2020-12-23,NA,Interventional,NA,NA,COVID-19 Convalescent Plasma,Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center,Completed,NA,Early Phase 1,10,Actual,University of Chicago,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database,NA,NA,Yes,We will share individual participant data that is de-identified available to all qualified investigators,2022-01-04T10:34:52Z,2022-01-04T10:34:52Z,404
NCT04339712,NA,2020-04-01,NA,NA,2021-01-08,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"April 2, 2020",Actual,2020-04-02,January 2021,2021-01-31,"January 8, 2021",Actual,2021-01-08,"December 1, 2020",Actual,2020-12-01,NA,Interventional,ESCAPE,NA,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial,Completed,NA,Phase 2,102,Actual,Hellenic Institute for the Study of Sepsis,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:35:15Z,2022-01-04T10:35:15Z,388
NCT04338958,NA,2020-04-07,NA,NA,2021-08-12,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"April 22, 2020",Actual,2020-04-22,August 2021,2021-08-31,"July 15, 2021",Actual,2021-07-15,"July 15, 2021",Actual,2021-07-15,NA,Interventional,RuxCoFlam,NA,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation,Completed,NA,Phase 2,193,Actual,University of Jena,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:35:37Z,2022-01-04T10:35:37Z,172
NCT04338841,NA,2020-04-05,NA,NA,2020-09-22,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-23,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"June 17, 2020",Actual,2020-06-17,"June 17, 2020",Actual,2020-06-17,NA,Interventional,HOME-CoV,NA,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With Confirmed or Probable SARS-CoV-2 Infection. A Before and After Implementation of a Consensus Help-decision Making Rule Study,Completed,NA,Not Applicable,3133,Actual,"University Hospital, Angers",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:35:56Z,2022-01-04T10:35:56Z,496
NCT04337996,NA,2020-04-01,NA,NA,2021-01-25,2020-04-03,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-26,Actual,"July 13, 2020",Actual,2020-07-13,January 2021,2021-01-31,"January 13, 2021",Actual,2021-01-13,"January 13, 2021",Actual,2021-01-13,NA,Interventional,TRODVID-19,NA,Dynamic Evaluation of COVID-19 Diagnostic Tests,Dynamic Evaluation of COVID-19 Diagnostic Tests,Completed,NA,Not Applicable,8,Actual,Tourcoing Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:36:08Z,2022-01-04T10:36:08Z,371
NCT04337541,NA,2020-04-02,NA,NA,2020-07-29,2020-04-05,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-08-03,Actual,"April 2, 2020",Actual,2020-04-02,July 2020,2020-07-31,"June 2, 2020",Actual,2020-06-02,"June 2, 2020",Actual,2020-06-02,NA,Interventional,NA,NA,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,NA,Not Applicable,6000,Actual,"Rigshospitalet, Denmark",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:36:42Z,2022-01-04T10:36:42Z,551
NCT04337918,NA,2020-04-06,NA,NA,2021-02-08,2020-04-06,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"May 8, 2020",Actual,2020-05-08,February 2021,2021-02-28,"February 2, 2021",Actual,2021-02-02,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NOCOVID,NA,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,"Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection",Completed,NA,Phase 2,143,Actual,Sanotize Research and Development corp.,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:36:28Z,2022-01-04T10:36:28Z,357
NCT04335851,NA,2020-04-02,NA,NA,2020-06-04,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-09,Actual,"April 6, 2020",Actual,2020-04-06,June 2020,2020-06-30,"June 3, 2020",Actual,2020-06-03,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,NA,Video-Based Exercises and Well-Being During Social Isolation,Effectiveness of Video-Based Exercises on Physical and Emotional Well-Being During COVID-19 Induced Social Isolation,Completed,NA,Not Applicable,68,Actual,Biruni University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:37:45Z,2022-01-04T10:37:45Z,606
NCT04335279,NA,2020-04-01,NA,NA,2020-11-26,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"April 9, 2020",Actual,2020-04-09,November 2020,2020-11-30,"July 24, 2020",Actual,2020-07-24,"June 3, 2020",Actual,2020-06-03,NA,Interventional,SPIN-CHAT,NA,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,A Partially Nested RCT to Evaluate the Effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to Reduce Anxiety Among At-Risk Scleroderma Patients,Completed,NA,Not Applicable,172,Actual,Lady Davis Institute,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,12 months after the collection of the primary outcome,Approval of proposed purpose for data access,NA,Yes,Upon request,2022-01-04T10:38:09Z,2022-01-04T10:38:09Z,431
NCT04335123,NA,2020-03-31,NA,NA,2021-05-06,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,"April 4, 2020",Actual,2020-04-04,May 2021,2021-05-31,"August 17, 2020",Actual,2020-08-17,"June 21, 2020",Actual,2020-06-21,NA,Interventional,NA,NA,Study of Open Label Losartan in COVID-19,An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19,Completed,NA,Phase 1,34,Actual,University of Kansas Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Beginning 3 months and ending 5 years following article publication,"Proposals should be directed to msalathe@kumc.edu. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)",2022-01-04T10:38:15Z,2022-01-04T10:38:15Z,270
NCT04334928,NA,2020-04-02,NA,NA,2021-09-15,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"April 15, 2020",Actual,2020-04-15,September 2021,2021-09-30,"July 11, 2021",Actual,2021-07-11,"February 25, 2021",Actual,2021-02-25,NA,Interventional,EPICOS,NA,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo,Completed,NA,Phase 3,1002,Actual,Plan Nacional sobre el Sida (PNS),NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:38:33Z,2022-01-04T10:38:33Z,138
NCT04334850,NA,2020-04-02,NA,NA,2021-07-31,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-31,2021-08-03,Actual,"April 20, 2020",Actual,2020-04-20,July 2021,2021-07-31,"June 23, 2021",Actual,2021-06-23,"December 20, 2020",Actual,2020-12-20,NA,Interventional,MultiCov,NA,Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,"Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial",Completed,NA,Not Applicable,194,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:38:36Z,2022-01-04T10:38:36Z,184
NCT04334434,NA,2020-04-02,NA,NA,2021-01-30,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-01-30,2021-02-03,Actual,"July 30, 2020",Actual,2020-07-30,January 2021,2021-01-31,"December 15, 2020",Actual,2020-12-15,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,NA,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Investigation Of The Effectiveness Of The Telerehabilitation Applied To Individuals Over The Age Of 65 Who Experience Social Isolation At Houses Due To The Coronavirus (Covid-19) Pandemic,Completed,NA,Not Applicable,30,Actual,Istanbul University-Cerrahpasa,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:39:00Z,2022-01-04T10:39:00Z,366
NCT04334044,NA,2020-04-01,NA,NA,2021-07-05,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-05,2021-07-07,Actual,"September 1, 2020",Actual,2020-09-01,July 2021,2021-07-31,"April 30, 2021",Actual,2021-04-30,"April 12, 2021",Actual,2021-04-12,NA,Interventional,NA,NA,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib,Completed,NA,Phase 1/Phase 2,77,Actual,Grupo Cooperativo de HemopatÃ­as Malignas,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:39:20Z,2022-01-04T10:39:20Z,210
NCT04332835,NA,2020-03-31,NA,NA,2020-11-25,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"August 8, 2020",Actual,2020-08-08,November 2020,2020-11-30,"November 15, 2020",Actual,2020-11-15,"October 31, 2020",Actual,2020-10-31,NA,Interventional,CP-COVID-19,NA,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study","Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Completed,NA,Phase 2/Phase 3,92,Actual,Universidad del Rosario,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:40:15Z,2022-01-04T10:40:15Z,432
NCT04332380,NA,2020-03-30,NA,NA,2020-08-12,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-17,Actual,"May 1, 2020",Actual,2020-05-01,August 2020,2020-08-31,"July 28, 2020",Actual,2020-07-28,"July 28, 2020",Actual,2020-07-28,NA,Interventional,CP-COVID-19,NA,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Completed,NA,Phase 2,10,Actual,Universidad del Rosario,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:40:21Z,2022-01-04T10:40:21Z,537
NCT04331795,NA,2020-04-01,NA,NA,2021-03-05,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-03-05,2021-03-09,Actual,"April 4, 2020",Actual,2020-04-04,March 2021,2021-03-31,"June 5, 2020",Actual,2020-06-05,"June 5, 2020",Actual,2020-06-05,NA,Interventional,COVIDOSE,NA,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis,Completed,NA,Phase 2,32,Actual,University of Chicago,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:40:53Z,2022-01-04T10:40:53Z,332
NCT04331600,NA,2020-03-30,NA,NA,2021-02-10,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,"December 17, 2020",Actual,2020-12-17,"December 17, 2020",Actual,2020-12-17,NA,Interventional,NA,NA,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,"Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications",Completed,NA,Phase 4,16,Actual,Wroclaw Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:40:57Z,2022-01-04T10:40:57Z,355
NCT04331834,NA,2020-04-01,NA,NA,2021-02-15,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-16,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"December 31, 2020",Actual,2020-12-31,"June 25, 2020",Actual,2020-06-25,NA,Interventional,PrEP_COVID,NA,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,"Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Multicentre, Double-Blinded Randomized Controlled Trial",Completed,NA,Phase 3,275,Actual,Barcelona Institute for Global Health,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:40:47Z,2022-01-04T10:40:47Z,350
NCT04330586,NA,2020-03-31,NA,NA,2021-06-19,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-19,2021-06-24,Actual,"April 1, 2020",Actual,2020-04-01,June 2021,2021-06-30,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,NA,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19,Completed,NA,Phase 2,68,Actual,Korea University Guro Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:41:49Z,2022-01-04T10:41:49Z,226
NCT04330638,NA,2020-03-31,NA,NA,2021-09-28,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"April 3, 2020",Actual,2020-04-03,September 2021,2021-09-30,"April 12, 2021",Actual,2021-04-12,"December 18, 2020",Actual,2020-12-18,NA,Interventional,COV-AID,NA,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome",Completed,NA,Phase 3,342,Actual,"University Hospital, Ghent",NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:42:06Z,2022-01-04T10:42:06Z,125
NCT04329533,NA,2020-03-26,NA,NA,2020-11-11,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"April 13, 2020",Actual,2020-04-13,November 2020,2020-11-30,"November 1, 2020",Actual,2020-11-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,NA,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Effects of a Mobile Meditation App on Stress During COVID-19 Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial,Completed,NA,Not Applicable,101,Actual,University of Arizona,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:42:37Z,2022-01-04T10:42:37Z,446
NCT04328493,NA,2020-03-27,NA,NA,2021-05-20,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-24,Actual,"April 7, 2020",Actual,2020-04-07,May 2021,2021-05-31,"September 10, 2020",Actual,2020-09-10,"September 10, 2020",Actual,2020-09-10,NA,Interventional,VICO,NA,The Vietnam Chloroquine Treatment on COVID-19,A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam,Completed,NA,Phase 2,10,Actual,"Oxford University Clinical Research Unit, Vietnam",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:43:15Z,2022-01-04T10:43:15Z,256
NCT04328480,NA,2020-03-30,NA,NA,2021-04-26,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-27,Actual,"April 17, 2020",Actual,2020-04-17,April 2021,2021-04-30,"April 26, 2021",Actual,2021-04-26,"April 25, 2021",Actual,2021-04-25,NA,Interventional,COLCOVID,NA,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,The ECLA PHRI COLCOVID Trial,Completed,NA,Phase 3,1279,Actual,Estudios ClÃ­nicos Latino AmÃ©rica,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:43:25Z,2022-01-04T10:43:25Z,280
NCT04326920,NA,2020-03-24,NA,NA,2021-03-01,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-02,Actual,"March 24, 2020",Actual,2020-03-24,March 2021,2021-03-31,"February 26, 2021",Actual,2021-02-26,"September 28, 2020",Actual,2020-09-28,NA,Interventional,SARPAC,NA,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (LeukineÂ®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.",Completed,NA,Phase 4,80,Actual,"University Hospital, Ghent",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:44:06Z,2022-01-04T10:44:06Z,336
NCT04325906,NA,2020-03-26,NA,NA,2021-04-21,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-23,Actual,"April 2, 2020",Actual,2020-04-02,April 2021,2021-04-30,"February 21, 2021",Actual,2021-02-21,"January 26, 2021",Actual,2021-01-26,NA,Interventional,NA,NA,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS,Completed,NA,Not Applicable,222,Actual,Rush University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:45:10Z,2022-01-04T10:45:10Z,285
NCT04324489,NA,2020-03-25,NA,NA,2020-05-01,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-05,Actual,"March 6, 2020",Actual,2020-03-06,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 16, 2020",Actual,2020-04-16,NA,Interventional,NA,NA,DAS181 for Severe COVID-19: Compassionate Use,DAS181 for Severe COVID-19: Compassionate Use,Completed,NA,Not Applicable,4,Actual,Renmin Hospital of Wuhan University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:46:06Z,2022-01-04T10:46:06Z,640
NCT04324528,NA,2020-03-25,NA,NA,2021-03-11,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-15,Actual,"March 27, 2020",Actual,2020-03-27,March 2021,2021-03-31,"January 27, 2021",Actual,2021-01-27,"January 27, 2021",Actual,2021-01-27,NA,Interventional,CYCOV,NA,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Completed,NA,Not Applicable,34,Actual,University Hospital Freiburg,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:46:16Z,2022-01-04T10:46:16Z,326
NCT04323527,NA,2020-03-19,NA,NA,2021-08-02,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-09,Actual,"March 23, 2020",Actual,2020-03-23,August 2021,2021-08-31,"June 7, 2020",Actual,2020-06-07,"May 7, 2020",Actual,2020-05-07,NA,Interventional,CloroCOVID19,NA,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,"Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial",Completed,NA,Phase 2,278,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,after study publication,upon request to researchers,NA,Yes,all patient data will be shared after study publication,2022-01-04T10:47:07Z,2022-01-04T10:47:07Z,182
NCT04321278,NA,2020-03-23,NA,NA,2021-01-15,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-20,Actual,"March 28, 2020",Actual,2020-03-28,March 2020,2020-03-31,"June 14, 2020",Actual,2020-06-14,"June 14, 2020",Actual,2020-06-14,NA,Interventional,NA,NA,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients,Completed,NA,Phase 3,440,Actual,Hospital Israelita Albert Einstein,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:48:54Z,2022-01-04T10:48:54Z,381
NCT04320953,NA,2020-03-21,NA,NA,2020-04-15,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"April 9, 2020",Actual,2020-04-09,"March 26, 2020",Actual,2020-03-26,NA,Interventional,NA,NA,Non-contact Endoscopy at Covid-19 Outbreak,Non-contact Endoscopy at Covid-19 Outbreak,Completed,NA,Not Applicable,5,Actual,Changhai Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T10:48:57Z,2022-01-04T10:48:57Z,656
NCT04321421,NA,2020-03-23,NA,NA,2020-05-27,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"March 17, 2020",Actual,2020-03-17,May 2020,2020-05-31,"May 7, 2020",Actual,2020-05-07,"April 28, 2020",Actual,2020-04-28,NA,Interventional,COV19-PLASMA,NA,Hyperimmune Plasma for Critical Patients With COVID-19,Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19,Completed,NA,Not Applicable,49,Actual,Foundation IRCCS San Matteo Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,will be decided,2022-01-04T10:48:48Z,2022-01-04T10:48:48Z,614
NCT04318431,NA,2020-03-20,NA,NA,2020-07-08,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-09,Actual,"April 14, 2020",Actual,2020-04-14,July 2020,2020-07-31,"June 1, 2020",Actual,2020-06-01,"May 12, 2020",Actual,2020-05-12,NA,Interventional,COVILLE,NA,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,"Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care.",Completed,NA,Not Applicable,605,Actual,Centre Hospitalier Intercommunal Creteil,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:50:46Z,2022-01-04T10:50:46Z,572
NCT04319445,NA,2020-03-20,NA,NA,2021-04-30,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-30,2021-05-06,Actual,"March 22, 2020",Actual,2020-03-22,March 2021,2021-03-31,"March 30, 2021",Actual,2021-03-30,"August 31, 2020",Actual,2020-08-31,NA,Interventional,NA,NA,Mindfulness During COVID-19,Mindfulness During COVID-19 - Remote Mindfulness Sessions,Completed,NA,Not Applicable,233,Actual,Wake Forest University Health Sciences,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:50:09Z,2022-01-04T10:50:09Z,276
NCT04312997,NA,2020-03-16,NA,NA,2021-07-14,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-07-14,2021-07-16,Actual,"June 16, 2020",Actual,2020-06-16,July 2021,2021-07-31,"July 2, 2021",Actual,2021-07-02,"July 2, 2021",Actual,2021-07-02,NA,Interventional,NA,NA,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Completed,NA,Phase 2,101,Actual,"Pulmotect, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:54:35Z,2022-01-04T10:54:35Z,201
NCT04313127,NA,2020-03-15,NA,NA,2021-08-02,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"March 16, 2020",Actual,2020-03-16,May 2020,2020-05-31,"February 20, 2021",Actual,2021-02-20,"January 20, 2021",Actual,2021-01-20,NA,Interventional,CTCOVID-19,NA,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old",Completed,NA,Phase 1,108,Actual,CanSino Biologics Inc.,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available beginning 3 months and ending one year following article publication,"Data access requests will be reviewed by the sponsorï¼Œinvestigator and collaborators on the basis of scientific merit. To gain access, data requestors will need to sign a data access agreement.",http://www.jshealth.com/,Yes,"We support data sharing of the individual participant data. The individual participant data that underlie the results reported in this article, after deidentiï¬cation (text, tables, figures, and appendixes) will be shared. Individual participant data will be available beginning 3 months and ending one year following article publication. Supporting clinical documents including study protocol, statistical analysis plan (SAP), and the informed consent form (ICF) will be available immediately following publication for at least one year. Supporting clinical documents access information will be available at http://www.jshealth.com/. Researchers who provide a scientifically sound proposal will be allowed to access to the individual participant data. Proposals should be directed to jszfc@vip.sina.com or cw0226@foxmail.com.",2022-01-04T10:54:23Z,2022-01-04T10:54:23Z,182
NCT04313023,NA,2020-03-16,NA,NA,2021-09-01,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"June 9, 2020",Actual,2020-06-09,September 2021,2021-09-30,"July 31, 2021",Actual,2021-07-31,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,NA,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,Completed,NA,Phase 2,217,Actual,"Pulmotect, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:54:37Z,2022-01-04T10:54:37Z,152
NCT04312009,NA,2020-03-13,NA,NA,2021-08-16,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-18,Actual,"April 13, 2020",Actual,2020-04-13,August 2021,2021-08-31,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,Completed,NA,Phase 2,205,Actual,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:55:25Z,2022-01-04T10:55:25Z,168
NCT04311177,NA,2020-03-13,NA,NA,2021-09-17,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-24,Actual,"April 9, 2020",Actual,2020-04-09,September 2021,2021-09-30,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,Completed,NA,Phase 2,162,Actual,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:56:15Z,2022-01-04T10:56:15Z,136
NCT04311697,NA,2020-03-14,NA,NA,2021-09-05,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-05,2021-09-13,Actual,"May 15, 2020",Actual,2020-05-15,September 2021,2021-09-30,"February 22, 2021",Actual,2021-02-22,"February 22, 2021",Actual,2021-02-22,NA,Interventional,COVID-AIV,NA,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure,Completed,NA,Phase 2/Phase 3,196,Actual,"NeuroRx, Inc.",NA,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Currently available,Public access,NA,Yes,NeuroRx will share study protocol and statistical analysis plan upon request by qualified researchers,2022-01-04T10:55:42Z,2022-01-04T10:55:42Z,148
NCT04306055,NA,2020-03-08,NA,NA,2020-04-09,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 13, 2020",Actual,2020-03-13,April 2020,2020-04-30,"April 3, 2020",Actual,2020-04-03,"March 13, 2020",Actual,2020-03-13,NA,Interventional,NA,NA,Blood Donor Recruitment During Epidemic of COVID-19,"Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China",Completed,NA,Not Applicable,19491,Actual,Guangzhou Blood Center,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T10:59:40Z,2022-01-04T10:59:40Z,662
NCT04303299,NA,2020-02-24,NA,NA,2021-08-28,2020-03-08,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-28,2021-09-02,Actual,"August 19, 2020",Actual,2020-08-19,August 2021,2021-08-31,"August 28, 2021",Actual,2021-08-28,"August 28, 2021",Actual,2021-08-28,NA,Interventional,FIGHT-COVID-19,NA,Fight COVID-19 Trial,"A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19",Completed,NA,Phase 3,320,Actual,Rajavithi Hospital,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T11:01:51Z,2022-01-04T11:01:51Z,156
NCT04304053,NA,2020-03-05,NA,NA,2020-06-26,2020-03-07,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-26,2020-06-30,Actual,"March 18, 2020",Actual,2020-03-18,June 2020,2020-06-30,"June 15, 2020",Actual,2020-06-15,"June 15, 2020",Actual,2020-06-15,NA,Interventional,HCQ4COV19,NA,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study),Completed,NA,Phase 3,2300,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,30 days after start of treatment,Open access for everybody,http://www.estudicovid19.org,Yes,Open access,2022-01-04T11:01:21Z,2022-01-04T11:01:21Z,584
NCT04291729,NA,2020-02-27,NA,NA,2020-04-09,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 17, 2020",Actual,2020-02-17,March 2020,2020-03-31,"March 19, 2020",Actual,2020-03-19,"March 19, 2020",Actual,2020-03-19,NA,Interventional,NA,NA,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Ganovoï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,11,Actual,The Ninth Hospital of Nanchang,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T11:11:12Z,2022-01-04T11:11:12Z,662
NCT04288102,NA,2020-02-24,NA,NA,2020-08-18,2020-02-25,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"March 5, 2020",Actual,2020-03-05,August 2020,2020-08-31,"July 9, 2020",Actual,2020-07-09,"May 12, 2020",Actual,2020-05-12,NA,Interventional,NA,NA,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),"A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients",Completed,NA,Phase 2,100,Actual,Beijing 302 Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"After approval from the steering committee and the Human Genetic Resources Administration of China, this trial data can be shared with qualifying researchers who submit a proposal with a valuable research question. A contract should be signed.",2022-01-04T11:14:15Z,2022-01-04T11:14:15Z,531
NCT04275414,NA,2020-02-14,NA,NA,2020-09-10,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"February 15, 2020",Actual,2020-02-15,February 2020,2020-02-29,"May 2, 2020",Actual,2020-05-02,"April 5, 2020",Actual,2020-04-05,NA,Interventional,BEST-CP,NA,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Effecacy and Safety of Bevacizumab in Severe Patients With Covid-19: a Pilot Study (BEST-CP),Completed,NA,Phase 2,27,Actual,Qilu Hospital of Shandong University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T11:23:39Z,2022-01-04T11:23:39Z,508
NCT04276987,NA,2020-02-16,NA,NA,2020-09-03,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-07,Actual,"February 15, 2020",Actual,2020-02-15,September 2020,2020-09-30,"July 31, 2020",Actual,2020-07-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,NA,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia,Completed,NA,Phase 1,24,Actual,Ruijin Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Starting 6 months after publication,NA,NA,Yes,all IPD that underlie results in a publication,2022-01-04T11:22:43Z,2022-01-04T11:22:43Z,515
NCT04276688,NA,2020-02-11,NA,NA,2020-04-13,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"February 10, 2020",Actual,2020-02-10,April 2020,2020-04-30,"March 31, 2020",Actual,2020-03-31,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,NA,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection",Completed,NA,Phase 2,127,Actual,The University of Hong Kong,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T11:22:45Z,2022-01-04T11:22:45Z,658
NCT04275245,NA,2020-02-06,NA,NA,2021-04-07,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-09,Actual,"February 3, 2020",Actual,2020-02-03,April 2021,2021-04-30,"March 9, 2020",Actual,2020-03-09,"March 9, 2020",Actual,2020-03-09,NA,Interventional,NA,NA,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,"Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia",Completed,NA,Phase 1/Phase 2,17,Actual,Tang-Du Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2022-01-04T11:24:07Z,2022-01-04T11:24:07Z,299
NCT04273321,NA,2020-02-15,NA,NA,2020-05-08,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"February 14, 2020",Actual,2020-02-14,April 2020,2020-04-30,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,NA,Efficacy and Safety of Corticosteroids in COVID-19,Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails,Completed,NA,Not Applicable,86,Actual,Beijing Chao Yang Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2022-01-04T11:25:25Z,2022-01-04T11:25:25Z,633
NCT04261517,NA,2020-02-06,NA,NA,2020-04-09,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 6, 2020",Actual,2020-02-06,April 2020,2020-04-30,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,NA,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,NA,Phase 3,30,Actual,Shanghai Public Health Clinical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2022-01-04T11:35:15Z,2022-01-04T11:35:15Z,662
NCT04260594,NA,2020-02-06,NA,NA,2021-09-06,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"February 8, 2020",Actual,2020-02-08,September 2021,2021-09-30,"December 30, 2020",Actual,2020-12-30,"March 12, 2020",Actual,2020-03-12,NA,Interventional,NA,NA,Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus,"Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).",Completed,NA,Phase 4,236,Actual,Ruijin Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2022-01-04T11:35:51Z,2022-01-04T11:35:51Z,147
NCT04252885,NA,2020-01-30,NA,NA,2020-06-29,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"January 28, 2020",Actual,2020-01-28,June 2020,2020-06-30,"May 31, 2020",Actual,2020-05-31,"April 30, 2020",Actual,2020-04-30,NA,Interventional,ELACOI,NA,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection",Completed,NA,Phase 4,86,Actual,Guangzhou 8th People's Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2022-01-04T11:42:03Z,2022-01-04T11:42:03Z,581
NCT04638842,NA,2020-11-19,NA,NA,2021-10-12,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Estimate,"December 24, 2020",Actual,2020-12-24,October 2021,2021-10-31,"June 1, 2021",Actual,2021-06-01,"June 1, 2021",Actual,2021-06-01,NA,Interventional,NA,NA,Online Multi-component Psychological Intervention for Prevention of Grief Disorder Due to COVID-19,"Effectiveness of a Self-applied Multi-component Psychological Online Intervention Based on UX, for the Prevention of Complicated Grief Disorder in the Mexican Population During the COVID-19 Outbreak: A Randomized Clinical Trial",Completed,NA,Not Applicable,43,Actual,Universidad Internacional de Valencia,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,This data will be available approximately in April 2021 and it will be permanently available. It will be shared in the databases of the journal where the article(s) will be published.,Through the servers of the journal(s) where we will publish the articles.,NA,Yes,"The information will be available in a private server or in a server of the journal(s) that we will publish the articles that will be the result of this study. The protocol of the study is currently in progress to be published, in this article will be included such study protocol, the informed consent is already shared in the register of clinical trials.",2021-10-13T20:04:31Z,2021-10-13T20:04:31Z,111
NCT04346693,NA,2020-04-08,NA,NA,2021-10-05,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-13,Estimate,"April 8, 2020",Actual,2020-04-08,October 2021,2021-10-31,"November 20, 2020",Actual,2020-11-20,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,NA,An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug in Patients With Severe and Critical Manifestations of SARS-COVID-19,An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19),Completed,NA,Phase 3,320,Actual,Burnasyan Federal Medical Biophysical Center,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-13T20:06:08Z,2021-10-13T20:06:08Z,118
NCT04468893,NA,2020-07-10,NA,NA,2021-10-12,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Estimate,"May 20, 2020",Actual,2020-05-20,October 2021,2021-10-31,"July 31, 2021",Actual,2021-07-31,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,NA,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,"Effectiveness of a Self-applied Positive Psychology Online Intervention Program ""Mental Health COVID-19"" in Mexican Population: A Randomized Controlled Trial.",Completed,NA,Not Applicable,35,Actual,Universidad Internacional de Valencia,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,This data will be available approximately in december 2020 and it will be permanently available. It will be shared in the databases of the journal where the article(s) will be published,Through the servers of the journal(s) where we will publish the articles.,NA,Yes,"The information will be available in a private server or in a server of the journal(s) that we will publish the articles that will be the result of this study. The protocol of the study is currently in progress to be published, in this article will be included such study protocol, the informed consent is already shared in the register of clinical trials.",2021-10-13T20:05:25Z,2021-10-13T20:05:25Z,111
NCT05077306,NA,2021-10-08,NA,NA,2021-10-12,2021-10-12,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-14,Actual,"April 15, 2021",Actual,2021-04-15,October 2021,2021-10-31,"June 30, 2021",Actual,2021-06-30,"May 15, 2021",Actual,2021-05-15,NA,Interventional,MADC-19,NA,Receptive Music Therapy on Anxiety and Vital Parameters in Hospitalized Covid-19 Patients.,Effect of Musical Listening on Anxiety and Depression in Patients Hospitalized for Covid-19: a Randomized Controlled Trial,Completed,NA,Not Applicable,40,Actual,Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:00:25Z,2021-10-15T22:00:25Z,111
NCT04890509,NA,2021-05-17,NA,NA,2021-10-13,2021-05-17,2021-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-14,Actual,"October 20, 2020",Actual,2020-10-20,October 2021,2021-10-31,"May 25, 2021",Actual,2021-05-25,"May 25, 2021",Actual,2021-05-25,NA,Interventional,NA,NA,A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients,"A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients",Completed,NA,Phase 2,115,Actual,BerGenBio ASA,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months and ending 5 years following article publication,"Proposal should be directed to HYPERLINK ""mailto:clinical@bergenbio.com"" clinical@bergenbio.com. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in the article, after deidentification [text, tables, figures and appendices].",2021-10-15T22:05:02Z,2021-10-15T22:05:02Z,110
NCT04808284,NA,2021-03-16,NA,NA,2021-10-13,2021-03-18,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-14,Actual,"August 10, 2021",Actual,2021-08-10,October 2021,2021-10-31,"October 11, 2021",Actual,2021-10-11,"October 11, 2021",Actual,2021-10-11,NA,Interventional,NA,NA,Neuromodulation in COVID-19 Patients,Neuromodulation in COVID-19 Patients,Completed,NA,Phase 1/Phase 2,60,Actual,D'Or Institute for Research and Education,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:06:14Z,2021-10-15T22:06:14Z,110
NCT04734886,NA,2020-12-10,NA,NA,2021-10-14,2021-01-30,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"November 27, 2020",Actual,2020-11-27,September 2021,2021-09-30,"September 13, 2021",Actual,2021-09-13,"September 13, 2021",Actual,2021-09-13,NA,Interventional,NA,NA,The Effect of Probiotic Supplementation on SARS-CoV-2 Antibody Response After COVID-19,Exploratory Study on the Effects of Probiotic Supplementation on SARS-CoV-2 Antibody Response in Healthy Adults,Completed,NA,Not Applicable,161,Actual,"Ã–rebro University, Sweden",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"IPD will not be shared, results will shared only on group-level",2021-10-15T22:07:30Z,2021-10-15T22:07:30Z,109
NCT04539275,NA,2020-08-27,NA,NA,2021-10-05,2020-09-03,2020-09-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-14,Actual,"November 16, 2020",Actual,2020-11-16,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,VA CURES-1,NA,COVID-19 (VA CURES-1),VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1),Completed,NA,Phase 3,75,Actual,VA Office of Research and Development,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:10:17Z,2021-10-15T22:10:17Z,118
NCT04551911,NA,2020-09-15,NA,NA,2021-10-14,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"October 26, 2020",Actual,2020-10-26,October 2021,2021-10-31,"October 8, 2021",Actual,2021-10-08,"October 8, 2021",Actual,2021-10-08,NA,Interventional,NA,NA,Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,"A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)",Completed,NA,Phase 2,171,Actual,"OPKO Health, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:10:03Z,2021-10-15T22:10:03Z,109
NCT04425915,NA,2020-06-07,NA,NA,2021-10-06,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"June 14, 2020",Actual,2020-06-14,June 2021,2021-06-30,"December 15, 2020",Actual,2020-12-15,"December 15, 2020",Actual,2020-12-15,NA,Interventional,NA,NA,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19: A Randomized Control Trial,Completed,NA,Phase 3,400,Actual,"Institute of Liver and Biliary Sciences, India",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After publication till 5 years,It will be available for researcher scientist & government agencies.,NA,Yes,NA,2021-10-15T22:11:36Z,2021-10-15T22:11:36Z,117
NCT04350723,NA,2020-04-14,NA,NA,2021-10-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"June 10, 2020",Actual,2020-06-10,October 2021,2021-10-31,"July 17, 2021",Actual,2021-07-17,"July 17, 2021",Actual,2021-07-17,NA,Interventional,COVI-PRONE,NA,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 COVID-19 (COVI-PRONE),Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Completed,NA,Not Applicable,400,Actual,St. Joseph's Healthcare Hamilton,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:12:35Z,2021-10-15T22:12:35Z,109
NCT04345991,NA,2020-04-10,NA,NA,2021-10-15,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-18,Estimate,"April 15, 2020",Actual,2020-04-15,October 2021,2021-10-31,"May 28, 2021",Actual,2021-05-28,"May 28, 2021",Actual,2021-05-28,NA,Interventional,CORIPLASM,NA,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - CORIMUNO-CORIPLASM : EFFICACY OF CONVALESCENT PLASMA TO TREAT SARS-COV2 INFECTED PATIENTS,Completed,NA,Phase 2,120,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-19T10:13:11Z,2021-10-19T10:13:11Z,108
NCT04516564,NA,2020-08-13,NA,NA,2021-10-15,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-18,Estimate,"September 29, 2020",Actual,2020-09-29,October 2021,2021-10-31,"June 18, 2021",Actual,2021-06-18,"March 4, 2021",Actual,2021-03-04,NA,Interventional,NA,NA,"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AK119 in Healthy Subjects",Completed,NA,Phase 1,29,Actual,Akeso,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-19T10:12:07Z,2021-10-19T10:12:07Z,108
NCT05042141,NA,2021-09-08,NA,NA,2021-10-16,2021-09-09,2021-09-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-16,2021-10-19,Estimate,"July 28, 2021",Actual,2021-07-28,September 2021,2021-09-30,"September 12, 2021",Actual,2021-09-12,"August 11, 2021",Actual,2021-08-11,NA,Interventional,KOVIR,NA,Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR),A Study to Evaluate the Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients Without Symptoms of Acute Respiratory Distress,Completed,NA,Not Applicable,66,Actual,Sunstar Joint Stock Company,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:07:31Z,2021-10-20T11:07:31Z,107
NCT04806074,NA,2021-03-17,NA,NA,2021-10-14,2021-03-17,2021-03-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-19,Estimate,"August 14, 2020",Actual,2020-08-14,October 2021,2021-10-31,"September 6, 2021",Actual,2021-09-06,"December 6, 2020",Actual,2020-12-06,NA,Interventional,NA,NA,FOODLIT-Trial: Digital Behaviour Change Intervention to Improve Food Literacy Amidst the COVID-19 Pandemic,FOODLIT-Trial: Protocol of a Randomised Controlled Digital Intervention to Promote Food Literacy and Food Sustainability Behaviours in Adults Using the Health Action Process Approach (HAPA) and the Behaviour Change Techniques Taxonomy (BCTT) During the COVID-19 Pandemic,Completed,NA,Not Applicable,215,Actual,"ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:10:40Z,2021-10-20T11:10:40Z,109
NCT04980534,NA,2021-07-26,NA,NA,2021-10-20,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"January 8, 2021",Actual,2021-01-08,July 2021,2021-07-31,"September 15, 2021",Actual,2021-09-15,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,NA,Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip,Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip,Completed,NA,Not Applicable,80,Actual,Catalysis SL,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-22T11:06:05Z,2021-10-22T11:06:05Z,103
NCT04790851,NA,2021-03-08,NA,NA,2021-10-12,2021-03-08,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-20,Actual,"March 10, 2021",Actual,2021-03-10,October 2021,2021-10-31,"September 5, 2021",Actual,2021-09-05,"September 5, 2021",Actual,2021-09-05,NA,Interventional,NA,NA,Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4,"A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Beijing) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)",Completed,NA,Phase 4,1133,Actual,China National Biotec Group Company Limited,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:09:15Z,2021-10-22T11:09:15Z,111
NCT04927182,NA,2021-06-14,NA,NA,2021-10-19,2021-06-14,2021-06-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-20,Actual,"October 15, 2020",Actual,2020-10-15,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 30, 2021",Actual,2021-09-30,NA,Interventional,NA,NA,Impact of Moderate Exercise Training on Vitals and Peak VO2 in Different Age Categories of Adult in COVID-19.,Impact of Moderate Exercise Training on Vitals and Peak VO2 in Different Age Categories of Adult in COVID-19.,Completed,NA,Not Applicable,102,Actual,Riphah International University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:07:20Z,2021-10-22T11:07:20Z,104
NCT04726098,NA,2021-01-23,NA,NA,2021-10-19,2021-01-26,2021-01-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-20,Actual,"January 15, 2021",Actual,2021-01-15,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"August 31, 2021",Actual,2021-08-31,NA,Interventional,HIGHLOWDEXA,NA,Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19,Efficacy of Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19,Completed,NA,Phase 4,198,Actual,Hospital Clinico Universitario de Santiago,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:10:19Z,2021-10-22T11:10:19Z,104
NCT04701502,NA,2021-01-04,NA,NA,2021-10-20,2021-01-07,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"November 9, 2020",Actual,2020-11-09,November 2020,2020-11-30,"February 15, 2021",Actual,2021-02-15,"February 15, 2021",Actual,2021-02-15,NA,Interventional,NA,NA,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Completed,NA,Phase 2,60,Actual,Catalysis SL,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-22T11:10:43Z,2021-10-22T11:10:43Z,103
NCT04400305,NA,2020-05-21,NA,NA,2021-10-19,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-21,Estimate,"May 20, 2020",Actual,2020-05-20,October 2021,2021-10-31,"August 30, 2021",Actual,2021-08-30,"August 30, 2021",Actual,2021-08-30,NA,Interventional,COVID-19,NA,"""Increasing Physical Activity in Canadian Adults Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""","""Increasing Physical Activity in Canadian Adults Who Have Been Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""",Completed,NA,Not Applicable,37,Actual,University of Victoria,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:14:05Z,2021-10-22T11:14:05Z,104
NCT05089045,NA,2021-10-11,NA,NA,2021-10-21,2021-10-21,2021-10-22,Estimate,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-22,Estimate,"August 31, 2021",Actual,2021-08-31,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 16, 2021",Actual,2021-09-16,NA,Interventional,NA,NA,Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity,A Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant New Coronavirus Vaccine (CHO Cells) After Vaccination With Two Inactivated Vaccine in Healthy People Aged 18 and Above,Completed,NA,Not Applicable,360,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:35:52Z,2021-10-25T10:35:52Z,102
NCT04874766,NA,2021-04-23,NA,NA,2021-10-19,2021-05-02,2021-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-25,Estimate,"May 28, 2021",Actual,2021-05-28,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"July 15, 2021",Actual,2021-07-15,NA,Interventional,NA,NA,The Effects of Wearing a Face Mask During Exercise in Youth Hockey Players During COVID-19,The Effects of Wearing a Face Mask on Exercise Tolerance in Children's Hockey During the COVID-19 Pandemic,Completed,NA,Not Applicable,26,Actual,University of Saskatchewan,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:32:43Z,2021-10-26T10:32:43Z,104
NCT04710199,NA,2021-01-05,NA,NA,2021-10-15,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-25,Estimate,"February 23, 2021",Actual,2021-02-23,April 2021,2021-04-30,"July 8, 2021",Actual,2021-07-08,"July 8, 2021",Actual,2021-07-08,NA,Interventional,COVIMAR,NA,Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19),Proof-of-concept Trial to Evaluate the Safety and Efficacy of Maraviroc in Severe Acute Respiratory Syndrome (SARS) Coronavirus-2 (CoV-2) Infected Patients Hospitalized for COVID-19,Completed,NA,Phase 2,44,Actual,FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-26T10:34:04Z,2021-10-26T10:34:04Z,108
NCT05079308,NA,2021-09-08,NA,NA,2021-10-18,2021-10-14,2021-10-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"March 1, 2021",Actual,2021-03-01,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,NA,"Clinical Trial on the Efficacy of Different Masks With and Without a Peripheral Sealing Device, Against Covid-19","Clinical Trial on the Level of Respiratory Protection of Surgical Face Masks and Filtering Face Pieces (FFP2), With and Without a Peripheral Sealing Device, Against Covid-19",Completed,NA,Not Applicable,210,Actual,University of the Balearic Islands,NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T12:58:54Z,2021-10-27T12:58:54Z,105
NCT04853836,NA,2021-04-16,NA,NA,2021-10-24,2021-04-20,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-24,2021-10-26,Estimate,"November 15, 2020",Actual,2020-11-15,October 2021,2021-10-31,"October 1, 2021",Actual,2021-10-01,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,NA,Olfactory Disfunction and Co-ultraPEALut,Olfactory Disfunction After COVID-19: Conventional Therapy Versus Intervention Treatment With Co-ultraPEALut,Completed,NA,Phase 4,200,Actual,University Of Perugia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,request to PI,NA,Yes,"Shared, only anonymized data directly requested to PI",2021-10-27T13:02:02Z,2021-10-27T13:02:02Z,99
NCT04631705,NA,2020-11-10,NA,NA,2021-10-23,2020-11-14,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-23,2021-10-26,Estimate,"December 14, 2020",Actual,2020-12-14,October 2021,2021-10-31,"September 23, 2021",Actual,2021-09-23,"September 23, 2021",Actual,2021-09-23,NA,Interventional,NA,NA,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation,A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,Completed,NA,Phase 1/Phase 2,45,Actual,University of Cologne,NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:03:50Z,2021-10-27T13:03:50Z,100
NCT04655638,NA,2020-12-03,NA,NA,2021-10-25,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"February 10, 2021",Actual,2021-02-10,October 2021,2021-10-31,"October 25, 2021",Actual,2021-10-25,"September 22, 2021",Actual,2021-09-22,NA,Interventional,COVID-HIGH,NA,HFNT vs. COT in COVID-19,High-Flow Nasal Therapy Versus Conventional Oxygen Therapy in Patients With COVID-19: A Randomized Controlled Trial (The COVID-HIGH Trial),Completed,NA,Not Applicable,364,Actual,Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T13:03:38Z,2021-10-27T13:03:38Z,98
NCT04657809,NA,2020-12-02,NA,NA,2021-10-25,2020-12-02,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"October 1, 2020",Actual,2020-10-01,October 2021,2021-10-31,"March 20, 2021",Actual,2021-03-20,"February 18, 2021",Actual,2021-02-18,NA,Interventional,NA,NA,Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia,"""Insulin Fast Dissolving Film for Intranasal Delivery Via Olfactory Region, a Promising Approach for the Treatment of Anosmia in COVID 19 Patients: Design, In-vitro Characterization and Clinical Evaluation.""",Completed,NA,Phase 2,40,Actual,Deraya University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-27T13:03:37Z,2021-10-27T13:03:37Z,98
NCT04444700,NA,2020-06-22,NA,NA,2021-10-25,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"July 4, 2020",Actual,2020-07-04,October 2021,2021-10-31,"October 14, 2021",Actual,2021-10-14,"May 10, 2021",Actual,2021-05-10,NA,Interventional,RAPID-BRAZIL,NA,A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic,UtilizaÃ§Ã£o da Enoxaparina em Dose Anticoagulante em Pacientes Hospitalizados Com sÃ­ndrome respiratÃ³ria Aguda Grave Por COVID-19,Completed,NA,Phase 3,465,Actual,University of Sao Paulo General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:05:18Z,2021-10-27T13:05:18Z,98
NCT04504240,NA,2020-08-06,NA,NA,2021-10-23,2020-08-06,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-23,2021-10-26,Estimate,"August 1, 2020",Actual,2020-08-01,October 2021,2021-10-31,"April 15, 2021",Actual,2021-04-15,"April 15, 2021",Actual,2021-04-15,NA,Interventional,NA,NA,Role of Famotidine in the Clinical Improvement of COVID-19 Patients.,Role of Famotidine in the Clinical Recovery and Symptomatic Improvement of COVID-19 Patients.,Completed,NA,Phase 3,208,Actual,Chattogram General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:04:54Z,2021-10-27T13:04:54Z,100
NCT04435379,NA,2020-06-16,NA,NA,2021-10-25,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"June 18, 2020",Actual,2020-06-18,October 2021,2021-10-31,"October 12, 2021",Actual,2021-10-12,"October 12, 2021",Actual,2021-10-12,NA,Interventional,NA,NA,Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in the SARS-CoV-2 Pandemic by Modulating the Immune System",Completed,NA,Phase 3,2038,Actual,Vakzine Projekt Management GmbH,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is uncertainty whether the European Union General Data Protection Regulation allows dissemination of individual participant data to other researchers. Some reasons why the EU Regulation would not allow this are the lack of suitable safeguards when personal data are transferred to any researcher asking for it and the impairment of the rights of the subjects for erasure of their data once they are disseminated.,2021-10-27T13:05:20Z,2021-10-27T13:05:20Z,98
NCT04429854,NA,2020-06-09,NA,NA,2021-10-18,2020-06-09,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"May 2, 2020",Actual,2020-05-02,October 2021,2021-10-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,DAWN-Plasma,NA,Donated Antibodies Working Against nCoV,"A Randomized, Open-label, Adaptive, Proof-of-concept Clinical Trial of Donated Antibodies Working Against With COVID-19: DAWN-PLASMA",Completed,NA,Phase 2,483,Actual,Universitaire Ziekenhuizen Leuven,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:05:23Z,2021-10-27T13:05:23Z,105
NCT04387760,NA,2020-05-09,NA,NA,2021-10-25,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"August 11, 2020",Actual,2020-08-11,August 2021,2021-08-31,"April 7, 2021",Actual,2021-04-07,"March 6, 2021",Actual,2021-03-06,NA,Interventional,NA,NA,Favipiravir vs Hydroxychloroquine vs Control in COVID -19,Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial,Completed,NA,Phase 2,150,Actual,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,"Dr Manaf will act as the data custodian and is responsible for the storage, handling and quality of the study data.

Data will be collected in the case report form to allow for cross referencing to check validity.

Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point). A label stating the date after which the documents can be destroyed will be placed on the inside front cover of the case notes of trial participants.",Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2021-10-27T13:05:42Z,2021-10-27T13:05:42Z,98
NCT04362085,NA,2020-04-20,NA,NA,2021-10-22,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-26,Estimate,"May 11, 2020",Actual,2020-05-11,October 2021,2021-10-31,"October 14, 2021",Actual,2021-10-14,"May 10, 2021",Actual,2021-05-10,NA,Interventional,NA,NA,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG),Completed,NA,Phase 3,465,Actual,Unity Health Toronto,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:05:56Z,2021-10-27T13:05:56Z,101
NCT04356534,NA,2020-04-15,NA,NA,2021-10-25,2020-04-17,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"April 19, 2020",Actual,2020-04-19,July 2020,2020-07-31,"July 9, 2020",Actual,2020-07-09,"June 15, 2020",Actual,2020-06-15,NA,Interventional,NA,NA,Convalescent Plasma Trial in COVID -19 Patients,Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial,Completed,NA,Not Applicable,40,Actual,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Dr Manaf will act as the data custodian and is responsible for the storage, handling and quality of the study data.

Data will be collected in the case report form to allow for cross referencing to check validity.

Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point). A label stating the date after which the documents can be destroyed will be placed on the inside front cover of the case notes of trial participants.",Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2021-10-27T13:05:57Z,2021-10-27T13:05:57Z,98
NCT05096026,NA,2021-10-25,NA,NA,2021-10-26,2021-10-26,2021-10-27,Estimate,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"March 29, 2021",Actual,2021-03-29,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"May 20, 2021",Actual,2021-05-20,NA,Interventional,NA,NA,Effect of Electronic and Mail Outreach From Primary Care Physicians for COVID-19 Vaccination Among Elderly Patients,Effect of Electronic and Mail Outreach From Primary Care Physicians for COVID-19 Vaccination Among Elderly Patients,Completed,NA,Not Applicable,8287,Actual,Kaiser Permanente,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"December 1, 2022 through December 1, 2024","Deidentified data will be shared on submission of a protocol approved by the Kaiser Permanente Northern California Institutional Review Board or Research Determination Official, and contingent on appropriate data sharing agreement being completed.",NA,Yes,"Deidentified data will be shared on submission of a protocol approved by the Kaiser Permanente Northern California Institutional Review Board or Research Determination Official, and contingent on appropriate data sharing agreement being completed.",2021-10-28T11:03:10Z,2021-10-28T11:03:10Z,97
NCT04960228,NA,2021-06-30,NA,NA,2021-10-26,2021-07-09,2021-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"July 30, 2021",Actual,2021-07-30,October 2021,2021-10-31,"September 13, 2021",Actual,2021-09-13,"September 13, 2021",Actual,2021-09-13,NA,Interventional,NA,NA,Exploring Changes in COVID-19 Vaccination Intentions by Prompting Altruistic Motives Using a Video Intervention,Enhancing COVID-19 Vaccination Intentions by Eliciting Prosocial Altruistic Motives: Evaluating the Efficacy of a Brief Video-Based Intervention,Completed,NA,Not Applicable,1623,Actual,Sir Mortimer B. Davis - Jewish General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Consent form, data collection method, and organizational policy means only aggregated data will be shared with other researchers.",2021-10-28T11:07:01Z,2021-10-28T11:07:01Z,97
NCT04507256,NA,2020-08-07,NA,NA,2021-10-26,2020-08-07,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"August 18, 2020",Actual,2020-08-18,October 2021,2021-10-31,"October 19, 2021",Actual,2021-10-19,"October 19, 2021",Actual,2021-10-19,NA,Interventional,NA,NA,AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19,"A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD7442 in Healthy Adults",Completed,NA,Phase 1,60,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",2021-10-28T11:11:34Z,2021-10-28T11:11:34Z,97
NCT04410549,NA,2020-05-21,NA,NA,2021-10-26,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"June 1, 2020",Actual,2020-06-01,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 30, 2021",Actual,2021-09-30,NA,Interventional,NA,NA,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Optical Coherence Tomography for Microvascular Lung Vessels Obstructive Thromboinflammatory Syndrome Assessment in Patients With COVID-19: an Exploratory Study,Completed,NA,Not Applicable,13,Actual,IRCCS San Raffaele,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:12:40Z,2021-10-28T11:12:40Z,97
NCT05012267,NA,2021-08-11,NA,NA,2021-10-27,2021-08-17,2021-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"March 25, 2021",Actual,2021-03-25,October 2021,2021-10-31,"October 27, 2021",Actual,2021-10-27,"October 27, 2021",Actual,2021-10-27,NA,Interventional,OmeLEtte,NA,Duration of Prone Position in the Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).,OptiMal pronE Position LEnghT in Patients With acuTE Respiratory Distress Syndrome Due to COVID-19.,Completed,NA,Not Applicable,61,Actual,Hospital Universitario 12 de Octubre,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:08:18Z,2021-10-29T11:08:18Z,96
NCT04414241,NA,2020-06-01,NA,NA,2021-10-20,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"June 25, 2020",Actual,2020-06-25,June 2020,2020-06-30,"November 23, 2020",Actual,2020-11-23,"November 23, 2020",Actual,2020-11-23,NA,Interventional,NA,NA,Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19,"Hydroxychloroquine to Prevent SARS-CoV-2 Infection Among Healthcare Workers: Randomized Controlled, Open-label, Phase 3 Clinical Trial",Completed,NA,Phase 3,68,Actual,Universidad Peruana Cayetano Heredia,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:14:06Z,2021-10-29T11:14:06Z,103
NCT04399356,NA,2020-05-19,NA,NA,2021-10-27,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"October 1, 2020",Actual,2020-10-01,October 2021,2021-10-31,"August 19, 2021",Actual,2021-08-19,"April 20, 2021",Actual,2021-04-20,NA,Interventional,NA,NA,Niclosamide for Mild to Moderate COVID-19,Niclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19),Completed,NA,Phase 2,73,Actual,Tufts Medical Center,NA,2,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-29T11:14:13Z,2021-10-29T11:14:13Z,96
NCT04497324,NA,2020-07-31,NA,NA,2021-10-20,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"September 21, 2020",Actual,2020-09-21,March 2021,2021-03-31,"April 17, 2021",Actual,2021-04-17,"April 17, 2021",Actual,2021-04-17,NA,Interventional,NA,NA,PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19,PERUCONPLASMA: Randomized Clinical Trial to Evaluate Safety and Efficacy of the Use of Convalescent Plasma in Hospitalized Patients With COVID-19,Completed,NA,Phase 2,100,Actual,Universidad Peruana Cayetano Heredia,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:13:47Z,2021-10-29T11:13:47Z,103
NCT04621071,NA,2020-11-05,NA,NA,2021-10-28,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-10-29,Estimate,"January 12, 2021",Actual,2021-01-12,October 2021,2021-10-31,"October 12, 2021",Actual,2021-10-12,"August 19, 2021",Actual,2021-08-19,NA,Interventional,PROVID-19,NA,Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19,"Evaluation of the Efficacy of Probiotics to Reduce the Duration and Symptoms of COVID-19 (PROVID-19 Study): a Randomized, Double-blind, Controlled Trial",Completed,NA,Not Applicable,17,Actual,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-01T10:45:40Z,2021-11-01T10:45:40Z,95
NCT04573322,NA,2020-09-29,NA,NA,2021-10-27,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-29,Estimate,"September 10, 2020",Actual,2020-09-10,October 2021,2021-10-31,"April 29, 2021",Actual,2021-04-29,"March 17, 2021",Actual,2021-03-17,NA,Interventional,NA,NA,Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects,"Open-label, Pharmacokinetic, Pharmacodynamic, Ascending Dose Safety lead-in Followed by a Single-center, Placebo-controlled, Double-blind, Adaptive, Safety and Efficacy, Pilot Study of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 Infected Subjects",Completed,NA,Phase 1/Phase 2,25,Actual,Diffusion Pharmaceuticals Inc,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-11-01T10:46:04Z,2021-11-01T10:46:04Z,96
NCT04422613,NA,2020-06-05,NA,NA,2021-10-29,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-01,Estimate,"May 28, 2020",Actual,2020-05-28,October 2021,2021-10-31,"October 29, 2021",Actual,2021-10-29,"July 1, 2021",Actual,2021-07-01,NA,Interventional,PULCO-19,NA,Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia,Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia,Completed,NA,Not Applicable,73,Actual,"University Hospital, Toulouse",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:35:09Z,2021-11-02T11:35:09Z,94
NCT04351295,NA,2020-04-15,NA,NA,2021-10-29,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-01,Estimate,"April 20, 2020",Actual,2020-04-20,October 2021,2021-10-31,"September 28, 2020",Actual,2020-09-28,"September 28, 2020",Actual,2020-09-28,NA,Interventional,NA,NA,Efficacy of Faviprevir in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment,Completed,NA,Phase 2/Phase 3,92,Actual,Tanta University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:35:45Z,2021-11-02T11:35:45Z,94
NCT04344587,NA,2020-04-08,NA,NA,2021-10-25,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-11-01,Estimate,"April 23, 2020",Actual,2020-04-23,October 2021,2021-10-31,"May 7, 2021",Actual,2021-05-07,"May 7, 2021",Actual,2021-05-07,NA,Interventional,APPEX-19,NA,Awake Prone Position for Early Hypoxemia in COVID-19,Awake Prone Position for Early Hypoxemia in COVID-19,Completed,NA,Not Applicable,305,Actual,Boston University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:35:50Z,2021-11-02T11:35:50Z,98
NCT04930861,NA,2021-06-16,NA,NA,2021-11-01,2021-06-17,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-02,Estimate,"March 29, 2021",Actual,2021-03-29,November 2021,2021-11-30,"August 9, 2021",Actual,2021-08-09,"May 27, 2021",Actual,2021-05-27,NA,Interventional,Codivir,NA,Study of Codivir in Patients With COVID-19,Phase 1 Clinical Study of Codivir in Outpatients With COVID-19,Completed,NA,Phase 1,12,Actual,Code Pharma,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:05:28Z,2021-11-03T11:05:28Z,91
NCT04667780,NA,2020-12-11,NA,NA,2021-10-30,2020-12-12,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-30,2021-11-02,Estimate,"December 1, 2020",Actual,2020-12-01,October 2021,2021-10-31,"July 9, 2021",Actual,2021-07-09,"July 9, 2021",Actual,2021-07-09,NA,Interventional,NA,NA,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Completed,NA,Phase 3,102,Actual,Ayub Teaching Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:07:39Z,2021-11-03T11:07:39Z,93
NCT04459286,NA,2020-07-03,NA,NA,2021-10-29,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-02,Estimate,"October 9, 2020",Actual,2020-10-09,October 2021,2021-10-31,"May 2, 2021",Actual,2021-05-02,"May 2, 2021",Actual,2021-05-02,NA,Interventional,NACOVID,NA,The Nitazoxanide Plus Atazanavir for COVID-19 Study,"A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir/Ritonavir for the Treatment of COVID-19: a Pilot Study",Completed,NA,Phase 2,57,Actual,Obafemi Awolowo University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:09:07Z,2021-11-03T11:09:07Z,94
NCT04459247,NA,2020-07-03,NA,NA,2021-10-30,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-30,2021-11-02,Estimate,"June 15, 2020",Actual,2020-06-15,October 2021,2021-10-31,"April 10, 2021",Actual,2021-04-10,"March 30, 2021",Actual,2021-03-30,NA,Interventional,SHADE,NA,"Short Term, High Dose Vitamin D Supplementation for COVID-19","Short Term, High Dose Vitamin D Supplementation for COVID-19 Disease: Double Blind, Controlled, Study",Completed,NA,Not Applicable,40,Actual,Postgraduate Institute of Medical Education and Research,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:09:07Z,2021-11-03T11:09:07Z,93
NCT04700462,NA,2021-01-06,NA,NA,2021-11-02,2021-01-06,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-03,Estimate,"February 5, 2021",Actual,2021-02-05,January 2021,2021-01-31,"October 30, 2021",Actual,2021-10-30,"October 30, 2021",Actual,2021-10-30,NA,Interventional,NA,NA,COVID-19 Preventive Behavior in African Americans,Optimizing Tailored-feedback Message to Promote Adherence Behavior to Prevent COVID-19 in African Americans,Completed,NA,Not Applicable,250,Actual,Johns Hopkins University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-04T08:51:52Z,2021-11-04T08:51:52Z,90
NCT04642950,NA,2020-11-19,NA,NA,2021-11-01,2020-11-19,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-03,Estimate,"December 17, 2020",Actual,2020-12-17,November 2021,2021-11-30,"October 25, 2021",Actual,2021-10-25,"October 25, 2021",Actual,2021-10-25,NA,Interventional,NA,NA,A Phase II/III Study of Sargramostim,A Phase II/III Study of Sargramostim in Patients With Coronavirus Disease-2019 (COVID-19),Completed,NA,Phase 2/Phase 3,70,Actual,Nobelpharma,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:52:18Z,2021-11-04T08:52:18Z,91
NCT04528667,NA,2020-08-20,NA,NA,2021-11-01,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-03,Estimate,"January 6, 2021",Actual,2021-01-06,November 2021,2021-11-30,"October 7, 2021",Actual,2021-10-07,"August 23, 2021",Actual,2021-08-23,NA,Interventional,NA,NA,Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19,"A Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19",Completed,NA,Phase 2,396,Actual,"Sorrento Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-04T08:53:26Z,2021-11-04T08:53:26Z,91
NCT04440007,NA,2020-06-17,NA,NA,2021-11-01,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-03,Estimate,"October 9, 2020",Actual,2020-10-09,November 2021,2021-11-30,"August 23, 2021",Actual,2021-08-23,"July 1, 2021",Actual,2021-07-01,NA,Interventional,SOC,NA,Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,92,Actual,"Sorrento Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-04T08:54:07Z,2021-11-04T08:54:07Z,91
NCT04821999,NA,2021-03-29,NA,NA,2021-11-03,2021-03-29,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-04,Estimate,"April 10, 2021",Actual,2021-04-10,November 2021,2021-11-30,"October 1, 2021",Actual,2021-10-01,"September 20, 2021",Actual,2021-09-20,NA,Interventional,NA,NA,Diode Laser 940 nm in Management of Loss of Taste Sensation,Diode Laser 940 nm in Management of Loss of Taste Sensation in Patients With Post SARS-CoV 2 Infection,Completed,NA,Not Applicable,40,Actual,Fayoum University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:08:06Z,2021-11-05T12:08:06Z,89
NCT04611425,NA,2020-10-07,NA,NA,2021-10-27,2020-10-30,2020-11-02,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-11-04,Estimate,"November 30, 2020",Actual,2020-11-30,October 2021,2021-10-31,"October 22, 2021",Actual,2021-10-22,"December 2, 2020",Actual,2020-12-02,NA,Interventional,REHSCU,NA,REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19: REHSCU Study,"REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19. The Non-randomized, Non-controlled, Pilot, Open, Mono-centric REHSCU Study",Completed,NA,Phase 2,30,Actual,Nantes University Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:10:26Z,2021-11-05T12:10:26Z,96
NCT04362176,NA,2020-04-21,NA,NA,2021-11-03,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-04,Estimate,"April 24, 2020",Actual,2020-04-24,November 2021,2021-11-30,"August 6, 2021",Actual,2021-08-06,"July 6, 2021",Actual,2021-07-06,NA,Interventional,PassItOn,NA,Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults,Passive Immunity Trial for Our Nation (PassItOn),Completed,NA,Phase 3,974,Actual,Vanderbilt University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:12:22Z,2021-11-05T12:12:22Z,89
NCT04849598,NA,2021-04-13,NA,NA,2021-11-04,2021-04-15,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"April 13, 2021",Actual,2021-04-13,November 2021,2021-11-30,"August 27, 2021",Actual,2021-08-27,"August 27, 2021",Actual,2021-08-27,NA,Interventional,NA,NA,Automatic Oxygen Titration in Patients After SARS-CoV-2 Infection,Effects of an Automatic Oxygen Titration vs. Constant Oxygen Flow Rates During Daily Activities in Patients After SARS-CoV-2 Infection,Completed,NA,Not Applicable,15,Actual,SchÃ¶n Klinik Berchtesgadener Land,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-08T11:23:32Z,2021-11-08T11:23:32Z,88
NCT04909905,NA,2021-05-30,NA,NA,2021-11-04,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"May 30, 2021",Actual,2021-05-30,November 2021,2021-11-30,"October 30, 2021",Actual,2021-10-30,"October 25, 2021",Actual,2021-10-25,NA,Interventional,NA,NA,Glutamine Supplementation and Short-term Mortality in Covid-19,The Impact of Glutamine Supplementation Upon the Short-term Mortality of COVID-19 Diseased Patients Admitted in ICU: A Double Blind Randomized Clinical Trial,Completed,NA,Phase 3,60,Actual,Assiut University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-08T11:22:55Z,2021-11-08T11:22:55Z,88
NCT04569383,NA,2020-09-21,NA,NA,2021-11-04,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"October 5, 2020",Actual,2020-10-05,November 2021,2021-11-30,"August 24, 2021",Actual,2021-08-24,"August 24, 2021",Actual,2021-08-24,NA,Interventional,NA,NA,Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19,"An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S and Heterologous Booster Vaccinations With a Licensed Vaccine Against COVID-19",Completed,NA,Phase 1,30,Actual,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-08T11:26:01Z,2021-11-08T11:26:01Z,88
NCT04625738,NA,2020-11-04,NA,NA,2021-10-28,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-11-05,Estimate,"November 6, 2020",Actual,2020-11-06,October 2021,2021-10-31,"September 1, 2021",Actual,2021-09-01,"May 14, 2021",Actual,2021-05-14,NA,Interventional,MSC-COVID19,NA,Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome,Efficacy of Infusions of Mesenchymal Stem Cells From Wharton Jelly in the Moderate to Severe SARS-Cov-2 Related Acute Respiratory Distress Syndrome (COVID-19): A Phase IIa Double-blind Randomized Controlled Trial,Completed,NA,Phase 2,30,Actual,"Central Hospital, Nancy, France",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:25:28Z,2021-11-08T11:25:28Z,95
NCT04464408,NA,2020-06-28,NA,NA,2021-11-04,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"July 23, 2020",Actual,2020-07-23,November 2021,2021-11-30,"August 4, 2021",Actual,2021-08-04,"August 4, 2021",Actual,2021-08-04,NA,Interventional,Avi-Mild,NA,Favipiravir Therapy in Adults With Mild COVID-19,A Trial of Favipiravir Therapy in Adults With Mild Coronavirus Disease COVID-19,Completed,NA,Phase 2/Phase 3,231,Actual,King Abdullah International Medical Research Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:26:39Z,2021-11-08T11:26:39Z,88
NCT04460703,NA,2020-07-02,NA,NA,2021-10-28,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-11-05,Estimate,"July 3, 2020",Actual,2020-07-03,October 2021,2021-10-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,NA,"COVID-19 Vaccine Messaging, Part 1","Persuasive Messages for COVID-19 Vaccine Uptake: a Randomized Controlled Trial, Part 1",Completed,NA,Not Applicable,4000,Actual,Yale University,NA,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After publication,Anonymized data and analysis code will be posted in a public replication archive,NA,Yes,Anonymized data and analysis code will be posted in a public replication archive after publication.,2021-11-08T11:26:40Z,2021-11-08T11:26:40Z,95
NCT05110560,NA,2021-10-06,NA,NA,2021-11-03,2021-11-03,2021-11-08,Estimate,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-08,Estimate,"June 1, 2021",Actual,2021-06-01,November 2021,2021-11-30,"September 1, 2021",Actual,2021-09-01,"August 1, 2021",Actual,2021-08-01,NA,Interventional,NA,NA,Effects of the Programme Developed for Sedentary Elderly in the COVID-19 Pandemic: Mobile Interventional Study,"Effects of the ""Stay at Home-Take a Step"" Programme Developed for Sedentary Elderly in the COVID-19 Pandemic: Mobile Interventional Study",Completed,NA,Not Applicable,32,Actual,Namik Kemal University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-09T12:28:50Z,2021-11-09T12:28:50Z,89
NCT05104346,NA,2021-10-31,NA,NA,2021-11-01,2021-11-01,2021-11-03,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-08,Estimate,"March 31, 2019",Actual,2019-03-31,November 2021,2021-11-30,"October 1, 2021",Actual,2021-10-01,"March 31, 2021",Actual,2021-03-31,NA,Interventional,AA,NA,Presentation and Outcomes of Acute Appendicitis During COVID Pandemic,Presentation and Outcomes of Acute Appendicitis During COVID Pandemic: Lessons Learned From the Middle East (Multicenter Study),Completed,NA,Not Applicable,1945,Actual,Mansoura University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,available for any researcher at any time,elnakeebayman@yahoo.com,http://www.mans.edu.eg/,Yes,the study protocol will be available for other researcher,2021-11-09T12:29:17Z,2021-11-09T12:29:17Z,91
NCT04910230,NA,2021-05-24,NA,NA,2021-10-29,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-08,Estimate,"March 1, 2020",Actual,2020-03-01,October 2021,2021-10-31,"April 2, 2020",Actual,2020-04-02,"April 2, 2020",Actual,2020-04-02,NA,Interventional,NA,NA,Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19,Efficiency and Safety of Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19: A Randomized Clinical Trial,Completed,NA,Not Applicable,24,Actual,Shenyang Northern Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-09T12:33:38Z,2021-11-09T12:33:38Z,94
NCT04709835,NA,2021-01-12,NA,NA,2021-11-01,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-08,Estimate,"February 3, 2021",Actual,2021-02-03,November 2021,2021-11-30,"October 13, 2021",Actual,2021-10-13,"September 17, 2021",Actual,2021-09-17,NA,Interventional,NA,NA,Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Pharmacokinetics, and Efficacy of RO7496998 (AT-527) in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19",Completed,NA,Phase 2,104,Actual,Hoffmann-La Roche,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)",2021-11-09T12:36:17Z,2021-11-09T12:36:17Z,91
NCT04689542,NA,2020-12-29,NA,NA,2021-11-05,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-08,Estimate,"January 1, 2021",Actual,2021-01-01,November 2021,2021-11-30,"April 2, 2021",Actual,2021-04-02,"April 2, 2021",Actual,2021-04-02,NA,Interventional,NA,NA,Surgical Face Mask Effects in Patients With COVID-19,Effects of Surgical Face Mask on Submaximal Exercise Test in Patients With COVID-19,Completed,NA,Not Applicable,28,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-09T12:36:27Z,2021-11-09T12:36:27Z,87
NCT04615936,NA,2020-11-02,NA,NA,2021-10-29,2020-11-02,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-08,Estimate,"October 13, 2020",Actual,2020-10-13,October 2021,2021-10-31,"October 19, 2021",Actual,2021-10-19,"July 7, 2021",Actual,2021-07-07,NA,Interventional,NA,NA,Nasal Photodisinfection COVID-19 Proof of Concept Study,Methylene Blue-mediated Photodisinfection for SARS-CoV-2 in the Upper Respiratory Tract,Completed,NA,Not Applicable,45,Actual,Sunnybrook Health Sciences Centre,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-09T12:37:34Z,2021-11-09T12:37:34Z,94
NCT04531254,NA,2020-08-24,NA,NA,2021-10-31,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-31,2021-11-08,Estimate,"August 10, 2020",Actual,2020-08-10,October 2021,2021-10-31,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,NA,NA,Back to School COVID-19 Simulation Study,Understanding the Impact of Public Health Measures Planned for School Reopening During COVID-19 Using Simulation Exercises,Completed,NA,Not Applicable,174,Actual,The Hospital for Sick Children,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-09T12:38:40Z,2021-11-09T12:38:40Z,92
NCT05115435,NA,2021-11-08,NA,NA,2021-11-09,2021-11-09,2021-11-10,Estimate,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-10,Estimate,"March 1, 2021",Actual,2021-03-01,November 2021,2021-11-30,"November 1, 2021",Actual,2021-11-01,"August 1, 2021",Actual,2021-08-01,NA,Interventional,NA,NA,The Effect of Neuro Linguistic Programming on COVID-19 Fear in Kidney Transplant,The Effect of Neuro Linguistic Programming on COVID-19 Fear in Kidney Transplant,Completed,NA,Not Applicable,74,Actual,Inonu University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Data can be shared with the permission of the researchers.,2021-11-10T21:57:26Z,2021-11-10T21:57:26Z,83
NCT04392323,NA,2020-05-15,NA,NA,2021-11-04,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-08,Estimate,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"October 4, 2020",Actual,2020-10-04,"October 1, 2020",Actual,2020-10-01,NA,Interventional,NA,NA,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Completed,NA,Not Applicable,111,Actual,Northwell Health,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-09T12:40:05Z,2021-11-09T12:40:05Z,88
NCT05115162,NA,2021-11-01,NA,NA,2021-11-01,2021-11-01,2021-11-10,Estimate,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-10,Estimate,"December 1, 2020",Actual,2020-12-01,October 2021,2021-10-31,"April 30, 2021",Actual,2021-04-30,"January 17, 2021",Actual,2021-01-17,NA,Interventional,NA,NA,The Effects of the Hybrid Telerehabilitation Exercise in Inactive Students,The Effects of the Hybrid Telerehabilitation Exercise Program in Inactive University Students During Covid-19 Pandemic - A Randomized Controlled Study,Completed,NA,Not Applicable,63,Actual,Marmara University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T21:57:40Z,2021-11-10T21:57:40Z,91
NCT05113823,NA,2021-10-25,NA,NA,2021-11-08,2021-11-08,2021-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"November 16, 2020",Actual,2020-11-16,November 2021,2021-11-30,"March 15, 2021",Actual,2021-03-15,"November 19, 2020",Actual,2020-11-19,NA,Interventional,NA,NA,In Situ Simulation Training in Transferring Critically Ill COVID-19 Patients,In Situ Simulation Training for a Better Interprofessional Team Performance in Transferring Critically Ill COVID-19 Patients: A Prospective Randomized Control Trial,Completed,NA,Not Applicable,40,Actual,Indonesia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T21:58:55Z,2021-11-10T21:58:55Z,84
NCT05112887,NA,2021-11-05,NA,NA,2021-11-05,2021-11-05,2021-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-09,Actual,"March 31, 2021",Actual,2021-03-31,March 2021,2021-03-31,"September 13, 2021",Actual,2021-09-13,"September 13, 2021",Actual,2021-09-13,NA,Interventional,NA,NA,Osteopathic Manipulative Therapy Effects on Prolonged Post-COVID Olfactory Dysfunction,Osteopathic Manipulative Therapy Effects on Prolonged Post-COVID Olfactory Dysfunction,Completed,NA,Not Applicable,20,Actual,Ohio University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T21:59:45Z,2021-11-10T21:59:45Z,87
NCT04818489,NA,2021-02-13,NA,NA,2021-11-07,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-07,2021-11-09,Actual,"March 25, 2021",Actual,2021-03-25,November 2021,2021-11-30,"October 20, 2021",Actual,2021-10-20,"August 25, 2021",Actual,2021-08-25,NA,Interventional,NA,NA,Colchicine and Post-COVID-19 Pulmonary Fibrosis,Impact of Colchicine on the Clinical Outcome of COVID-19 and the Development of Post-COVID-19 Pulmonary Fibrosis: Randomized Controlled Clinical Trial,Completed,NA,Phase 4,260,Actual,ClinAmygate,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:07:19Z,2021-11-10T22:07:19Z,85
NCT04633772,NA,2020-11-06,NA,NA,2021-11-08,2020-11-17,2020-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"August 5, 2020",Actual,2020-08-05,November 2021,2021-11-30,"November 1, 2021",Actual,2021-11-01,"November 1, 2021",Actual,2021-11-01,NA,Interventional,NA,NA,Use of Angiotensin-(1-7) in COVID-19,Randomized Clinical Trial Phase I/II for the Use of Angiotensin-(1-7) in the Treatment of Severe Infection by Sars-CoV-2,Completed,NA,Phase 1/Phase 2,112,Actual,Erasme University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:09:31Z,2021-11-10T22:09:31Z,84
NCT04359654,NA,2020-04-21,NA,NA,2021-11-08,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"June 16, 2020",Actual,2020-06-16,November 2021,2021-11-30,"November 5, 2021",Actual,2021-11-05,"August 12, 2021",Actual,2021-08-12,NA,Interventional,COVASE,NA,Nebulised Dornase Alfa for Treatment of COVID-19,"A Single-site, Randomised, Controlled, Parallel Design, Open-label Investigation of an Approved Nebulised Recombinant Human DNase Enzyme (Dornase Alfa) to Reduce Hyperinflammation in Hospitalised Participants With COVID-19",Completed,NA,Phase 2,41,Actual,"University College, London",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Anonymised results will be published in a scientific journal (TBC) and posted on the Breathing Matters website www.breathingatters@ucl.ac.uk,2021-11-10T22:13:15Z,2021-11-10T22:13:15Z,84
NCT04523571,NA,2020-08-18,NA,NA,2021-11-05,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-11,Estimate,"July 28, 2020",Actual,2020-07-28,November 2021,2021-11-30,"August 10, 2021",Actual,2021-08-10,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study",Completed,NA,Phase 1,144,Actual,BioNTech SE,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:28:12Z,2021-11-11T21:28:12Z,87
NCT04480424,NA,2020-07-20,NA,NA,2021-11-10,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-11,Estimate,"September 17, 2020",Actual,2020-09-17,November 2021,2021-11-30,"October 25, 2021",Actual,2021-10-25,"August 19, 2021",Actual,2021-08-19,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19),"A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit",Completed,NA,Phase 2,100,Actual,Grifols Therapeutics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:28:28Z,2021-11-11T21:28:28Z,82
NCT04375735,NA,2020-04-22,NA,NA,2021-11-04,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-11,Estimate,"November 23, 2020",Actual,2020-11-23,November 2021,2021-11-30,"October 6, 2021",Actual,2021-10-06,"September 1, 2021",Actual,2021-09-01,NA,Interventional,LESSCOVID,NA,London's Exogenous Surfactant Study for COVID19,Phase I/II Trial: Exogenous Surfactant Administration for Patients With COVID-19,Completed,NA,Phase 1/Phase 2,20,Actual,Lawson Health Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:29:06Z,2021-11-11T21:29:06Z,88
NCT05118373,NA,2021-08-18,NA,NA,2021-11-11,2021-11-11,2021-11-12,Estimate,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-12,Estimate,"August 18, 2021",Actual,2021-08-18,November 2021,2021-11-30,"September 23, 2021",Actual,2021-09-23,"September 23, 2021",Actual,2021-09-23,NA,Interventional,NA,NA,Generic Behavioural Change Campaign for COVID-19 Prevention,Evaluation of a Generic Behavioural Change Campaign for COVID-19 Prevention in Zambia,Completed,NA,Not Applicable,2004,Actual,Centre for Infectious Disease Research in Zambia,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-15T12:23:19Z,2021-11-15T12:23:19Z,81
NCT04530604,NA,2020-08-25,NA,NA,2021-11-10,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-12,Estimate,"October 1, 2020",Actual,2020-10-01,November 2021,2021-11-30,"April 9, 2021",Actual,2021-04-09,"March 26, 2021",Actual,2021-03-26,NA,Interventional,NA,NA,Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),Defibrotide Therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS),Completed,NA,Phase 1,12,Actual,University of Michigan,NA,1,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-15T12:28:27Z,2021-11-15T12:28:27Z,82
NCT05046548,NA,2021-08-26,NA,NA,2021-11-11,2021-09-13,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-12,Estimate,"October 3, 2020",Actual,2020-10-03,November 2021,2021-11-30,"October 1, 2021",Actual,2021-10-01,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,NA,"This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19","Double-blind, Placebo-controlled, Randomized Study of Tolerability, Safety and Immunogenicity of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine, Produced by FSBSI ""Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"", on Volunteers at the Age of 18-60 Years",Completed,NA,Phase 1/Phase 2,400,Actual,Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-15T12:24:34Z,2021-11-15T12:24:34Z,81
NCT04634409,NA,2020-11-17,NA,NA,2021-11-12,2020-11-17,2020-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-15,Estimate,"October 29, 2020",Actual,2020-10-29,November 2021,2021-11-30,"October 20, 2021",Actual,2021-10-20,"July 27, 2021",Actual,2021-07-27,NA,Interventional,BLAZE-4,NA,A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness,"A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)",Completed,NA,Phase 2,1631,Actual,Eli Lilly and Company,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",http://vivli.org/,Yes,NA,2021-11-16T00:53:26Z,2021-11-16T00:53:26Z,80
NCT05122234,NA,2021-11-13,NA,NA,2021-11-13,2021-11-13,2021-11-16,Estimate,NA,NA,NA,NA,NA,NA,2021-11-13,2021-11-16,Estimate,"August 10, 2020",Actual,2020-08-10,November 2021,2021-11-30,"November 14, 2021",Actual,2021-11-14,"July 30, 2021",Actual,2021-07-30,NA,Interventional,NA,NA,Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19,Effectiveness and Safety Profile of Mesenchymal Stem Cell Secretomes as a Treatment for Severe Cases of COVID-19,Completed,NA,Phase 3,40,Actual,Indonesia University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-17T09:51:27Z,2021-11-17T09:51:27Z,79
NCT04723446,NA,2021-01-05,NA,NA,2021-11-15,2021-01-22,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-16,Estimate,"May 19, 2021",Actual,2021-05-19,November 2021,2021-11-30,"October 25, 2021",Actual,2021-10-25,"October 25, 2021",Actual,2021-10-25,NA,Interventional,COVID-19,NA,Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva,Efficacy of Three Antimicrobial Mouthwashes in Reducing SARS-CoV-2 Viral Load in the Saliva of Patients Diagnosed With COVID-19: A Pilot Study,Completed,NA,Not Applicable,54,Actual,Queen Mary University of London,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Aggregated/collective data regarding the efficacy of the different mouthwashes will be shared with the scientific community as a de-identified/coded information,2021-11-17T09:57:46Z,2021-11-17T09:57:46Z,77
NCT04347681,NA,2020-04-08,NA,NA,2021-11-14,2020-04-12,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-14,2021-11-16,Estimate,"April 18, 2020",Actual,2020-04-18,November 2021,2021-11-30,"November 16, 2020",Actual,2020-11-16,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,NA,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Completed,NA,Phase 2,575,Actual,King Fahad Specialist Hospital Dammam,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T10:00:47Z,2021-11-17T10:00:47Z,78
NCT05126628,NA,2021-11-07,NA,NA,2021-11-17,2021-11-17,2021-11-19,Estimate,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-19,Estimate,"March 6, 2021",Actual,2021-03-06,November 2021,2021-11-30,"April 15, 2021",Actual,2021-04-15,"March 16, 2021",Actual,2021-03-16,NA,Interventional,NA,NA,The South Proxa-Rescue AndroCoV Trial Against COVID-19,Proxalutamide Treatment for Hospitalized COVID-19 Patients in Southern Brazil - The South Proxa-Rescue AndroCoV Trial,Completed,NA,Phase 3,133,Actual,Corpometria Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:22:03Z,2021-11-19T20:22:03Z,75
NCT04640168,NA,2020-11-19,NA,NA,2021-11-16,2020-11-19,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-17,Estimate,"November 24, 2020",Actual,2020-11-24,"April 15, 2021",2021-04-15,"June 18, 2021",Actual,2021-06-18,"May 18, 2021",Actual,2021-05-18,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial 4 (ACTT-4),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-4)",Completed,NA,Phase 3,4074,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:29:44Z,2021-11-18T11:29:44Z,76
NCT05126602,NA,2021-11-12,NA,NA,2021-11-17,2021-11-17,2021-11-19,Estimate,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-19,Estimate,"April 1, 2021",Actual,2021-04-01,November 2021,2021-11-30,"November 1, 2021",Actual,2021-11-01,"September 30, 2021",Actual,2021-09-30,NA,Interventional,NA,NA,Vitamin D Supplementation and Clinical Improvement in COVID-19,"Vitamin D Supplementation and Changes of Hematology Parameter, Coagulation Profile, and Clinical Improvement Among COVID-19 Patients",Completed,NA,Not Applicable,60,Actual,Hasanuddin University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No data sharing will be done,2021-11-19T20:22:04Z,2021-11-19T20:22:04Z,75
NCT04584567,NA,2020-10-06,NA,NA,2021-11-18,2020-10-06,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-19,Estimate,"November 20, 2020",Actual,2020-11-20,November 2021,2021-11-30,"November 1, 2021",Actual,2021-11-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,"OD-doxy-PNV-COVID-19 Old Drug "" DOXY "" for Prevention of New Virus "" COVID-19 """,Covid-19 Infection Prophylaxis With Low Dose of Doxycycline and Zinc in Health Care Workers,Completed,NA,Phase 3,194,Actual,"General Administration of Military Health, Tunisia",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:34:16Z,2021-11-19T20:34:16Z,74
NCT04405934,NA,2020-05-07,NA,NA,2021-11-18,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-19,Estimate,"October 15, 2020",Actual,2020-10-15,November 2021,2021-11-30,"October 8, 2021",Actual,2021-10-08,"April 26, 2021",Actual,2021-04-26,NA,Interventional,COG-UK HOCI,NA,COG-UK Project Hospital-Onset COVID-19 Infections Study,"A Phase III Prospective, Interventional, Cohort, Superiority Study to Evaluate the Benefit of Rapid COVID-19 Genomic Sequencing (the COVID-19 GENOMICS UK Project) on Infection Control in Preventing the Spread of the Virus in United Kingdom NHS Hospitals",Completed,NA,Not Applicable,2170,Actual,"University College, London",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:36:30Z,2021-11-19T20:36:30Z,74
NCT04373733,NA,2020-05-01,NA,NA,2021-11-17,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-18,Actual,"May 1, 2020",Actual,2020-05-01,November 2021,2021-11-30,"June 25, 2021",Actual,2021-06-25,"June 25, 2021",Actual,2021-06-25,NA,Interventional,PIONEER,NA,Early Intervention in COVID-19: Favipiravir Verses Standard Care,A Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19: Favipiravir and StaNdard Care vErsEs Standard CaRe,Completed,NA,Phase 3,502,Actual,Chelsea and Westminster NHS Foundation Trust,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Research team wishes to enable any meta-analyses of COVID-19 trials making appropriate requests. No plan to share IPD has been made at this time.,2021-11-19T20:36:57Z,2021-11-19T20:36:57Z,75
NCT04539795,NA,2020-09-03,NA,NA,2021-11-16,2020-09-03,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-18,Actual,"January 25, 2021",Actual,2021-01-25,November 2021,2021-11-30,"October 29, 2021",Actual,2021-10-29,"October 29, 2021",Actual,2021-10-29,NA,Interventional,COSTA,NA,COVID-19 Study of Safety and Tolerability of Alvelestat,"A Phase Ib/II, Single Center, Placebo-Controlled, Randomized, Blinded Study in Adult Patients (> 18 Years) With COVID-19 Respiratory Disease, to Evaluate, Safety, Tolerability and Mechanistic Effect of Alvelestat on Top of Standard of Care (COSTA)",Completed,NA,Phase 1/Phase 2,15,Actual,University of Alabama at Birmingham,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:35:00Z,2021-11-19T20:35:00Z,76
NCT04397562,NA,2020-05-19,NA,NA,2021-11-15,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-18,Actual,"April 29, 2020",Actual,2020-04-29,November 2020,2020-11-30,"August 3, 2020",Actual,2020-08-03,"July 3, 2020",Actual,2020-07-03,NA,Interventional,CORONA,NA,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19",Completed,NA,Phase 3,206,Actual,Biocad,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-19T20:36:38Z,2021-11-19T20:36:38Z,77
NCT04458363,NA,2020-06-25,NA,NA,2021-11-13,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-11-13,2021-11-22,Estimate,"July 4, 2020",Actual,2020-07-04,November 2021,2021-11-30,"September 1, 2020",Actual,2020-09-01,"September 1, 2020",Actual,2020-09-01,NA,Interventional,NA,NA,Convalescent Plasma in Pediatric COVID-19,Convalescent Plasma to Optimize Treatment of COVID-19 Disease in Pediatric Patients: A Feasibility Study,Completed,NA,Early Phase 1,3,Actual,Emory University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:44:40Z,2021-11-23T11:44:40Z,79
NCT04442087,NA,2020-06-08,NA,NA,2021-11-19,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-22,Estimate,"June 19, 2020",Actual,2020-06-19,November 2021,2021-11-30,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,FamilyPEDCOVID,NA,Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP,Seroprevalence of Anti-SARS-CoV2 Among Children According to Parents' SARS-CoV2 Serological Status. Study in a Hospital Population Assistance Publique-HÃ´pitaux Paris,Completed,NA,Not Applicable,563,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:44:47Z,2021-11-23T11:44:47Z,73
NCT05130541,NA,2021-05-04,NA,NA,2021-11-21,2021-11-21,2021-11-23,Estimate,NA,NA,NA,NA,NA,NA,2021-11-21,2021-11-23,Estimate,"June 1, 2020",Actual,2020-06-01,November 2021,2021-11-30,"May 1, 2021",Actual,2021-05-01,"March 1, 2021",Actual,2021-03-01,NA,Interventional,PREACHR,NA,Proning Early in Awake COVID-19 Hypoxic Respiratory Failure (PREACHR) Study,Proning Early in Awake COVID-19 Hypoxic Respiratory Failure (PREACHR) Study,Completed,NA,Not Applicable,219,Actual,New York Hospital Queens,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Will consider compelling cases if appropriately deidentified and, of course, if reviewers or journal editors request",2021-11-24T09:54:06Z,2021-11-24T09:54:06Z,71
NCT05043376,NA,2021-09-11,NA,NA,2021-11-21,2021-09-11,2021-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-21,2021-11-23,Estimate,"September 10, 2021",Actual,2021-09-10,November 2021,2021-11-30,"November 21, 2021",Actual,2021-11-21,"November 21, 2021",Actual,2021-11-21,NA,Interventional,NA,NA,Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Mild-to-moderate COVID-19,"A Randomized, Open-label, and Controlled Clinical Trial to Study the Adjuvant Treatment Benefits of Probiotic Streptococcus Salivarius K12 to Prevent/Reduce Lung Inflammation in Mild-to-moderate Hospitalised Patients With COVID-19",Completed,NA,Not Applicable,50,Actual,King Edward Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-24T09:56:19Z,2021-11-24T09:56:19Z,71
NCT04590586,NA,2020-10-14,NA,NA,2021-11-19,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-23,Estimate,"November 24, 2020",Actual,2020-11-24,November 2021,2021-11-30,"August 3, 2021",Actual,2021-08-03,"August 3, 2021",Actual,2021-08-03,NA,Interventional,NA,NA,Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Completed,NA,Phase 3,516,Actual,Amgen,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.,"Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.",http://www.amgen.com/datasharing,Yes,De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.,2021-11-24T10:00:30Z,2021-11-24T10:00:30Z,73
NCT04377100,NA,2020-05-05,NA,NA,2021-11-20,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-11-20,2021-11-23,Estimate,"May 8, 2020",Actual,2020-05-08,"November 19, 2021",2021-11-19,"November 19, 2021",Actual,2021-11-19,"April 9, 2021",Actual,2021-04-09,NA,Interventional,NA,NA,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses.,Completed,NA,Not Applicable,2962,Actual,National Institutes of Health Clinical Center (CC),NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-24T10:02:15Z,2021-11-24T10:02:15Z,72
NCT04353128,NA,2020-04-16,NA,NA,2021-11-22,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,"December 1, 2020",Actual,2020-12-01,"October 1, 2020",Actual,2020-10-01,NA,Interventional,MeCOVID,NA,Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.,Completed,NA,Phase 2/Phase 3,450,Actual,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-24T10:02:22Z,2021-11-24T10:02:22Z,70
NCT04818320,NA,2021-03-24,NA,NA,2021-11-15,2021-03-24,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-24,Estimate,"February 16, 2021",Actual,2021-02-16,November 2021,2021-11-30,"July 13, 2021",Actual,2021-07-13,"July 1, 2021",Actual,2021-07-01,NA,Interventional,NA,NA,Favipiravir in High-risk COVID-19 Patients,"Efficacy of Favipiravir in High Risk COVID-19 Patients: A Randomised, Open-label, Multicenter Clinical Trial",Completed,NA,Phase 3,500,Actual,"Penang Hospital, Malaysia",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:13:15Z,2021-11-25T10:13:15Z,77
NCT04589117,NA,2020-10-12,NA,NA,2021-11-16,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-24,Estimate,"May 27, 2020",Actual,2020-05-27,November 2021,2021-11-30,"August 2, 2020",Actual,2020-08-02,"August 2, 2020",Actual,2020-08-02,NA,Interventional,NA,NA,Expressive Writing for COVID-19 Resilience for Parents,Expressive Writing for COVID-19 Resilience for Parents,Completed,NA,Not Applicable,11,Actual,Duke University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:14:51Z,2021-11-25T10:14:51Z,76
NCT04509947,NA,2020-08-11,NA,NA,2021-11-23,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"August 11, 2020",Actual,2020-08-11,November 2021,2021-11-30,"November 16, 2021",Actual,2021-11-16,"February 22, 2021",Actual,2021-02-22,NA,Interventional,NA,NA,A Study of Ad26.COV2.S in Adults (COVID-19),"A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Adults",Completed,NA,Phase 1,250,Actual,Janssen Pharmaceutical K.K.,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-11-25T10:15:21Z,2021-11-25T10:15:21Z,69
NCT04644705,NA,2020-11-02,NA,NA,2021-11-26,2020-11-19,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-26,2021-11-29,Estimate,"November 2, 2020",Actual,2020-11-02,November 2021,2021-11-30,"May 3, 2021",Actual,2021-05-03,"May 3, 2021",Actual,2021-05-03,NA,Interventional,NIC-002,NA,Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat,A 3-part Study to Investigate the Safety and Pharmacokinetics of a Novel Niclosamide Solution as a Treatment Option for COVID-19 in Combination With Camostat,Completed,NA,Phase 1,28,Actual,CharitÃ© Research Organisation GmbH,NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-30T11:27:16Z,2021-11-30T11:27:16Z,66
NCT04387955,NA,2020-04-29,NA,NA,2021-11-26,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-26,2021-11-29,Estimate,"April 30, 2020",Actual,2020-04-30,November 2021,2021-11-30,"July 30, 2021",Actual,2021-07-30,"July 30, 2021",Actual,2021-07-30,NA,Interventional,ACROVID,NA,Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID),Analysis of Chilblains Profile During COVID-19 Epidemic,Completed,NA,Not Applicable,11,Actual,Poitiers University Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:30:07Z,2021-11-30T11:30:07Z,66
NCT04803812,NA,2021-02-08,NA,NA,2021-11-29,2021-03-16,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-29,2021-11-30,Estimate,"January 26, 2021",Actual,2021-01-26,November 2021,2021-11-30,"September 2, 2021",Actual,2021-09-02,"September 2, 2021",Actual,2021-09-02,NA,Interventional,NA,NA,Supporting the Wellness of Ontario Physicians During COVID-19,Supporting the Wellness of Ontario Physicians During COVID-19,Completed,NA,Not Applicable,19124,Actual,Ontario Medical Association,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-01T10:30:08Z,2021-12-01T10:30:08Z,63
NCT04602000,NA,2020-10-18,NA,NA,2021-11-18,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-30,Estimate,"September 25, 2020",Actual,2020-09-25,November 2021,2021-11-30,"October 20, 2021",Actual,2021-10-20,"May 21, 2021",Actual,2021-05-21,NA,Interventional,NA,NA,To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19,"A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination With Standard of Care in Outpatients With Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection",Completed,NA,Phase 2/Phase 3,1642,Actual,Celltrion,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-01T10:32:15Z,2021-12-01T10:32:15Z,74
NCT04568031,NA,2020-08-21,NA,NA,2021-11-29,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-11-29,2021-11-30,Estimate,"August 23, 2020",Actual,2020-08-23,November 2021,2021-11-30,"November 22, 2021",Actual,2021-11-22,"November 22, 2021",Actual,2021-11-22,NA,Interventional,NA,NA,Study of AZD1222 for the Prevention of COVID-19 in Japan,"A Phase I/II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19",Completed,NA,Phase 1/Phase 2,256,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-12-01T10:32:40Z,2021-12-01T10:32:40Z,63
NCT04405076,NA,2020-05-13,NA,NA,2021-11-27,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-11-27,2021-11-30,Estimate,"May 29, 2020",Actual,2020-05-29,November 2021,2021-11-30,"October 26, 2021",Actual,2021-10-26,"October 26, 2021",Actual,2021-10-26,NA,Interventional,NA,NA,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older",Completed,NA,Phase 2,660,Actual,"ModernaTX, Inc.",NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-01T10:33:49Z,2021-12-01T10:33:49Z,65
NCT05054114,NA,2021-09-21,NA,NA,2021-09-23,2021-09-21,2021-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-29,Actual,"December 21, 2020",Actual,2020-12-21,September 2021,2021-09-30,"September 2, 2021",Actual,2021-09-02,"May 25, 2021",Actual,2021-05-25,NA,Interventional,NA,NA,"Study of the Use of Nasal IFN-Î³ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19","Prospective Randomized Open-label Comparative Study of the Use of Intranasal Form of Interferon Gamma Human Recombinant in Patients for the Prevention of Acute Respiratory Viral Infections, Including COVID-19",Completed,NA,Not Applicable,630,Actual,SPP Pharmaclon Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:47:09Z,2021-12-02T01:47:09Z,130
NCT05045989,NA,2021-09-06,NA,NA,2021-09-15,2021-09-09,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-22,Actual,"April 1, 2021",Actual,2021-04-01,September 2021,2021-09-30,"July 31, 2021",Actual,2021-07-31,"July 31, 2021",Actual,2021-07-31,NA,Interventional,RB-TPP,NA,Process Evaluation of a Residence-Based SARS-CoV-2 Testing Participation Pilot,Mixed-methods Process Evaluation of a Residence-Based SARS-CoV-2 Testing Participation Pilot on a UK University Campus During the COVID-19 Pandemic.,Completed,NA,Not Applicable,152,Actual,University of Nottingham,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The datasets generated and/or analysed during the current study are not publicly available due to risk of identification of participants and service providers but are available from the corresponding author on reasonable request.,2021-12-02T01:52:30Z,2021-12-02T01:52:30Z,138
NCT05037240,NA,2021-09-03,NA,NA,2021-09-06,2021-09-06,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"January 12, 2021",Actual,2021-01-12,September 2021,2021-09-30,"May 25, 2021",Actual,2021-05-25,"April 6, 2021",Actual,2021-04-06,NA,Interventional,NA,NA,Quercetin in the Prevention of Covid-19 Infection,"Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of an Oral Nutritional Supplement Based on Quercetin in the Prevention of Covid-19 Infection for a Duration of 3 Months",Completed,NA,Not Applicable,80,Actual,Azienda di Servizi alla Persona di Pavia,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:58:21Z,2021-12-02T01:58:21Z,147
NCT05037448,NA,2021-08-24,NA,NA,2021-08-31,2021-08-31,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-08,Actual,"August 17, 2020",Actual,2020-08-17,March 2021,2021-03-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,NA,Exploring Telehealth to Deliver Me & My Wishes During Coronavirus-19,Me & My Wishes: An Efficacy Trial of Long Term Care Residents With Alzheimer's Using Videos to Communicate Care Preferences With Caregivers,Completed,NA,Not Applicable,17,Actual,University of Utah,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:58:22Z,2021-12-02T01:58:22Z,153
NCT05037253,NA,2021-08-25,NA,NA,2021-09-06,2021-09-06,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"October 30, 2020",Actual,2020-10-30,August 2021,2021-08-31,"May 30, 2021",Actual,2021-05-30,"May 30, 2021",Actual,2021-05-30,NA,Interventional,NA,NA,COVID-19 Morbidity in Healthcare Workers and Vitamin D Supplementation,The Effect of Vitamin D Supplementation in Reducing COVID-19 Morbidity Among Healthcare Workers,Completed,NA,Phase 4,128,Actual,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:58:20Z,2021-12-02T01:58:20Z,147
NCT05035550,NA,2021-08-12,NA,NA,2021-09-02,2021-09-02,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"February 4, 2021",Actual,2021-02-04,September 2021,2021-09-30,"May 5, 2021",Actual,2021-05-05,"May 5, 2021",Actual,2021-05-05,NA,Interventional,NA,NA,Effects of Open-label Placebos on COVID-related Psychological Health,"Effects of Open-label Placebos Administered Through Telehealth on COVID-related Stress, Anxiety, and Depression",Completed,NA,Not Applicable,64,Actual,Michigan State University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,IPD will be available one year after publication,IPD will be available upon request.,NA,Yes,The investigators plan to share the IPD used in the analysis for manuscript submission.,2021-12-02T01:59:28Z,2021-12-02T01:59:28Z,151
NCT04922905,NA,2021-06-09,NA,NA,2021-06-09,2021-06-09,2021-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-11,Actual,"April 2, 2020",Actual,2020-04-02,June 2021,2021-06-30,"April 2, 2021",Actual,2021-04-02,"May 7, 2020",Actual,2020-05-07,NA,Interventional,NS-COV,NA,Nervous System Symptoms Associated With COVID 19,Nervous System Symptoms Associated With COVID 19 : NS-COV,Completed,NA,Not Applicable,99,Actual,"University Hospital, Toulouse",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:21:55Z,2021-12-02T03:21:55Z,236
NCT05021588,NA,2021-08-16,NA,NA,2021-08-23,2021-08-23,2021-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-25,Actual,"April 12, 2020",Actual,2020-04-12,August 2021,2021-08-31,"September 10, 2020",Actual,2020-09-10,"August 2, 2020",Actual,2020-08-02,NA,Interventional,SARS-CoV-2,NA,Steroid and Anticoagulant Therapy in covid19,Challenges in Steroid and Anticoagulant Therapy in Severe COVID-19 Pneumonia: A Prospective Study,Completed,NA,Not Applicable,123,Actual,Assiut University,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:08:59Z,2021-12-02T02:08:59Z,161
NCT05021016,NA,2021-08-19,NA,NA,2021-08-26,2021-08-19,2021-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-27,Actual,"November 19, 2020",Actual,2020-11-19,August 2021,2021-08-31,"January 30, 2021",Actual,2021-01-30,"January 30, 2021",Actual,2021-01-30,NA,Interventional,NA,NA,Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above,"An Open Study of the Safety, Reactogenicity and Immunogenicity of the Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), With the Involvement of Volunteers Aged 60 Years and Above (Phase III-IV)",Completed,NA,Phase 3,150,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:09:19Z,2021-12-02T02:09:19Z,158
NCT05019287,NA,2021-07-03,NA,NA,2021-08-28,2021-08-22,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-28,2021-09-02,Actual,"April 17, 2021",Actual,2021-04-17,August 2021,2021-08-31,"June 9, 2021",Actual,2021-06-09,"May 21, 2021",Actual,2021-05-21,NA,Interventional,NA,NA,Menstrual Blood Stem Cells in Severe Covid-19,"Safety and Efficacy Study of Allogeneic Human Menstrual Blood Stem Cells Secretome to Treat Severe Covid-19 Patients, Clinical Trial Phase I&II",Completed,NA,Phase 1/Phase 2,29,Actual,Avicenna Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:10:40Z,2021-12-02T02:10:40Z,156
NCT05018065,NA,2021-08-23,NA,NA,2021-08-24,2021-08-23,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-27,Actual,"May 1, 2020",Actual,2020-05-01,January 2021,2021-01-31,"December 30, 2020",Actual,2020-12-30,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,NA,Sexual Functions and Covid-19,Evaluation of Women's Sexual Functions After Having Covid-19,Completed,NA,Not Applicable,101,Actual,Gaziosmanpasa Research and Education Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:11:30Z,2021-12-02T02:11:30Z,160
NCT05010876,NA,2021-08-16,NA,NA,2021-08-17,2021-08-17,2021-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"February 4, 2021",Actual,2021-02-04,August 2021,2021-08-31,"June 21, 2021",Actual,2021-06-21,"June 13, 2021",Actual,2021-06-13,NA,Interventional,AntagoBrad-Cov,NA,Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).,Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).,Completed,NA,Phase 2,44,Actual,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:16:39Z,2021-12-02T02:16:39Z,167
NCT05007600,NA,2021-08-05,NA,NA,2021-08-12,2021-08-12,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-16,Actual,"February 1, 2021",Actual,2021-02-01,August 2021,2021-08-31,"July 30, 2021",Actual,2021-07-30,"July 1, 2021",Actual,2021-07-01,NA,Interventional,NA,NA,Online Interactive Courses on Loneliness and Quality of Life of Older Adults,Investigating the Effectiveness of Online Interactive Courses on Loneliness and Quality of Life of Older Adults in the Community During COVID-19 Pandemic: A Pilot Study and a Randomized Controlled Trial,Completed,NA,Not Applicable,89,Actual,National Cheng Kung University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:18:47Z,2021-12-02T02:18:47Z,172
NCT05007496,NA,2021-08-11,NA,NA,2021-08-16,2021-08-12,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-20,Actual,"April 14, 2021",Actual,2021-04-14,August 2021,2021-08-31,"May 31, 2021",Actual,2021-05-31,"May 31, 2021",Actual,2021-05-31,NA,Interventional,NA,NA,"Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19","Phase II Randomized Double Blind Clinical Trial Three Preventive Vaccine Formulations Consisting of Autologous Dendritic Cells and Lymphocytes Incubated With Different Quantities of Spike Protein Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Not Proven Actively Infected or Never Infected With COVID-19",Completed,NA,Phase 2,145,Actual,"Aivita Biomedical, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:18:52Z,2021-12-02T02:18:52Z,168
NCT05004753,NA,2021-07-26,NA,NA,2021-09-01,2021-08-11,2021-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-09,Actual,"September 30, 2020",Actual,2020-09-30,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects,"A Prospective, Randomized, Multi-center, Open Label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg Capsule in Treatment of Adult Subjects With COVID-19",Completed,NA,Phase 4,120,Actual,Mateon Therapeutics,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:20:41Z,2021-12-02T02:20:41Z,152
NCT05001542,NA,2021-07-28,NA,NA,2021-10-05,2021-08-05,2021-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-07,Actual,"May 31, 2021",Actual,2021-05-31,October 2021,2021-10-31,"August 30, 2021",Actual,2021-08-30,"August 30, 2021",Actual,2021-08-30,NA,Interventional,VR,NA,Digital Interventions for Detection and Reduction of Moral Distress,"Could Digital Interventions Help Understand And ""Flatten The Curve"" Of Distress Due To Moral Injury Among Health Care Workers During The COVID Pandemic?",Completed,NA,Not Applicable,15,Actual,Unity Health Toronto,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:22:43Z,2021-12-02T02:22:43Z,118
NCT04998253,NA,2021-05-19,NA,NA,2021-08-09,2021-08-07,2021-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-13,Actual,"October 1, 2020",Actual,2020-10-01,August 2021,2021-08-31,"May 15, 2021",Actual,2021-05-15,"November 30, 2020",Actual,2020-11-30,NA,Interventional,COVID-19,NA,Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2,A Randomized Pilot Clinical Trial of the Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction of Sevoflurane in Patient's Whit ARDS Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2),Completed,NA,Early Phase 1,24,Actual,Unidad Temporal COVID-19 en Centro Citibanamex,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:25:22Z,2021-12-02T02:25:22Z,175
NCT04998708,NA,2021-08-08,NA,NA,2021-08-08,2021-08-08,2021-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-08,2021-08-10,Actual,"December 1, 2020",Actual,2020-12-01,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,Relaxation Exercise in Patients With COVID-19,An Integrated Relaxation Protocol Improves Immune Biomarkers and Reduces COVID-19 Severity and Progression in Patients With COVID-19,Completed,NA,Not Applicable,30,Actual,Beni-Suef University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:24:55Z,2021-12-02T02:24:55Z,176
NCT04993547,NA,2021-08-04,NA,NA,2021-08-05,2021-08-05,2021-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-06,Actual,"March 31, 2021",Actual,2021-03-31,March 2021,2021-03-31,"June 10, 2021",Actual,2021-06-10,"June 9, 2021",Actual,2021-06-09,NA,Interventional,NA,NA,Cluster-RCT Collective Nasopharyngeal COVID-19 Testing Amongst Pupils,Peers' and Parent's Presence During Collective Nasopharyngeal COVID-19 Testing Amongst Pupils: A Cluster-Randomized Controlled Trial,Completed,NA,Not Applicable,952,Actual,"University Hospital, Ghent",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:28:47Z,2021-12-02T02:28:47Z,179
NCT04992000,NA,2021-07-29,NA,NA,2021-08-05,2021-07-29,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-12,Actual,"June 1, 2020",Actual,2020-06-01,August 2021,2021-08-31,"December 1, 2020",Actual,2020-12-01,"September 1, 2020",Actual,2020-09-01,NA,Interventional,NA,NA,Self-Care of Hypertension Among Older Adults During COVID-19,Self-Care of Hypertension of Older Adults During COVID-19 Lockdown Period: A Randomized Controlled Trial,Completed,NA,Not Applicable,120,Actual,"Near East University, Turkey",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:30:18Z,2021-12-02T02:30:18Z,179
NCT04990830,NA,2021-07-29,NA,NA,2021-08-03,2021-08-03,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-05,Actual,"February 3, 2021",Actual,2021-02-03,August 2021,2021-08-31,"May 21, 2021",Actual,2021-05-21,"April 21, 2021",Actual,2021-04-21,NA,Interventional,NA,NA,Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia,Early Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia: A Phase IIb Trial,Completed,NA,Phase 2/Phase 3,80,Actual,Istanbul University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data sharing will be decided on a later date depending on completion of further study Phases,2021-12-02T02:31:00Z,2021-12-02T02:31:00Z,181
NCT04981379,NA,2021-07-26,NA,NA,2021-07-26,2021-07-26,2021-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-29,Actual,"November 16, 2020",Actual,2020-11-16,June 2021,2021-06-30,"February 16, 2021",Actual,2021-02-16,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NA,NA,Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment,"Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment",Completed,NA,Phase 3,1120,Actual,Health Institutes of Turkey,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:37:50Z,2021-12-02T02:37:50Z,189
NCT04980508,NA,2021-07-26,NA,NA,2021-07-26,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-28,Actual,"February 20, 2021",Actual,2021-02-20,July 2021,2021-07-31,"May 30, 2021",Actual,2021-05-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,Effects of COVID-19 on Cavernous Smooth Muscle,COVID-19 Can Cause Cavernous Smooth Muscle Damage: Investigation of the Effects of COVID-19 on Cavernous Smooth Muscle by Corpus Cavernosum Electromyography,Completed,NA,Not Applicable,29,Actual,Ankara Yildirim BeyazÄ±t University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:38:17Z,2021-12-02T02:38:17Z,189
NCT04977921,NA,2021-07-17,NA,NA,2021-07-22,2021-07-22,2021-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-27,Actual,"January 17, 2021",Actual,2021-01-17,July 2021,2021-07-31,"May 30, 2021",Actual,2021-05-30,"May 15, 2021",Actual,2021-05-15,NA,Interventional,EDU,NA,Lab Skills Nursing Education Into Effective Clinical Practice During COVID-19: Elsevier Clinical Skill Platform,An Authentic Solution to Translate Lab Skills Nursing Education Into Effective Clinical Practice During COVID-19: Elsevier Clinical Skill Platform,Completed,NA,Not Applicable,50,Actual,Beni-Suef University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,data analysis completed July writing paper on August publish paper on September,2021-12-02T02:40:24Z,2021-12-02T02:40:24Z,193
NCT04973488,NA,2021-07-20,NA,NA,2021-07-20,2021-07-20,2021-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-22,Actual,"July 25, 2020",Actual,2020-07-25,July 2021,2021-07-31,"January 10, 2021",Actual,2021-01-10,"January 10, 2021",Actual,2021-01-10,NA,Interventional,NA,NA,Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients,Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients,Completed,NA,Phase 2/Phase 3,38,Actual,"University of Medicine and Pharmacy ""Victor Babes"" Timisoara",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will become available at 6 months after registering the study. It will be available for 36 months,"Data will be shared with interested researchers, contact: novacescu_alex@yahoo.com",NA,Yes,"We plan on sharing treatment protocol, demographic data of the study cohort, primary outcomes, secondary outcomes, miscellaneous data, treatment scheme, statystical data",2021-12-02T02:43:29Z,2021-12-02T02:43:29Z,195
NCT04972864,NA,2021-07-15,NA,NA,2021-07-21,2021-07-21,2021-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"March 1, 2021",Actual,2021-03-01,July 2021,2021-07-31,"July 18, 2021",Actual,2021-07-18,"July 18, 2021",Actual,2021-07-18,NA,Interventional,NA,NA,Effects of Respiratory Muscle Training in Patients With Post COVID-19,Effects of Respiratory Muscle Training in Patients With Post COVID-19,Completed,NA,Not Applicable,24,Actual,Gazi University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:44:05Z,2021-12-02T02:44:05Z,194
NCT04962906,NA,2021-07-08,NA,NA,2021-08-18,2021-07-13,2021-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-20,Actual,"July 5, 2021",Actual,2021-07-05,July 2021,2021-07-31,"August 15, 2021",Actual,2021-08-15,"August 5, 2021",Actual,2021-08-05,NA,Interventional,NA,NA,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes,"Randomised Phase II Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes (rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV).",Completed,NA,Phase 2,192,Actual,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:51:35Z,2021-12-02T02:51:35Z,166
NCT04957017,NA,2021-07-04,NA,NA,2021-07-07,2021-07-07,2021-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-09,Actual,"August 15, 2020",Actual,2020-08-15,July 2021,2021-07-31,"June 10, 2021",Actual,2021-06-10,"January 25, 2021",Actual,2021-01-25,NA,Interventional,NA,NA,Effect of Hand-Washing Training in Covid-19,"Effect of Training on Given to Women With Chronic Disease on Hand-Washing Behaviours, Attitudes and Nutrition During the Covid-19 Pandemic",Completed,NA,Not Applicable,90,Actual,Mehmet Akif Ersoy University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,There is not plan.,2021-12-02T02:55:53Z,2021-12-02T02:55:53Z,208
NCT04958863,NA,2021-06-30,NA,NA,2021-07-09,2021-07-09,2021-07-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"January 1, 2021",Actual,2021-01-01,July 2021,2021-07-31,"June 30, 2021",Actual,2021-06-30,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,NA,Impact of Facemasks on Running During COVID-19 Pandemic,Running and Facemasks During COVID-19 Pandemic: a Randomized Crossover Trial,Completed,NA,Not Applicable,18,Actual,Fundacion Clinica Valle del Lili,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:54:44Z,2021-12-02T02:54:44Z,206
NCT04957940,NA,2021-07-06,NA,NA,2021-09-26,2021-07-07,2021-07-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-26,2021-09-28,Actual,"July 5, 2021",Actual,2021-07-05,September 2021,2021-09-30,"September 26, 2021",Actual,2021-09-26,"September 20, 2021",Actual,2021-09-20,NA,Interventional,NA,NA,Lipid Emulsion Infusion and COVID-19 Patients,Fish-Oil-Based Lipid Emulsion Infusion (FOBLE): Could Early Use Provide a Potential Therapy to Stop Moderate Cases of COVID-19 Diseased Patient's Shift to ICU?,Completed,NA,Phase 3,74,Actual,Assiut University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:55:12Z,2021-12-02T02:55:12Z,127
NCT04954118,NA,2021-07-04,NA,NA,2021-07-07,2021-07-07,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"March 20, 2020",Actual,2020-03-20,July 2021,2021-07-31,"September 30, 2020",Actual,2020-09-30,"March 20, 2020",Actual,2020-03-20,NA,Interventional,NA,NA,A Different Use of The Aerosol Box in COVID-19 Patients; Internal Jugular Vein Cannulation,Use of Aerosol Box for Ultrasound-guided Internal Jugular Vein Cannulation in COVID-19 Patients; Single Center Experience,Completed,NA,Not Applicable,40,Actual,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:57:49Z,2021-12-02T02:57:49Z,208
NCT04953234,NA,2021-07-04,NA,NA,2021-07-04,2021-07-04,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-04,2021-07-07,Actual,"February 23, 2021",Actual,2021-02-23,July 2021,2021-07-31,"April 26, 2021",Actual,2021-04-26,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,NA,"Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge","A Pilot, Open-Label Study of NovoTTF-100L (TTFields, 150Hz) in Hospitalized Patients With COVID-19 and Continued Treatment After Hospitalization",Completed,NA,Not Applicable,10,Actual,NovoCure Ltd.,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:58:53Z,2021-12-02T02:58:53Z,211
NCT04951349,NA,2021-06-30,NA,NA,2021-07-01,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-06,Actual,"January 21, 2021",Actual,2021-01-21,July 2021,2021-07-31,"May 30, 2021",Actual,2021-05-30,"May 30, 2021",Actual,2021-05-30,NA,Interventional,NA,NA,Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.,"Phase 2b Clinical Trial to Evaluate the Tolerability and Efficacy in Reducing the Nasal Viral Load of SARS-CoV-2 of Benzalkonium Chloride 0.0065% (GX-03), in the Form of Nasal Ointment, in Patients Infected With COVID -19, and Evaluation of Its Tolerability in Health Care Providers, as a Preventive of Nasal Colonization, Complementary to Personal Protective Equipment",Completed,NA,Phase 2,85,Actual,Turn Therapeutics,NA,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,Within 30 days of announcement of study completion.,By official request for qualified use.,NA,Yes,NA,2021-12-02T03:00:04Z,2021-12-02T03:00:04Z,214
NCT04945811,NA,2021-06-29,NA,NA,2021-06-29,2021-06-29,2021-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-06-30,Actual,"April 1, 2020",Actual,2020-04-01,June 2021,2021-06-30,"May 30, 2021",Actual,2021-05-30,"May 15, 2021",Actual,2021-05-15,NA,Interventional,NA,NA,Role of Interleukin-6 and Procalcitonin as Novel Inflammatory Biomarkers in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta,Role of Interleukin-6 and Procalcitonin in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta,Completed,NA,Not Applicable,100,Actual,"Combined Military Hospital, Pakistan",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:04:03Z,2021-12-02T03:04:03Z,216
NCT04942990,NA,2021-06-21,NA,NA,2021-06-29,2021-06-21,2021-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-07-01,Actual,"April 1, 2021",Actual,2021-04-01,June 2021,2021-06-30,"June 21, 2021",Actual,2021-06-21,"June 21, 2021",Actual,2021-06-21,NA,Interventional,NA,NA,The Effectiveness of Calistenic Exercise Training in Adolescents,The Effectiveness of Calistenic Exercise Training in Adolescents Receiving Online Education During COVID-19 Pandemic,Completed,NA,Not Applicable,38,Actual,Baskent University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:06:23Z,2021-12-02T03:06:23Z,216
NCT04942392,NA,2021-06-23,NA,NA,2021-06-24,2021-06-24,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-28,Actual,"September 4, 2020",Actual,2020-09-04,June 2021,2021-06-30,"December 3, 2020",Actual,2020-12-03,"December 3, 2020",Actual,2020-12-03,NA,Interventional,NA,NA,Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic,Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic: A Feasibility Study,Completed,NA,Not Applicable,33,Actual,UmeÃ¥ University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:06:56Z,2021-12-02T03:06:56Z,221
NCT04935502,NA,2021-06-14,NA,NA,2021-09-17,2021-06-21,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-23,Actual,"March 15, 2021",Actual,2021-03-15,September 2021,2021-09-30,"August 30, 2021",Actual,2021-08-30,"August 30, 2021",Actual,2021-08-30,NA,Interventional,NA,NA,Home Based Exercises With and Without Posture and Ergonomics Training Among Students During COVID-19,Effects of Home Based Exercises With and Without Posture and Ergonomics Training on Pain and Physical Activity Level Among Students With Musculoskeletal Pain Due to COVID-19 Pandemic: A Randomised Controlled Trial,Completed,NA,Not Applicable,216,Actual,Riphah International University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:11:56Z,2021-12-02T03:11:56Z,136
NCT04936503,NA,2021-06-02,NA,NA,2021-06-22,2021-06-22,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-23,Actual,"June 18, 2020",Actual,2020-06-18,June 2021,2021-06-30,"March 2, 2021",Actual,2021-03-02,"March 2, 2021",Actual,2021-03-02,NA,Interventional,ASCCOVID19,NA,Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19,Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19,Completed,NA,Not Applicable,984,Actual,"University Hospital, Bordeaux",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:10:59Z,2021-12-02T03:10:59Z,223
NCT04935515,NA,2021-06-20,NA,NA,2021-06-22,2021-06-22,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-23,Actual,"April 15, 2021",Actual,2021-04-15,June 2021,2021-06-30,"June 6, 2021",Actual,2021-06-06,"May 9, 2021",Actual,2021-05-09,NA,Interventional,NA,NA,C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.,C Reactive Protein Based Early Intervention for Home Quarantined COVID -19 Patients to Avoid Complications and Hospitalization.,Completed,NA,Not Applicable,25,Actual,UR Anoop Research Group,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:11:50Z,2021-12-02T03:11:50Z,223
NCT04933864,NA,2021-06-15,NA,NA,2021-06-21,2021-06-21,2021-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"April 24, 2020",Actual,2020-04-24,June 2021,2021-06-30,"July 30, 2020",Actual,2020-07-30,"May 20, 2020",Actual,2020-05-20,NA,Interventional,NA,NA,COVID-19 Treatment Using Methylene Blue and Photodynamic Therapy,The Clinical Trial of Methylene Blue Application Combined With Photodynamic Therapy for Treatment of SARS-CoV-2 Infected Patients,Completed,NA,Phase 1,60,Actual,I.M. Sechenov First Moscow State Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The Local Ethics Committee of I.M. Sechenov First Moscow State Medical University did not give permission to provide individual participant data.,2021-12-02T03:13:27Z,2021-12-02T03:13:27Z,224
NCT04932369,NA,2021-06-12,NA,NA,2021-08-29,2021-06-12,2021-06-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-29,2021-09-02,Actual,"March 1, 2020",Actual,2020-03-01,August 2021,2021-08-31,"March 1, 2021",Actual,2021-03-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,"The Effect of Emotion Regulation Training on Anxiety, in College Students in Egypt","The Effect of Emotion Regulation Training on Anxiety, in College Students in Egypt During COVID-19 Lockdown",Completed,NA,Not Applicable,200,Actual,British University In Egypt,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:14:26Z,2021-12-02T03:14:26Z,155
NCT04926428,NA,2021-06-13,NA,NA,2021-06-16,2021-06-13,2021-06-15,Actual,NA,NA,NA,NA,NA,NA,2021-06-16,2021-06-21,Actual,"December 25, 2020",Actual,2020-12-25,June 2021,2021-06-30,"March 30, 2021",Actual,2021-03-30,"March 30, 2021",Actual,2021-03-30,NA,Interventional,NA,NA,In Situ Thrombolysis With tPA and Inflow Perfusion Analysis in Patient With Severe Covid-19 Infection,In Situ Thrombolysis With tPA and Inflow Lung Perfusion Analysis in Patient With Severe Covid-19 Infection,Completed,NA,Not Applicable,15,Actual,Grupo Mexicano para el Estudio de la Medicina Intensiva,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,3 months up to 5 years after completion,"proposal should be directed to gmemiinv@gmails.com, to gain access, requestor will need to sign a data access agreement",NA,Yes,IPD will be shared by petition.,2021-12-02T03:18:49Z,2021-12-02T03:18:49Z,229
NCT04920773,NA,2021-06-06,NA,NA,2021-06-09,2021-06-09,2021-06-10,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-10,Actual,"May 3, 2021",Actual,2021-05-03,June 2021,2021-06-30,"June 6, 2021",Actual,2021-06-06,"May 21, 2021",Actual,2021-05-21,NA,Interventional,NA,NA,Community-based Post-exposure Prophylaxis for COVID-19,Community-based Post-exposure Prophylaxis for COVID-19: Results and Implications of Ayurveda Practice Guidelines,Completed,NA,Not Applicable,216,Actual,NMP Medical Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:24:46Z,2021-12-02T03:24:46Z,236
NCT04916574,NA,2021-06-03,NA,NA,2021-06-07,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-09,Actual,"March 20, 2021",Actual,2021-03-20,June 2021,2021-06-30,"June 3, 2021",Actual,2021-06-03,"March 28, 2021",Actual,2021-03-28,NA,Interventional,NA,NA,Clinical Trial of BioBlock COVID-19 Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum,Clinical Trial of Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum,Completed,NA,Not Applicable,16,Actual,Icosagen Cell Factory,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T03:35:03Z,2021-12-02T03:35:03Z,238
NCT04915820,NA,2021-05-28,NA,NA,2021-09-10,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-14,Actual,"May 29, 2021",Actual,2021-05-29,September 2021,2021-09-30,"September 9, 2021",Actual,2021-09-09,"September 9, 2021",Actual,2021-09-09,NA,Interventional,NA,NA,Iron and COVID-19 Vaccine Response,Iron and Vaccine-preventable Viral Disease,Completed,NA,Not Applicable,121,Actual,Jomo Kenyatta University of Agriculture and Technology,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:35:56Z,2021-12-02T03:35:56Z,143
NCT04910932,NA,2021-06-01,NA,NA,2021-09-21,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"June 10, 2021",Actual,2021-06-10,September 2021,2021-09-30,"September 14, 2021",Actual,2021-09-14,"September 14, 2021",Actual,2021-09-14,NA,Interventional,NA,NA,"Effects of Breathing Exercises on Fear of COVID-19, Anxiety, Sleep and Quality of Life During the COVID-19 Pandemic","Effects of Breathing Exercises on Fear of COVID-19, Anxiety, Sleep and Quality of Life During the COVID-19 Pandemic",Completed,NA,Not Applicable,50,Actual,Izmir Bakircay University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:42:08Z,2021-12-02T03:42:08Z,132
NCT04909918,NA,2021-05-30,NA,NA,2021-09-04,2021-05-30,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-04,2021-09-08,Actual,"May 28, 2021",Actual,2021-05-28,September 2021,2021-09-30,"August 20, 2021",Actual,2021-08-20,"August 15, 2021",Actual,2021-08-15,NA,Interventional,NA,NA,Impact of Steroids on Inflammatory Response in Covid-19,The Impact of Dexamethasone Versus Methylprednisolone Upon Neutrophil/Lymphocyte Ratio (NLR) in COVID-19 Diseased Patients Admitted in ICU,Completed,NA,Phase 3,60,Actual,Assiut University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T03:43:23Z,2021-12-02T03:43:23Z,149
NCT04904510,NA,2021-05-19,NA,NA,2021-05-25,2021-05-25,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-27,Actual,"November 20, 2020",Actual,2020-11-20,May 2021,2021-05-31,"March 9, 2021",Actual,2021-03-09,"March 9, 2021",Actual,2021-03-09,NA,Interventional,NA,NA,Evaluation of the INDICAIDâ„¢ COVID-19 Rapid Antigen Test,Evaluation of the INDICAIDâ„¢ COVID-19 Rapid Antigen Test in Symptomatic Populations and Asymptomatic Community Testing,Completed,NA,Not Applicable,22994,Actual,"University of California, Los Angeles",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:49:53Z,2021-12-02T03:49:53Z,251
NCT04900129,NA,2021-05-18,NA,NA,2021-05-23,2021-05-23,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-23,2021-05-25,Actual,"December 1, 2020",Actual,2020-12-01,May 2021,2021-05-31,"December 30, 2020",Actual,2020-12-30,"December 30, 2020",Actual,2020-12-30,NA,Interventional,NA,NA,"Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study","Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study",Completed,NA,Phase 1,43,Actual,Sher-E-Bangla Medical College,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:55:30Z,2021-12-02T03:55:30Z,253
NCT04898088,NA,2021-05-21,NA,NA,2021-05-21,2021-05-21,2021-05-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-24,Actual,"January 1, 2020",Actual,2020-01-01,May 2021,2021-05-31,"September 30, 2020",Actual,2020-09-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,REPAIR,NA,A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients,A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients,Completed,NA,Not Applicable,30,Actual,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T03:57:15Z,2021-12-02T03:57:15Z,255
NCT04894409,NA,2021-05-16,NA,NA,2021-05-18,2021-05-18,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-20,Actual,"April 24, 2020",Actual,2020-04-24,May 2021,2021-05-31,"September 29, 2020",Actual,2020-09-29,"June 30, 2020",Actual,2020-06-30,NA,Interventional,COVID-19,NA,Evaluation of Silver Nanoparticles for the Prevention of COVID-19,"Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2",Completed,NA,Not Applicable,231,Actual,"Cluster de Bioeconomia de Baja California, A.C",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:00:40Z,2021-12-02T04:00:40Z,258
NCT04883203,NA,2021-04-20,NA,NA,2021-05-10,2021-05-10,2021-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,"April 22, 2020",Actual,2020-04-22,May 2021,2021-05-31,"October 31, 2020",Actual,2020-10-31,"September 30, 2020",Actual,2020-09-30,NA,Interventional,COVID-VITD,NA,The Effect of Vitamin D Supplementation on COVID-19 Recovery,The Effect of Vitamin D Supplementation on Recovery Delays for Non Severe COVID-19 Cases,Completed,NA,Phase 3,130,Actual,University of Monastir,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:12:08Z,2021-12-02T04:12:08Z,266
NCT04880122,NA,2021-05-05,NA,NA,2021-05-06,2021-05-06,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,"August 1, 2020",Actual,2020-08-01,May 2021,2021-05-31,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Dried Blood Spots for SARS-CoV-2 Serology (COVID-19).,Comparison of Dried Blood Spots and Venous Blood for the Detection of SARS-CoV-2 2 Antibodies in a Population of Nursing Home Residents.,Completed,NA,Not Applicable,440,Actual,University Ghent,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:15:50Z,2021-12-02T04:15:50Z,270
NCT04878809,NA,2021-04-28,NA,NA,2021-06-17,2021-05-04,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-18,Actual,"April 22, 2021",Actual,2021-04-22,June 2021,2021-06-30,"June 17, 2021",Actual,2021-06-17,"June 17, 2021",Actual,2021-06-17,NA,Interventional,NA,NA,"Rapid Screening Circuit of COVID 19 in Schools, Pilot Study","Rapid Screening Circuit of COVID 19 in Schools, Pilot Study",Completed,NA,Not Applicable,153,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:16:42Z,2021-12-02T04:16:42Z,228
NCT04880135,NA,2021-05-06,NA,NA,2021-09-17,2021-05-06,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-20,Actual,"March 1, 2021",Actual,2021-03-01,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"August 30, 2021",Actual,2021-08-30,NA,Interventional,NA,NA,Supervised Versus Home Based Exercises Neck and Low Back Pain Among Students Due to Quarantine During COVID-19,Effects of Supervised Versus Home Based Stretching and Strengthening Exercise Program on Neck Pain and Back Pain Among University Students Due to Quarantine During COVID-19: A Randomised Controlled Trial,Completed,NA,Not Applicable,404,Actual,Riphah International University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:15:47Z,2021-12-02T04:15:47Z,136
NCT04876560,NA,2021-04-27,NA,NA,2021-05-05,2021-05-05,2021-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"March 11, 2020",Actual,2020-03-11,May 2021,2021-05-31,"April 15, 2021",Actual,2021-04-15,"October 10, 2020",Actual,2020-10-10,NA,Interventional,CDSS,NA,Implementation of a CDSS in Oncology Patients During COVID-19,"The Use of Clinical Decision Support Systems (CDSS) to Provide Nutritional Care to Breast Cancer Patients During the COVID-19 Pandemic: a Randomised Controlled, Pilot Trial",Completed,NA,Not Applicable,44,Actual,"Iaso Maternity Hospital, Athens, Greece",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:21:45Z,2021-12-02T04:21:45Z,271
NCT04872075,NA,2021-04-29,NA,NA,2021-07-12,2021-04-29,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-13,Actual,"May 26, 2021",Actual,2021-05-26,July 2021,2021-07-31,"June 13, 2021",Actual,2021-06-13,"June 13, 2021",Actual,2021-06-13,NA,Interventional,SPRING,NA,Study on Prevention of SARS-CoV-2 Transmission During a Large Indoor Gathering Event,Study on Prevention of SARS-CoV-2 Transmission During a Large Indoor Gathering Event,Completed,NA,Not Applicable,6678,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:27:02Z,2021-12-02T04:27:02Z,203
NCT04871633,NA,2021-01-11,NA,NA,2021-05-02,2021-05-02,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-04,Actual,"August 1, 2020",Actual,2020-08-01,May 2021,2021-05-31,"December 30, 2020",Actual,2020-12-30,"November 15, 2020",Actual,2020-11-15,NA,Interventional,NA,NA,Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore,Effectiveness of Remedesvir in SARS-CoV2 Patients Presenting at Mayo Hospital Lahore,Completed,NA,Not Applicable,66,Actual,King Edward Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:27:15Z,2021-12-02T04:27:15Z,274
NCT04869072,NA,2021-04-08,NA,NA,2021-04-27,2021-04-27,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-05-03,Actual,"April 29, 2020",Actual,2020-04-29,April 2021,2021-04-30,"March 30, 2021",Actual,2021-03-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,CPT-ZHP,NA,Convalescent Plasma Therapy - Zurich Protocol,"A Phase i, Open-label, Single-centre Clinical Study to Evaluate Safety and Efficacy of Passive Immunization of High-risk SARS-CoV-2 Positive Patients With Convalescent Plasma Therapy",Completed,NA,Phase 1,30,Actual,University of Zurich,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:30:16Z,2021-12-02T04:30:16Z,279
NCT04867265,NA,2021-04-26,NA,NA,2021-06-02,2021-04-28,2021-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-02,2021-06-03,Actual,"May 3, 2021",Actual,2021-05-03,June 2021,2021-06-30,"June 2, 2021",Actual,2021-06-02,"June 2, 2021",Actual,2021-06-02,NA,Interventional,MOVERESP,NA,Mouth-to-mouth Ventilation Efficiency Through Breathable Self-sterilizing Respirator During BLS in COVID-19 Pandemic,Mouth-to-mouth Ventilation Efficiency Through Breathable Self-sterilizing Respirator During BLS in COVID-19 Pandemic: a Crossover Simulation-based Study,Completed,NA,Not Applicable,104,Actual,Brno University Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:32:06Z,2021-12-02T04:32:06Z,243
NCT04867226,NA,2021-04-25,NA,NA,2021-06-19,2021-04-28,2021-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-19,2021-06-22,Actual,"May 8, 2021",Actual,2021-05-08,June 2021,2021-06-30,"June 18, 2021",Actual,2021-06-18,"June 18, 2021",Actual,2021-06-18,NA,Interventional,NA,NA,Effectiveness of Colchicine Among Patients With COVID-19 Infection,Effectiveness of Colchicine Among Patients With COVID-19 Infection,Completed,NA,Phase 2,100,Actual,Hawler Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:31:46Z,2021-12-02T04:31:46Z,226
NCT04864015,NA,2021-04-27,NA,NA,2021-10-07,2021-04-27,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-08,Actual,"March 17, 2021",Actual,2021-03-17,October 2021,2021-10-31,"June 30, 2021",Actual,2021-06-30,"May 15, 2021",Actual,2021-05-15,NA,Interventional,NA,NA,COVID-19 Aerosol in EGD Using a Droplet Reduction Mouthpiece,COVID-19: a Study About Aerosol Formation During Gastroscopy With a Adjusted Mouthpiece for Droplet Reduction,Completed,NA,Not Applicable,80,Actual,Universitaire Ziekenhuizen Leuven,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,We won't share individual participant data,2021-12-02T04:34:28Z,2021-12-02T04:34:28Z,116
NCT04861298,NA,2021-04-25,NA,NA,2021-09-03,2021-04-25,2021-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-08,Actual,"January 11, 2021",Actual,2021-01-11,April 2021,2021-04-30,"August 29, 2021",Actual,2021-08-29,"August 29, 2021",Actual,2021-08-29,NA,Interventional,NA,NA,Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early COVID-19 Symptoms at Home,Study to Investigate the Benefits of Dietary Supplement Quercetin for COVID-19,Completed,NA,Not Applicable,100,Actual,King Edward Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:36:29Z,2021-12-02T04:36:29Z,150
NCT04860258,NA,2021-04-22,NA,NA,2021-10-01,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"April 22, 2021",Actual,2021-04-22,January 2021,2021-01-31,"September 21, 2021",Actual,2021-09-21,"September 21, 2021",Actual,2021-09-21,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities for COVID-19","COVID-19: A Phase 3 Multicenter Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Above With Co-morbidities",Completed,NA,Phase 3,129,Actual,CureVac AG,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:37:19Z,2021-12-02T04:37:19Z,122
NCT04859023,NA,2021-04-22,NA,NA,2021-05-03,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-06,Actual,"February 22, 2021",Actual,2021-02-22,May 2021,2021-05-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,AutoCoV,NA,Comparison of Strategies Based on RT-PCR or Antigenic Test for the Screening of SARS-CoV-2 Infection (COVID-19).,Comparison of Strategies Based on RT-PCR or Antigenic Test for the Screening of SARS-CoV-2 Infection in General Population Using Self-samples (COVID-19).,Completed,NA,Not Applicable,10000,Actual,Centre Hospitalier Universitaire de Saint Etienne,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:38:14Z,2021-12-02T04:38:14Z,273
NCT04859244,NA,2021-04-19,NA,NA,2021-08-07,2021-04-21,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-07,2021-08-10,Actual,"January 1, 2021",Actual,2021-01-01,April 2021,2021-04-30,"August 1, 2021",Actual,2021-08-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,NA,NA,First-in-Human Study of Orally Administered GS-441524 for COVID-19,"First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of Orally Administered GS-441524 in a Healthy Human Volunteer",Completed,NA,Phase 1,1,Actual,Copycat Sciences LLC,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,Within 6 months after publication,Materials available upon request,NA,Yes,All collected IPD,2021-12-02T04:38:06Z,2021-12-02T04:38:06Z,177
NCT04853901,NA,2021-03-01,NA,NA,2021-04-17,2021-04-17,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-17,2021-04-22,Actual,"July 27, 2020",Actual,2020-07-27,April 2021,2021-04-30,"March 1, 2021",Actual,2021-03-01,"January 1, 2021",Actual,2021-01-01,NA,Interventional,NA,NA,Remdesivir Efficacy In Management Of COVID-19 Patients,Remdesivir Efficacy In Management Of COVID-19 Patients,Completed,NA,Phase 3,77,Actual,Ain Shams University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:42:17Z,2021-12-02T04:42:17Z,289
NCT04851821,NA,2021-02-06,NA,NA,2021-07-26,2021-04-18,2021-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"January 4, 2021",Actual,2021-01-04,July 2021,2021-07-31,"June 30, 2021",Actual,2021-06-30,"May 30, 2021",Actual,2021-05-30,NA,Interventional,Quercetix,NA,The Effectiveness of Phytotherapy in SARS-COV2(COVID-19),The Effectiveness of Phytotherapy in the Treatment of SARS-COV2 (COVID-19),Completed,NA,Phase 1,80,Actual,HÃ´pital Universitaire Sahloul,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,In the publication of the article,we will publish the Access criteria after the final Statistical analysis,NA,Yes,Statistical analysis Plan can be shared in supplimentary data,2021-12-02T04:43:25Z,2021-12-02T04:43:25Z,189
NCT04845880,NA,2021-04-13,NA,NA,2021-04-13,2021-04-13,2021-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-15,Actual,"October 1, 2020",Actual,2020-10-01,April 2021,2021-04-30,"April 1, 2021",Actual,2021-04-01,"March 1, 2021",Actual,2021-03-01,NA,Interventional,NA,NA,SARS Cov_2 Incidence of Healthy Health Workers,Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 Patients in Our Hospital,Completed,NA,Not Applicable,182,Actual,Baskent University,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:48:26Z,2021-12-02T04:48:26Z,293
NCT04845971,NA,2020-11-17,NA,NA,2021-09-07,2021-04-14,2021-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"November 5, 2020",Actual,2020-11-05,April 2021,2021-04-30,"June 30, 2021",Actual,2021-06-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,COral-MAF1,NA,Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia,Phase II Clinical Trial Evaluating Efficacy and Safety of Oral Immunotherapy With Third Generation Gc Protein Derived Macrophage Activating Factor (GcMAF) in Hospitalized Patients With COVID-19 Pneumonia: the COral-MAF1 Trial,Completed,NA,Phase 2,97,Actual,Ospedale del Mare,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"This is a multicenter trial. However, we reserve the possibility of enrolling further COVID-19 Hospital Units that are interested in participating in the trial, in order to get the correct sample size as needed for the study.Thus, if needed, we'll share IPD with the involved research centers.",2021-12-02T04:48:23Z,2021-12-02T04:48:23Z,146
NCT04844710,NA,2021-04-12,NA,NA,2021-04-12,2021-04-12,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-14,Actual,"September 1, 2020",Actual,2020-09-01,April 2021,2021-04-30,"November 20, 2020",Actual,2020-11-20,"November 15, 2020",Actual,2020-11-15,NA,Interventional,NA,NA,The Effects of Acupuncture in Overcoming Inflammatory Response to COVID-19 Mild-moderate Symptoms,The Effects of Combined Treatment of Acupuncture Intervention & Standard of Care on Laboratory and Clinical Outcomes in Hospitalized COVID-19 Patients With Mild-Moderate Symptoms,Completed,NA,Not Applicable,22,Actual,Indonesia University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:49:31Z,2021-12-02T04:49:31Z,294
NCT04841681,NA,2021-04-06,NA,NA,2021-04-08,2021-04-08,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-12,Actual,"June 7, 2020",Actual,2020-06-07,April 2021,2021-04-30,"August 26, 2020",Actual,2020-08-26,"August 25, 2020",Actual,2020-08-25,NA,Interventional,NA,NA,Video-based Psychotherapy for COVID-19 Patients in Isolation Ward in Jakarta,Effectiveness of Video-based Psychotherapy in Reducing Distress in Patients With COVID-19 Treated in a Hospital Isolation Ward in Jakarta,Completed,NA,Not Applicable,42,Actual,Indonesia University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,1 month after publication.,"The data will be available through request to Petrin Redayani Lukman MD as the contact person, e-mail ptrn1010@yahoo.com.",NA,Yes,We plan to share the data of participants' (identities will be initials only) demographic data and SUDS score before and after watching the video.,2021-12-02T04:51:49Z,2021-12-02T04:51:49Z,298
NCT04834856,NA,2021-04-06,NA,NA,2021-09-07,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"April 1, 2021",Actual,2021-04-01,September 2021,2021-09-30,"August 20, 2021",Actual,2021-08-20,"August 20, 2021",Actual,2021-08-20,NA,Interventional,NA,NA,"Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients","A Phase 2a Open Label, Non-comparative, Single Dose Escalation Study to Evaluate the Dynamics of Viral Clearance, Pharmacokinetics and Tolerability of Ensovibep in Patients With Symptomatic COVID-19 Disease",Completed,NA,Phase 2,12,Actual,Molecular Partners AG,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:56:38Z,2021-12-02T04:56:38Z,146
NCT04834726,NA,2021-04-06,NA,NA,2021-08-30,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"April 29, 2021",Actual,2021-04-29,August 2021,2021-08-31,"July 6, 2021",Actual,2021-07-06,"June 4, 2021",Actual,2021-06-04,NA,Interventional,NA,NA,COVID-19 Vaccine Text Outreach,Pragmatic Trial of COVID Vaccine Text Outreach Interventions,Completed,NA,Not Applicable,19554,Actual,University of Pennsylvania,NA,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:57:04Z,2021-12-02T04:57:04Z,154
NCT04834739,NA,2021-01-10,NA,NA,2021-08-23,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"January 4, 2021",Actual,2021-01-04,January 2021,2021-01-31,"April 30, 2021",Actual,2021-04-30,"March 28, 2021",Actual,2021-03-28,NA,Interventional,NA,NA,Comparison of Functional Capacities of Healthcare Workers With and Without Covid-19,Comparison of Functional Capacities of Healthcare Workers With and Without Covid-19,Completed,NA,Not Applicable,60,Actual,Gaziosmanpasa Research and Education Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:57:11Z,2021-12-02T04:57:11Z,161
NCT04830943,NA,2020-12-24,NA,NA,2021-04-01,2021-04-01,2021-04-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-05,Actual,"August 1, 2020",Actual,2020-08-01,April 2021,2021-04-30,"March 30, 2021",Actual,2021-03-30,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,NA,Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia,The Effectiveness of Cerebrolycin for Treatment of Post-covid Olfactory and Gustatory Dysfunctions: A Pilot Study,Completed,NA,Phase 4,100,Actual,Assiut University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:00:05Z,2021-12-02T05:00:05Z,305
NCT04822285,NA,2021-03-26,NA,NA,2021-03-26,2021-03-26,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-03-30,Actual,"January 22, 2020",Actual,2020-01-22,March 2021,2021-03-31,"March 21, 2021",Actual,2021-03-21,"April 22, 2020",Actual,2020-04-22,NA,Interventional,Triaging,NA,Effect Psychological Triaging Intervention on Students' Psychological Distress and Resilience Capacity,Psychological Triaging Intervention: Rescue From Psychological Distress and Improving Senior Nursing Students' Resilience Capacity During COVID-19 Crisis,Completed,NA,Not Applicable,64,Actual,Alexandria University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:08:04Z,2021-12-02T05:08:04Z,311
NCT04820803,NA,2021-03-23,NA,NA,2021-07-01,2021-03-26,2021-03-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-07,Actual,"February 3, 2021",Actual,2021-02-03,March 2021,2021-03-31,"June 30, 2021",Actual,2021-06-30,"April 29, 2021",Actual,2021-04-29,NA,Interventional,NA,NA,Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load in Patients With COVID-19,PILOT CLINICAL TRIAL TO ASSESS THE IMPACT OF ORAL INTERVENTION WITH CETIL PYRIDINIUM CHLORIDE TO REDUCE THE VIRAL LOAD OF SARS-CoV-2,Completed,NA,Not Applicable,80,Actual,Instituto de InvestigaciÃ³n Sanitaria AragÃ³n,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:09:19Z,2021-12-02T05:09:19Z,214
NCT04817332,NA,2021-01-25,NA,NA,2021-08-12,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-17,Actual,"June 5, 2020",Actual,2020-06-05,August 2021,2021-08-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,STOP-COVID19,NA,STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19,A Randomised Double-blind Placebo-controlled Trial of Brensocatib (INS1007) in Patients With Severe COVID-19,Completed,NA,Phase 3,406,Actual,University of Dundee,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:12:12Z,2021-12-02T05:12:12Z,172
NCT04816656,NA,2021-03-24,NA,NA,2021-03-25,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-26,Actual,"August 3, 2020",Actual,2020-08-03,March 2021,2021-03-31,"March 22, 2021",Actual,2021-03-22,"February 1, 2021",Actual,2021-02-01,NA,Interventional,COVID-ONCO,NA,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,Completed,NA,Not Applicable,43,Actual,Jessa Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:13:00Z,2021-12-02T05:13:00Z,312
NCT04816084,NA,2021-03-19,NA,NA,2021-03-24,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"November 5, 2020",Actual,2020-11-05,March 2021,2021-03-31,"March 15, 2021",Actual,2021-03-15,"December 1, 2020",Actual,2020-12-01,NA,Interventional,SERUR,NA,SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes,SERUR : Etude sÃ©rologique COVID-19 (Anti-SARS CoV 2) du Personnel de l'UniversitÃ© de Reims Champagne-Ardenne,Completed,NA,Not Applicable,389,Actual,UniversitÃ© de Reims Champagne-Ardenne,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:13:35Z,2021-12-02T05:13:35Z,313
NCT04816942,NA,2021-02-12,NA,NA,2021-03-24,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"April 23, 2020",Actual,2020-04-23,March 2021,2021-03-31,"October 12, 2020",Actual,2020-10-12,"July 21, 2020",Actual,2020-07-21,NA,Interventional,NA,NA,Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt,Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt,Completed,NA,Phase 3,102,Actual,"Ministry of Health and Population, Egypt",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:12:43Z,2021-12-02T05:12:43Z,313
NCT04815057,NA,2021-03-11,NA,NA,2021-04-11,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-11,2021-04-14,Actual,"November 2, 2020",Actual,2020-11-02,April 2021,2021-04-30,"March 8, 2021",Actual,2021-03-08,"November 23, 2020",Actual,2020-11-23,NA,Interventional,NA,NA,The Effects of Wellness Training Given to Fifth Grade Students During the Covid-19 Epidemic Period,The Effects of Wellness Education Given to 5th Grade Students During the Covid-19 Pandemic Process on Their Quality of Life and Physical Activity,Completed,NA,Not Applicable,176,Actual,Saglik Bilimleri Universitesi,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:14:40Z,2021-12-02T05:14:40Z,295
NCT04813770,NA,2021-03-23,NA,NA,2021-05-05,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"April 6, 2021",Actual,2021-04-06,May 2021,2021-05-31,"April 26, 2021",Actual,2021-04-26,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,NA,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,Completed,NA,Not Applicable,1113,Actual,University of Glasgow,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,On publication of the study results for a period of ten years.,Data will be made publicly available.,NA,Yes,Anonymised individual level study data will be shared via the University of Glasgow's repository Enlighten: Research Data.,2021-12-02T05:15:30Z,2021-12-02T05:15:30Z,271
NCT04810728,NA,2021-03-16,NA,NA,2021-04-17,2021-03-20,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-04-17,2021-04-20,Actual,"June 20, 2020",Actual,2020-06-20,April 2021,2021-04-30,"January 30, 2021",Actual,2021-01-30,"December 4, 2020",Actual,2020-12-04,NA,Interventional,NA,NA,Efficacy of Psidii Guava's Extract For COVID-19,Efficacy of Psidii Guava's Extract For Mild And Symptomless Coronavirus Disease-19 (COVID-19),Completed,NA,Phase 3,90,Actual,Faculty of Medicine Baiturrahmah University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:18:18Z,2021-12-02T05:18:18Z,289
NCT04810065,NA,2021-03-19,NA,NA,2021-09-27,2021-03-19,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"March 29, 2021",Actual,2021-03-29,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"July 29, 2021",Actual,2021-07-29,NA,Interventional,ss,NA,SingStrong: Strong Lungs Through Song - Long COVID-19 Study,SingStrong: Strong Lungs Through Song,Completed,NA,Not Applicable,30,Actual,University of Limerick,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:18:46Z,2021-12-02T05:18:46Z,126
NCT04808921,NA,2021-03-18,NA,NA,2021-04-05,2021-03-18,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"January 9, 2021",Actual,2021-01-09,April 2021,2021-04-30,"January 28, 2021",Actual,2021-01-28,"January 18, 2021",Actual,2021-01-18,NA,Interventional,NA,NA,Performance Evaluation of SARS-COV-2 (Covid-19) Antigen Rapid Test,Rapid Diagnostic Test for Detection of SARS-CoV-2 Antigen,Completed,NA,Not Applicable,151,Actual,"Sky Medical Supplies & Equipments, LLC",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:19:20Z,2021-12-02T05:19:20Z,301
NCT04805684,NA,2021-03-15,NA,NA,2021-03-17,2021-03-17,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-18,Actual,"January 1, 2021",Actual,2021-01-01,March 2021,2021-03-31,"March 5, 2021",Actual,2021-03-05,"March 5, 2021",Actual,2021-03-05,NA,Interventional,NA,NA,Different Lung Ultrasound Imaging Protocols in COVID-19 Pneumonia,Comparison of Two Different Lung Ultrasound Imaging Protocols in COVID -19 Pneumonia,Completed,NA,Not Applicable,59,Actual,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:21:55Z,2021-12-02T05:21:55Z,320
NCT04801888,NA,2021-03-15,NA,NA,2021-07-23,2021-03-15,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"March 23, 2021",Actual,2021-03-23,March 2021,2021-03-31,"May 28, 2021",Actual,2021-05-28,"May 28, 2021",Actual,2021-05-28,NA,Interventional,NA,NA,Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine,A Study to Evaluate the Safety and Immunogenicity of Concomitant Administration of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) With Quadrivalent Influenza Vaccine in Adults Aged From 18 to 59 Years,Completed,NA,Phase 4,480,Actual,"Sinovac Biotech Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:24:57Z,2021-12-02T05:24:57Z,192
NCT04797936,NA,2021-03-08,NA,NA,2021-03-12,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-03-12,2021-03-15,Actual,"May 1, 2020",Actual,2020-05-01,March 2021,2021-03-31,"January 8, 2021",Actual,2021-01-08,"December 19, 2020",Actual,2020-12-19,NA,Interventional,NA,NA,BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19,"A Randomized, Open-label, Multicentre, Comparative Study of Therapeutic Efficacy, Safety, and Tolerability of BNO 1030 Extract, in the Treatment of Mild Forms of COVID-19",Completed,NA,Phase 4,133,Actual,Ivano-Frankivsk National Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:27:57Z,2021-12-02T05:27:57Z,325
NCT04796064,NA,2021-03-10,NA,NA,2021-03-11,2021-03-11,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-12,Actual,"March 30, 2020",Actual,2020-03-30,March 2021,2021-03-31,"December 15, 2020",Actual,2020-12-15,"November 5, 2020",Actual,2020-11-05,NA,Interventional,NA,NA,Low Versus High-Intensity Aerobic Training in Community-dwelling Older Men With Post-COVID 19 (SARS-CoV-2) Sarcopenia,Comparative Effectiveness Study of Low Versus High-Intensity Aerobic Training in Community-dwelling Older Men With Post-COVID 19 Sarcopenia,Completed,NA,Not Applicable,76,Actual,Cairo University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:29:10Z,2021-12-02T05:29:10Z,326
NCT04794400,NA,2021-03-10,NA,NA,2021-06-05,2021-03-10,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-05,2021-06-09,Actual,"February 4, 2021",Actual,2021-02-04,June 2021,2021-06-30,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,NA,The Application of a Mask in Patients With Severe Covid-19 Already Treated With High-flow Nasal Cannula.,The Application of a Mask in Patients With Severe Covid-19 Already Treated With High-flow Nasal Cannula.,Completed,NA,Not Applicable,18,Actual,Region Skane,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:30:48Z,2021-12-02T05:30:48Z,240
NCT04793243,NA,2021-03-03,NA,NA,2021-03-09,2021-03-09,2021-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"August 17, 2020",Actual,2020-08-17,March 2021,2021-03-31,"October 24, 2020",Actual,2020-10-24,"October 10, 2020",Actual,2020-10-10,NA,Interventional,NA,NA,Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico,Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico: Clinical Correlation and Effect of Its Supplementation,Completed,NA,Not Applicable,42,Actual,University of Guadalajara,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:31:48Z,2021-12-02T05:31:48Z,328
NCT04789525,NA,2021-03-05,NA,NA,2021-03-09,2021-03-08,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"March 10, 2020",Actual,2020-03-10,March 2021,2021-03-31,"December 25, 2020",Actual,2020-12-25,"October 1, 2020",Actual,2020-10-01,NA,Interventional,NA,NA,Physical Training and Diet for Childhood Obesity,"Clinical (BMI & MRI) and Biochemical (Adiponectin, Leptin, TNF-Î± & IL-6) Effects of High-intensity Aerobic Training With High Protein Diet in Childhood Obesity Following COVID-19 Infection",Completed,NA,Not Applicable,76,Actual,Cairo University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:34:59Z,2021-12-02T05:34:59Z,328
NCT04788355,NA,2020-09-05,NA,NA,2021-03-06,2021-03-06,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-06,2021-03-09,Actual,"July 1, 2020",Actual,2020-07-01,March 2021,2021-03-31,"December 23, 2020",Actual,2020-12-23,"November 15, 2020",Actual,2020-11-15,NA,Interventional,NA,NA,Prevention of Complications (SARS-CoV-2): Clinical Study,Hydroxychloroquine and Apixaban: Analysis of Physiological Parameters for the Prevention of Complications in Patients With Infection With the New Coronavirus (Covid-19). A Randomized Clinical Trial,Completed,NA,Phase 3,176,Actual,Universidade do Vale do Sapucai,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:35:52Z,2021-12-02T05:35:52Z,331
NCT04784481,NA,2021-02-20,NA,NA,2021-04-22,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-26,Actual,"September 20, 2020",Actual,2020-09-20,April 2021,2021-04-30,"January 18, 2021",Actual,2021-01-18,"December 20, 2020",Actual,2020-12-20,NA,Interventional,IVER-Leve,NA,Ivermectin Reproposing for Mild Stage COVID-19 Outpatients,Ivermectin Reproposing for COVID-19 Treatment in Outpatients With Mild Stage,Completed,NA,Phase 1/Phase 2,254,Actual,"Ministry of Public Health, Argentina",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,N/D,2021-12-02T05:39:14Z,2021-12-02T05:39:14Z,284
NCT04784897,NA,2021-03-03,NA,NA,2021-08-11,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-13,Actual,"February 22, 2021",Actual,2021-02-22,August 2021,2021-08-31,"July 30, 2021",Actual,2021-07-30,"July 1, 2021",Actual,2021-07-01,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19",Completed,NA,Phase 2,120,Actual,"Innovation Pharmaceuticals, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:38:55Z,2021-12-02T05:38:55Z,173
NCT04782700,NA,2021-02-25,NA,NA,2021-06-17,2021-03-03,2021-03-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-18,Actual,"April 1, 2021",Actual,2021-04-01,June 2021,2021-06-30,"June 8, 2021",Actual,2021-06-08,"June 8, 2021",Actual,2021-06-08,NA,Interventional,NA,NA,P-Co-Li (Pulmonary Covid-19 Study),P-CO-Li (Pulmonary Covid-19 Longterm Intervention Study),Completed,NA,Not Applicable,6,Actual,Northwell Health,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:40:37Z,2021-12-02T05:40:37Z,228
NCT04772859,NA,2021-02-13,NA,NA,2021-09-23,2021-02-24,2021-02-26,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-27,Actual,"February 1, 2021",Actual,2021-02-01,September 2021,2021-09-30,"July 16, 2021",Actual,2021-07-16,"July 16, 2021",Actual,2021-07-16,NA,Interventional,NA,NA,Evaluation of an Online Lifestyle Intervention in Mexican School Children During COVID-19 Pandemic,Evaluation of a 4-month Online Lifestyle Intervention on the BMI Z-score of Mexican School Children During COVID-19 Pandemic: Randomized Controlled Pilot Trial,Completed,NA,Not Applicable,54,Actual,Universidad de Sonora,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:48:29Z,2021-12-02T05:48:29Z,130
NCT04771559,NA,2021-02-17,NA,NA,2021-08-01,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-01,2021-08-03,Actual,"March 1, 2021",Actual,2021-03-01,August 2021,2021-08-31,"July 1, 2021",Actual,2021-07-01,"June 1, 2021",Actual,2021-06-01,NA,Interventional,NA,NA,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients,Completed,NA,Not Applicable,1500,Actual,Bezmialem Vakif University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:49:19Z,2021-12-02T05:49:19Z,183
NCT04771585,NA,2021-01-26,NA,NA,2021-08-25,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-26,Actual,"March 29, 2021",Actual,2021-03-29,August 2021,2021-08-31,"August 20, 2021",Actual,2021-08-20,"August 20, 2021",Actual,2021-08-20,NA,Interventional,QUELLE,NA,Quantification of Exhaled Particles to Identify Airborne Transmission Risks of COVID-19,Quantification of Exhaled Particles to Identify Airborne Transmission Risks of SARS-Co-V-2,Completed,NA,Not Applicable,30,Actual,Fraunhofer-Institute of Toxicology and Experimental Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:49:18Z,2021-12-02T05:49:18Z,159
NCT04771013,NA,2021-02-24,NA,NA,2021-05-14,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-18,Actual,"February 10, 2021",Actual,2021-02-10,May 2021,2021-05-31,"May 14, 2021",Actual,2021-05-14,"May 14, 2021",Actual,2021-05-14,NA,Interventional,NA,NA,Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras,"A Single-arm, Open-Label, Phase II Clinical Study to Evaluate the Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras",Completed,NA,Phase 2,22,Actual,Universidad CatÃ³lica de Honduras,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months and ending 5 years following article publication.,"Investigators whose proposed use of the data has been approved by an independent review committee (""learned intermediary"") identified for this purpose.

For individual participant data meta-analysis.",NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2021-12-02T05:49:45Z,2021-12-02T05:49:45Z,262
NCT04769999,NA,2020-07-13,NA,NA,2021-02-22,2021-02-22,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-25,Actual,"June 4, 2020",Actual,2020-06-04,December 2020,2020-12-31,"October 30, 2020",Actual,2020-10-30,"October 16, 2020",Actual,2020-10-16,NA,Interventional,CALM-ED,NA,Computer Assisted Lessening of Intrusive Memories in the Emergency Department,"Reducing Intrusive Memories of Work-Related Traumatic Events, Including Events During the COVID-19 Pandemic, in NHS Staff Using a Brief Cognitive Task Intervention",Completed,NA,Not Applicable,14,Actual,University of Oxford,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:50:43Z,2021-12-02T05:50:43Z,343
NCT04765839,NA,2021-02-02,NA,NA,2021-07-28,2021-02-19,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-30,Actual,"February 12, 2021",Actual,2021-02-12,July 2021,2021-07-31,"April 3, 2021",Actual,2021-04-03,"April 3, 2021",Actual,2021-04-03,NA,Interventional,CERC,NA,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With Minority Populations,Completed,NA,Not Applicable,74,Actual,Mayo Clinic,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:53:35Z,2021-12-02T05:53:35Z,187
NCT04767477,NA,2020-12-21,NA,NA,2021-10-04,2021-02-22,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"March 28, 2021",Actual,2021-03-28,October 2021,2021-10-31,"September 10, 2021",Actual,2021-09-10,"August 31, 2021",Actual,2021-08-31,NA,Interventional,NA,NA,Telerehabilitation and Face-to-face Rehabilitation on COVID-19 Survivors,Telerehabilitation and Face-to-face Rehabilitation on Tolerance to Exercise and Quality of Life of COVID-19 Survivors: a Study Protocol,Completed,NA,Not Applicable,26,Actual,Universidade Federal de Pernambuco,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:52:29Z,2021-12-02T05:52:29Z,119
NCT04762173,NA,2021-02-15,NA,NA,2021-07-09,2021-02-18,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"November 6, 2020",Actual,2020-11-06,July 2021,2021-07-31,"May 31, 2021",Actual,2021-05-31,"May 31, 2021",Actual,2021-05-31,NA,Interventional,NA,NA,Self-Help for Stress Related to COVID-19,Self-Help for Stress Related to COVID-19,Completed,NA,Not Applicable,585,Actual,Penn State University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:56:26Z,2021-12-02T05:56:26Z,206
NCT04762628,NA,2021-02-11,NA,NA,2021-08-06,2021-02-18,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-09,Actual,"October 27, 2020",Actual,2020-10-27,August 2021,2021-08-31,"August 6, 2021",Actual,2021-08-06,"July 5, 2021",Actual,2021-07-05,NA,Interventional,SaiseiCovUKR,NA,"Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients","Randomized Trial to Assess the Efficacy and Safety of Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Addition to the Standard of Care (SOC) Compared SOC in the Treatment of Hospitalized With COVID-19 Patients Who Not Requiring the Mechanical Ventilation",Completed,NA,Not Applicable,600,Actual,Saisei Pharma,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be indefinitely available for requesting,Reasonable request to investigators,NA,Yes,The data will be shared via ISARIC COVID-19 Clinical Database.,2021-12-02T05:56:08Z,2021-12-02T05:56:08Z,178
NCT04761874,NA,2021-02-15,NA,NA,2021-04-19,2021-02-17,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-19,2021-04-22,Actual,"December 1, 2019",Actual,2019-12-01,April 2021,2021-04-30,"September 29, 2020",Actual,2020-09-29,"June 29, 2020",Actual,2020-06-29,NA,Interventional,TELECAST-CSC,NA,Telestroke at Comprehensive Stroke Center During the COVID-19 Pandemic,TELEstroke to CAre for STroke Patients at a Comprehensive Stroke Center During the COVID-19 Pandemic,Completed,NA,Not Applicable,296,Actual,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:56:39Z,2021-12-02T05:56:39Z,287
NCT04758299,NA,2021-02-12,NA,NA,2021-05-21,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"March 13, 2021",Actual,2021-03-13,May 2021,2021-05-31,"April 30, 2021",Actual,2021-04-30,"April 15, 2021",Actual,2021-04-15,NA,Interventional,NA,NA,Understanding Communications Included With COVID-19 (Corona Virus Disease of 2019) Home Testing Kits,At Home Self-testing Kits for SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) : A Randomized Trial Assessing How Consumers Interpret and Act on Test Results,Completed,NA,Not Applicable,360,Actual,Carnegie Mellon University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:00:04Z,2021-12-02T06:00:04Z,255
NCT04757818,NA,2021-02-16,NA,NA,2021-07-13,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-19,Actual,"February 17, 2021",Actual,2021-02-17,July 2021,2021-07-31,"June 3, 2021",Actual,2021-06-03,"May 25, 2021",Actual,2021-05-25,NA,Interventional,CPC COVID,NA,"Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 (COVID-19) in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%.","Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%",Completed,NA,Not Applicable,118,Actual,Dentaid SL,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:00:06Z,2021-12-02T06:00:06Z,202
NCT04758286,NA,2021-02-11,NA,NA,2021-02-16,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"July 1, 2020",Actual,2020-07-01,February 2021,2021-02-28,"February 11, 2021",Actual,2021-02-11,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,Anesthetic & Surgical Protocol for Emergency Surgeries During the Era of COVID-19,Protocol for Anesthesia for Emergency Surgery,Completed,NA,Not Applicable,209,Actual,Benha University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,after publishing,email,NA,Yes,The study protocol may be shared,2021-12-02T05:59:59Z,2021-12-02T05:59:59Z,349
NCT04751474,NA,2021-02-08,NA,NA,2021-04-18,2021-02-08,2021-02-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-18,2021-04-20,Actual,"February 1, 2021",Actual,2021-02-01,April 2021,2021-04-30,"March 31, 2021",Actual,2021-03-31,"March 1, 2021",Actual,2021-03-01,NA,Interventional,NA,NA,"The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction","The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction of Intensive Care Nurses During the COVID-19 Pandemic : A Randomized Controlled Study",Completed,NA,Not Applicable,93,Actual,Saglik Bilimleri Universitesi,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:05:32Z,2021-12-02T06:05:32Z,288
NCT04750317,NA,2021-02-10,NA,NA,2021-02-11,2021-02-10,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-15,Actual,"May 11, 2020",Actual,2020-05-11,February 2021,2021-02-28,"September 1, 2020",Actual,2020-09-01,"August 1, 2020",Actual,2020-08-01,NA,Interventional,TOFA-COV-2,NA,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,Completed,NA,Phase 2,414,Actual,I.M. Sechenov First Moscow State Medical University,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:06:43Z,2021-12-02T06:06:43Z,354
NCT04749121,NA,2021-02-04,NA,NA,2021-02-09,2021-02-09,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-11,Actual,"April 1, 2020",Actual,2020-04-01,February 2021,2021-02-28,"February 5, 2021",Actual,2021-02-05,"February 5, 2021",Actual,2021-02-05,NA,Interventional,NA,NA,Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators,"Impact of Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators (VJR-NMU) Respirator Performances, Structural Integrity and Sterility During COVID -19 Pandemic:",Completed,NA,Not Applicable,20,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Plan to share in protocol.io,2021-12-02T06:07:47Z,2021-12-02T06:07:47Z,356
NCT04748536,NA,2021-02-01,NA,NA,2021-04-22,2021-02-08,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-26,Actual,"January 29, 2021",Actual,2021-01-29,February 2021,2021-02-28,"April 5, 2021",Actual,2021-04-05,"April 5, 2021",Actual,2021-04-05,NA,Interventional,NA,NA,Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers,"A Randomised, Double-blind, Placebo-controlled, Parallel Group Study in Healthy Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of IRL201104 to Support a Future COVID-19 Patient Study",Completed,NA,Phase 1,18,Actual,Revolo Biotherapeutics,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:08:32Z,2021-12-02T06:08:32Z,284
NCT04747158,NA,2021-01-27,NA,NA,2021-02-25,2021-02-08,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-02,Actual,"August 10, 2020",Actual,2020-08-10,February 2021,2021-02-28,"January 10, 2021",Actual,2021-01-10,"December 10, 2020",Actual,2020-12-10,NA,Interventional,TPCC,NA,COVID-19 Convalescent Plasma Therapy,COVID-19 Convalescent Plasma Therapy,Completed,NA,Phase 2/Phase 3,350,Actual,Universidad Nacional de AsunciÃ³n,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The investigators will publish the results to compare data with other studies with COVID-19 convalescent plasma patients,2021-12-02T06:09:39Z,2021-12-02T06:09:39Z,340
NCT04747132,NA,2021-02-06,NA,NA,2021-02-08,2021-02-08,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"July 20, 2020",Actual,2020-07-20,February 2021,2021-02-28,"November 16, 2020",Actual,2020-11-16,"October 20, 2020",Actual,2020-10-20,NA,Interventional,NA,NA,Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency,Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency,Completed,NA,Not Applicable,110,Actual,"Universidad Iberoamericana A.C., Mexico",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:09:41Z,2021-12-02T06:09:41Z,357
NCT04746365,NA,2021-02-06,NA,NA,2021-02-08,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"December 6, 2020",Actual,2020-12-06,February 2021,2021-02-28,"February 6, 2021",Actual,2021-02-06,"January 31, 2021",Actual,2021-01-31,NA,Interventional,IRICT,NA,Ivermectin Role in Covid-19 Clinical Trial,"Ivermectin Role in Severe Covid-19 Treatment; a Double-blinded, Randomized Clinical Trial",Completed,NA,Phase 4,300,Actual,Elaraby Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:10:08Z,2021-12-02T06:10:08Z,357
NCT04745442,NA,2021-02-08,NA,NA,2021-02-08,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"April 27, 2020",Actual,2020-04-27,February 2021,2021-02-28,"January 15, 2021",Actual,2021-01-15,"December 20, 2020",Actual,2020-12-20,NA,Interventional,NA,NA,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Completed,NA,Phase 2,48,Actual,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The information will be provided after the results are published in a journal.,Upon request to uicec@imibic.org,NA,Yes,NA,2021-12-02T06:11:04Z,2021-12-02T06:11:04Z,357
NCT04739410,NA,2021-02-02,NA,NA,2021-02-03,2021-02-03,2021-02-04,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-04,Actual,"May 1, 2020",Actual,2020-05-01,February 2021,2021-02-28,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,NA,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Completed,NA,Phase 4,50,Actual,FMH College of Medicine and Dentistry,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,as soon as i will have time to respond,NA,NA,Yes,"whatever is needed, will share if needed at any time",2021-12-02T06:15:55Z,2021-12-02T06:15:55Z,362
NCT04734561,NA,2020-12-31,NA,NA,2021-09-29,2021-01-30,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-09-30,Actual,"February 8, 2021",Actual,2021-02-08,September 2021,2021-09-30,"September 29, 2021",Actual,2021-09-29,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,NA,Effects of Respiratory Muscle Training in People Who Have Had COVID-19 Disease,"Effects of Respiratory Muscle Training on Quality of Life, Physical and Pulmonary Function and Psychological Status in Patients Who Have Had COVID-19 Disease",Completed,NA,Not Applicable,88,Actual,Universidad Complutense de Madrid,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:19:53Z,2021-12-02T06:19:53Z,124
NCT04734171,NA,2021-01-29,NA,NA,2021-02-01,2021-02-01,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"April 2, 2020",Actual,2020-04-02,February 2021,2021-02-28,"April 16, 2020",Actual,2020-04-16,"April 16, 2020",Actual,2020-04-16,NA,Interventional,NA,NA,"Social Activity, Loneliness and Stigma During COVID-19 Outbreak","COVID-19 and Its Implications on Social Activity, Loneliness and Stigma",Completed,NA,Not Applicable,1200,Actual,Columbia University,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:20:22Z,2021-12-02T06:20:22Z,364
NCT04733625,NA,2021-01-31,NA,NA,2021-01-31,2021-01-31,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-31,2021-02-02,Actual,"September 15, 2020",Actual,2020-09-15,January 2021,2021-01-31,"December 17, 2020",Actual,2020-12-17,"December 17, 2020",Actual,2020-12-17,NA,Interventional,NA,NA,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,Completed,NA,Not Applicable,56,Actual,Kasr El Aini Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:20:55Z,2021-12-02T06:20:55Z,365
NCT04732819,NA,2021-01-27,2021-07-22,NA,2021-09-01,2021-01-29,2021-02-01,Actual,2021-09-01,2021-09-05,Actual,NA,NA,NA,2021-09-01,2021-09-05,Actual,"December 21, 2020",Actual,2020-12-21,September 2021,2021-09-30,"April 16, 2021",Actual,2021-04-16,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,"The overall number of baseline participants includes the number of residents and staff in each arm. The unit analyzed was nursing home facility. Baseline characteristics were obtained for residents and nursing home facilities, but not for staff.",Improving COVID-19 Vaccine Uptake in Nursing Homes,IMPACT-C: Improving Vaccine Uptake in Skilled Nursing Facilities,Completed,NA,Not Applicable,23768,Actual,Brown University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,The IPD and supporting documentation will be available through the CDCC within 6 months of the completion of the trial.,"Staff and patient data will be aggregated at the level of the facility. This data will be shared with the RADx-UP CDCC, who plans to make a central database that will ultimately be publicly available.",NA,Yes,"Data will be aggregated at the level of the facility. We will provide aggregated data to the RADx-UP Coordination and Data Collection Center (CDCC); however, given the nature of this data it will not be identifiable or linkable. The CDCC will facilitate cross-site pooling of data, whenever possible, and create a publicly available dataset with this information.",2021-12-02T06:21:40Z,2021-12-02T06:21:40Z,152
NCT04730323,NA,2021-01-26,NA,NA,2021-01-28,2021-01-28,2021-01-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"May 12, 2020",Actual,2020-05-12,January 2021,2021-01-31,"June 12, 2020",Actual,2020-06-12,"June 12, 2020",Actual,2020-06-12,NA,Interventional,NA,NA,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,Completed,NA,Phase 4,93,Actual,FMH College of Medicine and Dentistry,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"Whenever will be asked to, within few days",Only officials can access the data,NA,Yes,IPD can be shared with researchers in future too,2021-12-02T06:23:26Z,2021-12-02T06:23:26Z,368
NCT04729491,NA,2021-01-25,NA,NA,2021-01-25,2021-01-25,2021-01-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-28,Actual,"June 30, 2020",Actual,2020-06-30,June 2020,2020-06-30,"October 7, 2020",Actual,2020-10-07,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,NA,EAT-DUTA AndroCoV Trial,Early Antiandrogen Treatment (EAT) With Dutasteride for COVID-19 (EAT-DUTA AndroCoV Trial),Completed,NA,Phase 2/Phase 3,138,Actual,Corpometria Institute,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:24:18Z,2021-12-02T06:24:18Z,371
NCT04728802,NA,2021-01-27,2021-06-15,NA,2021-06-22,2021-01-27,2021-01-28,Actual,2021-06-15,2021-06-23,Actual,NA,NA,NA,2021-06-22,2021-06-24,Actual,"February 1, 2021",Actual,2021-02-01,June 2021,2021-06-30,"April 15, 2021",Actual,2021-04-15,"April 15, 2021",Actual,2021-04-15,NA,Interventional,NA,NA,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Completed,NA,Phase 3,645,Actual,"Applied Biology, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Available upon request after peer review and publication.,Available upon request at data@appliedbiology.com,NA,Yes,"Yes, study data sets will be made available upon request after peer review and publication.",2021-12-02T06:24:34Z,2021-12-02T06:24:34Z,223
NCT04728594,NA,2021-01-26,2021-07-16,NA,2021-07-22,2021-01-26,2021-01-28,Actual,2021-07-22,2021-07-26,Actual,NA,NA,NA,2021-07-22,2021-07-26,Actual,"January 15, 2021",Actual,2021-01-15,July 2021,2021-07-31,"January 20, 2021",Actual,2021-01-20,"January 17, 2021",Actual,2021-01-17,NA,Interventional,NA,"The baseline outcome measure was not applicable, since registration for vaccination was the outcome, and all participants were selected for not being registered.",Emails Promoting COVID-19 Vaccination Among Healthcare Workers,Evaluation of an Email Intervention Promoting COVID-19 Vaccination Among Healthcare Workers,Completed,NA,Not Applicable,9566,Actual,Geisinger Clinic,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will become available after publication of study results in a scientific journal and will be available as long as the Open Science Framework hosts the data.,The data on the Open Science Framework will be open to anyone requesting that information.,http://osf.io,Yes,Data with no personally identifiable information will be made available to other researchers on the Open Science Framework for transparency. This will include the essential data and code needed to replicate the analysis that yielded reported findings.,2021-12-02T06:24:45Z,2021-12-02T06:24:45Z,193
NCT04724538,NA,2020-12-29,2021-05-02,NA,2021-07-04,2021-01-23,2021-01-26,Actual,2021-07-04,2021-07-07,Actual,NA,NA,NA,2021-07-04,2021-07-07,Actual,"October 15, 2020",Actual,2020-10-15,July 2021,2021-07-31,"March 15, 2021",Actual,2021-03-15,"February 10, 2021",Actual,2021-02-10,NA,Interventional,NA,NA,Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19,Inhalation Low Dose Radionuclide Therapy in Comprehensive Treatment of COVID-19 Viral Pneumonia,Completed,NA,Phase 1/Phase 2,25,Actual,National Medical Research Radiological Centre of the Ministry of Health of Russia,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:28:21Z,2021-12-02T06:28:21Z,211
NCT04723563,NA,2021-01-22,NA,NA,2021-09-03,2021-01-22,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-05,Actual,"February 22, 2021",Actual,2021-02-22,September 2021,2021-09-30,"August 23, 2021",Actual,2021-08-23,"August 23, 2021",Actual,2021-08-23,NA,Interventional,INHALE-HEP,NA,Nebulized Heparin for the Treatment of COVID-19,INHALEd Unfractionated HEParin for the Treatment of Hospitalized Patients With COVID-19 Pneumonia,Completed,NA,Phase 4,50,Actual,Frederick Health,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:29:03Z,2021-12-02T06:29:03Z,150
NCT04723524,NA,2021-01-22,NA,NA,2021-10-05,2021-01-22,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"September 22, 2020",Actual,2020-09-22,October 2021,2021-10-31,"August 23, 2021",Actual,2021-08-23,"August 23, 2021",Actual,2021-08-23,NA,Interventional,RCT,NA,Jinhua Qinggan Granules in the Treatment of COVID-19,"Multi-center, Randomized, Double Blind and Placebo Controlled Clinical Trial on the Effectiveness and Safety of Jinhua Qinggan Granules (JHQG) for the Treatment of COVID 19 Patients",Completed,NA,Phase 2,402,Actual,University of Karachi,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:29:04Z,2021-12-02T06:29:04Z,118
NCT04723290,NA,2021-01-21,NA,NA,2021-03-24,2021-01-21,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"June 20, 2020",Actual,2020-06-20,March 2021,2021-03-31,"December 31, 2020",Actual,2020-12-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,NA,COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020,SARS-CoV-2 Seroconversion Study Among GHdC Staff Members,Completed,NA,Not Applicable,2817,Actual,Grand HÃ´pital de Charleroi,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"At this moment, there is no plan to share the results",2021-12-02T06:29:12Z,2021-12-02T06:29:12Z,313
NCT04720794,NA,2020-10-13,NA,NA,2021-01-22,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-26,Actual,"September 25, 2020",Actual,2020-09-25,January 2021,2021-01-31,"October 20, 2020",Actual,2020-10-20,"October 20, 2020",Actual,2020-10-20,NA,Interventional,NA,NA,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay,Completed,NA,Not Applicable,101,Actual,Lucira Health Inc,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:31:21Z,2021-12-02T06:31:21Z,374
NCT04720235,NA,2021-01-15,NA,NA,2021-04-09,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-12,Actual,"December 9, 2020",Actual,2020-12-09,January 2021,2021-01-31,"March 30, 2021",Actual,2021-03-30,"March 9, 2021",Actual,2021-03-09,NA,Interventional,NA,NA,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay Among Asymptomatic Subjects,Completed,NA,Not Applicable,304,Actual,Lucira Health Inc,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:31:56Z,2021-12-02T06:31:56Z,297
NCT04719234,NA,2021-01-20,NA,NA,2021-01-21,2021-01-21,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"June 15, 2020",Actual,2020-06-15,January 2021,2021-01-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,NA,Lung Ultrasonography in COVID-19 Pneumonia,Comparison of Lung Ultrasonography Findings With Chest Computerized Tomography Results in Corona virÃ¼s (COVID-19) Pneumonia,Completed,NA,Not Applicable,60,Actual,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:32:44Z,2021-12-02T06:32:44Z,375
NCT04716556,NA,2021-01-14,NA,NA,2021-08-25,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-26,Actual,"July 16, 2020",Actual,2020-07-16,August 2021,2021-08-31,"May 31, 2021",Actual,2021-05-31,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,NA,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa Due to SARS-CoV2 (TSUNAMI Study): a Multicenter Open Label Randomized Control Trial,Completed,NA,Not Applicable,474,Actual,Istituto Superiore di SanitÃ ,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:35:08Z,2021-12-02T06:35:08Z,159
NCT04716647,NA,2021-01-18,NA,NA,2021-01-19,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-20,Actual,"October 9, 2020",Actual,2020-10-09,January 2021,2021-01-31,"December 18, 2020",Actual,2020-12-18,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,NA,Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research,A Community-Based Participatory Research to Assess the Feasibility of Ayurveda Intervention in Patients With Mild-to-Moderate COVID-19,Completed,NA,Not Applicable,28,Actual,Aarogyam UK,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:35:09Z,2021-12-02T06:35:09Z,377
NCT04715932,NA,2021-01-15,NA,NA,2021-07-08,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-08,2021-07-12,Actual,"February 18, 2021",Actual,2021-02-18,July 2021,2021-07-31,"June 7, 2021",Actual,2021-06-07,"May 25, 2021",Actual,2021-05-25,NA,Interventional,Hesperidin,NA,Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN),"A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Hesperidin Therapy on COVID-19 Symptoms: The Hesperidin Coronavirus Study (Hesperidin)",Completed,NA,Phase 2,216,Actual,Montreal Heart Institute,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:35:59Z,2021-12-02T06:35:59Z,207
NCT04715607,NA,2021-01-12,NA,NA,2021-09-28,2021-01-15,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-30,Actual,"January 22, 2021",Actual,2021-01-22,September 2021,2021-09-30,"May 31, 2021",Actual,2021-05-31,"May 30, 2021",Actual,2021-05-30,NA,Interventional,NA,NA,"COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens","Comparison of Detection Rate of SARS-CoV-2 in Saliva, Oropharyngeal and Nasopharyngeal Specimens in a Public COVID-19 Test Setting",Completed,NA,Not Applicable,27947,Actual,"Rigshospitalet, Denmark",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:36:05Z,2021-12-02T06:36:05Z,125
NCT04716426,NA,2021-01-18,2021-03-31,NA,2021-04-06,2021-01-18,2021-01-20,Actual,2021-04-06,2021-04-08,Actual,NA,NA,NA,2021-04-06,2021-04-08,Actual,"January 28, 2021",Actual,2021-01-28,April 2021,2021-04-30,"March 25, 2021",Actual,2021-03-25,"March 25, 2021",Actual,2021-03-25,NA,Interventional,NA,NA,APTâ„¢ T3X on the COVID-19 Contamination Rate,Use of APTâ„¢ T3X to Decrease the COVID-19 Contamination Rate in Humans,Completed,NA,Not Applicable,100,Actual,University of Nove de Julho,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:35:47Z,2021-12-02T06:35:47Z,300
NCT04713878,NA,2021-01-09,NA,NA,2021-01-16,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-16,2021-01-20,Actual,"May 8, 2020",Actual,2020-05-08,January 2021,2021-01-31,"July 15, 2020",Actual,2020-07-15,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,NA,Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,A 8-Week Trial of Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,Completed,NA,Not Applicable,21,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:37:44Z,2021-12-02T06:37:44Z,380
NCT04713553,NA,2021-01-15,NA,NA,2021-08-04,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"February 15, 2021",Actual,2021-02-15,August 2021,2021-08-31,"July 22, 2021",Actual,2021-07-22,"July 22, 2021",Actual,2021-07-22,NA,Interventional,NA,NA,"A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162b2 AGAINST COVID-19 IN HEALTHY PARTICIPANTS 12 THROUGH 50 YEARS OF AGE AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED COVID-19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50 YEARS OF AGE",Completed,NA,Phase 3,1530,Actual,BioNTech SE,NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-02T06:38:06Z,2021-12-02T06:38:06Z,180
NCT04712045,NA,2021-01-11,NA,NA,2021-01-13,2021-01-13,2021-01-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-15,Actual,"August 1, 2020",Actual,2020-08-01,January 2021,2021-01-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,RUPERT,NA,Rational Use of Personal Protective Equipment During COVID-19 Pandemic,Rational Use of Personal Protective Equipment: a Randomised Trial and Quality Improvement Intervention During COVID-19 Pandemic,Completed,NA,Not Applicable,67,Actual,University of Oxford,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:39:11Z,2021-12-02T06:39:11Z,383
NCT04713111,NA,2021-01-08,NA,NA,2021-03-10,2021-01-14,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-03-10,2021-03-12,Actual,"May 4, 2020",Actual,2020-05-04,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,NA,Stress and Recovery in Frontline COVID-19 Workers,Stress and Recovery in Frontline Healthcare COVID-19 Workers: A Feasibility Study Using Wearable and Smartphone Devices,Completed,NA,Not Applicable,383,Actual,4YouandMe,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Internal collaborative researchers will have access to all coded data during the full duration of the study. Consented participants' coded data will be available in the Synapse at Sage Bionetworks for selected researchers to access indefinitely, one year after study completion.","As coded study data will then exist among consenting participants in the Synapse at Sage Bionetworks in de-identified form, the electronic data files will be kept indefinitely. The Principal Investigator will be responsible for receipt and/or transmission of data as required.",NA,Yes,"Under the 4YouandMe open source model, we will make all data, findings, digital health applications and algorithms available in the public domain. Accordingly, de-identified data produced from this project will be shared broadly with qualified researchers (among participants who opt in) through Sage Bionetworks Synapse and will serve as an immense resource, reflecting a highly granular and high- dimensional map of physiological stress responses and knowledge surrounding inadvertent consequences of objective stress measurement. Only data from consenting participants will be shared through Sage Bionetworks Synapse. Additionally, Source code for the developed app will be made available as open source software on GitHub so it can be evolved for future work by others.",2021-12-02T06:38:20Z,2021-12-02T06:38:20Z,327
NCT04710381,NA,2021-01-13,NA,NA,2021-07-20,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"February 1, 2021",Actual,2021-02-01,July 2021,2021-07-31,"June 2, 2021",Actual,2021-06-02,"June 2, 2021",Actual,2021-06-02,NA,Interventional,NA,NA,IMUNORÂ® Preparation in the Prevention of COVID-19,"Pilot, Monocentric, Phase-IV Clinical Trial Assessing the Clinical Effect of Peroral Immunomodulation Treatment Using the IMUNORÂ® Preparation in the Prevention of COVID-19 Disease",Completed,NA,Phase 4,56,Actual,University Hospital Ostrava,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no plan to make individual participant data available to other researchers.,2021-12-02T06:40:29Z,2021-12-02T06:40:29Z,195
NCT04709172,NA,2021-01-12,NA,NA,2021-10-05,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"January 5, 2021",Actual,2021-01-05,January 2021,2021-01-31,"August 15, 2021",Actual,2021-08-15,"August 15, 2021",Actual,2021-08-15,NA,Interventional,NA,NA,Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia,"Prospective, Non-controlled Pilot Study to Evaluate the Efficacy and Safety of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia",Completed,NA,Phase 4,20,Actual,Meiji Pharma Spain S.A.,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:41:24Z,2021-12-02T06:41:24Z,118
NCT04707742,NA,2021-01-07,NA,NA,2021-10-06,2021-01-12,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-11,Actual,"June 15, 2020",Actual,2020-06-15,September 2021,2021-09-30,"September 30, 2021",Actual,2021-09-30,"September 18, 2021",Actual,2021-09-18,NA,Interventional,BUCOSARS,NA,Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients,Clinical Evaluation of Antiseptic Mouth Rinses to Reduce Salivary Viral Load of SARS-CoV-2 in COVID-19 Patients,Completed,NA,Not Applicable,160,Actual,FundaciÃ³n para el Fomento de la InvestigaciÃ³n Sanitaria y BiomÃ©dica de la Comunitat Valenciana,NA,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:42:36Z,2021-12-02T06:42:36Z,117
NCT04705753,NA,2021-01-06,NA,NA,2021-01-11,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"April 1, 2020",Actual,2020-04-01,January 2021,2021-01-31,"October 15, 2020",Actual,2020-10-15,"October 15, 2020",Actual,2020-10-15,NA,Interventional,COVID-19-IAMA,NA,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients","Evaluation of the Clinical Outcomes and the Quality of Life of Patients Exhibiting Symptoms Characteristic of Viral Respiratory Infection (VRI), Including Infection by SARS-CoV-2 (COVID-19), and Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in These Patients and the People Cohabiting With Them Via an Open-label, Single-arm Trial",Completed,NA,Phase 2/Phase 3,20,Actual,University of Crete,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:44:26Z,2021-12-02T06:44:26Z,385
NCT04703114,NA,2020-11-30,NA,NA,2021-09-27,2021-01-07,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"February 5, 2021",Actual,2021-02-05,September 2021,2021-09-30,"September 15, 2021",Actual,2021-09-15,"September 15, 2021",Actual,2021-09-15,NA,Interventional,AMBUCOV,NA,Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV),Study of the Immunological and Virological Response of Patients Infected With SARS-CoV-2 and Presenting an Asymptomatic or Pauci-symptomatic Form,Completed,NA,Not Applicable,57,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:46:50Z,2021-12-02T06:46:50Z,126
NCT04701489,NA,2021-01-05,NA,NA,2021-06-01,2021-01-06,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-04,Actual,"January 14, 2021",Actual,2021-01-14,June 2021,2021-06-30,"April 7, 2021",Actual,2021-04-07,"March 15, 2021",Actual,2021-03-15,NA,Interventional,NA,NA,UNITE Study (UMN-GE) for COVID-19,Ultrasound Neural and Immunomodulation Treatment Evaluation Study (UMN-GE) for COVID-19,Completed,NA,Not Applicable,30,Actual,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:48:13Z,2021-12-02T06:48:13Z,244
NCT04701710,NA,2021-01-07,NA,NA,2021-02-22,2021-01-07,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-23,Actual,"October 15, 2020",Actual,2020-10-15,February 2021,2021-02-28,"December 31, 2020",Actual,2020-12-31,"December 18, 2020",Actual,2020-12-18,NA,Interventional,Ivercar-Tuc,NA,Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan,A Randomized Trial - Intensive Treatment Based in Ivermectin and Iota-carrageenan as Prophylaxis for Covid-19 In Healthcare Agents,Completed,NA,Phase 1/Phase 2,300,Actual,"Ministry of Public Health, Argentina",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,N/C,2021-12-02T06:48:02Z,2021-12-02T06:48:02Z,343
NCT04699916,NA,2021-01-06,NA,NA,2021-09-23,2021-01-06,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"January 4, 2021",Actual,2021-01-04,September 2021,2021-09-30,"September 23, 2021",Actual,2021-09-23,"May 23, 2021",Actual,2021-05-23,NA,Interventional,NA,NA,EEG-based Sedation Protocol for Patients on Mechanical Ventilation Due to SARS-CoV-2 Pneumonia,EEG-based Protocol to Guide Deep Sedation Decreases the Days of Mechanical Ventilation in Patients With SARS-CoV-2 Pneumonia: Randomized Clinical Trial,Completed,NA,Not Applicable,50,Actual,University of Chile,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:49:27Z,2021-12-02T06:49:27Z,130
NCT04698798,NA,2021-01-04,NA,NA,2021-07-07,2021-01-04,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"January 2, 2021",Actual,2021-01-02,July 2021,2021-07-31,"April 3, 2021",Actual,2021-04-03,"April 3, 2021",Actual,2021-04-03,NA,Interventional,SMW,NA,Skeletal Muscle Wasting in SARS-CoV-2,Skeletal Muscle Wasting in SARS-CoV-2 Infected ICU (Intensive Care Unit) Patients,Completed,NA,Not Applicable,22,Actual,Hasselt University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:50:43Z,2021-12-02T06:50:43Z,208
NCT04691908,NA,2020-12-21,NA,NA,2021-07-23,2020-12-29,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"December 25, 2020",Actual,2020-12-25,December 2020,2020-12-31,"July 11, 2021",Actual,2021-07-11,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,NA,"Immunogenicity, Efficacy and Safety of QazCovid-inÂ® COVID-19 Vaccine","Multicenter, Randomized, Blind, Placebo-controlled Clinical Study of III Phase on Assessment of Preventive Efficiency, Safety and Immunogenicity QazCovid-inÂ®-Vaccine Against COVID-19 in Healthy Adult Volunteers",Completed,NA,Phase 3,3000,Actual,Research Institute for Biological Safety Problems,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:56:25Z,2021-12-02T06:56:25Z,192
NCT04690920,NA,2020-12-19,NA,NA,2020-12-30,2020-12-30,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-30,2020-12-31,Actual,"July 23, 2020",Actual,2020-07-23,December 2020,2020-12-31,"December 10, 2020",Actual,2020-12-10,"December 10, 2020",Actual,2020-12-10,NA,Interventional,NA,NA,Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins,Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach,Completed,NA,Not Applicable,200,Actual,University of Lahore,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,"statistical analysis, results",2021-12-02T06:56:58Z,2021-12-02T06:56:58Z,397
NCT04690413,NA,2020-08-31,NA,NA,2021-03-02,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"September 1, 2020",Actual,2020-09-01,March 2021,2021-03-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,NA,NOWDx Test for the Detection of Antibodies to COVID-19,NOWDx Test for the Detection of Antibodies to COVID-19,Completed,NA,Not Applicable,129,Actual,"NOWDiagnostics, Inc.",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:57:46Z,2021-12-02T06:57:46Z,335
NCT04687488,NA,2020-12-03,NA,NA,2020-12-22,2020-12-22,2020-12-29,Actual,NA,NA,NA,NA,NA,NA,2020-12-22,2020-12-29,Actual,"July 23, 2020",Actual,2020-07-23,December 2020,2020-12-31,"November 9, 2020",Actual,2020-11-09,"November 9, 2020",Actual,2020-11-09,NA,Interventional,NA,NA,Aerosol and Droplet Dispersion During Gastrointestinal Motility Investigations,COVID-19: The Study of Aerosol Generation and Droplet Dispersion and Deposition During Naso-gastric Intubation for Gastrointestinal Motility Investigations,Completed,NA,Not Applicable,15,Actual,Universitaire Ziekenhuizen Leuven,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:00:52Z,2021-12-02T07:00:52Z,405
NCT04689399,NA,2020-12-26,NA,NA,2021-03-25,2020-12-28,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-30,Actual,"December 26, 2020",Actual,2020-12-26,March 2021,2021-03-31,"March 25, 2021",Actual,2021-03-25,"March 25, 2021",Actual,2021-03-25,NA,Interventional,NA,NA,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test,Completed,NA,Not Applicable,4697,Actual,"Rigshospitalet, Denmark",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:58:40Z,2021-12-02T06:58:40Z,312
NCT04685512,NA,2020-11-16,NA,NA,2021-06-29,2020-12-24,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-07-01,Actual,"November 18, 2020",Actual,2020-11-18,June 2021,2021-06-30,"May 1, 2021",Actual,2021-05-01,"April 1, 2021",Actual,2021-04-01,NA,Interventional,AR0-CORONA,NA,Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home,Effect of Tenofovir/Emtricitabine Short Course on Viral Clearance in Patients Recently Infected With SARS-COV2 (Covid-19) Not Requiring Hospitalization: a Phase IIB/III Multicenter Open-label Randomized Controlled Trial,Completed,NA,Phase 2/Phase 3,60,Actual,"University Hospital, Caen",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,We encourage contact the corresponding author for academic IPD sharing,2021-12-02T07:02:44Z,2021-12-02T07:02:44Z,216
NCT04679493,NA,2020-12-18,NA,NA,2021-09-21,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"December 17, 2020",Actual,2020-12-17,September 2021,2021-09-30,"April 9, 2021",Actual,2021-04-09,"April 9, 2021",Actual,2021-04-09,NA,Interventional,NA,NA,"Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers","Double Blind, Randomized, Placebo-controlled Study of Safety, Tolerability, and Pharmacokinetics of Ascending Doses of XC7 After Single and Multiple Oral Administration in Healthy Volunteers",Completed,NA,Phase 1,16,Actual,NP Therapeutics,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:08:53Z,2021-12-02T07:08:53Z,132
NCT04679415,NA,2020-12-21,NA,NA,2021-08-24,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-26,Actual,"December 17, 2020",Actual,2020-12-17,December 2020,2020-12-31,"August 19, 2021",Actual,2021-08-19,"August 19, 2021",Actual,2021-08-19,NA,Interventional,NA,NA,Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia,"A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous (IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients",Completed,NA,Phase 2,63,Actual,"ImmuneMed, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:09:17Z,2021-12-02T07:09:17Z,160
NCT04676867,NA,2020-12-17,NA,NA,2021-06-01,2020-12-18,2020-12-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"January 11, 2021",Actual,2021-01-11,June 2021,2021-06-30,"May 17, 2021",Actual,2021-05-17,"May 17, 2021",Actual,2021-05-17,NA,Interventional,NA,NA,Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19,"A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19",Completed,NA,Phase 2,227,Actual,DalCor Pharmaceuticals,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:11:51Z,2021-12-02T07:11:51Z,244
NCT04678778,NA,2020-12-11,NA,NA,2021-04-27,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-29,Actual,"March 19, 2019",Actual,2019-03-19,April 2021,2021-04-30,"February 19, 2021",Actual,2021-02-19,"February 19, 2021",Actual,2021-02-19,NA,Interventional,NRVR,NA,Virtual Reality Study - COVID-19 Protocol,Targeted Physical and Cognitive Activity in a VR Environment - COVID-19 Protocol,Completed,NA,Not Applicable,14,Actual,University of Southern California,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:09:53Z,2021-12-02T07:09:53Z,279
NCT04678739,NA,2020-12-19,NA,NA,2021-03-31,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-02,Actual,"August 15, 2020",Actual,2020-08-15,March 2021,2021-03-31,"February 10, 2021",Actual,2021-02-10,"January 30, 2021",Actual,2021-01-30,NA,Interventional,NA,NA,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,Completed,NA,Phase 3,205,Actual,M Abdur Rahim Medical College and Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:09:56Z,2021-12-02T07:09:56Z,306
NCT04678830,NA,2020-12-14,NA,NA,2021-07-30,2020-12-18,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-02,Actual,"March 1, 2021",Actual,2021-03-01,July 2021,2021-07-31,"July 8, 2021",Actual,2021-07-08,"June 5, 2021",Actual,2021-06-05,NA,Interventional,NA,NA,COVID-19 Long-Haulers Study,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers]",Completed,NA,Phase 2,56,Actual,"CytoDyn, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:09:52Z,2021-12-02T07:09:52Z,185
NCT04676971,NA,2020-12-16,NA,NA,2021-11-29,2020-12-17,2020-12-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-29,2021-12-01,Estimate,"December 11, 2020",Actual,2020-12-11,December 2020,2020-12-31,"October 28, 2021",Actual,2021-10-28,"August 29, 2021",Actual,2021-08-29,NA,Interventional,NA,NA,Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia,"Efficacy and Safety of Intravenously Administered hzVSF-v13 in Patients With COVID-19 Pneumonia: a Phase II, Proof of Concept, Multicentre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study",Completed,NA,Phase 2,115,Actual,"ImmuneMed, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:11:49Z,2021-12-02T07:11:49Z,63
NCT04677270,NA,2020-12-18,NA,NA,2020-12-18,2020-12-18,2020-12-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-18,2020-12-21,Actual,"August 31, 2020",Actual,2020-08-31,December 2020,2020-12-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,COVIDPROBLEM,NA,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic,Completed,NA,Not Applicable,397,Actual,Karolinska Institutet,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:11:52Z,2021-12-02T07:11:52Z,409
NCT04674644,NA,2020-12-16,2021-01-02,NA,2021-01-30,2020-12-17,2020-12-19,Actual,2021-01-27,2021-01-29,Actual,NA,NA,NA,2021-01-30,2021-02-02,Actual,"October 16, 2020",Actual,2020-10-16,January 2021,2021-01-31,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,NA,NA,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Suleyman Demirel University Faculty of Dentistry Pediatric Dentistry Department,Completed,NA,Not Applicable,850,Actual,Suleyman Demirel University,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:13:39Z,2021-12-02T07:13:39Z,366
NCT04673214,NA,2020-12-16,2021-03-08,NA,2021-08-12,2020-12-16,2020-12-17,Actual,2021-08-12,2021-08-16,Actual,NA,NA,NA,2021-08-12,2021-08-16,Actual,"December 16, 2020",Actual,2020-12-16,August 2021,2021-08-31,"February 25, 2021",Actual,2021-02-25,"February 25, 2021",Actual,2021-02-25,NA,Interventional,NA,"Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis.",Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Prognostic Modification in Patients With COVID-19 Under Early Intervention Treatment at U.M.F 13 and U.M.F 20,Completed,NA,Phase 3,114,Actual,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,SHARED VIA EMAIL IF OTHER RESEARCHERS REQUIRE IT,2021-12-02T07:15:11Z,2021-12-02T07:15:11Z,172
NCT04668625,NA,2020-12-09,NA,NA,2021-02-05,2020-12-14,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-05,2021-02-08,Actual,"November 30, 2020",Actual,2020-11-30,January 2021,2021-01-31,"January 8, 2021",Actual,2021-01-08,"December 20, 2020",Actual,2020-12-20,NA,Interventional,NA,NA,"Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures",Risk of Infection of SARS-CoV-2 in a Massive Musical Show With Transmission Prevention Measures: Randomized Study,Completed,NA,Not Applicable,1000,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:18:49Z,2021-12-02T07:18:49Z,360
NCT04668469,NA,2020-11-25,NA,NA,2020-12-11,2020-12-11,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-16,Actual,"June 8, 2020",Actual,2020-06-08,December 2020,2020-12-31,"October 30, 2020",Actual,2020-10-30,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,NA,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Completed,NA,Not Applicable,600,Actual,Benha University,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:19:04Z,2021-12-02T07:19:04Z,416
NCT04666233,NA,2020-12-11,NA,NA,2021-03-27,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-27,2021-04-01,Actual,"March 16, 2021",Actual,2021-03-16,March 2021,2021-03-31,"March 23, 2021",Actual,2021-03-23,"March 23, 2021",Actual,2021-03-23,NA,Interventional,NA,NA,Personal Protective Equipment for the Prevention of SARS-Cov-2 During Neonatal Resuscitation,Does Personal Protective Equipment for the Prevention of SARS-Cov-2 Infection Impact the Timing of Ventilation in Neonates Needing Resuscitation at Birth? A Crossover Randomized Controlled Trial,Completed,NA,Not Applicable,48,Actual,University Hospital Padova,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:21:00Z,2021-12-02T07:21:00Z,310
NCT04666441,NA,2020-12-10,NA,NA,2021-09-30,2020-12-10,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-08,Actual,"December 15, 2020",Actual,2020-12-15,September 2021,2021-09-30,"September 21, 2021",Actual,2021-09-21,"March 4, 2021",Actual,2021-03-04,NA,Interventional,NA,NA,COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection,A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection,Completed,NA,Phase 2,1164,Actual,Regeneron Pharmaceuticals,NA,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-12-02T07:20:53Z,2021-12-02T07:20:53Z,123
NCT04665193,NA,2020-12-08,NA,NA,2021-04-29,2020-12-10,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-05-04,Actual,"November 23, 2020",Actual,2020-11-23,April 2021,2021-04-30,"April 28, 2021",Actual,2021-04-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,NA,An Approach to Screening for COVID-19 at Vancouver Airport,An Approach to Screening for SARS-CoV-2 at YVR: UBC-PHC-WestJet-YVR COVID-19 Screening Study,Completed,NA,Not Applicable,592,Actual,University of British Columbia,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:21:57Z,2021-12-02T07:21:57Z,277
NCT04663594,NA,2020-11-27,NA,NA,2021-10-01,2020-12-04,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-08,Actual,"December 4, 2020",Actual,2020-12-04,November 2020,2020-11-30,"February 10, 2021",Actual,2021-02-10,"February 10, 2021",Actual,2021-02-10,NA,Interventional,O-ACEPOP,NA,Online Culture for Mental Health in People Aged 16-24,An Online Cultural Experience to Support Mental Health in People Aged 16-24 During COVID-19: the O-ACEPOP (Online Active Community Engagement Proof of Principle) Study,Completed,NA,Not Applicable,413,Actual,University of Oxford,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will be made available on OSF once peer reviewed,NA,NA,Yes,The data will be made available on OSF once peer reviewed,2021-12-02T07:23:03Z,2021-12-02T07:23:03Z,122
NCT04662671,NA,2020-12-09,NA,NA,2021-02-10,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"November 18, 2020",Actual,2020-11-18,February 2021,2021-02-28,"January 30, 2021",Actual,2021-01-30,"December 9, 2020",Actual,2020-12-09,NA,Interventional,NA,NA,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19","Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19",Completed,NA,Phase 1/Phase 2,31,Actual,KNOWBio Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:23:54Z,2021-12-02T07:23:54Z,355
NCT04659109,NA,2020-11-30,NA,NA,2021-09-10,2020-12-07,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-13,Actual,"December 16, 2020",Actual,2020-12-16,September 2021,2021-09-30,"August 6, 2021",Actual,2021-08-06,"August 6, 2021",Actual,2021-08-06,NA,Interventional,GARDEN,NA,Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19,"A Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel Group, Exploratory Efficacy and Safety Study of Glenzocimab in SARS-Cov-2-related Acute Respiratory Distress Syndrome",Completed,NA,Phase 2,60,Actual,Acticor Biotech,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:27:03Z,2021-12-02T07:27:03Z,143
NCT04657471,NA,2020-12-06,NA,NA,2021-03-12,2020-12-06,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-03-12,2021-03-15,Actual,"December 8, 2020",Actual,2020-12-08,December 2020,2020-12-31,"March 8, 2021",Actual,2021-03-08,"March 8, 2021",Actual,2021-03-08,NA,Interventional,NA,NA,Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study,Hospitalization or Outpatient ManagEment of Patients With Suspected or Confirmed SRAS-CoV-2 Infection: the Revised HOME-CoV Score Study.,Completed,NA,Not Applicable,1300,Actual,"University Hospital, Angers",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:28:13Z,2021-12-02T07:28:13Z,325
NCT04657497,NA,2020-11-09,NA,NA,2021-06-11,2020-12-06,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-14,Actual,"November 9, 2020",Actual,2020-11-09,May 2021,2021-05-31,"April 9, 2021",Actual,2021-04-09,"March 26, 2021",Actual,2021-03-26,NA,Interventional,NA,NA,A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19),"A Placebo-controlled, Multicenter, Double-blind, Randomized, Parallel-group Comparative Study in SARS-CoV-2 Infection (COVID-19)",Completed,NA,Phase 3,155,Actual,Ono Pharmaceutical Co. Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,https://www.ono.co.jp/eng/rd/policy.html,Yes,NA,2021-12-02T07:28:23Z,2021-12-02T07:28:23Z,234
NCT04656626,NA,2020-12-04,NA,NA,2020-12-08,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-10,Actual,"July 7, 2020",Actual,2020-07-07,December 2020,2020-12-31,"September 5, 2020",Actual,2020-09-05,"July 21, 2020",Actual,2020-07-21,NA,Interventional,NA,NA,Brief Mindfulness Based Intervention to Improve Psychological Wellbeing,"Brief Mindfulness Based Intervention for Front-Line Medical Staff in the COVID19 Pandemic to Improve Psychological Wellbeing, a Randomized Controlled Multicenter Trial",Completed,NA,Not Applicable,146,Actual,Imam Abdulrahman Bin Faisal University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:28:58Z,2021-12-02T07:28:58Z,419
NCT04656691,NA,2020-12-04,NA,NA,2021-04-27,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-29,Actual,"January 4, 2021",Actual,2021-01-04,April 2021,2021-04-30,"April 18, 2021",Actual,2021-04-18,"April 18, 2021",Actual,2021-04-18,NA,Interventional,UNITED,NA,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,Completed,NA,Phase 4,4000,Actual,UnitedHealth Group,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No plan to share participant level data with other projects or researchers.,2021-12-02T07:29:08Z,2021-12-02T07:29:08Z,279
NCT04652648,NA,2020-12-02,NA,NA,2020-12-02,2020-12-02,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-03,Actual,"May 27, 2020",Actual,2020-05-27,December 2020,2020-12-31,"November 15, 2020",Actual,2020-11-15,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,NA,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Completed,NA,Phase 4,54,Actual,Bryn Mawr Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:32:25Z,2021-12-02T07:32:25Z,425
NCT04647305,NA,2020-11-24,NA,NA,2021-04-26,2020-11-25,2020-11-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-27,Actual,"January 16, 2021",Actual,2021-01-16,April 2021,2021-04-30,"March 4, 2021",Actual,2021-03-04,"March 4, 2021",Actual,2021-03-04,NA,Interventional,COVPROSHIELD,NA,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission: A Randomized Controlled Trial,Completed,NA,Not Applicable,233,Actual,"University of Los Andes, Columbia",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months after publication,A formal request sent to the principal investigator.,NA,Yes,"After publication of main results, data will be available for other researchers such as: Study Protocol, Statistical Analysis Plan, Informed Consent Form, Clinical Study Report and Analytic Code.",2021-12-02T07:36:59Z,2021-12-02T07:36:59Z,280
NCT04649424,NA,2020-11-27,NA,NA,2021-07-14,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-07-14,2021-07-15,Actual,"December 22, 2020",Actual,2020-12-22,July 2021,2021-07-31,"April 13, 2021",Actual,2021-04-13,"April 13, 2021",Actual,2021-04-13,NA,Interventional,NA,NA,COVID-19 Nasal Swab Trial,Comparative Evaluation of Nasopharyngeal Swabs for Sampling and Detection of SARS-CoV2,Completed,NA,Not Applicable,169,Actual,Orthopaedic Innovation Centre,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:35:00Z,2021-12-02T07:35:00Z,201
NCT04646109,NA,2020-11-15,2020-12-03,NA,2021-01-25,2020-11-25,2020-11-27,Actual,2021-01-25,2021-01-27,Actual,NA,NA,NA,2021-01-25,2021-01-27,Actual,"May 11, 2020",Actual,2020-05-11,January 2021,2021-01-31,"September 2, 2020",Actual,2020-09-02,"September 2, 2020",Actual,2020-09-02,NA,Interventional,NA,"36 patients were included in the study group. But, 6 patients in the study group were excluded from the study and analysis because ivermectin treatments were terminated due to the detection of a mutation that impairs ivermectin metabolism. As a result, overall number of baseline participants in the study group was 30.",Ivermectin for Severe COVID-19 Management,The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management,Completed,NA,Phase 3,66,Actual,Afyonkarahisar Health Sciences University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:38:08Z,2021-12-02T07:38:08Z,371
NCT04645407,NA,2020-02-15,NA,NA,2020-11-25,2020-11-25,2020-11-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"February 1, 2020",Actual,2020-02-01,November 2020,2020-11-30,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,NA,Effects of Fuzheng Huayu Tablets on COVID-19,Efficacy of Fuzheng Huayu Tablets for Treating Pulmonary Inflammation in Patients With COVID-19: A Case-Control Study,Completed,NA,Phase 4,66,Actual,ShuGuang Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:38:33Z,2021-12-02T07:38:33Z,432
NCT04644120,NA,2020-11-23,NA,NA,2021-08-30,2020-11-23,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-02,Actual,"December 10, 2020",Actual,2020-12-10,August 2021,2021-08-31,"August 24, 2021",Actual,2021-08-24,"August 24, 2021",Actual,2021-08-24,NA,Interventional,NA,NA,Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19),"A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ABBV-47D11 and ABBV-2B04 as Monotherapy or Combination Therapy in Adults With COVID-19",Completed,NA,Phase 1,25,Actual,AbbVie,NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:39:50Z,2021-12-02T07:39:50Z,154
NCT04643964,NA,2020-11-12,NA,NA,2021-07-15,2020-11-20,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-07-15,2021-07-22,Actual,"November 17, 2020",Actual,2020-11-17,July 2021,2021-07-31,"June 5, 2021",Actual,2021-06-05,"June 5, 2021",Actual,2021-06-05,NA,Interventional,NA,NA,Brief Video Interventions for Depression,Building Mental Health Resilience in the COVID-19 Pandemic.,Completed,NA,Not Applicable,531,Actual,Ohio State University,NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,IPD will be available upon reasonable request within one year of primary outcome manuscript being published.,Proposals should be directed to Daniel R. Strunk at strunk.20@osu.edu,NA,Yes,"Results will be posted to clinicaltrials.gov within one year after completion of the final participant's participation in the clinical trial. Following initial publication, deidentified individual participant data (IPD) that underlie results in the primary outcome data reported will be available on reasonable request for 5 years after study completion.",2021-12-02T07:39:51Z,2021-12-02T07:39:51Z,200
NCT04640181,NA,2020-11-19,NA,NA,2021-06-28,2020-11-19,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-30,Actual,"December 1, 2020",Actual,2020-12-01,June 2021,2021-06-30,"June 28, 2021",Actual,2021-06-28,"June 28, 2021",Actual,2021-06-28,NA,Interventional,XACT,NA,Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT),"A Phase 2-3, Multi-Center, Randomized Trial to Study the Potential Benefit of Factor Xa Inhibitor (Rivaroxaban) Versus Standard of Care Low Molecular Weight Heparin (Lovenox) in Hospitalized Patients With COVID-19 (XACT)",Completed,NA,Phase 2,150,Actual,St. David's HealthCare,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:43:04Z,2021-12-02T07:43:04Z,217
NCT04637867,NA,2020-11-16,NA,NA,2021-06-03,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-04,Actual,"November 23, 2020",Actual,2020-11-23,June 2021,2021-06-30,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,NA,NA,COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO),Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study,Completed,NA,Not Applicable,189,Actual,Hospices Civils de Lyon,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:45:04Z,2021-12-02T07:45:04Z,242
NCT04637477,NA,2020-11-06,NA,NA,2021-09-14,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"August 1, 2020",Actual,2020-08-01,September 2021,2021-09-30,"August 25, 2021",Actual,2021-08-25,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,NA,Virtual Enhanced Lifestyle for Metabolic Syndrome (ELM) Proof-of-Concept Study,Rush Coronavirus Disease Virtual Lifestyle Program to Boost Host Resistance in Patients With Elevated Cardiometabolic Risk: A Proof-of-Concept Study,Completed,NA,Not Applicable,10,Actual,Rush University Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:45:19Z,2021-12-02T07:45:19Z,139
NCT04634903,NA,2020-11-11,2021-05-18,NA,2021-05-21,2020-11-17,2020-11-18,Actual,2021-05-21,2021-05-25,Actual,NA,NA,NA,2021-05-21,2021-05-25,Actual,"November 19, 2020",Actual,2020-11-19,May 2021,2021-05-31,"March 15, 2021",Actual,2021-03-15,"March 15, 2021",Actual,2021-03-15,NA,Interventional,NA,NA,"Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19",Comparing Two Online Single-Session Interventions for Adolescent Depression: Outcomes of a Randomized Trial,Completed,NA,Not Applicable,2452,Actual,Stony Brook University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Protocol and statistical plan have been posted to Open Science Framework prior to the start of this trial as part of study pre-registration (https://osf.io/kumdv/). Code will be made available upon publication of trial results.,NA,https://osf.io/8mk6x,Yes,NA,2021-12-02T07:47:37Z,2021-12-02T07:47:37Z,255
NCT04632602,NA,2020-11-16,NA,NA,2021-08-12,2020-11-16,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"April 14, 2020",Actual,2020-04-14,August 2021,2021-08-31,"December 31, 2020",Actual,2020-12-31,"November 29, 2020",Actual,2020-11-29,NA,Interventional,ProneSpontCov,NA,Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure,Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure: a Randomized Cross Over Electrical Impedance Tomography Study,Completed,NA,Not Applicable,20,Actual,Assistance Publique Hopitaux De Marseille,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:49:06Z,2021-12-02T07:49:06Z,172
NCT04632368,NA,2020-11-11,NA,NA,2021-08-19,2020-11-16,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-23,Actual,"November 20, 2020",Actual,2020-11-20,May 2021,2021-05-31,"August 16, 2021",Actual,2021-08-16,"August 10, 2021",Actual,2021-08-10,NA,Interventional,NA,NA,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,Completed,NA,Not Applicable,80,Actual,Duke University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:49:19Z,2021-12-02T07:49:19Z,165
NCT04631666,NA,2020-11-05,NA,NA,2021-08-22,2020-11-14,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-22,2021-08-24,Actual,"December 8, 2020",Actual,2020-12-08,August 2021,2021-08-31,"August 11, 2021",Actual,2021-08-11,"August 11, 2021",Actual,2021-08-11,NA,Interventional,NA,NA,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion,A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,Completed,NA,Phase 1/Phase 2,57,Actual,University of Cologne,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:50:20Z,2021-12-02T07:50:20Z,162
NCT04629989,NA,2020-11-13,NA,NA,2021-03-08,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-09,Actual,"November 13, 2020",Actual,2020-11-13,March 2021,2021-03-31,"March 5, 2021",Actual,2021-03-05,"March 5, 2021",Actual,2021-03-05,NA,Interventional,NA,NA,Comparison of the Surgical Facemask With the Double-trunk Mask on Oxygenation in COVID-19,The Effects of Two Systems Above Low-flow Nasal Cannula on Arterial Oxygen Tension in Patients With COVID-19 : Surgical Face Mask Versus Double-trunk Mask,Completed,NA,Not Applicable,27,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:51:28Z,2021-12-02T07:51:28Z,329
NCT04629157,NA,2020-11-04,NA,NA,2021-08-02,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"November 5, 2020",Actual,2020-11-05,November 2020,2020-11-30,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,LAVA,NA,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,Completed,NA,Not Applicable,185,Actual,Alder Hey Children's NHS Foundation Trust,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD will not be shared outside of the research team,2021-12-02T07:52:27Z,2021-12-02T07:52:27Z,182
NCT04628143,NA,2020-11-10,NA,NA,2021-08-09,2020-11-10,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-13,Actual,"December 21, 2020",Actual,2020-12-21,April 2021,2021-04-30,"April 5, 2021",Actual,2021-04-05,"April 5, 2021",Actual,2021-04-05,NA,Interventional,NA,NA,A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,"Open-label, Multi-center, Randomized Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19",Completed,NA,Phase 2,13,Actual,Chong Kun Dang Pharmaceutical,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:53:15Z,2021-12-02T07:53:15Z,175
NCT04625985,NA,2020-10-23,NA,NA,2021-04-05,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"July 14, 2020",Actual,2020-07-14,April 2021,2021-04-30,"March 18, 2021",Actual,2021-03-18,"March 8, 2021",Actual,2021-03-08,NA,Interventional,DMMETCOV19-2,NA,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.","Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb",Completed,NA,Phase 2,20,Actual,Laboratorios Silanes S.A. de C.V.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:54:58Z,2021-12-02T07:54:58Z,301
NCT04627467,NA,2020-10-30,NA,NA,2021-10-05,2020-11-11,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-07,Actual,"March 28, 2020",Actual,2020-03-28,September 2020,2020-09-30,"September 30, 2021",Actual,2021-09-30,"July 9, 2020",Actual,2020-07-09,NA,Interventional,TS-COVID,NA,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19),Completed,NA,Phase 2,3217,Actual,Fundacion Clinica Valle del Lili,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"We do not plan to share IPD, since we are not allowed to share information concerning medical history of our patients or health workers.",2021-12-02T07:53:31Z,2021-12-02T07:53:31Z,118
NCT04623021,NA,2020-11-05,NA,NA,2021-01-31,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2021-01-31,2021-02-02,Actual,"September 25, 2020",Actual,2020-09-25,January 2021,2021-01-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,NA,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,"An Open-label, Randomized, Multicenter, Controlled Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia",Completed,NA,Phase 2,104,Actual,Chong Kun Dang Pharmaceutical,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:57:20Z,2021-12-02T07:57:20Z,365
NCT04622891,NA,2020-11-06,NA,NA,2020-11-07,2020-11-07,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"April 1, 2020",Actual,2020-04-01,November 2020,2020-11-30,"July 30, 2020",Actual,2020-07-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,NA,Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection,"Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial",Completed,NA,Not Applicable,300,Actual,South Valley University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:57:36Z,2021-12-02T07:57:36Z,450
NCT04621461,NA,2020-11-06,NA,NA,2021-02-08,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-11,Actual,"December 20, 2020",Actual,2020-12-20,February 2021,2021-02-28,"February 8, 2021",Actual,2021-02-08,"February 8, 2021",Actual,2021-02-08,NA,Interventional,NA,NA,Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting,"A Randomized, Placebo-Controlled Study Evaluating the Efficacy of Zinc for the Treatment of COVID-19 in the Outpatient Setting",Completed,NA,Phase 4,3,Actual,"St. Francis Hospital, New York",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:58:34Z,2021-12-02T07:58:34Z,357
NCT04621903,NA,2020-11-06,NA,NA,2020-11-18,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-18,2020-11-19,Actual,"October 8, 2020",Actual,2020-10-08,November 2020,2020-11-30,"November 3, 2020",Actual,2020-11-03,"October 27, 2020",Actual,2020-10-27,NA,Interventional,NA,NA,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19: Community Based Participatory Research,Completed,NA,Not Applicable,26,Actual,Aarogyam UK,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:58:21Z,2021-12-02T07:58:21Z,439
NCT04621123,NA,2020-11-04,NA,NA,2021-09-04,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-04,2021-09-08,Actual,"November 10, 2020",Actual,2020-11-10,September 2021,2021-09-30,"July 28, 2021",Actual,2021-07-28,"May 31, 2021",Actual,2021-05-31,NA,Interventional,NA,NA,Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients,Convalescent Methylene Blue Treated (MBT) Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients: a Randomized Double Blind Study (COnV-ert),Completed,NA,Phase 2,384,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:59:02Z,2021-12-02T07:59:02Z,149
NCT04620798,NA,2020-11-04,NA,NA,2021-08-23,2020-11-05,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"September 14, 2020",Actual,2020-09-14,August 2021,2021-08-31,"November 11, 2020",Actual,2020-11-11,"November 11, 2020",Actual,2020-11-11,NA,Interventional,NA,NA,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,Completed,NA,Not Applicable,1076,Actual,Indiana University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"These study protocol documents will be made available upon completion of the study and the analyses. A de-identified, limited data set and analytic code will be available from the Principal Investigator upon request.","Protocol will be available on clinicaltrials.gov while the other documents, data, and analytic code from the Principal Investigator upon request.",NA,Yes,"The study team will make the following documents available to the public upon completion of the study: (1) Study Protocol, (2) Statistical Analysis Plan (SAP), (3) Informed Consent Form (ICF), and (4) Clinical Study Report (CSR). The individual participant data as well as the analytic code will not be made available to the public due to privacy concerns and in order to protect participants' private health information but will be available from the Principal Investigator upon request.",2021-12-02T07:59:06Z,2021-12-02T07:59:06Z,161
NCT04618042,NA,2020-10-23,NA,NA,2021-06-21,2020-11-04,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"November 13, 2020",Actual,2020-11-13,June 2021,2021-06-30,"June 13, 2021",Actual,2021-06-13,"May 14, 2021",Actual,2021-05-14,NA,Interventional,FX-COVID,NA,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,Completed,NA,Phase 2,50,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:03:03Z,2021-12-02T08:03:03Z,224
NCT04617483,NA,2020-11-04,NA,NA,2021-07-26,2020-11-04,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"October 31, 2020",Actual,2020-10-31,November 2020,2020-11-30,"May 31, 2021",Actual,2021-05-31,"November 28, 2020",Actual,2020-11-28,NA,Interventional,NA,NA,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults","A Randomized, Double-Blinded Clinical Trial, to Evaluate the Non-inferiority of the Commercial Scale Inactivated SARS-CoV-2 Vaccine Against That of the Pilot Scale Among Adults Aged 26-45 Years, and the Open-labelled, Bridging Non-inferiority of the Vaccine Induced Immunogenicity in Elderly Against That in Adults",Completed,NA,Phase 3,1040,Actual,"Sinovac Biotech Co., Ltd",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:04:10Z,2021-12-02T08:04:10Z,189
NCT04616989,NA,2020-10-20,NA,NA,2021-06-01,2020-11-03,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"November 1, 2020",Actual,2020-11-01,June 2021,2021-06-30,"January 30, 2021",Actual,2021-01-30,"January 30, 2021",Actual,2021-01-30,NA,Interventional,NA,NA,Mental Health in Communities Affected by COVID-19 in Uganda,Integration of Mental Health Care in Communities Affected by the COVID-19 Pandemic in Central Uganda,Completed,NA,Not Applicable,814,Actual,Makerere University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:05:24Z,2021-12-02T08:05:24Z,244
NCT04615741,NA,2020-10-29,NA,NA,2021-04-28,2020-10-29,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-29,Actual,"November 9, 2020",Actual,2020-11-09,April 2021,2021-04-30,"April 20, 2021",Actual,2021-04-20,"January 22, 2021",Actual,2021-01-22,NA,Interventional,NA,NA,Finding Wellness in the Pandemic,Improving Health and Wellness During COVID-19,Completed,NA,Not Applicable,187,Actual,University of Lethbridge,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"After April 2021, for up to 10 years",Researchers must make a reasonable request to the PI,NA,Yes,De-identified data relevant to the researcher's research question may be shared upon a reasonable request,2021-12-02T08:06:24Z,2021-12-02T08:06:24Z,278
NCT04614883,NA,2020-11-02,NA,NA,2021-06-11,2020-11-03,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-16,Actual,"October 21, 2020",Actual,2020-10-21,June 2021,2021-06-30,"February 26, 2021",Actual,2021-02-26,"February 26, 2021",Actual,2021-02-26,NA,Interventional,VOC-COVID-Diag,NA,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in the Context of Suspicion of COVID-19 Infection,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in Patients Referred to the Emergency Reception Service for Suspected COVID-19 Infection: Diagnostic Value and for Rapid Screening,Completed,NA,Not Applicable,130,Actual,Hopital Foch,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:07:07Z,2021-12-02T08:07:07Z,234
NCT04610502,NA,2020-09-15,NA,NA,2021-03-18,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-18,2021-03-19,Actual,"September 6, 2020",Actual,2020-09-06,March 2021,2021-03-31,"December 6, 2020",Actual,2020-12-06,"October 6, 2020",Actual,2020-10-06,NA,Interventional,SECR-01,NA,Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients,"Randomized, Controlled, Double-blind, Multicenter Clinical Study to Compare the Efficacy and Safety of the Administration of Two Hyperimmune Equine Anti-Sars-CoV-2 (""S"" and ""M"") Serum Formulations in Hospitalized Patients With COVID-19",Completed,NA,Phase 2,26,Actual,Caja Costarricense de Seguro Social,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:11:02Z,2021-12-02T08:11:02Z,319
NCT04609969,NA,2020-10-28,NA,NA,2020-12-04,2020-10-28,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-04,2020-12-07,Actual,"October 13, 2020",Actual,2020-10-13,December 2020,2020-12-31,"October 17, 2020",Actual,2020-10-17,"October 17, 2020",Actual,2020-10-17,NA,Interventional,COVID-VIRO,NA,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test on Nasopharyngeal Specimens i,Completed,NA,Not Applicable,200,Actual,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:11:07Z,2021-12-02T08:11:07Z,423
NCT04609462,NA,2020-09-24,NA,NA,2021-03-26,2020-10-28,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-04-01,Actual,"August 11, 2020",Actual,2020-08-11,March 2021,2021-03-31,"February 10, 2021",Actual,2021-02-10,"January 13, 2021",Actual,2021-01-13,NA,Interventional,HiFlo-COVID,NA,High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.,A Trial of High-Flow Nasal Cannula vs. Conventional Oxygen Therapy in Patients With SARS-CoV-2-Related Acute Respiratory Failure: the HiFlo-COVID Trial.,Completed,NA,Not Applicable,199,Actual,Fundacion Clinica Valle del Lili,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:11:39Z,2021-12-02T08:11:39Z,311
NCT04609371,NA,2020-10-19,NA,NA,2021-09-20,2020-10-25,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"October 21, 2020",Actual,2020-10-21,September 2021,2021-09-30,"May 1, 2021",Actual,2021-05-01,"March 1, 2021",Actual,2021-03-01,NA,Interventional,NA,NA,PanDirect: Self-care Tools and Telephone Coaching for Depression and Anxiety During Pandemics,Assisting Family Physicians With Gaps in Mental Health Care Generated by the COVID-19 Pandemic: A Randomized Controlled Trial,Completed,NA,Not Applicable,90,Actual,"St. Mary's Research Center, Canada",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:11:54Z,2021-12-02T08:11:54Z,133
NCT04608097,NA,2020-10-28,NA,NA,2021-04-29,2020-10-28,2020-10-29,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-04-30,Actual,"October 28, 2020",Actual,2020-10-28,April 2021,2021-04-30,"March 12, 2021",Actual,2021-03-12,"March 12, 2021",Actual,2021-03-12,NA,Interventional,NA,NA,Understanding Reactions to Emotional Material in the Media During COVID-19,Understanding Reactions to Emotional Material in the Media During COVID-19 and the Connections to Cognitive Activities,Completed,NA,Not Applicable,74,Actual,Uppsala University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:12:51Z,2021-12-02T08:12:51Z,277
NCT04604145,NA,2020-10-23,NA,NA,2021-08-24,2020-10-23,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-30,Actual,"February 3, 2021",Actual,2021-02-03,August 2021,2021-08-31,"August 18, 2021",Actual,2021-08-18,"August 18, 2021",Actual,2021-08-18,NA,Interventional,NA,NA,Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR,Evaluation of Self-Collected Saliva Samples Without Viral Transport Media for SARS-CoV-2 Testing Via RT-PCR,Completed,NA,Not Applicable,60,Actual,David Grant U.S. Air Force Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:16:01Z,2021-12-02T08:16:01Z,160
NCT04603729,NA,2020-10-21,NA,NA,2020-10-24,2020-10-24,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-24,2020-10-27,Actual,"May 30, 2020",Actual,2020-05-30,October 2020,2020-10-31,"July 1, 2020",Actual,2020-07-01,"June 30, 2020",Actual,2020-06-30,NA,Interventional,covid19,NA,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Completed,NA,Phase 3,100,Actual,Fatima Memorial Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,"patient name and medical record will be confidential, onle the principal investigator will have access to data. Results of study will be shared with other researchers",2021-12-02T08:16:15Z,2021-12-02T08:16:15Z,464
NCT04602871,NA,2020-10-21,NA,NA,2021-04-11,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-11,2021-04-13,Actual,"July 3, 2020",Actual,2020-07-03,October 2020,2020-10-31,"January 30, 2021",Actual,2021-01-30,"January 30, 2021",Actual,2021-01-30,NA,Interventional,COVID-19,NA,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,Early Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis - Feasibility Study,Completed,NA,Not Applicable,108,Actual,Scentech Medical Technologies Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No IPDs are to be shared with other researchers.,2021-12-02T08:17:04Z,2021-12-02T08:17:04Z,295
NCT04599959,NA,2020-10-22,2021-07-21,NA,2021-07-21,2020-10-22,2020-10-23,Actual,2021-07-21,2021-07-26,Actual,NA,NA,NA,2021-07-21,2021-07-26,Actual,"October 26, 2020",Actual,2020-10-26,July 2021,2021-07-31,"January 20, 2021",Actual,2021-01-20,"January 20, 2021",Actual,2021-01-20,NA,Interventional,NA,All eligible participants in this study who had been diagnosed with COVID-19 confirmed by polymerase chain reaction (PCR) test within the past 5 days before study entry.,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With SalivetteÂ® Cortisol for Viral RNA Sampling for RT-qPCR,"COVID-19 Tests: a Systematic Comparison of Viral RNA Test Sample Taking for RT-qPCR, in This Case With a Nasopharyngeal Swab or Saliva Collected With SalivetteÂ® Cortisol, to Diagnose SARS-CoV-2 Virus Infection",Completed,NA,Not Applicable,151,Actual,Boehringer Ingelheim,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:

studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).

For more details refer to: http://trials.boehringer-ingelheim.com/",2021-12-02T08:19:02Z,2021-12-02T08:19:02Z,194
NCT04598594,NA,2020-10-15,NA,NA,2021-06-21,2020-10-21,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"November 6, 2020",Actual,2020-11-06,June 2021,2021-06-30,"June 20, 2021",Actual,2021-06-20,"April 29, 2021",Actual,2021-04-29,NA,Interventional,NICOVID-REA,NA,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Completed,NA,Phase 3,220,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:20:26Z,2021-12-02T08:20:26Z,224
NCT04598581,NA,2020-10-20,NA,NA,2021-04-14,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-14,2021-04-19,Actual,"November 2, 2020",Actual,2020-11-02,April 2021,2021-04-30,"April 9, 2021",Actual,2021-04-09,"April 9, 2021",Actual,2021-04-09,NA,Interventional,COVID-RT-01,NA,"Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19",Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2),Completed,NA,Not Applicable,22,Actual,"University Hospital, Basel, Switzerland",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:20:20Z,2021-12-02T08:20:20Z,292
NCT04596839,NA,2020-10-20,NA,NA,2021-08-09,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-10,Actual,"September 4, 2020",Actual,2020-09-04,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19),"Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19): An Open Label, Multi-Center, Randomized Controlled Trial",Completed,NA,Phase 2,60,Actual,Beximco Pharmaceuticals Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:21:50Z,2021-12-02T08:21:50Z,175
NCT04596085,NA,2020-10-19,2021-07-29,NA,2021-08-11,2020-10-20,2020-10-22,Actual,2021-08-11,2021-08-12,Actual,NA,NA,NA,2021-08-11,2021-08-12,Actual,"September 16, 2020",Actual,2020-09-16,August 2021,2021-08-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,NA,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)","A Double Blind, Randomized, Placebo Controlled Study to Evaluate Efficacy and Safety of ""VIRACIDE"" in the Management of Corona Virus Disease 2019 (COVID-19)",Completed,NA,Not Applicable,118,Actual,"The Herb, Inc",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:22:23Z,2021-12-02T08:22:23Z,173
NCT04594343,NA,2020-10-18,NA,NA,2021-09-30,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-08,Actual,"November 20, 2020",Actual,2020-11-20,September 2021,2021-09-30,"September 25, 2021",Actual,2021-09-25,"September 10, 2021",Actual,2021-09-10,NA,Interventional,NA,NA,Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19,"A Randomized, Double-blind, Placebo-controlled Safety and Clinical Outcomes Study of Disulfiram in Subjects With Moderate COVID-19",Completed,NA,Phase 2,140,Actual,ETICA,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T08:23:58Z,2021-12-02T08:23:58Z,123
NCT04593433,NA,2020-10-13,NA,NA,2021-08-23,2020-10-13,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"March 4, 2021",Actual,2021-03-04,August 2021,2021-08-31,"July 4, 2021",Actual,2021-07-04,"July 4, 2021",Actual,2021-07-04,NA,Interventional,VGV,NA,A 3-month Cycle of Virtual Guided Tours to Promote Health in Older Community Members in a Context of COVID-19 Induced Social Isolation: a Pilot Study,"A 3-month Cycle of Virtual Weekly Montreal Museum of Fine Arts Tours to Promote Social Inclusion, Well-being, Quality of Life and Health in Older Community Members : a Pilot Study",Completed,NA,Not Applicable,44,Actual,Jewish General Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:24:33Z,2021-12-02T08:24:33Z,161
NCT04591158,NA,2020-09-15,NA,NA,2021-07-12,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-14,Actual,"September 15, 2020",Actual,2020-09-15,July 2021,2021-07-31,"June 9, 2021",Actual,2021-06-09,"June 9, 2021",Actual,2021-06-09,NA,Interventional,NA,NA,COVID-19 and Lung Ultrasound Utility,The Utility of Self-administered Lung Ultrasound in Patients With COVID-19,Completed,NA,Not Applicable,6,Actual,Bridge to Health Medical and Dental USA,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,"Notes pertaining to performance characterization of the device, as well as imaging data for additional quantitative evaluation of the image quality will be collected. This date is recorded for future device development. No IPD will be made available to other researchers.",2021-12-02T08:26:16Z,2021-12-02T08:26:16Z,203
NCT04591600,NA,2020-10-15,NA,NA,2020-10-16,2020-10-16,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"July 1, 2020",Actual,2020-07-01,October 2020,2020-10-31,"October 14, 2020",Actual,2020-10-14,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,"Controlled Randomized Clinical Trial on Using Ivermectin With Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq",Completed,NA,Phase 1/Phase 2,140,Actual,Alkarkh Health Directorate-Baghdad,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:26:12Z,2021-12-02T08:26:12Z,472
NCT04589104,NA,2020-10-12,NA,NA,2020-10-14,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"May 26, 2020",Actual,2020-05-26,October 2020,2020-10-31,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,NA,Expressive Writing for COVID-19 Resilience,Expressive Writing for COVID-19 Resilience,Completed,NA,Not Applicable,63,Actual,Duke University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:27:54Z,2021-12-02T08:27:54Z,474
NCT04579393,NA,2020-10-06,NA,NA,2021-07-09,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"October 8, 2020",Actual,2020-10-08,May 2021,2021-05-31,"April 30, 2021",Actual,2021-04-30,"March 30, 2021",Actual,2021-03-30,NA,Interventional,NA,NA,Fostamatinib for Hospitalized Adults With COVID-19,A Phase II Study Evaluating Fostamatinib for Hospitalized Adults With COVID-19,Completed,NA,Phase 2,62,Actual,National Institutes of Health Clinical Center (CC),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:35:15Z,2021-12-02T08:35:15Z,206
NCT04583189,NA,2020-10-01,NA,NA,2020-12-01,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-02,Actual,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,"November 25, 2020",Actual,2020-11-25,"November 25, 2020",Actual,2020-11-25,NA,Interventional,NA,NA,Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department,Evaluation Des Performances du Test Rapide antigÃ©nique Covid-19 Ag BSS Chez l'Enfant Symptomatique Dans un Service d'Urgences pÃ©diatriques,Completed,NA,Not Applicable,500,Actual,Centre Hospitalier Intercommunal Creteil,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:32:12Z,2021-12-02T08:32:12Z,426
NCT04581811,NA,2020-10-07,NA,NA,2021-05-21,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"November 10, 2020",Actual,2020-11-10,May 2021,2021-05-31,"March 20, 2021",Actual,2021-03-20,"March 20, 2021",Actual,2021-03-20,NA,Interventional,NA,NA,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS): A Pilot Study,Completed,NA,Not Applicable,52,Actual,University of Alabama at Birmingham,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:33:12Z,2021-12-02T08:33:12Z,255
NCT04581291,NA,2020-10-04,NA,NA,2020-10-07,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-09,Actual,"January 1, 2020",Actual,2020-01-01,October 2020,2020-10-31,"October 1, 2020",Actual,2020-10-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,NA,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,Completed,NA,Not Applicable,30,Actual,Istanbul Gelisim University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:33:44Z,2021-12-02T08:33:44Z,481
NCT04578158,NA,2020-10-06,NA,NA,2021-04-21,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-22,Actual,"September 29, 2020",Actual,2020-09-29,April 2021,2021-04-30,"April 15, 2021",Actual,2021-04-15,"March 28, 2021",Actual,2021-03-28,NA,Interventional,NA,NA,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,"A Prospective, Randomized, Open-labelled, Controlled Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With Diagnosis of COVID-19.",Completed,NA,Phase 3,152,Actual,Liaquat University of Medical & Health Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:36:26Z,2021-12-02T08:36:26Z,285
NCT04577534,NA,2020-09-03,NA,NA,2021-06-17,2020-10-05,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"August 14, 2020",Actual,2020-08-14,June 2021,2021-06-30,"June 16, 2021",Actual,2021-06-16,"June 16, 2021",Actual,2021-06-16,NA,Interventional,COVIDSTORM,NA,COVID-19: Salvage TOcilizumab as a Rescue Measure,COVID-19: Salvage TOcilizumab as a Rescue Measure. Use of Tocilizumab in the Inflammatory Phase of COVID-19 / New Coronavirus Disease,Completed,NA,Phase 3,88,Actual,Turku University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,plan to investigate if it is possible by law,2021-12-02T08:36:46Z,2021-12-02T08:36:46Z,228
NCT04577235,NA,2020-09-29,NA,NA,2020-10-05,2020-10-05,2020-10-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"June 5, 2020",Actual,2020-06-05,October 2020,2020-10-31,"September 5, 2020",Actual,2020-09-05,"August 5, 2020",Actual,2020-08-05,NA,Interventional,NA,NA,Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.,Evaluation of the Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores of Patients With Severe COVID 19 Pneumonia in Intensive Care.,Completed,NA,Not Applicable,29,Actual,Gaziosmanpasa Research and Education Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:37:23Z,2021-12-02T08:37:23Z,483
NCT04576312,NA,2020-09-28,NA,NA,2021-08-20,2020-10-05,2020-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-26,Actual,"June 29, 2020",Actual,2020-06-29,August 2021,2021-08-31,"December 4, 2020",Actual,2020-12-04,"December 4, 2020",Actual,2020-12-04,NA,Interventional,NA,NA,Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers,"Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19",Completed,NA,Phase 1,64,Actual,UNION therapeutics,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:38:00Z,2021-12-02T08:38:00Z,164
NCT04575038,NA,2020-10-01,NA,NA,2021-07-26,2020-10-01,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"November 19, 2020",Actual,2020-11-19,July 2021,2021-07-31,"April 28, 2021",Actual,2021-04-28,"April 28, 2021",Actual,2021-04-28,NA,Interventional,CRISIS2,NA,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,"The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2",Completed,NA,Phase 2,115,Actual,"Clear Creek Bio, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:38:57Z,2021-12-02T08:38:57Z,189
NCT04570254,NA,2020-09-26,NA,NA,2021-05-19,2020-09-28,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2021-05-19,2021-05-21,Actual,"August 19, 2020",Actual,2020-08-19,May 2021,2021-05-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,ANTIOX-COVID,NA,Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19,Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia,Completed,NA,Not Applicable,110,Actual,Unidad Temporal COVID-19 en Centro Citibanamex,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:42:52Z,2021-12-02T08:42:52Z,257
NCT04573270,NA,2020-09-23,NA,NA,2020-09-30,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"April 24, 2020",Actual,2020-04-24,September 2020,2020-09-30,"September 1, 2020",Actual,2020-09-01,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,NA,Mesenchymal Stem Cells for the Treatment of COVID-19,A Pilot Phase Study Evaluating the Effects of a Single Mesenchymal Stem Cell Injection in Patients With Suspected or Confirmed COVID-19 Infection and Healthcare Providers Exposed to Coronavirus Patients,Completed,NA,Phase 1,40,Actual,Thomas Advanced Medical LLC,NA,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Data will be blinded and password protected. Research publications will be produced for medical journals. Participating Investigators will have password protected access only.,2021-12-02T08:40:33Z,2021-12-02T08:40:33Z,488
NCT04573361,NA,2020-09-29,NA,NA,2020-09-30,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"May 2, 2020",Actual,2020-05-02,September 2020,2020-09-30,"May 27, 2020",Actual,2020-05-27,"May 27, 2020",Actual,2020-05-27,NA,Interventional,NA,NA,Access to Chiropractic Care During the COVID-19 Healthcare Emergency in Spain,Access to Chiropractic Care During the State of Emergency Generated by the COVID-19 Pandemic in Spain: a Pragmatic Controlled Trial,Completed,NA,Not Applicable,723,Actual,Real Centro Universitario Maria Cristina,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"All collected IPD will be shared, though a next phase of the study is being debated, which is why we are still undecided.",2021-12-02T08:40:21Z,2021-12-02T08:40:21Z,488
NCT04569188,NA,2020-09-04,NA,NA,2020-09-30,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"May 15, 2020",Actual,2020-05-15,September 2020,2020-09-30,"September 3, 2020",Actual,2020-09-03,"August 15, 2020",Actual,2020-08-15,NA,Interventional,RESCUE,NA,Convalescent Plasma in COVID-19 Elderly Patients,Real-time Evaluation of Safety and Efficacy of Convalescent Plasma Units Transfused to Elderly Patients With COVID-19,Completed,NA,Phase 2,21,Actual,Azienda Socio Sanitaria Territoriale di Mantova,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:43:33Z,2021-12-02T08:43:33Z,488
NCT04568525,NA,2020-09-23,NA,NA,2020-09-28,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,"August 1, 2020",Actual,2020-08-01,"July 25, 2020",Actual,2020-07-25,NA,Interventional,NA,NA,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,Microwave Radiation for Early Diagnostics of Pneumonia in Patients With COVID-19,Completed,NA,Not Applicable,195,Actual,Kyrgyz State Medical Academy,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:44:00Z,2021-12-02T08:44:00Z,490
NCT04568863,NA,2020-09-28,NA,NA,2021-03-17,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-18,Actual,"June 20, 2020",Actual,2020-06-20,September 2020,2020-09-30,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,MELCOVID,NA,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,"A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)",Completed,NA,Phase 2,18,Actual,Pharmamel S.L.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:43:55Z,2021-12-02T08:43:55Z,320
NCT04568876,NA,2020-09-24,NA,NA,2021-08-24,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"October 23, 2020",Actual,2020-10-23,August 2021,2021-08-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,NA,Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients,"Efficacy of Palmitoylethanolamide, in add-on to Standard Therapy, on Inflammatory Markers of Patients With Interstitial Pneumonia Due to COVID-19. A Pilot Controlled, Randomized, Open Lable Clinical Study",Completed,NA,Phase 4,40,Actual,Epitech Group SpA,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:43:59Z,2021-12-02T08:43:59Z,160
NCT04567810,NA,2020-09-18,NA,NA,2021-09-16,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-20,Actual,"September 18, 2020",Actual,2020-09-18,September 2021,2021-09-30,"December 14, 2020",Actual,2020-12-14,"December 14, 2020",Actual,2020-12-14,NA,Interventional,NA,NA,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)","A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single -Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)",Completed,NA,Phase 1,48,Actual,Stanford University,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:44:22Z,2021-12-02T08:44:22Z,137
NCT04568356,NA,2020-09-27,NA,NA,2020-10-16,2020-09-27,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"April 24, 2020",Actual,2020-04-24,October 2020,2020-10-31,"September 24, 2020",Actual,2020-09-24,"June 12, 2020",Actual,2020-06-12,NA,Interventional,NA,NA,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,"A Clinical Performance Evaluation of the SARS-COV-2 Direct Antigen Rapid Test ""DART""",Completed,NA,Not Applicable,200,Actual,"E25Bio, Inc.",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,One month after the USA-FDA approval date and for the duration of one year after the date of approval,"via email to: Irene Bosch, PhD at ibosch@e25bio.com",http://www.e25bio.com,Yes,"The sponsor E25Bio, Inc. is in agreement to share the outcome of this Clinical Trial. Because the device product has not been previously approved or cleared by FDA, we will be publicly posting not earlier than the date of FDA approval or clearance.",2021-12-02T08:44:37Z,2021-12-02T08:44:37Z,472
NCT04563689,NA,2020-09-22,NA,NA,2020-11-19,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-19,2020-11-20,Actual,"June 18, 2020",Actual,2020-06-18,September 2020,2020-09-30,"October 23, 2020",Actual,2020-10-23,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,NA,Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients,Efecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado mÃ©dico en Casa en Cali - 2020.,Completed,NA,Not Applicable,23,Actual,Dentaid SL,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:47:25Z,2021-12-02T08:47:25Z,438
NCT04561219,NA,2020-09-22,NA,NA,2021-07-15,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-15,2021-07-22,Actual,"April 19, 2020",Actual,2020-04-19,July 2021,2021-07-31,"October 2, 2020",Actual,2020-10-02,"October 2, 2020",Actual,2020-10-02,NA,Interventional,NA,NA,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,"Nitazoxanide for Moderate to Severe COVID-19 Pneumonia: a Multicenter, Randomized, Placebo-controlled, Double-Blind Clinical Trial",Completed,NA,Phase 2,500,Actual,Universidade Federal do Rio de Janeiro,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2021-12-02T08:49:11Z,2021-12-02T08:49:11Z,200
NCT04558372,NA,2020-09-20,NA,NA,2020-12-28,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"April 1, 2020",Actual,2020-04-01,December 2020,2020-12-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,NA,Genosvid Diagnostic Test for Early Detection of COVID-19,Genosvid Diagnostic Test for Early Detection of COVID-19: UGM Electronic-Nose Innovation for Indonesia,Completed,NA,Not Applicable,1999,Actual,Gadjah Mada University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:51:38Z,2021-12-02T08:51:38Z,399
NCT04558411,NA,2020-09-20,NA,NA,2021-09-23,2020-09-20,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-29,Actual,"September 12, 2020",Actual,2020-09-12,September 2021,2021-09-30,"December 15, 2020",Actual,2020-12-15,"December 15, 2020",Actual,2020-12-15,NA,Interventional,NA,NA,"Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students","Pilot Study of a Brief, Scaleable Intervention for COVID-19 Mental Health Sequelae in College Students",Completed,NA,Not Applicable,153,Actual,"Rutgers, The State University of New Jersey",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,We will share data after the publication of primary manuscripts.,NA,NA,Yes,We will share data after the publication of primary manuscripts.,2021-12-02T08:51:26Z,2021-12-02T08:51:26Z,130
NCT04557241,NA,2020-09-16,NA,NA,2021-02-08,2020-09-17,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"January 14, 2020",Actual,2020-01-14,February 2021,2021-02-28,"January 31, 2021",Actual,2021-01-31,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,NA,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Completed,NA,Not Applicable,1017,Actual,Indiana University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Fully de-identified data will be made available along with the publication of the primary results paper from this study.,NA,NA,Yes,Fully de-identified data (full dataset) will be made available along with the publication of the primary results paper from this study.,2021-12-02T08:52:05Z,2021-12-02T08:52:05Z,357
NCT04557605,NA,2020-09-09,NA,NA,2020-10-16,2020-09-15,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-20,Actual,"September 14, 2020",Actual,2020-09-14,October 2020,2020-10-31,"October 15, 2020",Actual,2020-10-15,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,NA,Effects of a Face Mask on Oxygenation During Exercise,The Effects of Wearing a Face Mask During COVID-19 on Blood and Muscle Oxygenation While Performing Exercise,Completed,NA,Not Applicable,14,Actual,University of Saskatchewan,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:52:22Z,2021-12-02T08:52:22Z,472
NCT04555213,NA,2020-09-16,NA,NA,2021-08-24,2020-09-16,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-26,Actual,"September 30, 2020",Actual,2020-09-30,August 2021,2021-08-31,"August 10, 2021",Actual,2021-08-10,"August 10, 2021",Actual,2021-08-10,NA,Interventional,NOXCOVID,NA,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID),Completed,NA,Phase 1,41,Actual,Noxopharm Limited,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:53:48Z,2021-12-02T08:53:48Z,160
NCT04555148,NA,2020-09-16,NA,NA,2021-08-17,2020-09-16,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-24,Actual,"September 19, 2020",Actual,2020-09-19,August 2021,2021-08-31,"April 23, 2021",Actual,2021-04-23,"January 22, 2021",Actual,2021-01-22,NA,Interventional,NA,NA,COVIDIG (COVID-19 Hyper-ImmunoGlobulin),"A Prospective, Open-label, Randomized, Multi-center, Phase 2a Study to Evaluation the Dose Response, Efficacy and Safety of Hyper-Ig (Hyper-immunoglobulin) GC5131 in Patients With COVID-19",Completed,NA,Phase 2,63,Actual,Green Cross Corporation,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:54:00Z,2021-12-02T08:54:00Z,167
NCT04555005,NA,2020-06-11,NA,NA,2020-09-17,2020-09-17,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-17,2020-09-18,Actual,"March 10, 2020",Actual,2020-03-10,March 2020,2020-03-31,"April 26, 2020",Actual,2020-04-26,"April 26, 2020",Actual,2020-04-26,NA,Interventional,NA,NA,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,"Implementation of a Mindfulness-based Crisis Intervention for Frontline Healthcare Workers During the COVID-19 Outbreak in a Public General Hospital in Madrid, Spain",Completed,NA,Not Applicable,1000,Actual,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:54:07Z,2021-12-02T08:54:07Z,501
NCT04552483,NA,2020-09-09,NA,NA,2020-11-01,2020-09-15,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-01,2020-11-03,Actual,"June 8, 2020",Actual,2020-06-08,November 2020,2020-11-30,"September 5, 2020",Actual,2020-09-05,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,NA,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Effects of Nitazoxanide Administration to Patients in the Initial Phase of COVID-19,Completed,NA,Phase 2,392,Actual,Universidade Federal do Rio de Janeiro,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2021-12-02T08:56:02Z,2021-12-02T08:56:02Z,456
NCT04552379,NA,2020-08-21,NA,NA,2021-09-02,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-10,Actual,"December 1, 2020",Actual,2020-12-01,December 2020,2020-12-31,"June 30, 2021",Actual,2021-06-30,"May 31, 2021",Actual,2021-05-31,NA,Interventional,ConCorD-19,NA,The Containing Coronavirus Disease 19 (COVID-19) Trial,A Cluster Randomised Trial of Interferon Versus Standard of Care in the Reduction of Transmission of SARS-Cov-2. The Containing Coronavirus Disease 19 Trial (ConCorD-19),Completed,NA,Phase 3,1173,Actual,Pontificia Universidad Catolica de Chile,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,We are evaluating the best time to share the information.,We are evaluating the best way to share the information.,NA,Yes,We are evaluating the best way to share the information.,2021-12-02T08:56:07Z,2021-12-02T08:56:07Z,151
NCT04550325,NA,2020-09-10,NA,NA,2021-01-04,2020-09-13,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-01-04,2021-01-05,Actual,"August 5, 2020",Actual,2020-08-05,January 2021,2021-01-31,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,NA,Interventional,NA,NA,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19","A Phase 1/2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia",Completed,NA,Phase 1/Phase 2,12,Actual,"Kamada, Ltd.",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:57:36Z,2021-12-02T08:57:36Z,392
NCT04551768,NA,2020-09-15,NA,NA,2021-08-25,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-26,Actual,"February 10, 2021",Actual,2021-02-10,August 2021,2021-08-31,"August 17, 2021",Actual,2021-08-17,"August 17, 2021",Actual,2021-08-17,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of VIRAZOLEÂ® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19,"An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLEÂ® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19",Completed,NA,Phase 1,51,Actual,"Bausch Health Americas, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T08:56:44Z,2021-12-02T08:56:44Z,159
NCT04551781,NA,2020-09-13,NA,NA,2020-09-14,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"July 30, 2020",Actual,2020-07-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,NA,Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,Short Term Low Dose Corticosteroids for Management of Post Covid-19 Pulmonary Fibrosis,Completed,NA,Not Applicable,450,Actual,South Valley University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T08:56:45Z,2021-12-02T08:56:45Z,504
NCT04551339,NA,2020-09-09,NA,NA,2021-08-07,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-07,2021-08-10,Actual,"September 28, 2020",Actual,2020-09-28,August 2021,2021-08-31,"May 28, 2021",Actual,2021-05-28,"May 28, 2021",Actual,2021-05-28,NA,Interventional,ZnCOVID-19,NA,Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19,Zinc Versus Multivitamin Micronutrient Supplementation to Support Immune Health in the Setting of COVID-19 Pandemic: A Randomized Study,Completed,NA,Not Applicable,2700,Actual,Mayo Clinic,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:56:57Z,2021-12-02T08:56:57Z,177
NCT04548934,NA,2020-09-02,NA,NA,2021-02-01,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"September 13, 2020",Actual,2020-09-13,September 2020,2020-09-30,"January 31, 2021",Actual,2021-01-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,NA,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,Completed,NA,Not Applicable,34,Actual,Institute of Mountain Emergency Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:58:51Z,2021-12-02T08:58:51Z,364
NCT04547283,NA,2020-09-09,NA,NA,2021-07-03,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-03,2021-07-07,Actual,"June 14, 2020",Actual,2020-06-14,July 2021,2021-07-31,"September 30, 2020",Actual,2020-09-30,"September 20, 2020",Actual,2020-09-20,NA,Interventional,NA,NA,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19: A Pilot Randomized Controlled Trial,Completed,NA,Not Applicable,40,Actual,Atrium Health,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.,Data will be accessible to researchers who provide a methodologically sound proposal After approval by the AtriumHealth Institutional Review Board and the study investigators.,NA,Yes,Individual patient data underlying reported results will be made available with data dictionaries after de-identification.,2021-12-02T08:59:50Z,2021-12-02T08:59:50Z,212
NCT04548531,NA,2020-09-09,NA,NA,2021-08-31,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-01,Actual,"September 10, 2020",Actual,2020-09-10,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Completed,NA,Not Applicable,800,Actual,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Three months after the end of the funded grant period, the study materials and de-identified data will be available, by request, from the PI. Once data are placed on an open access service such as ICPSR they will be available indefinitely.","The PI will share a de-identified data set with outside investigators at no cost, according to approved Partners and Massachusetts General Hospital policies for data sharing. Investigators from other sites will be able to request the data and will be required to complete a data use agreement that ensures that all local Institutional Review Board requirements are met before using the data, that they will not attempt to identify any data in the dataset, and that they will not share the data set with anyone outside their project team.

On ICPSR, individuals must register and agree to ICPSR's Responsible Use statement prior to accessing datasets.",NA,Yes,"Yes To promote research replicability, transparency and future use of the data, de-identified data sets of the patient survey data will be created and will be available, by request, to outside researchers.

After the main manuscripts have been published, de-identified data sets will also be deposited in an open access service such as, ICPSR (https://www.icpsr.umich.edu/icpsrweb/). Before a dataset is made available for access, ICPSR completes a detailed review of all datasets to assess disclosure risk. If necessary, ICPSR modifies data to reduce disclosure risk or limits access to datasets for which modifying the data would substantially limit their utility or the risk of disclosure remains high. No information that contains identifiers or that could be used to link an individual to the data will be included in the de-identified data set.",2021-12-02T08:59:00Z,2021-12-02T08:59:00Z,153
NCT04548544,NA,2020-09-11,NA,NA,2020-09-11,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-14,Actual,"October 18, 2019",Actual,2019-10-18,September 2020,2020-09-30,"May 20, 2020",Actual,2020-05-20,"May 20, 2020",Actual,2020-05-20,NA,Interventional,NA,NA,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During the COVID-19 Pandemic,Completed,NA,Not Applicable,21,Actual,"University of California, San Francisco",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:59:02Z,2021-12-02T08:59:02Z,507
NCT04547660,NA,2020-09-09,NA,NA,2021-02-08,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"July 16, 2020",Actual,2020-07-16,February 2021,2021-02-28,"January 7, 2021",Actual,2021-01-07,"January 7, 2021",Actual,2021-01-07,NA,Interventional,PLACOVID,NA,Convalescent Plasma for Severe COVID-19 Patients,"Convalescent Plasma for Severe COVID-19 Patients: a Randomized, Open-label, Phase 3 Trial",Completed,NA,Phase 3,160,Actual,Hospital de Clinicas de Porto Alegre,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:59:33Z,2021-12-02T08:59:33Z,357
NCT04545060,NA,2020-09-04,NA,NA,2021-09-24,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-27,Actual,"August 27, 2020",Actual,2020-08-27,September 2021,2021-09-30,"September 2, 2021",Actual,2021-09-02,"April 8, 2021",Actual,2021-04-08,NA,Interventional,COMET-ICE,NA,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,"A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients",Completed,NA,Phase 2/Phase 3,1057,Actual,"Vir Biotechnology, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:01:40Z,2021-12-02T09:01:40Z,129
NCT04546581,NA,2020-09-08,NA,NA,2021-08-09,2020-09-08,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-11,Actual,"October 8, 2020",Actual,2020-10-08,August 2021,2021-08-31,"May 21, 2021",Actual,2021-05-21,"May 21, 2021",Actual,2021-05-21,NA,Interventional,NA,NA,Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC),"An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19",Completed,NA,Phase 3,593,Actual,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,A public data set will be made available at the end of the trial,2021-12-02T09:00:26Z,2021-12-02T09:00:26Z,175
NCT04547127,NA,2020-09-10,NA,NA,2021-03-02,2020-09-10,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"April 29, 2020",Actual,2020-04-29,March 2021,2021-03-31,"February 4, 2021",Actual,2021-02-04,"February 4, 2021",Actual,2021-02-04,NA,Interventional,NA,NA,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),"A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)",Completed,NA,Phase 2,200,Actual,Grifols Therapeutics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:00:11Z,2021-12-02T09:00:11Z,335
NCT04545749,NA,2020-09-02,NA,NA,2021-06-04,2020-09-10,2020-09-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"September 25, 2020",Actual,2020-09-25,June 2021,2021-06-30,"May 24, 2021",Actual,2021-05-24,"January 18, 2021",Actual,2021-01-18,NA,Interventional,NA,NA,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Completed,NA,Phase 1,60,Actual,"United Biomedical Inc., Asia",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:01:16Z,2021-12-02T09:01:16Z,241
NCT04543760,NA,2020-09-08,NA,NA,2021-05-18,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-19,Actual,"October 1, 2020",Actual,2020-10-01,May 2021,2021-05-31,"March 14, 2021",Actual,2021-03-14,"January 15, 2021",Actual,2021-01-15,NA,Interventional,DeCOPO,NA,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to Sars-covid-2: a Randomized Crossover Trial.,Completed,NA,Not Applicable,18,Actual,"Hospital St. Joseph, Marseille, France",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:02:31Z,2021-12-02T09:02:31Z,258
NCT04542941,NA,2020-08-31,NA,NA,2021-01-13,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-15,Actual,"June 16, 2020",Actual,2020-06-16,January 2021,2021-01-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,COVIDIT,NA,Assessment of Safety and Efficacy of CCP,Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial,Completed,NA,Not Applicable,136,Actual,Makerere University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Arrangments to enable sharing of de-identified data will be instituted by the research team.,2021-12-02T09:03:16Z,2021-12-02T09:03:16Z,383
NCT04542967,NA,2020-09-04,NA,NA,2021-05-06,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,"June 23, 2020",Actual,2020-06-23,September 2020,2020-09-30,"September 30, 2020",Actual,2020-09-30,"September 2, 2020",Actual,2020-09-02,NA,Interventional,PC-COVID-HCM,NA,Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,Convalescent Plasma as a Treatment for Patients With Severe COVID-19 Disease,Completed,NA,Phase 2,150,Actual,Hospital Central Militar,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,From 6 months after publication,PRIOR APPLICATION,NA,Yes,Plan to make IPD still not decided and would need approval by regulatory authorities,2021-12-02T09:03:20Z,2021-12-02T09:03:20Z,270
NCT04542213,NA,2020-09-03,NA,NA,2021-03-19,2020-09-04,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-19,2021-03-23,Actual,"August 1, 2020",Actual,2020-08-01,March 2021,2021-03-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,Covid19DPP4i,NA,Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19,Completed,NA,Phase 3,70,Actual,Hospital Regional de Alta Especialidad del Bajio,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Data will be available once the main results of the study are published, and in accordance with the journal",Direct contact with the principal investigator,NA,Yes,"Sharing of the data can be done, depending on the requested purposes",2021-12-02T09:03:50Z,2021-12-02T09:03:50Z,318
NCT04542694,NA,2020-09-04,2020-10-11,NA,2020-11-03,2020-09-04,2020-09-09,Actual,2020-11-03,2020-11-05,Actual,NA,NA,NA,2020-11-03,2020-11-05,Actual,"May 21, 2020",Actual,2020-05-21,November 2020,2020-11-30,"August 20, 2020",Actual,2020-08-20,"August 10, 2020",Actual,2020-08-10,NA,Interventional,NA,NA,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19",Completed,NA,Phase 3,200,Actual,"Promomed, LLC",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:03:26Z,2021-12-02T09:03:26Z,454
NCT04542876,NA,2020-09-08,NA,NA,2020-09-08,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-09,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"August 18, 2020",Actual,2020-08-18,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,NA,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection: An Open Label Feasibility Study,Completed,NA,Not Applicable,46,Actual,Aarogyam UK,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:03:30Z,2021-12-02T09:03:30Z,510
NCT04539262,NA,2020-08-26,NA,NA,2021-04-08,2020-09-03,2020-09-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-09,Actual,"September 14, 2020",Actual,2020-09-14,April 2021,2021-04-30,"March 22, 2021",Actual,2021-03-22,"February 26, 2021",Actual,2021-02-26,NA,Interventional,NA,NA,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation","A Phase 1b/2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",Completed,NA,Phase 1/Phase 2,156,Actual,Gilead Sciences,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:06:08Z,2021-12-02T09:06:08Z,298
NCT04539821,NA,2020-09-03,NA,NA,2021-08-13,2020-09-03,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-13,2021-08-16,Actual,"October 1, 2020",Actual,2020-10-01,August 2021,2021-08-31,"August 12, 2021",Actual,2021-08-12,"May 31, 2021",Actual,2021-05-31,NA,Interventional,VCPM,NA,Virtual Pain Care Management (COVID-19),Virtual Pain Care for High Risk Veterans on Opioids During COVID19 (and Beyond),Completed,NA,Not Applicable,51,Actual,VA Office of Research and Development,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:05:55Z,2021-12-02T09:05:55Z,171
NCT04536935,NA,2020-08-22,NA,NA,2021-06-28,2020-08-27,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"November 30, 2020",Actual,2020-11-30,June 2021,2021-06-30,"June 20, 2021",Actual,2021-06-20,"June 20, 2021",Actual,2021-06-20,NA,Interventional,NA,NA,Mobile Mental Health Apps for Suicide Prevention,"Acceptability, Usability and Effectiveness of Mental Health Apps for Suicide Prevention in Essential Workers and the Unemployed During SARS-CoV-2",Completed,NA,Not Applicable,3000,Actual,University of Washington,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:08:04Z,2021-12-02T09:08:04Z,217
NCT04536441,NA,2020-08-26,NA,NA,2020-09-01,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"June 30, 2020",Actual,2020-06-30,"May 30, 2020",Actual,2020-05-30,NA,Interventional,NA,NA,Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order,Effects of an Ultra-brief Online Mindfulness-based Intervention on Mental Health During the Coronavirus Disease (COVID-19) Outbreak in Malaysia: A Randomised Controlled Trial,Completed,NA,Not Applicable,161,Actual,Universiti Tunku Abdul Rahman,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"The data will be become available once the study is being published, for 5 years.",The data will be made available upon request to the corresponding author.,NA,Yes,NA,2021-12-02T09:08:22Z,2021-12-02T09:08:22Z,517
NCT04535856,NA,2020-08-28,NA,NA,2021-01-25,2020-08-31,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"November 14, 2020",Actual,2020-11-14,January 2021,2021-01-31,"January 14, 2021",Actual,2021-01-14,"January 14, 2021",Actual,2021-01-14,NA,Interventional,DW-MSC,NA,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,"Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients: Randomized, Double-blind, and Placebo-controlled",Completed,NA,Phase 1,9,Actual,Ina-Respond,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:08:53Z,2021-12-02T09:08:53Z,371
NCT04535167,NA,2020-08-21,NA,NA,2021-06-23,2020-08-31,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-23,2021-06-24,Actual,"September 9, 2020",Actual,2020-09-09,June 2021,2021-06-30,"June 7, 2021",Actual,2021-06-07,"June 7, 2021",Actual,2021-06-07,NA,Interventional,NA,NA,"First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.","A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND MULTIPLE ASCENDING (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID-19",Completed,NA,Phase 1,26,Actual,Pfizer,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-02T09:09:23Z,2021-12-02T09:09:23Z,222
NCT04534790,NA,2020-08-05,NA,NA,2021-02-08,2020-08-30,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"July 24, 2020",Actual,2020-07-24,February 2021,2021-02-28,"January 8, 2021",Actual,2021-01-08,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,NA,Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,"Randomized Trial, Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia",Completed,NA,Not Applicable,30,Actual,Instituto Mexicano del Seguro Social,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:09:48Z,2021-12-02T09:09:48Z,357
NCT04532931,NA,2020-08-26,NA,NA,2021-09-16,2020-08-28,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-20,Actual,"September 3, 2020",Actual,2020-09-03,September 2021,2021-09-30,"August 23, 2021",Actual,2021-08-23,"August 5, 2021",Actual,2021-08-05,NA,Interventional,NA,NA,COVID-19 Treatment in South Africa,"Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19",Completed,NA,Phase 2,192,Actual,Shin Poong Pharmaceutical Co. Ltd.,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:10:57Z,2021-12-02T09:10:57Z,137
NCT04530422,NA,2020-08-26,NA,NA,2020-08-27,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-28,Actual,"April 15, 2020",Actual,2020-04-15,August 2020,2020-08-31,"July 23, 2020",Actual,2020-07-23,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,NA,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Completed,NA,Phase 3,250,Actual,Almaza Military Fever Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:12:56Z,2021-12-02T09:12:56Z,522
NCT04530357,NA,2020-08-26,NA,NA,2021-05-01,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-04,Actual,"September 19, 2020",Actual,2020-09-19,February 2021,2021-02-28,"April 25, 2021",Actual,2021-04-25,"November 25, 2020",Actual,2020-11-25,NA,Interventional,NA,NA,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine","Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-INÂ®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder",Completed,NA,Phase 1/Phase 2,244,Actual,Research Institute for Biological Safety Problems,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:13:10Z,2021-12-02T09:13:10Z,275
NCT04528641,NA,2020-08-19,NA,NA,2021-07-09,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"August 10, 2020",Actual,2020-08-10,August 2020,2020-08-31,"May 19, 2021",Actual,2021-05-19,"May 19, 2021",Actual,2021-05-19,NA,Interventional,NA,NA,GRAd-COV2 Vaccine Against COVID-19,"A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects",Completed,NA,Phase 1,90,Actual,ReiThera Srl,NA,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:14:13Z,2021-12-02T09:14:13Z,206
NCT04529525,NA,2020-08-21,NA,NA,2021-07-04,2020-08-26,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-04,2021-07-07,Actual,"August 19, 2020",Actual,2020-08-19,September 2020,2020-09-30,"February 22, 2021",Actual,2021-02-22,"February 22, 2021",Actual,2021-02-22,NA,Interventional,IVERCORCOVID19,NA,Ivermectin to Prevent Hospitalizations in COVID-19,"Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled",Completed,NA,Phase 2/Phase 3,501,Actual,Instituto de CardiologÃ­a de Corrientes,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:13:43Z,2021-12-02T09:13:43Z,211
NCT04527562,NA,2020-08-25,NA,NA,2021-01-07,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-11,Actual,"July 14, 2020",Actual,2020-07-14,January 2021,2021-01-31,"December 10, 2020",Actual,2020-12-10,"November 15, 2020",Actual,2020-11-15,NA,Interventional,COLCOVIDBD,NA,Colchicine in Moderate Symptomatic COVID-19 Patients,"Colchicine in Moderate Symptomatic COVID-19 Patients: Double Blind, Randomized, Placebo Controlled Trial to Observe the Efficacy",Completed,NA,Not Applicable,299,Actual,Dhaka Medical College,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:15:01Z,2021-12-02T09:15:01Z,389
NCT04527354,NA,2020-08-24,NA,NA,2021-04-02,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-05,Actual,"September 1, 2020",Actual,2020-09-01,March 2021,2021-03-31,"February 10, 2021",Actual,2021-02-10,"February 10, 2021",Actual,2021-02-10,NA,Interventional,NA,NA,Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,"Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study of Treamid Efficacy and Safety in the Rehabilitation of Patients After COVID-19 Pneumonia",Completed,NA,Phase 2,60,Actual,PHARMENTERPRISES LLC,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:15:14Z,2021-12-02T09:15:14Z,304
NCT04844658,NA,2021-04-12,NA,NA,2021-11-30,2021-04-12,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-30,2021-12-01,Estimate,"February 17, 2021",Actual,2021-02-17,November 2021,2021-11-30,"October 29, 2021",Actual,2021-10-29,"October 29, 2021",Actual,2021-10-29,NA,Interventional,NA,NA,"Covid-19, Hospitalized, PatIents, Nasafytol",A Comparative Randomized Clinical Trial on Covid-19 Positive Hospitalized Patients Treated With NASAFYTOL,Completed,NA,Not Applicable,51,Actual,Tilman S.A.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:32:07Z,2021-12-02T09:32:07Z,62
NCT05080179,NA,2021-10-12,NA,NA,2021-11-18,2021-10-13,2021-10-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-12-01,Estimate,"December 11, 2020",Actual,2020-12-11,November 2021,2021-11-30,"January 28, 2021",Actual,2021-01-28,"January 28, 2021",Actual,2021-01-28,NA,Interventional,NA,NA,Impact of Nudges on Downloads of COVID-19 Exposure Notification Smartphone Apps: A Randomized Trial,The Interactive Effect of Social Norm and Self (vs. Others) Benefit Nudges on Downloads of COVID-19 Exposure Notification Smartphone Apps: A Randomized Trial,Completed,NA,Not Applicable,39937,Actual,University of Pennsylvania,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:28:59Z,2021-12-02T09:28:59Z,74
NCT04426695,NA,2020-06-08,NA,NA,2021-11-29,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-11-29,2021-12-01,Estimate,"June 11, 2020",Actual,2020-06-11,November 2021,2021-11-30,"October 22, 2021",Actual,2021-10-22,"May 7, 2021",Actual,2021-05-07,NA,Interventional,NA,NA,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19","A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19",Completed,NA,Phase 1/Phase 2,2252,Actual,Regeneron Pharmaceuticals,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-12-02T09:34:58Z,2021-12-02T09:34:58Z,63
NCT04389294,NA,2020-05-08,NA,NA,2021-02-10,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"May 5, 2020",Actual,2020-05-05,February 2021,2021-02-28,"September 4, 2020",Actual,2020-09-04,"June 16, 2020",Actual,2020-06-16,NA,Interventional,NA,NA,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,Hospital for Special Surgery COVID-19 Antibody Serology Among Anesthesiologists and Surgeons 2020,Completed,NA,Not Applicable,143,Actual,"Hospital for Special Surgery, New York",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-03T00:50:25Z,2021-12-03T00:50:25Z,355
NCT05017493,NA,2021-04-04,2021-09-21,NA,2021-11-30,2021-08-16,2021-08-24,Actual,2021-11-30,2021-12-02,Estimate,NA,NA,NA,2021-11-30,2021-12-02,Estimate,"July 1, 2020",Actual,2020-07-01,November 2021,2021-11-30,"February 8, 2021",Actual,2021-02-08,"December 7, 2020",Actual,2020-12-07,NA,Interventional,NA,Both paitients who received and NOT received Xagrotin,"Treatment of Covid-19 With a Herbal Compound, Xagrotin","Treatment of Early-Stage Covid-19 With a Herbal Compound, Xagrotin",Completed,NA,Phase 1/Phase 2,661,Actual,Biomad AS,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-03T11:56:50Z,2021-12-03T11:56:50Z,62
NCT04374149,NA,2020-04-20,2021-11-19,NA,2021-11-30,2020-05-02,2020-05-05,Actual,2021-11-30,2021-12-02,Estimate,NA,NA,NA,2021-11-30,2021-12-02,Estimate,"April 30, 2020",Actual,2020-04-30,November 2021,2021-11-30,"December 1, 2020",Actual,2020-12-01,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,"Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)",Completed,NA,Phase 2,20,Actual,Prisma Health-Upstate,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Available April 2021 through December 2021,Data can be requested from the Principal Investigator via email and should include a description of the request and the associated project or use of the data.,NA,Yes,All individual participant date (IPD) that underlie results in a publication.,2021-12-03T12:03:23Z,2021-12-03T12:03:23Z,62
NCT04348500,NA,2020-04-13,2021-11-23,NA,2021-11-30,2020-04-13,2020-04-16,Actual,2021-11-30,2021-12-02,Estimate,NA,NA,NA,2021-11-30,2021-12-02,Estimate,"April 28, 2020",Actual,2020-04-28,November 2021,2021-11-30,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,Enrolled patients who received the initial dose of the IP were analyzed.,Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19),A Phase II Trial to Evaluate the Safety and Tolerability of ClazakizumabÂ® (Anti-IL-6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection,Completed,NA,Phase 2,17,Actual,Cedars-Sinai Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-03T12:03:33Z,2021-12-03T12:03:33Z,62
